DISEASE	ALTERATION	GENE	PROTEIN	ACC_ID	GENE_ID	HU_CHR_LOC	MW_kD	ORGANISM	SITE_GRP_ID	MOD_RSD	DOMAIN	SITE_+/-7_AA	PMIDs	LT_LIT	MS_LIT	MS_CST	CST_CAT#	NOTES	
Alzheimer's disease	mutation of site	APP	APP iso4	P05067-4	351	21q21.3	78.66	human	448523	T668-p	APP_amyloid	VEVDAAVtPEERHLS	16554819	38	5	3	3823; 6986	Pin1 binds to the pT668-Pro motif but not when mutated to Ala. 
endometrial cancer	increased	Akt1	Akt1	P31750	11651	12 F1|12 61.2 cM	55.71	mouse	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	16585156	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
endometrial cancer	increased	Esr1	ER-alpha	P19785	13982	10 A1|10 2.03 cM	66.95	mouse	448102	S171-p	Oest_recep	NGRERLSsSNEKGNM	16585156	46	5	0	64508; 42101	
breast cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	12244301	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	Expression of phosphorylated S473 in invasive breast carcinomas correlates with cytosolic p27.  
acute myelogenous leukemia	deletion of site	Myb	Myb	P06876	17863	10 A3|10 9.75 cM	71.42	mouse	448186	S11-p		RPRHSIYsSDEDDED	2157164	5	1	1		
acute myelogenous leukemia	deletion of site	Myb	Myb	P06876	17863	10 A3|10 9.75 cM	71.42	mouse	448187	S12-p		PRHSIYSsDEDDEDI	2157164	5	1	2		
Alzheimer's disease	increased	APP	APP iso4	P05067-4	351	21q21.3	78.66	human	448523	T668-p	APP_amyloid	VEVDAAVtPEERHLS	14970211	38	5	3	3823; 6986	
Alzheimer's disease	increased	APLP2	APLP2	Q06481	334	11q24.3	86.96	human	451599	T736-p	APP_amyloid	VEVDPMLtPEERHLN	14970211	3	2	1		
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	449805	S16-p	Androgen_recep	RVYPRPPsKTYRGAF	12015328	4	1	0		
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	448414	S651-p		GEASSTTsPTEETTQ	12015328	11	4	0		
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	449807	S426-p	Androgen_recep	AAGPGSGsPSAAASS	12015328	3	1	0		
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	448413	S310-p	Androgen_recep	TEDTAEYsPFKGGYT	12015328	11	5	0		
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	449806	S258-p	Androgen_recep	VEALEHLsPGEQLRG	12015328	3	2	1	16969	
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	448416	S96-p	Androgen_recep	QQQGEDGsPQAHRRG	12015328	9	11	0		
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	448714	S83-p	Androgen_recep	QQQQQETsPRQQQQQ	12015328	22	1	0		
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448101	S118-p	Oest_recep	LHPPPQLsPFLQPHG	12118371	89	2	0	2511	
small-cell lung cancer	increased	CHEK2	Chk2	O96017	11200	22q12.1	60.91	human	447491	T68-p		SSLETVStQELYSIP	16705183	194	5	0	2661; 12812; 59068; 28130; 2197; 82263	
acute lymphocytic leukemia; chronic myelogenous leukemia; leukemia	increased	MYC	Myc	P01106	4609	8q24.21	48.80	human	448586	S62-p	Myc_N	LLPTPPLsPSRRSGL	16855632	72	37	33	13748	
colorectal cancer	mutation of site	CTNNB1	CTNNB1	P35222	1499	3p22.1	85.50	human	447583	T41-p		GIHSGATtTAPSLSG	11955436	88	3	0	9565; 4270; 9561; 13537; 60180; 41334	
colorectal cancer	mutation of site	CTNNB1	CTNNB1	P35222	1499	3p22.1	85.50	human	447582	S37-p		YLDSGIHsGATTTAP	11955436	97	3	12	2009; 4270; 9561; 13537; 60180; 41334	
colorectal cancer	mutation of site	CTNNB1	CTNNB1	P35222	1499	3p22.1	85.50	human	447488	S45-p		GATTTAPsLSGKGNP	11955436	49	7	0	70034; 9565; 19807; 77605; 9564; 96727	
colorectal cancer	mutation of site	CTNNB1	CTNNB1	P35222	1499	3p22.1	85.50	human	447487	S33-p		QQQSYLDsGIHSGAT	11955436	96	3	2	2009; 4270; 9561; 13537; 60180; 41334	
Alzheimer's disease	increased	MAP2K1	MEK1	Q02750	5604	15q22.31	43.44	human	448513	S222-p	Pkinase	LIDSMANsFVGTRSY	17064357	116	20	203	9154; 9121; 86128; 3958; 2338; 16211; 75262; 16780	
Alzheimer's disease	increased	RAF1	RAF1	P04049	5894	3p25.2	73.05	human	447741	S259-p		SQRQRSTsTPNVHMV	17064357	57	32	142	9421; 20011	
Alzheimer's disease	increased	RAF1	RAF1	P04049	5894	3p25.2	73.05	human	447742	S338-p		RPRGQRDsSYYWEIE	17064357	88	2	7	9427	
Alzheimer's disease	increased	MAP2K1	MEK1	Q02750	5604	15q22.31	43.44	human	448514	S218-p	Pkinase	VSGQLIDsMANSFVG	17064357	122	13	83	9154; 9121; 86128; 3958	
Alzheimer's disease	increased	MAP2K2	MEK2	P36507	5605	19p13.3	44.42	human	448074	S226-p	Pkinase	LIDSMANsFVGTRSY	17064357	56	19	201	9154; 9121; 86128; 3958; 2338; 16211; 75262; 16780	
Alzheimer's disease	increased	RAF1	RAF1	P04049	5894	3p25.2	73.05	human	447750	Y341-p		GQRDSSYyWEIEASE	17064357	34	1	1		
Alzheimer's disease	increased	MAP2K2	MEK2	P36507	5605	19p13.3	44.42	human	448073	S222-p	Pkinase	VSGQLIDsMANSFVG	17064357	62	12	83	9154; 9121; 86128; 3958	
Alzheimer's disease	increased	RAF1	RAF1	P04049	5894	3p25.2	73.05	human	447749	Y340-p		RGQRDSSyYWEIEAS	17064357	27	1	1		
colorectal carcinoma	increased	SRC	Src	P12931	6714	20q11.23	59.83	human	448234	Y419-p	PK_Tyr_Ser-Thr	RLIEDNEyTARQGAK	17148760	416	102	3046	6943; 2101; 78740; 70926; 94361; 59548; 17320	colon adenocarcinoma
Alzheimer's disease	increased	APP	APP	P05067	351	21q21.3	86.94	human	448201	T729-p	APP_amyloid	MLKKKQYtSIHHGVV	17634293	4	0	0		
Bloom's syndrome	increased	ATM	ATM	Q13315	472	11q22.3	350.69	human	448797	S1981-p		SLAFEEGsQSTTISS	17634426	203	24	4	5883; 13050; 4526	
lung cancer	mutation of site	Ccne1	CCNE1	Q61457	12447	7 B3|7 25.35 cM	46.99	mouse	447676	T393-p		PPPSVVLtPPPSSKK	16023597	15	11	0		experimental mutation of site to alanine increased tumorigenesis in p53 knockout mice and susceptibility to Ras-induced lung cancer
ischemia	increased	Camk2a	CAMK2A	P11275	25400	18q12.1	54.11	rat	447797	T286-p		SCMHRQEtVDCLKKF	14687884	143	33	72	12716	
ischemia	increased	Gria1	GluR1	P19490	50592	10q22	101.58	rat	467226	S836-p		CYKSRSEsKRMKGFC	14687884	6	0	0		
rhabdomyosarcoma	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	17848913	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
rhabdomyosarcoma	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	17848913	732	14	18	5106; 48646; 13842; 4056; 2965; 43506; 77440; 9275; 13038; 86758; 80722; 5056	
pancreatic cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	15467756	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
Burkitt's lymphoma	mutation of site	MYC	Myc	P01106	4609	8q24.21	48.80	human	448496	T58-p	Myc_N	KKFELLPtPPLSPSR	10866684	71	39	30	46650	
papillary thyroid carcinoma; follicular thyroid carcinoma; anaplastic thyroid carcinoma	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	15743786	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
papillary thyroid carcinoma; follicular thyroid carcinoma; anaplastic thyroid carcinoma	increased	CDKN1B	p27Kip1	P46527	1027	12p13.1	22.07	human	448645	T157-p		GIRKRPAtDDSSTQN	15743786	25	0	1		
papillary thyroid carcinoma; follicular thyroid carcinoma; anaplastic thyroid carcinoma	increased	CDKN1B	p27Kip1	P46527	1027	12p13.1	22.07	human	448781	T198-p		PGLRRRQt_______	15743786	27	0	6		
breast cancer; colorectal cancer	increased	CAV1	caveolin-1	Q03135	857	7q31.2	20.47	human	448422	Y14-p		VDSEGHLyTVPIREQ	18922892	49	45	830	3251	involved in metastasis
breast adenocarcinoma	mutation of site	Birc5	Survivin	O70201	11799	11|11 E2	16.30	mouse	447705	T34-p	BIR	FLEDCACtPERMAEA	18816410	17	6	7	8888	inhibition of growth and metastases
non-small cell lung adenocarcinoma	increased	EGFR	EGFR	P00533	1956	7p11.2	134.28	human	448059	Y1172-p		ISLDNPDyQQDFFPK	18687633	43	60	967	4404	
non-small cell lung adenocarcinoma	increased	EGFR	EGFR	P00533	1956	7p11.2	134.28	human	448057	Y1092-p		TFLPVPEyINQSVPK	18687633	161	30	352	8543; 2236; 14565; 3777; 2234; 48576	
ventricular tachycardia; hypertrophic cardiomyopathy	increased	MAPK1	ERK2	P28482	5594	22q11.22	41.39	human	3949250	T190-p	Pkinase	FLTEYVAtRWYRAPE	19060905	3	17	17		
ventricular tachycardia; hypertrophic cardiomyopathy	increased	Mapk1	ERK2	P63085	26413	16 A3|16 10.53 cM	41.28	mouse	3949250	T188-p	Pkinase	FLTEYVAtRWYRAPE	19060905	3	17	17		
cervical squamous cell carcinoma	increased	MTOR	mTOR	P42345	2475	1p36.22	288.89	human	447578	S2448-p		RSRTRTDsYSAGQSV	19079619	187	17	106	2971; 5536; 54932; 2976	
cervical squamous cell carcinoma	increased	RPS6KB1	p70S6K	P23443	6198	17q23.1	59.14	human	448607	T412-p	Pkinase_C	NQVFLGFtYVAPSVL	19079619	438	8	1	9209; 9205; 9234; 9206; 97596	
Down syndrome	increased	CRYAB	CRYAB	P02511	1410	11q23.1	20.16	human	448783	S59-p		PSFLRAPsWFDTGLS	19272359	44	22	0		in the brain tissues isolated from children and young adults
Down syndrome	increased	CRYAB	CRYAB	P02511	1410	11q23.1	20.16	human	448748	S45-p	Crystallin	FPTSTSLsPFYLRPP	19272359	35	7	1		in the brain tissues isolated from children and young adults
Hodgkin's lymphoma	increased	TRAF2	TRAF2	Q12933	7186	9q34.3	55.86	human	7378202	S55-p	zf-C3HC4	QCGHRYCsFCLASIL	19336568	2	0	0		constitutive phosphorylation
lung cancer	increased	RASSF1	RASSF1 iso2	Q9NS23-2	11186	3p21.31	38.81	human	484000	S203-p	RA	TSVRRRTsFYLPKDA	19276349	7	10	1		
PSP	decreased	TH	TH iso3	P07101-3	7054	11p15.5	55.61	human	448544	S31-p	TOH_N	KQAEAIMsPRFIGRR	9920892	42	8	0	13041; 3370	TH isoform lacking S31 and S40 is overexpressed in PSP patients
PSP	decreased	TH	TH iso3	P07101-3	7054	11p15.5	55.61	human	448545	S40-p	TOH_N	RFIGRRQsLIEDARK	9920892	61	11	11	2791	TH isoform lacking S31 and S40 is overexpressed in PSP patients
Parkinson's disease	decreased	Grin1	NMDAR1	P35439	24408	3p13	105.51	rat	447737	S890-p		ITSTLASsFKRRRSS	19283475	12	2	3	3381	
Parkinson's disease	decreased	Grin1	NMDAR1	P35439	24408	3p13	105.51	rat	448256	S897-p		SFKRRRSsKDTSTGG	19283475	27	0	0	3385	
Parkinson's disease	decreased	Grin1	NMDAR1	P35439	24408	3p13	105.51	rat	448255	S896-p		SSFKRRRsSKDTSTG	19283475	24	0	0	3384	
prostate cancer	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	19147545	468	74	3065	4324; 8119; 9145; 4113; 52075; 73533; 9138; 4323; 4093; 4074; 52527; 74309; 16185; 61958; 9131; 73452	
Alzheimer's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	449132	S701-p		DTSPRHLsNVSSTGS	10460255	13	10	5		
Alzheimer's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	447929	S506-p		GSRSRTPsLPTPPTR	10460255	60	23	42	77348	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	8318230	170	45	90	9632	
Alzheimer's disease	decreased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449084	S413-p		RHLSNVSsTGSIDMV	8930358	5	9	1		
ischemia	increased	Golga3	GOLGA3	P55937	269682	5 F|5 53.36 cM	167.22	mouse	487482	S174-p		VKRHRERsSQPATKM	17888676	1	0	0		
ischemia	increased	Golga3	GOLGA3	P55937	269682	5 F|5 53.36 cM	167.22	mouse	478659	S385-p		EVRSRRDsICSSVSM	17888676	1	8	28		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	12766916	130	44	14	20473; 71429	potential biomarker for Alzheimer's as distinct from other dementias. Phosphorylation occurs at early and later stages of AD.
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447927	S199-p		GDRSGYSsPGSPGTP	12766916	87	30	33	29957	potential biomarker for Alzheimer's as distinct from other dementias. Phosphorylation occurs at early and later stages of AD.
Alzheimer's disease; FTLD	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	15136685	85	33	23	62672; 66224; 12885	increased in early-onset Alzheimer disease patients, as compared to  frontotemporal lobar degeneration or normal control patients. AD was highest, and FTLD higher than normal controls.
X-linked hypophosphatemia	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	455736	S117-p	Osteopontin	DVDDTDDsHQSDESH	19775205	1	4	0		ASARM peptide carrying phosphorylated residues S117, S120, S123, S126 and S129 contributes towards the hypomineralization occuring in XLH
HAM/TSP	increased	NEFL	NFL	P07196	4747	8p21.2	61.52	human	10211802	S221-p	Filament	DSLMDEIsFLKKVHE	19678766	0	1	0		
HAM/TSP	increased	NEFL	NFL	P07196	4747	8p21.2	61.52	human	10211801	S215-p	Filament	ELEKRIDsLMDEISF	19678766	0	1	1		
HAM/TSP	increased	NEFL	NFL	P07196	4747	8p21.2	61.52	human	3926308	S103-p	Filament	DLNDRFAsFIERVHE	19678766	0	4	1		
HAM/TSP	increased	NEFL	NFL	P07196	4747	8p21.2	61.52	human	450895	S472-p		EAKDEPPsEGEAEEE	19678766	3	18	0		
X-linked hypophosphatemia	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	455739	S126-p	Osteopontin	QSDESHHsDESDELV	19775205	1	5	0		ASARM peptide carrying phosphorylated residues S117, S120, S123, S126 and S129 contributes towards the hypomineralization occuring in XLH
X-linked hypophosphatemia	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	455737	S120-p	Osteopontin	DTDDSHQsDESHHSD	19775205	1	5	0		ASARM peptide carrying phosphorylated residues S117, S120, S123, S126 and S129 contributes towards the hypomineralization occuring in XLH
X-linked hypophosphatemia	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	455738	S123-p	Osteopontin	DSHQSDEsHHSDESD	19775205	1	5	0		ASARM peptide carrying phosphorylated residues S117, S120, S123, S126 and S129 contributes towards the hypomineralization occuring in XLH
X-linked hypophosphatemia	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	455740	S129-p	Osteopontin	ESHHSDEsDELVTDF	19775205	1	5	0		ASARM peptide carrying phosphorylated residues S117, S120, S123, S126 and S129 contributes towards the hypomineralization occuring in XLH
hepatitis	decreased	FOXO1	FOXO1A	Q12778	2308	13q14.11	69.66	human	448075	S256-p		SPRRRAAsMDNNSKF	18316359	90	8	48	84192; 9461	nonalcoholic steatohepatitis (NASH)
hepatitis	decreased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	18316359	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	nonalcoholic steatohepatitis (NASH)
Kaposi's sarcoma	increased	NPM1	NPM1	P06748	4869	5q35.1	32.58	human	448515	T199-p		VKKSIRDtPAKNAQK	20333249	23	29	30	3541	
atrial fibrillation	increased	RYR2	RYR2	Q92736	6262	1q43	564.57	human	458801	S2814-p		ISQTSQVsVDAAHGY	20056922	61	8	5		
kidney cancer	increased; translocation	MDM2	MDM2	Q00987	4193	12q15	55.23	human	448130	S166-p		SSRRRAIsETEENSD	19920202	47	19	5	3521	nuclear localization
sporadic inclusion-body myositis	increased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	448569	Y216-p	Pkinase	RGEPNVSyICSRYYR	19878439	91	127	4206		
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448102	S167-p	Oest_recep	GGRERLAsTNDKGSM	19940156	46	5	0	64508; 42101	high S167 phosphorylation in tamoxifen resistant tumors
lymphoma	increased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	449111	S9-p		SGRPRTTsFAESCKP	20224723	513	44	227	5558; 14630; 14026; 14332; 79774; 9322; 9327; 9331; 9323; 9336; 9325; 8466; 8566; 14310	mantle cell lymphoma, 67% of tumors showed positive S9 phosphorylation.
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448805	S305-p		IKRSKKNsLALSLTA	20179234	16	0	0		
Parkinson's disease	decreased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	19800394	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
pancreatic carcinoma	increased	ENO1	ENO1	P06733	2023	1p36.23	47.17	human	11321358	K221-ac	Enolase_C	APNILENkEGLELLK	20433201	1	7	1		sites phosphorylated in pancreatic ductal adenocarcinoma (PDAC) cells and not in normal pancreatic duct cells
pancreatic carcinoma	increased	ENO1	ENO1	P06733	2023	1p36.23	47.17	human	14146804	K105-ac	Enolase_N	DGTENKSkFGANAIL	20433201	0	1	2		sites phosphorylated in pancreatic ductal adenocarcinoma (PDAC) cells and not in normal pancreatic duct cells
pancreatic carcinoma	increased	ENO1	ENO1	P06733	2023	1p36.23	47.17	human	474652	K285-ac	Enolase_C	DLYKSFIkDYPVVSI	20433201	0	2	1		sites phosphorylated in pancreatic ductal adenocarcinoma (PDAC) cells and not in normal pancreatic duct cells
pancreatic carcinoma	increased	ENO1	ENO1	P06733	2023	1p36.23	47.17	human	14146808	K262-ac	Enolase_C	GKYDLDFkSPDDPSR	20433201	0	1	2		sites phosphorylated in pancreatic ductal adenocarcinoma (PDAC) cells and not in normal pancreatic duct cells
pancreatic carcinoma	increased	ENO1	ENO1	P06733	2023	1p36.23	47.17	human	14146803	K103-ac	Enolase_N	EMDGTENkSKFGANA	20433201	0	1	0		sites phosphorylated in pancreatic ductal adenocarcinoma (PDAC) cells and not in normal pancreatic duct cells
pancreatic carcinoma	increased	ENO1	ENO1	P06733	2023	1p36.23	47.17	human	14146801	K28-ac	Enolase_N	EVDLFTSkGLFRAAV	20433201	0	2	0		sites phosphorylated in pancreatic ductal adenocarcinoma (PDAC) cells and not in normal pancreatic duct cells
pancreatic carcinoma	increased	ENO1	ENO1	P06733	2023	1p36.23	47.17	human	14146806	K239-ac	Enolase_C	GKAGYTDkVVIGMDV	20433201	0	1	0		sites phosphorylated in pancreatic ductal adenocarcinoma (PDAC) cells and not in normal pancreatic duct cells
pancreatic carcinoma	increased	ENO1	ENO1	P06733	2023	1p36.23	47.17	human	14146807	K330-ac	Enolase_C	TNPKRIAkAVNEKSC	20433201	0	1	0		sites phosphorylated in pancreatic ductal adenocarcinoma (PDAC) cells and not in normal pancreatic duct cells
pancreatic carcinoma	increased	ENO1	ENO1	P06733	2023	1p36.23	47.17	human	461589	K256-ac	Enolase_C	SEFFRSGkYDLDFKS	20433201	1	9	31		sites phosphorylated in pancreatic ductal adenocarcinoma (PDAC) cells and not in normal pancreatic duct cells
glioblastoma multiforme	decreased	CTNNA1	CTNNA1	P35221	1495	5q31.2	100.07	human	449139	S641-p	Vinculin	TPEELDDsDFETEDF	19941816	5	98	78		
prostate cancer	increased	Akt1	Akt1	P31750	11651	12 F1|12 61.2 cM	55.71	mouse	14515900	Y176-p	Pkinase	EKATGRYyAMKILKK	20333297	2	1	0		murine prostatic intraepithelial neoplasia (mPINs)
breast cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	14515900	Y176-p	Pkinase	EKATGRYyAMKILKK	20333297	2	1	0		
breast cancer	increased	TNK2	Ack	Q07912	10188	3q29	114.57	human	450946	Y284-p	PK_Tyr_Ser-Thr	LPQNDDHyVMQEHRK	20333297	11	27	235	3138	
HIV Encephalitis	increased	GRIN2A	NMDAR2A	Q12879	2903	16p13.2	165.28	human	458211	Y1325-p	NMDAR2_C	RLLEGNFyGSLFSVP	20448061	7	2	84		
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448100	S106-p	Oest_recep	PLNSVSPsPLMLLHP	20418363	25	1	0		S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. 
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	449929	T311-p		NSLALSLtADQMVSA	20418363	7	0	0		S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. 
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448102	S167-p	Oest_recep	GGRERLAsTNDKGSM	20418363	46	5	0	64508; 42101	S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. 
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	6048401	S282-p		EGRGEVGsAGDMRAA	20418363	4	0	0		S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. 
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	6048400	S559-p	ESR1_C	PTSRGGAsVEETDQS	20418363	4	1	0		S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. 
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	451560	S294-p		RAANLWPsPLMIKRS	20418363	11	4	0		S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. 
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448099	S104-p	Oest_recep	FPPLNSVsPSPLMLL	20418363	24	1	0		S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. 
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448101	S118-p	Oest_recep	LHPPPQLsPFLQPHG	20418363	89	2	0	2511	S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. 
tuberous sclerosis	increased	TSC2	TSC2	P49815	7249	16p13.3	200.61	human	448546	T1462-p		GLRPRGYtISDSAPS	12150915	58	14	48	3611; 3617	
tuberous sclerosis	increased	TSC2	TSC2	P49815	7249	16p13.3	200.61	human	448501	S939-p		SFRARSTsLNERPKS	12150915	21	34	50	3615	
Wilm's tumor	deletion of site	CTNNB1	CTNNB1	P35222	1499	3p22.1	85.50	human	447488	S45-p		GATTTAPsLSGKGNP	12239584	49	7	0	70034; 9565; 19807; 77605; 9564; 96727	Observed frequent mutations of S45 of beta-catenin in Wilm's tumors.
ataxia-telangiectasic cancer	decreased	SMC1A	Smc1	Q14683	8243	Xp11.22	143.23	human	448698	S966-p	SMC_N	GEDSVSGsQRISSIY	12447382	20	14	67		
Fanconi's anaemia		FANCG	FANCG	O15287	2189	9p13.3	68.55	human	453422	S7-p		_MSRQTTsVGSSCLD	15299017	2	1	0		
Waardenburg syndrome type 2	mutation of site	MITF	MITF iso9	O75030-9	4286	3p13	46.94	human	448503	S298-p	DUF3371	QARAHGLsLIPSTGL	10587587	3	1	0		
breast cancer	increased	AKT2	Akt2	P31751	208	19q13.2	55.77	human	448520	S474-p	Pkinase_C	RTHFPQFsYSASIRE	11507039	30	9	55	5012; 4051; 4070; 68035; 5315; 8599; 4075; 31957; 11962; 2337; 9271; 3787; 5102; 88106; 15116; 4058; 26580; 9563; 2336; 4060; 4071; 23430; 12694	
leukemia	translocation	ABL1	Abl	P00519	25	9q34.12	122.87	human	450300	Y257-p	PK_Tyr_Ser-Thr	GGQYGEVyEGVWKKY	15256422	4	13	323		
medullary thyroid carcinoma	mutation of site	RET	Ret	P07949	5979	10q11.21	124.32	human	455479	Y791-p	PK_Tyr_Ser-Thr	HPHVIKLyGACSQDG	15753368	2	0	0		
medullary thyroid carcinoma	mutation of site	RET	Ret	P07949	5979	10q11.21	124.32	human	455478	S891-p	PK_Tyr_Ser-Thr	EGRKMKIsDFGLSRD	15753368	1	0	0		
spinocerebellar ataxia type 1	increased	ATXN1	ataxin-1	P54253	6310	6p22.3	86.92	human	449110	S775-p		ATRKRRWsAPESRKL	15757972	19	28	3		
Xeroderma pigmentosum	mutation of site	RARA	RARA	P10276	5914	17q21.2	50.77	human	455459	S77-p		EIVPSPPsPPPLPRI	11955452	11	2	0		
chronic myelogenous leukemia		RB1	Rb	P06400	5925	13q14.2	106.16	human	456752	Y805-p	Rb_C	RIPGGNIyISPLKSP	16158058	1	2	37		phosphorylation of this site has a positive role in survival of Bcr/Abl-positive CML cells
synucleinopathy; Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	12505616	104	7	0	87281; 23706	
Alzheimer's disease	increased	RPS6KB1	p70S6K	P23443	6198	17q23.1	59.14	human	448358	T444-p		RFIGSPRtPVSPVKF	16364302	105	37	109	9204	p70S6K T421/S424 phosphorylation correlates with tau phosphorylation in AD brains
Alzheimer's disease	increased	RPS6KB1	p70S6K	P23443	6198	17q23.1	59.14	human	448357	S447-p		GSPRTPVsPVKFSPG	16364302	100	54	247	9204	p70S6K T421/S424 phosphorylation correlates with tau phosphorylation in AD brains
breast cancer	increased; mutation of site	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	459012	K303-ac		LMIKRSKkNSLALSL	15604293	4	1	0		K303R mutation in 1/3 premalignant breast hyperplasias
esophageal cancer	mutation of site	EGFR	EGFR	P00533	1956	7p11.2	134.28	human	452119	S768-p	PK_Tyr_Ser-Thr	DEAYVMAsVDNPHVC	16357520	6	0	0		
cervical cancer	increased	GJA1	GJA1	P17302	2697	6q22.31	43.01	human	448854	S282-p		TAPLSPMsPPGYKLV	15958277	40	7	1		
cervical cancer	increased	GJA1	GJA1	P17302	2697	6q22.31	43.01	human	448853	S279-p		SSPTAPLsPMSPPGY	15958277	42	6	1		
congenital progressive hydronephrosis	mutation of site	Aqp2	AQP2	P56402	11827	15 F1|15 56.13 cM	28.96	mouse	449854	S256-p		REVRRRQsVELHSPQ	16641094	77	9	0		in mice
cystic fibrosis	decreased	KRT18	K18	P05783	3875	12q13.13	48.06	human	447734	S53-p		ISVSRSTsFRGGMGS	16424149	17	12	14		increased phosphorylation caused by curcumin rescue of CFTR F508 deletion
rheumatoid arthritis	increased	NCF1	p47phox	P14598	653361	7q11.23	44.68	human	451727	S345-p		QARPGPQsPGSPLEE	16778989	20	7	0		TAT-Ser345 peptide (ARPGPQSPGSPL) may have potenital antiinflammatory properties
synucleinopathy; Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	16847063	104	7	0	87281; 23706	
acute lymphocytic leukemia	deletion of site	NOTCH1	Notch 1	P46531	4851	9q34.3	272.50	human	467290	S2524-p		PDQWSSSsPHSNVSD	16880534	1	0	0		mutation of four serines (2521-2524) to alanine increases leukemogenetic activity of Notch 1; region deleted in ALL
acute lymphocytic leukemia	deletion of site	NOTCH1	Notch 1	P46531	4851	9q34.3	272.50	human	467289	S2523-p		SPDQWSSsSPHSNVS	16880534	1	0	0		mutation of four serines (2521-2524) to alanine increases leukemogenetic activity of Notch 1; region deleted in ALL
acute lymphocytic leukemia	deletion of site	NOTCH1	Notch 1	P46531	4851	9q34.3	272.50	human	467288	S2522-p		ESPDQWSsSSPHSNV	16880534	1	0	0		mutation of four serines (2521-2524) to alanine increases leukemogenetic activity of Notch 1; region deleted in ALL
acute lymphocytic leukemia	deletion of site	NOTCH1	Notch 1	P46531	4851	9q34.3	272.50	human	467287	S2521-p		PESPDQWsSSSPHSN	16880534	1	0	0		mutation of four serines (2521-2524) to alanine increases leukemogenetic activity of Notch 1; region deleted in ALL
ataxia-telangiectasic cancer	decreased	COP1	COP1	Q8NHY2	64326	1q25.1-q25.2	80.47	human	467307	S387-p		SDDSRTAsQLDEFQE	16931761	3	0	1		alternation: mutation of ATM protein kinase 
Alzheimer's disease; schizophrenia	increased	STMN1	STMN1	P16949	3925	1p36.11	17.30	human	448555	S25-p	Stathmin	QAFELILsPRSKESV	16925597	50	122	91		increased in some schizophrenic patients; decreased in patients with Alzheimer's disease
Alzheimer's disease; schizophrenia	increased	STMN1	STMN1	P16949	3925	1p36.11	17.30	human	448556	S38-p	Stathmin	SVPEFPLsPPKKKDL	16925597	48	114	166	3426; 4191	increased in some schizophrenic patients; not significantly changed in patients with the Alzheimer's disease
type 2 diabetes	decreased	Vasp	VASP	B5DEX4	361517	1q21	39.72	rat	448381	T274-p		LARRRKAtQVGEKPP	17082196	10	3	19		
type 2 diabetes	decreased	Vasp	VASP	B5DEX4	361517	1q21	39.72	rat	448380	S236-p		GAKLRKVsKEEASGG	17082196	58	26	3	3114	
type 2 diabetes	decreased	Prkaa1	AMPKA1	P54645	65248	2q16	63.97	rat	448786	T183-p	Pkinase	SDGEFLRtSCGSPNY	17082196	221	16	33	5256; 2531; 2535; 4188; 50081; 74281	
Cowden disease	increased	Ctnnb1	CTNNB1	Q02248	12387	9 F4|9 72.19 cM	85.47	mouse	472273	S552-p		QDTQRRTsMGGTQQQ	17237784	39	62	9	9566; 5651	observed in PTEN mouse mutant
ischemia	increased	Gabbr2	GABBR2	O88871	83633	5q22	105.75	rat	473060	S783-p	GBR2_CC	VTSVNQAsTSRLEGL	17224405	10	0	0		
Parkinson's disease	decreased	PRKN	PARK2	O60260	5071	6q26	51.64	human	454421	S131-p		HTDSRKDsPPAGSPA	17327227	4	2	0		
atherosclerosis	decreased	HSPB1	HSP27	P04792	3315	7q11.23	22.78	human	448403	S82-p		RALSRQLsSGVSEIR	15249501	70	103	289	9709; 11892; 64293; 2406; 2401	
ataxia-telangiectasia	decreased	TP53	p53	P04637	7157	17p13.1	43.65	human	447490	S15-p	P53_TAD	PSVEPPLsQETFSDL	9733515	456	11	0	8514; 82530; 56979; 8695; 9286; 4030; 9284; 9235; 12571	
breast cancer	increased	CHEK1	Chk1	O14757	1111	11q24.2	54.43	human	447831	S280-p		AKRPRVTsGGVSESP	17418864	11	27	145	2347	
tuberous sclerosis	increased	TSC2	TSC2	P49815	7249	16p13.3	200.61	human	455575	S664-p	Tuberin	KKTSGPLsPPTGPPG	17671177	9	9	1	40729	
glioblastoma multiforme	increased	EGFR	EGFR	P00533	1956	7p11.2	134.28	human	448055	Y1016-p		DVVDADEyLIPQQGF	17575160	45	7	12	2235	
Parkinson's disease	increased	Snca	SNCA	O55042	20617	6 B3|6 29.15 cM	14.49	mouse	448278	S129-p	Synuclein	SEAYEMPsEEGYQDY	17360705	104	7	0	87281; 23706	
prostate cancer	increased	SRC	Src	P12931	6714	20q11.23	59.83	human	448234	Y419-p	PK_Tyr_Ser-Thr	RLIEDNEyTARQGAK	17045208	416	102	3046	6943; 2101; 78740; 70926; 94361; 59548; 17320	phosphorylated Src and AR higher in hormone-refractory prostate cancers than hormone-sensitive ones.
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	470068	Y535-p		MDSYSGPyGDMRLET	17045208	4	1	0		phosphorylated Src and AR higher in hormone-refractory prostate cancers than hormone-sensitive ones.
bladder cancer	increased	MET	Met	P08581	4233	7q31.2	155.54	human	448470	Y1234-p	PK_Tyr_Ser-Thr	RDMYDKEyYSVHNKT	17062641	51	36	740	4091; 98954; 3077; 3126; 3129; 4033; 12468	
bladder cancer	increased	MET	Met	P08581	4233	7q31.2	155.54	human	448469	Y1003-p		VSNESVDyRATFPED	17062641	16	26	366	3135	
bladder cancer	increased	MET	Met	P08581	4233	7q31.2	155.54	human	448471	Y1235-p	PK_Tyr_Ser-Thr	DMYDKEYySVHNKTG	17062641	48	16	442	4091; 98954; 3077; 3126; 3129; 4033; 12468	
type 2 diabetes	decreased	Gsk3b	GSK3B	Q9WV60	56637	16|16 B3	46.71	mouse	449111	S9-p		SGRPRTTsFAESCKP	17130464	513	44	227	5558; 14630; 14026; 14332; 79774; 9322; 9327; 9331; 9323; 9336; 9325; 8466; 8566; 14310	using high fat diet-induced insulin resistance in mice as a model.
type 2 diabetes	decreased	Gsk3a	GSK3A	Q2NL51	606496	7|7 A3	51.66	mouse	448584	S21-p		SGRARTSsFAEPGGG	17130464	145	24	277	8452; 9327; 9331; 9316; 9337; 5090; 8566	using high fat diet-induced insulin resistance in mice as a model.
type 2 diabetes	decreased	Akt1	Akt1	P31750	11651	12 F1|12 61.2 cM	55.71	mouse	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	17130464	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	using high fat diet-induced insulin resistance in mice as a model.
type 2 diabetes	decreased	Tbc1d4	AS160	Q8BYJ6	210789	14|14 E2.3	147.45	mouse	455921	T649-p		QFRRRAHtFSHPPSS	17130464	40	21	134	4288; 8881	using high fat diet-induced insulin resistance in mice as a model.
type 2 diabetes	decreased	Akt1s1	PRAS40	Q9D1F4	67605	7|7 B3	27.48	mouse	470067	T247-p	PRAS	LPRPRLNtSDFQKLK	17130464	44	69	781	13175; 2997; 2640; 60202	using high fat diet-induced insulin resistance in mice as a model.
leukemia	increased	ABL1	Abl	P00519	25	9q34.12	122.87	human	450300	Y257-p	PK_Tyr_Ser-Thr	GGQYGEVyEGVWKKY	17164333	4	13	323		elevated in drug resistant leukemias with T315I mutations in Abl, and is associated with increased oncogenicity
colorectal cancer	increased	FOSL1	FRA1	P15407	8061	11q13.1	29.41	human	478351	S252-p		ASAHRKSsSSSGDPS	17371847	3	1	3		In cancers where Erk1/2 is upregulated
colorectal cancer	increased	FOSL1	FRA1	P15407	8061	11q13.1	29.41	human	478352	S265-p		PSSDPLGsPTLLAL_	17371847	3	8	6	5841; 3880	In cancers where Erk1/2 is upregulated
leukemia	decreased	MYB	Myb	P01103	396244		72.47	chicken	448757	S116-p	Myb_DNA-binding	KYGPKRWsVIAKHLK	12456674	1	0	0		AMV virus-induced monocytic leukemia has a v-Myb V117D mutation which inhibits phosphorylation of S116.
melanoma skin cancer	increased	RB1	Rb	P06400	5925	13q14.2	106.16	human	447980	S807-p	Rb_C	PGGNIYIsPLKSPYK	15502804	89	45	112	8974; 11917; 9308; 4277; 99274; 8957; 41359; 8516	phosphorylation increases as goes from melanocytic nevus to metastatic tumor; increased p-Rb correlates with a worse prognosis
melanoma skin cancer	increased	RB1	Rb	P06400	5925	13q14.2	106.16	human	448717	S811-p	Rb_C	IYISPLKsPYKISEG	15502804	85	40	80	8974; 11917; 9308; 4277; 8957; 41359; 8516; 63276	phosphorylation increases as goes from melanocytic nevus to metastatic tumor; increased p-Rb correlates with a worse prognosis
melanoma skin cancer	increased	RB1	Rb	P06400	5925	13q14.2	106.16	human	447979	S795-p	Rb_C	SPYKFPSsPLRIPGG	15502804	48	17	94	9301	phosphorylation increases as goes from melanocytic nevus to metastatic tumor; increased p-Rb correlates with a worse prognosis
nephrosis	increased	Kirrel1	KIRREL	Q6X936	310695	2q34	87.24	rat	463752	Y638-p		KDPTNGYyNVRAHED	18258597	3	5	49		
nephrosis	increased	Kirrel1	KIRREL	Q6X936	310695	2q34	87.24	rat	463751	Y637-p		MKDPTNGyYNVRAHE	18258597	3	12	84		
Huntington's disease	decreased	Ppp1r1b	DARPP-32	Q60829	19049	11|11 D	21.78	mouse	448047	T34-p	DARPP-32	MIRRRRPtPAMLFRV	10829080	64	6	44	12438	decreased in Huntington's disease mouse model
vesicoureteral reflux	mutation of site	RET	Ret iso2	P07949-2	5979	10q11.21	119.85	human	2246703	G691-p		PVSYSSSgARRPSLD	18273880	1	0	0		mutation of G691 to serine due to SNP
Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	11813001	104	7	0	87281; 23706	
Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	14579119	104	7	0	87281; 23706	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447929	S214-p		GSRSRTPsLPTPPTR	16645045	60	23	42	77348	
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	6048401	S282-p		EGRGEVGsAGDMRAA	19104930	4	0	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449082	S404-p		PVVSGDTsPRHLSNV	11943712	132	53	69	20194; 35834; 98523; 49562; 91600	S396 and S304 are hyperphosphorylated in the CSF of AD patients as compared with normal controls. -useful diagnostic marker of AD
diabetes mellitus	decreased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	17272402	732	14	18	5106; 48646; 13842; 4056; 2965; 43506; 77440; 9275; 13038; 86758; 80722; 5056	
diabetes mellitus	decreased	INSR	INSR	P06213	3643	19p13.2	156.33	human	1012666	Y1149-p	PK_Tyr_Ser-Thr	EIADGMAyLNAKKFV	17272402	1	1	1		
cancer, squamous cell carcinoma	decreased	WWOX	WWOX	Q9NZC7	51741	16q23.1-q23.2	46.68	human	449043	Y33-p	WW	TTKDGWVyYANHTEE	16115915	21	1	0		
nephrogenic diabetes insipidus	decreased	AQP2	AQP2	P41181	359	12q13.12	28.84	human	449854	S256-p		REVRRRQsVELHSPQ	16120822	77	9	0		
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084635	S404-p		FNGGFGSsMDSKSSG	18546284	13	2	0		
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084615	S379-p		NSYSGSNsGAAIGWG	18546284	6	2	0		
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084617	S403-p		GFNGGFGsSMDSKSS	18546284	13	3	0		
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084616	S409-p		GSSMDSKsSGWGM__	18546284	48	4	0		
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084601	S410-p		SSMDSKSsGWGM___	18546284	49	4	0		
breast cancer	increased	PTK2B	Pyk2	Q14289	2185	8p21.2	115.87	human	447955	Y402-p		CSIESDIyAEIPDET	10713673	84	2	22	3291	breast carcinoma cell invasion
angiosarcoma	mutation of site	GJA4	GJA4	P35212	2701	1p34.3	37.41	human	3243300	P319-p		PPQNGQKpPSRPSSS	10728596	2	2	0		
myxoid liposarcoma	translocation	FUS	hnRNP P2	P35637	2521	16p11.2	53.43	human	3306333	S42-p		QQSYSGYsQSTDTSG	18620545	6	2	0		t(12;16)(q13;p11) translocation
cardiomyopathy	mutation of site	Creb1	CREB	Q01147	12912	1 C2|1 32.74 cM	35.12	mouse	448228	S119-p	pKID	EILSRRPsYRKILND	17616745	289	4	61	14001; 54960; 9187; 80120; 95995; 14228; 44864; 39561; 9196; 9198; 4095	
stroke	decreased	NOS3	eNOS	Q7YSG7	397557		133.33	pig	447884	S1179-p		TSRIRTQsFSLQERH	17557122	194	18	7	9570; 9571	S1179D mutant develops less severe strokes and have improved cerebral blood flow. S1179D has greater vascular reactivity,less infarct volume, and have improved cerebral blood flow as compared with S1179A.
atherosclerosis	decreased	Nos3	eNOS	P70313	18127	5 A3|5 11.32 cM	132.92	mouse	467802	S1178-p		RIRTQSFsLQERQLR	17982133	10	8	1		
fibrosarcoma of soft tissue	mutation of site	MMP14	MMP14	P50281	4323	14q11.2	65.89	human	478362	Y573-p	DUF3377	GTPRRLLyCQRSLLD	18621744	7	3	39		experimental mustation of site interferes with tumor cell proliferation and tumor growth
breast cancer	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	18353781	468	74	3065	4324; 8119; 9145; 4113; 52075; 73533; 9138; 4323; 4093; 4074; 52527; 74309; 16185; 61958; 9131; 73452	
mantle cell lymphoma	increased	MDM2	MDM2	Q00987	4193	12q15	55.23	human	448130	S166-p		SSRRRAIsETEENSD	18467333	47	19	5	3521	
mantle cell lymphoma	increased	MDM2	MDM2	Q00987	4193	12q15	55.23	human	448131	S186-p		RQRKRHKsDSISLSF	18467333	12	9	2		
testicular cancer	increased	H2AX	H2AX	P16104	3014	11q23.3	15.01	human	448841	S139-p		GKKATQAsQEY____	15846060	254	31	29	85410; 97148; 20304; 5438; 80312; 59141; 4309; 9719; 60566; 5763; 9720; 2577; 9718	
testicular cancer	increased	ATM	ATM	Q13315	472	11q22.3	350.69	human	448797	S1981-p		SLAFEEGsQSTTISS	15846060	203	24	4	5883; 13050; 4526	
DCM	decreased	HSPB6	HSP20	O14558	126393	19q13.12	17.14	human	450706	S16-p	Crystallin	PSWLRRAsAPLPGLS	18790732	21	31	2		in patients carrying P20L substitution in Hsp20 
breast cancer	increased	Ncoa3	SRC-3	O09000	17979	2|2 H3	151.57	mouse	4668109	Y1331-p		HPQPTPMyQPSDMKG	18765637	1	1	0		
non-melanoma skin cancer	increased	Jun	Jun	P05627	16476	4 C5|4 43.34 cM	35.94	mouse	447686	S63-p	Jun	KNSDLLTsPDVGLLK	10851065	127	43	4	91952; 5464; 2361; 9261	
non-melanoma skin cancer	increased	Jun	Jun	P05627	16476	4 C5|4 43.34 cM	35.94	mouse	447943	S73-p	Jun	VGLLKLAsPELERLI	10851065	80	65	16	8752; 77955; 3270; 9164; 12714	
chronic lymphocytic leukemia	increased	PRKCD	PKCD	Q05655	5580	3p21.1	77.51	human	447511	T507-p	Pkinase	FGESRAStFCGTPDY	12393602	48	21	108	9379; 93292; 2060; 9374; 38938	
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	449929	T311-p		NSLALSLtADQMVSA	19104930	7	0	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	11943712	170	45	90	9632	S396 and S304 are hyperphosphorylated in the CSF of AD patients as compared with normal controls. -useful diagnostic marker of AD
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448101	S118-p	Oest_recep	LHPPPQLsPFLQPHG	19104930	89	2	0	2511	
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448102	S167-p	Oest_recep	GGRERLAsTNDKGSM	19104930	46	5	0	64508; 42101	
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448100	S106-p	Oest_recep	PLNSVSPsPLMLLHP	19104930	25	1	0		
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	6048400	S559-p	ESR1_C	PTSRGGAsVEETDQS	19104930	4	1	0		
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448099	S104-p	Oest_recep	FPPLNSVsPSPLMLL	19104930	24	1	0		
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	451560	S294-p		RAANLWPsPLMIKRS	19104930	11	4	0		
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084601	S410-p		SSMDSKSsGWGM___	18656473	49	4	0		
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084616	S409-p		GSSMDSKsSGWGM__	18656473	48	4	0		
breast cancer	increased	YBX1	YB-1	P67809	4904	1p34.2	35.92	human	455636	S102-p	CSD	NPRKYLRsVGDGETV	19036157	20	33	2	2900	
lung cancer	mutation of site	Ptk2	FAK iso2	P34152-2	14083	15 D3|15 33.94 cM	122.77	mouse	447966	Y956-p	Focal_AT	DRSNDKVyENVTGLV	18606490	96	17	427	3284	regulates metastasis and invasion
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084616	S409-p		GSSMDSKsSGWGM__	19235466	48	4	0		phosphorylated and degraded TDP-43 has been found in brains of FTLD and ALS patients
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084601	S410-p		SSMDSKSsGWGM___	19235466	49	4	0		phosphorylated and degraded TDP-43 has been found in brains of FTLD and ALS patients
Parkinson's disease; ALS	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449082	S404-p		PVVSGDTsPRHLSNV	8858002	132	53	69	20194; 35834; 98523; 49562; 91600	Guam ALS/parkinsonism-dementia complex
lymphoma	increased	PTPN11	SHP-2	Q06124	5781	12q24.13	68.01	human	448493	Y580-p		REDSARVyENVGLMQ	17483340	19	60	1189	3703; 5431; 13328	Anaplastic large cell lymphomas (ALCL) which contain NPM-ALK translocations
lymphoma	increased	PTPN11	SHP-2	Q06124	5781	12q24.13	68.01	human	448492	Y542-p		SKRKGHEyTNIKYSL	17483340	36	25	442	15543; 3751	Anaplastic large cell lymphomas (ALCL) which contain NPM-ALK translocations
myopathy	mutation of site	DES	desmin	P17661	1674	2q35	53.54	human	466346	S13-p	Filament_head	SSSQRVSsYRRTFGG	18061454	2	0	0		
diabetes mellitus	increased	Aqp2	AQP2	P34080	25386	7q36	28.93	rat	449854	S256-p		REVRRRQsVELHSPQ	18029369	77	9	0		
breast cancer	increased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	449111	S9-p		SGRPRTTsFAESCKP	17495324	513	44	227	5558; 14630; 14026; 14332; 79774; 9322; 9327; 9331; 9323; 9336; 9325; 8466; 8566; 14310	phosphorylation correlates with Mcl-1 and poor prognosis in breast cancer, in multiple cell lines and primary human cancer samples. 
ARVC	mutation of site	DSP	Desmoplakin	P15924	1832	6p24.3	331.77	human	3067800	S299-p		EELLYDWsDKNTNIA	12373648	1	0	0		
hepatocellular carcinoma	increased	RXRA	RXRA	P19793	6256	9q34.2	50.81	human	450891	S260-p	Hormone_recep	NMGLNPSsPNDPVTN	11826406	11	1	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	15324364	130	44	14	20473; 71429	AD diagnostic tool
myotonic dystrophy type1	increased	CELF1	CELF1	Q92879	10658	11p11.2	52.06	human	3347300	S28-p	RRM_1	GQVPRTWsEKDLREL	18570922	3	9	1		indirect evidence - Akt site, and Akt activity increased in DM1
ataxia-telangiectasia	decreased	BRCA1	BRCA1	P38398	672	17q21.31	207.72	human	455495	S1387-p		EDCSGLSsQSDILTT	10866324	9	0	0		
ataxia-telangiectasia	decreased	BRCA1	BRCA1	P38398	672	17q21.31	207.72	human	448036	S1423-p		AVLEQHGsQPSNSYP	10866324	14	1	1		
ataxia-telangiectasia	decreased	BRCA1	BRCA1	P38398	672	17q21.31	207.72	human	450008	S1457-p		SEKAVLTsQKSSEYP	10866324	7	4	1		
ovarian cancer	increased	MTOR	mTOR	P42345	2475	1p36.22	288.89	human	447578	S2448-p		RSRTRTDsYSAGQSV	15208673	187	17	106	2971; 5536; 54932; 2976	
liver cancer	decreased	Cebpa	C/EBP-alpha	P53566	12606	7 B2|7 21.02 cM	37.43	mouse	1868113505	S193-p		PPPHPHAsPAHLAAP	15684384	14	0	0		
liver cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	15684384	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
schizophrenia	mutation of site	SYN3	SYN3	O14994	8224	22q12.3	63.30	human	455901	S470-p		PQGQQPLsPQSGSPQ	15900227	2	7	9		
GIST	increased	KIT	Kit	P10721	3815	4q12	109.86	human	448017	Y721-p	PK_Tyr_Ser-Thr	CSDSTNEyMDMKPGV	15007386	17	5	52	3391	
GIST	increased	KIT	Kit	P10721	3815	4q12	109.86	human	448016	Y703-p	PK_Tyr_Ser-Thr	DHAEAALyKNLLHSK	15007386	5	4	22	3073	
nephrosis	decreased	Nphs1	NPHS1	Q9R044	64563	1q21	136.28	rat	469566	Y1228-p		CEDPRGIyDQVAADM	18256598	10	0	0		
nephrosis	decreased	Nphs1	NPHS1	Q9R044	64563	1q21	136.28	rat	469565	Y1204-p		PGAWGPLyDEVRMDP	18256598	15	1	0		
PSP	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449080	S235-p		VVRTPPKsPSSAKSR	18315566	43	36	25	20473	
PSP	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449130	S400-p		VYKSPVVsGDTSPRH	18315566	14	42	70	20194; 35834; 98523; 49562; 91600	
PSP	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447928	S202-p		SGYSSPGsPGTPGSR	18315566	149	55	116	30505; 39357	
PSP	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449082	S404-p		PVVSGDTsPRHLSNV	18315566	132	53	69	20194; 35834; 98523; 49562; 91600	
PSP	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	18315566	130	44	14	20473; 71429	
PSP	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	18315566	170	45	90	9632	
PSP	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449131	T403-p		SPVVSGDtSPRHLSN	18315566	6	30	26	20194; 35834; 98523; 49562; 91600	
PSP	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449078	T217-p		SRTPSLPtPPTREPK	18315566	33	31	6	51625	
PSP	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	18315566	85	33	23	62672; 66224; 12885	
PSP	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447926	S46-p		TDAGLKEsPLQTPTE	18315566	3	8	0	20296	
breast adenocarcinoma	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	455676	S10-p	Histone	TKQTARKsTGGKAPR	16461563	228	15	1	3465; 9701; 8552; 66065; 9706; 3377; 5764; 64522; 3475; 29237; 9711; 8481; 9606; 52725; 43185; 3642; 3458; 53348	
kidney cancer	increased	MET	Met	P08581	4233	7q31.2	155.54	human	448472	Y1349-p		STFIGEHyVHVNATY	16914575	29	6	125	3121; 3133	
chronic lymphocytic leukemia	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	16940331	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
chronic lymphocytic leukemia	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	16940331	732	14	18	5106; 48646; 13842; 4056; 2965; 43506; 77440; 9275; 13038; 86758; 80722; 5056	
bipolar disprder	increased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	449111	S9-p		SGRPRTTsFAESCKP	16806104	513	44	227	5558; 14630; 14026; 14332; 79774; 9322; 9327; 9331; 9323; 9336; 9325; 8466; 8566; 14310	
breast cancer	increased	MKNK1	Mnk1	Q9BUB5	8569	1p33	51.34	human	447622	T255-p	Pkinase	ITTPELTtPCGSAEY	17130135	12	1	0	2111; 43507	
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448102	S167-p	Oest_recep	GGRERLAsTNDKGSM	17157789	46	5	0	64508; 42101	
melanoma skin cancer	decreased	STAT1	STAT1	P42224	6772	2q32.2	87.33	human	447754	Y701-p		DGPKGTGyIKTELIS	17785551	179	7	64	5375; 8062; 8009; 76285; 25809; 9167; 8183; 9174; 39205; 88845; 7649; 88211; 90145	
chronic myelogenous leukemia	increased	NBN	NBS1	O60934	4683	8q21.3	84.96	human	448605	S343-p		TTPGPSLsQGVSVDE	17431132	46	20	69	3001	
AIDS-related lymphoma	decreased	MYC	Myc	P01106	4609	8q24.21	48.80	human	448496	T58-p	Myc_N	KKFELLPtPPLSPSR	17310999	71	39	30	46650	primary effusion lymphoma
breast cancer	increased	MKNK1	Mnk1	Q9BUB5	8569	1p33	51.34	human	447621	T250-p	Pkinase	NSCTPITtPELTTPC	17130135	13	1	1	2111; 43507	
colorectal carcinoma	decreased	SRC	Src	P12931	6714	20q11.23	59.83	human	448235	Y530-p		FTSTEPQyQPGENL_	17974954	144	24	968	2105	
prostate cancer	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	455680	T11-p	Histone	KQTARKStGGKAPRK	18066052	17	5	0	9764; 9767	
gastric carcinoma	mutation of site	TLR4	TLR4	O00206	7099	9q33.1	95.68	human	3597308	T175-p	LRR_8	PEYFSNLtNLEHLDL	16786156	1	0	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	17314187	85	33	23	62672; 66224; 12885	
retinitis pigmentosa	mutation of site	NRL	NRL	P54845	4901	14q11.2-q12	25.94	human	478419	S50-p		PYSSVPPsPTFSEPG	17335001	2	0	1		
breast cancer	mutation of site	BRCA2	BRCA2	P51587	675	13q13.1	384.23	human	455462	S3291-p		SPICTFVsPAAQKAF	15800615	8	1	0		
melanoma skin cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	12499277	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
ovarian cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	15208673	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
ovarian cancer	increased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	449111	S9-p		SGRPRTTsFAESCKP	15208673	513	44	227	5558; 14630; 14026; 14332; 79774; 9322; 9327; 9331; 9323; 9336; 9325; 8466; 8566; 14310	
bladder cancer	increased	CHEK2	Chk2	O96017	11200	22q12.1	60.91	human	447491	T68-p		SSLETVStQELYSIP	15361851	194	5	0	2661; 12812; 59068; 28130; 2197; 82263	
AIDS-related lymphoma; B cell lymphoma; Burkitt's lymphoma	mutation of site	MYC	Myc	P01106	4609	8q24.21	48.80	human	448496	T58-p	Myc_N	KKFELLPtPPLSPSR	10706881	71	39	30	46650	
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448101	S118-p	Oest_recep	LHPPPQLsPFLQPHG	16168121	89	2	0	2511	
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448102	S167-p	Oest_recep	GGRERLAsTNDKGSM	16168121	46	5	0	64508; 42101	
schizophrenia	decreased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	449111	S9-p		SGRPRTTsFAESCKP	14745448	513	44	227	5558; 14630; 14026; 14332; 79774; 9322; 9327; 9331; 9323; 9336; 9325; 8466; 8566; 14310	
T cell leukemia	mutation of site	TP53	p53	P04637	7157	17p13.1	43.65	human	447532	S37-p	TAD2	NVLSPLPsQAMDDLM	11042698	67	2	0	9289	
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084601	S410-p		SSMDSKSsGWGM___	19125255	49	4	0		
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084616	S409-p		GSSMDSKsSGWGM__	19125255	48	4	0		
hepatocellular carcinoma		SMAD2	SMAD2	Q15796	4087	18q21.1	52.31	human	448796	S255-p		ELSPTTLsPVNHSLD	19115199	10	0	0	3104	
hepatocellular carcinoma		ITGB1	ITGB1	P05556	3688	10p11.22	88.42	human	447709	T789-p	Integrin_b_cyt	IYKSAVTtVVNPKYE	19115199	14	3	1		
hepatocellular carcinoma		SMAD2	SMAD2	Q15796	4087	18q21.1	52.31	human	448794	S245-p		NQSMDTGsPAELSPT	19115199	12	0	0	3104	
hepatocellular carcinoma		SMAD2	SMAD2	Q15796	4087	18q21.1	52.31	human	448795	S250-p		TGSPAELsPTTLSPV	19115199	11	1	0	3104	
hepatocellular carcinoma		ITGB1	ITGB1	P05556	3688	10p11.22	88.42	human	448600	T788-p	Integrin_b_cyt	PIYKSAVtTVVNPKY	19115199	15	2	1		
prostate cancer	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448191	S727-p		NTIDLPMsPRTLDSL	18829527	199	55	67	49081; 34911; 50804; 58978; 71958; 87544; 94994; 9136; 9134	
type 2 diabetes	increased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447542	T202-p	Pkinase	HDHTGFLtEYVATRW	12765939	1283	106	2017	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 54240; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
type 2 diabetes	increased	IRS1	IRS1	P35568	3667	2q36.3	131.59	human	447506	S636-p		SGDYMPMsPKSVSAP	12765939	40	25	1	2388	
type 2 diabetes	increased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447543	Y204-p	Pkinase	HTGFLTEyVATRWYR	12765939	1304	138	3549	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 14474; 54240; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
type 2 diabetes	increased	MAPK1	ERK2	P28482	5594	22q11.22	41.39	human	447593	T185-p	Pkinase	HDHTGFLtEYVATRW	12765939	1116	120	2416	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 54240; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
type 2 diabetes	increased	MAPK1	ERK2	P28482	5594	22q11.22	41.39	human	447594	Y187-p	Pkinase	HTGFLTEyVATRWYR	12765939	1139	157	4003	13214; 8544; 14227; 5726; 98168; 3510; 9106; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 54240; 4376; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
Lafora disease		PPP1R3C	PPP1R3C	Q9UQK1	5507	10q23.32	36.45	human	6423500	S33-p		MRLCLAHsPPVKSFL	19171932	1	7	1		
type 2 diabetes	increased	Gsk3b	GSK3B	Q9WV60	56637	16|16 B3	46.71	mouse	449111	S9-p		SGRPRTTsFAESCKP	18701453	513	44	227	5558; 14630; 14026; 14332; 79774; 9322; 9327; 9331; 9323; 9336; 9325; 8466; 8566; 14310	
type 2 diabetes	decreased	Eif2b5	eIF2B-epsilon	Q8CHW4	224045	16|16 A3	80.09	mouse	449906	S540-p		ELDSRAGsPQLDDIR	18701453	5	77	9		
IPF	increased	CTNNB1	CTNNB1	P35222	1499	3p22.1	85.50	human	447585	Y654-p		RNEGVATyAAAVLFR	19104148	29	2	20		accumulation of pY654??-catenin in myofibroblasts
IPF	increased	Ctnnb1	CTNNB1	Q02248	12387	9 F4|9 72.19 cM	85.47	mouse	447585	Y654-p		RNEGVATyAAAVLFR	19104148	29	2	20		accumulation of pY654??-catenin in myofibroblasts
Fetal growth restriction	increased; molecular association	IGFBP1	IGFBP1	P08833	3484	7p12.3	27.90	human	451659	S144-p		NFHLMAPsEEDHSIL	19193607	14	10	0		
PFCP	deletion of site	Epor	EPOR	P14753	13857	9 A3|9 7.93 cM	55.19	mouse	455532	Y455-p		PPHLKYLyLVVSDSG	19336760	8	0	0		
PFCP	deletion of site	Epor	EPOR	P14753	13857	9 A3|9 7.93 cM	55.19	mouse	455531	Y453-p		PTPPHLKyLYLVVSD	19336760	6	0	0		
PFCP	deletion of site	Epor	EPOR	P14753	13857	9 A3|9 7.93 cM	55.19	mouse	449885	Y503-p		SEPLHPGyVACS___	19336760	9	0	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447928	S202-p		SGYSSPGsPGTPGSR	8506352	149	55	116	30505; 39357	
Alzheimer's disease	mutation of site	APP	APP	P05067	351	21q21.3	86.94	human	3173810	K670-sm		TEEISEVkMDAEFRH	1302033	2	0	0		
Parkinson's disease; ALS	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	8858002	85	33	23	62672; 66224; 12885	Guam ALS/parkinsonism-dementia complex
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447934	T212-p		TPGSRSRtPSLPTPP	19451179	45	16	5		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	19451179	170	45	90	9632	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447927	S199-p		GDRSGYSsPGSPGTP	19451179	87	30	33	29957	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449078	T217-p		SRTPSLPtPPTREPK	19451179	33	31	6	51625	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449082	S404-p		PVVSGDTsPRHLSNV	19451179	132	53	69	20194; 35834; 98523; 49562; 91600	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447930	S262-p	Tubulin-binding	NVKSKIGsTENLKHQ	19451179	108	24	2		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447933	T205-p		SSPGSPGtPGSRSRT	19451179	113	24	26	30505; 43964; 49561; 20060; 53001; 20739	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447928	S202-p		SGYSSPGsPGTPGSR	19451179	149	55	116	30505; 39357	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449083	S422-p		GSIDMVDsPQLATLA	19451179	38	9	0		
Parkinson's disease; ALS	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	8858002	170	45	90	9632	Guam ALS/parkinsonism-dementia complex
Parkinson's disease; ALS	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449083	S422-p		GSIDMVDsPQLATLA	8858002	38	9	0		Guam ALS/parkinsonism-dementia complex
Parkinson's disease; ALS	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447930	S262-p	Tubulin-binding	NVKSKIGsTENLKHQ	8858002	108	24	2		Guam ALS/parkinsonism-dementia complex
Parkinson's disease; ALS	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	8858002	130	44	14	20473; 71429	Guam ALS/parkinsonism-dementia complex
Parkinson's disease	decreased; increased	HTRA2	HTRA2	O43464	27429	2p13.1	48.84	human	487466	S142-p	Peptidase_M50	VPSPPPAsPRSQYNF	17906618	4	0	1		hyperphosphorylation in Parkinsons disease brains; hypophosphorylation in Parkinson's disease brains carrying C575R and Y431H mutations 
prostate cancer	increased	CREB1	CREB	P16220	1385	2q33.3	35.14	human	450092	S115-p	pKID	QKRREILsRRPSYRK	12900420	10	0	2		high in the low grade (well differentiated) and decreased in high grade (poorly differentiated) prostate cancer 
prostate cancer	increased	CREB1	CREB	P16220	1385	2q33.3	35.14	human	448228	S119-p	pKID	EILSRRPsYRKILND	12900420	289	4	61	14001; 54960; 9187; 80120; 95995; 14228; 44864; 39561; 9196; 9198; 4095	high in the low grade (well differentiated) and decreased in high grade (poorly differentiated) prostate cancer 
ALS	increased	Met	Met	P16056	17295	6 A2|6 7.83 cM	153.55	mouse	448471	Y1233-p	PK_Tyr_Ser-Thr	DMYDKEYySVHNKTG	19595710	48	16	442	4091; 98954; 3077; 3126; 3129; 4033; 12468	
ALS	increased	Met	Met	P16056	17295	6 A2|6 7.83 cM	153.55	mouse	448470	Y1232-p	PK_Tyr_Ser-Thr	RDMYDKEyYSVHNKT	19595710	51	36	740	4091; 98954; 3077; 3126; 3129; 4033; 12468	
ALS	increased	Met	Met	P16056	17295	6 A2|6 7.83 cM	153.55	mouse	448866	Y1228-p	PK_Tyr_Ser-Thr	FGLARDMyDKEYYSV	19595710	6	11	108		
ALS	decreased	Met	Met	P16056	17295	6 A2|6 7.83 cM	153.55	mouse	450188	S983-p		PHLDRLVsARSVSPT	19595710	7	1	0		
type 2 diabetes; Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449083	S422-p		GSIDMVDsPQLATLA	19659459	38	9	0		
type 2 diabetes; Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447928	S202-p		SGYSSPGsPGTPGSR	19659459	149	55	116	30505; 39357	
type 2 diabetes; Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449082	S404-p		PVVSGDTsPRHLSNV	19659459	132	53	69	20194; 35834; 98523; 49562; 91600	
type 2 diabetes; Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447930	S262-p	Tubulin-binding	NVKSKIGsTENLKHQ	19659459	108	24	2		
type 2 diabetes; Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449078	T217-p		SRTPSLPtPPTREPK	19659459	33	31	6	51625	
type 2 diabetes; Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447927	S199-p		GDRSGYSsPGSPGTP	19659459	87	30	33	29957	
type 2 diabetes; Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	19659459	170	45	90	9632	
type 2 diabetes; Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	19659459	85	33	23	62672; 66224; 12885	
retinitis pigmentosa	mutation of site	PRPF3	PRPF3	O43395	9129	1q21.2	77.53	human	999610	T494-p	PRP3	TEAVQDPtKVEAHVR	17932117	1	0	0		retinitis pigmentosa type 18 (RP18);  T494M mutation
Parkinson's disease	mutation of site	NR4A2	NR4A2	P43354	4929	2q24.1	66.59	human	487428	S125-p		GSVYYKPsSPPTPTT	17890097	1	0	0		patient with S125C mutation
non-small cell lung cancer	increased	EGFR	EGFR	P00533	1956	7p11.2	134.28	human	448055	Y1016-p		DVVDADEyLIPQQGF	19002495	45	7	12	2235	Mutations in EGFR in NSCLC patients affect Y1016 and Y1197 phosphorylation. 
non-small cell lung cancer	increased	EGFR	EGFR	P00533	1956	7p11.2	134.28	human	448060	Y1197-p		STAENAEyLRVAPQS	19002495	99	58	1028	47737; 4407; 2244	Mutations in EGFR in NSCLC patients affect Y1016 and Y1197 phosphorylation. 
colorectal cancer	mutation of site	Ctnnb1	CTNNB1	Q9WU82	84353	8q32	85.45	rat	447582	S37-p		YLDSGIHsGATTTAP	11181454	97	3	12	2009; 4270; 9561; 13537; 60180; 41334	
colorectal cancer	mutation of site	Ctnnb1	CTNNB1	Q9WU82	84353	8q32	85.45	rat	447488	S45-p		GATTTAPsLSGKGNP	11181454	49	7	0	70034; 9565; 19807; 77605; 9564; 96727	
colorectal cancer	mutation of site	Ctnnb1	CTNNB1	Q9WU82	84353	8q32	85.45	rat	447583	T41-p		GIHSGATtTAPSLSG	11181454	88	3	0	9565; 4270; 9561; 13537; 60180; 41334	
depression	mutation of site	Grin2a	NMDAR2A	P35436	14811	16 A1|16 5.28 cM	165.42	mouse	458211	Y1325-p	NMDAR2_C	RLLEGNLyGSLFSVP	19834457	7	2	84		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	454127	S416-p		SNVSSTGsIDMVDSP	9832145	8	13	0	15013; 61160	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	450220	S185-p		APKTPPSsGEPPKSG	9832145	2	4	1		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449130	S400-p		VYKSPVVsGDTSPRH	9832145	14	42	70	20194; 35834; 98523; 49562; 91600	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	487451	S238-p		TPPKSPSsAKSRLQT	9832145	2	5	1		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	456456	T414-p		HLSNVSStGSIDMVD	9832145	1	7	2		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	452074	S237-p		RTPPKSPsSAKSRLQ	9832145	2	10	1		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449104	S356-p	Tubulin-binding	RVQSKIGsLDNITHV	9832145	33	24	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447934	T212-p		TPGSRSRtPSLPTPP	9832145	45	16	5		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447930	S262-p	Tubulin-binding	NVKSKIGsTENLKHQ	9832145	108	24	2		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449131	T403-p		SPVVSGDtSPRHLSN	9832145	6	30	26	20194; 35834; 98523; 49562; 91600	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449078	T217-p		SRTPSLPtPPTREPK	9832145	33	31	6	51625	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449082	S404-p		PVVSGDTsPRHLSNV	9832145	132	53	69	20194; 35834; 98523; 49562; 91600	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447928	S202-p		SGYSSPGsPGTPGSR	9832145	149	55	116	30505; 39357	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	464351	Y197-p		KSGDRSGySSPGSPG	9832145	5	7	34		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	9832145	170	45	90	9632	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	9832145	130	44	14	20473; 71429	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	487450	S210-p		PGTPGSRsRTPSLPT	9832145	2	6	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449077	T175-p		ATRIPAKtPPAPKTP	9832145	8	8	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449132	S409-p		DTSPRHLsNVSSTGS	9832145	13	10	5		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449080	S235-p		VVRTPPKsPSSAKSR	9832145	43	36	25	20473	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449551	S198-p		SGDRSGYsSPGSPGT	9832145	21	15	10		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	456455	S412-p		PRHLSNVsSTGSIDM	9832145	1	7	3		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447929	S214-p		GSRSRTPsLPTPPTR	9832145	60	23	42	77348	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	452062	S184-p		PAPKTPPsSGEPPKS	9832145	3	4	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	9832145	85	33	23	62672; 66224; 12885	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449084	S413-p		RHLSNVSsTGSIDMV	9832145	5	9	1		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447927	S199-p		GDRSGYSsPGSPGTP	9832145	87	30	33	29957	
depression	mutation of site	Ppp1r1b	DARPP-32	Q60829	19049	11|11 D	21.78	mouse	448047	T34-p	DARPP-32	MIRRRRPtPAMLFRV	19834457	64	6	44	12438	
lung cancer	increased	CDCA8	Borealin	Q53HL2	55143	1p34.3	31.32	human	482837	T278-p		QICSSIRtHK_____	17483322	1	0	0		
lung cancer	increased	CDCA8	Borealin	Q53HL2	55143	1p34.3	31.32	human	482836	S275-p	Borealin	RLAQICSsIRTHK__	17483322	1	1	0		
ovarian cancer	increased	STK4	MST1	Q13043	6789	20q13.12	55.63	human	11496001	T120-p	Pkinase	IIRLRNKtLTEDEIA	19940129	3	0	0		
ovarian cancer	decreased	STK4	MST1	Q13043	6789	20q13.12	55.63	human	447925	T183-p	Pkinase	DTMAKRNtVIGTPFW	19940129	22	2	5	3681; 49332	
Aarskog-Scott syndrome	mutation of site	Fgd1	FGD1	P52734	14163	X F3|X 68.46 cM	106.36	mouse	3193805	S205-p		LVPRAEAsTSSAAVS	20045932	2	2	0		
colorectal cancer	increased	PXN	PXN iso2	P49023-2	5829	12q24.23	60.97	human	448909	Y88-p	Paxillin	PQSSSPVyGSSAKTS	20133777	5	48	1343		dephosphorylation of PXN Y88 is tumor suppressive
psoriasis	increased	EIF4EBP1	4E-BP1	Q13541	1978	8p11.23	12.58	human	447496	T46-p	eIF_4EBP	GGTLFSTtPGGTRII	19663871	140	36	91	7547; 3929; 4923; 2855; 2846; 45613; 39788; 5123; 9459	in lesional, but not in nonlesional, plaque-type psoriatic skin
psoriasis	increased	EIF4EBP1	4E-BP1	Q13541	1978	8p11.23	12.58	human	447497	T37-p	eIF_4EBP	PPGDYSTtPGGTLFS	19663871	140	44	88	7547; 3929; 2855; 4923; 2846; 45613; 39788; 5123; 9459	in lesional, but not in nonlesional, plaque-type psoriatic skin
myeloproliferative disorder	increased	Mpl	MPL	Q08351	17480	4 D2.1|4 54.61 cM	69.79	mouse	450267	Y616-p		THIANHSyLPLSYWQ	19996410	9	1	1	12712	constitutive phosphorylation of this site in Mpl W515K/L mutant
Alzheimer's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	19889641	104	7	0	87281; 23706	Lewybody disease
pancreatic cancer		RALA	RALA	P11233	5898	7p14.1	23.57	human	483989	S194-p		NGKKKRKsLAKRIRE	19901077	5	1	1		
Huntington's disease	decreased	HTT	Huntingtin	P42858	3064	4p16.3	347.60	human	12056100	S16-p		KAFESLKsFQQQQQQ	20064390	17	2	0		
Huntington's disease	decreased	HTT	Huntingtin	P42858	3064	4p16.3	347.60	human	10206805	S13-p		KLMKAFEsLKSFQQQ	20064390	18	3	0		
osteopenia		Naca	NACA	P70670	17938	10|10 D3	220.50	mouse	454238	S2015-p		PELEEQDsTQTATQQ	19884350	2	1	0		S43A homozygote mice shows a decreased bone volume
colorectal cancer	increased	Pxn	PXN	Q8VI36	19303	5 F|5 56.1 cM	64.48	mouse	448909	Y88-p	Paxillin	PPSPLPVySSSAKNS	20133777	5	48	1343		dephosphorylation of PXN Y88 is tumor suppressive
colorectal cancer	decreased	RORA	RORA	P35398	6095	15q22.2	58.97	human	12613703	S35-p		ETPLNQEsARKSEPP	20122401	1	1	0		
hepatitis B	increased	KRT18	K18	P05783	3875	12q13.13	48.06	human	447734	S53-p		ISVSRSTsFRGGMGS	20334631	17	12	14		
hepatitis B	increased	KRT18	K18	P05783	3875	12q13.13	48.06	human	447733	S34-p		RPVSSAAsVYAGAGG	20334631	14	27	13		
sickle-cell anaemia	increased	EPB41	EPB41 iso4	P11171-4	2035	1p35.3	66.40	human	463285	Y13-p	FERM_N	SLLDDTVyECVVEKH	20206558	1	5	46		
Parkinson's disease	increased	PRDX2	PRDX2	P32119	7001	19p13.13	21.89	human	487517	T89-p	AhpC-TSA	THLAWINtPRKEGGL	17610816	1	1	0		
ovarian cancer	increased	PAK1	PAK1	Q13153	5058	11q13.5-q14.1	60.65	human	448176	T212-p		VIEPLPVtPTRDVAT	19876919	16	27	19		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447934	T212-p		TPGSRSRtPSLPTPP	19821112	45	16	5		
breast cancer	increased	CDKN1B	p27Kip1	P46527	1027	12p13.1	22.07	human	475060	Y74-p	CDI	HKPLEGKyEWQEVEK	17254967	10	0	0		
breast cancer	increased	HSPB1	HSP27	P04792	3315	7q11.23	22.78	human	448402	S78-p		PAYSRALsRQLSSGV	17697330	36	25	30	2405	Only in HER-2/neu positive tumors
type 2 diabetes	increased	Rps6kb1	p70S6K	Q8BSK8	72508	11|11 C	59.15	mouse	448607	T412-p	Pkinase_C	NQVFLGFtYVAPSVL	17709744	438	8	1	9209; 9205; 9234; 9206; 97596	
type 2 diabetes	increased	Rps6kb1	p70S6K	P67999	83840	10q26	59.13	rat	448607	T412-p	Pkinase_C	NQVFLGFtYVAPSVL	17709744	438	8	1	9209; 9205; 9234; 9206; 97596	
type 2 diabetes	increased	IRS1	IRS1	P35568	3667	2q36.3	131.59	human	453434	S1101-p		GCRRRHSsETFSSTP	17709744	11	39	122	2385	
type 2 diabetes	increased	Irs1	IRS1	P35569	16367	1 C5|1 42.0 cM	130.72	mouse	453434	S1097-p		GCRRRHSsETFSAPT	17709744	11	39	122	2385	
type 2 diabetes	increased	Irs1	IRS1	P35570	25467	9q34	131.18	rat	453434	S1100-p		GCRRRHSsETFSAPT	17709744	11	39	122	2385	
type 2 diabetes	increased	RPS6KB1	p70S6K	P23443	6198	17q23.1	59.14	human	448607	T412-p	Pkinase_C	NQVFLGFtYVAPSVL	17709744	438	8	1	9209; 9205; 9234; 9206; 97596	
breast cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	17545609	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
infertility	mutation of site	Espl1	separase	P60330	105988	15|15 F3	233.03	mouse	447673	S1121-p		IQSSVNSsPVLKTKP	18232736	11	10	0		Ser1121Ala mutant mice are infertile
ovarian cancer	increased	AKT2	Akt2	P31751	208	19q13.2	55.77	human	448520	S474-p	Pkinase_C	RTHFPQFsYSASIRE	10822383	30	9	55	5012; 4051; 4070; 68035; 5315; 8599; 4075; 31957; 11962; 2337; 9271; 3787; 5102; 88106; 15116; 4058; 26580; 9563; 2336; 4060; 4071; 23430; 12694	
Alzheimer's disease	decreased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449083	S422-p		GSIDMVDsPQLATLA	16606369	38	9	0		The tangles associated with Alzheimer's disease are correlated with a loss of phosphorylation at S422 in those cells.  However, phosphorylation of S422 appears to precede the cleavage event and may serve to protect Tau from cleavage.
ataxia-telangiectasia	decreased	ABL1	Abl	P00519	25	9q34.12	122.87	human	450296	S446-p	PK_Tyr_Ser-Thr	PYPGIDLsQVYELLE	9168116	2	0	0		
Alzheimer's disease	increased	PPP2CA	PPP2CA	P67775	5515	5q31.1	35.59	human	448571	Y307-p		VTRRTPDyFL_____	18208556	70	0	0		
Alzheimer's disease	increased	Ppp2ca	PPP2CA	P63330	19052	11|11 B1.3	35.61	mouse	448571	Y307-p		VTRRTPDyFL_____	18208556	70	0	0		
Status epilepticus	decreased	Gabrb3	GABRB3	P63080	14402	7 B5|7 33.53 cM	54.17	mouse	450246	S433-p	Neur_chan_memb	THLRRRSsQLKIKIP	18184780	13	0	3		
Status epilepticus	decreased	Gabrb3	GABRB3	P63080	14402	7 B5|7 33.53 cM	54.17	mouse	450245	S432-p	Neur_chan_memb	KTHLRRRsSQLKIKI	18184780	12	0	0		
Alzheimer's disease	increased	DPYSL2	CRMP-2	Q16555	1808	8p21.2	62.29	human	448081	S518-p		KTVTPASsAKTSPAK	10757975	9	33	17		
Alzheimer's disease	increased	DPYSL2	CRMP-2	Q16555	1808	8p21.2	62.29	human	448082	S522-p		PASSAKTsPAKQQAP	10757975	29	49	84		
Alzheimer's disease	increased	DPYSL2	CRMP-2	Q16555	1808	8p21.2	62.29	human	448083	T509-p		PVCEVSVtPKTVTPA	10757975	14	63	34		
Wilm's tumor	increased	STAT1	STAT1	P42224	6772	2q32.2	87.33	human	447753	S727-p	STAT1_TAZ2bind	TDNLLPMsPEEFDEV	16799645	107	32	90	8826; 9177; 62390	
Parkinson's disease	increased	WWOX	WWOX	Q9NZC7	51741	16q23.1-q23.2	46.68	human	449043	Y33-p	WW	TTKDGWVyYANHTEE	18371080	21	1	0		
major depressive disorder	decreased	Mapk1	ERK2	P63086	116590	11q23	41.28	rat	447594	Y185-p	Pkinase	HTGFLTEyVATRWYR	16959794	1139	157	4003	13214; 8544; 14227; 5726; 98168; 3510; 9106; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 54240; 4376; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	using DISC1 ser704cys allele
major depressive disorder	decreased	Mapk1	ERK2	P63086	116590	11q23	41.28	rat	447593	T183-p	Pkinase	HDHTGFLtEYVATRW	16959794	1116	120	2416	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 54240; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	using DISC1 ser704cys allele
major depressive disorder	decreased	Mapk3	ERK1	P21708	50689	1q36	43.08	rat	447543	Y205-p	Pkinase	HTGFLTEyVATRWYR	16959794	1304	138	3549	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 14474; 54240; 48735; 45899; 9101; 4374; 4370; 14196; 15892	using DISC1 ser704cys allele
major depressive disorder	decreased	Akt1	Akt1	P47196	24185	6q32	55.74	rat	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	16959794	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	using DISC1 ser704cys allele
major depressive disorder	decreased	Mapk3	ERK1	P21708	50689	1q36	43.08	rat	447542	T203-p	Pkinase	HDHTGFLtEYVATRW	16959794	1283	106	2017	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 54240; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	using DISC1 ser704cys allele
neuroblastoma	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	17234785	732	14	18	5106; 48646; 13842; 4056; 2965; 43506; 77440; 9275; 13038; 86758; 80722; 5056	
neuroblastoma	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	17234785	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
medullary thyroid carcinoma	increased	MAPK1	ERK2	P28482	5594	22q11.22	41.39	human	447594	Y187-p	Pkinase	HTGFLTEyVATRWYR	17209045	1139	157	4003	13214; 8544; 14227; 5726; 98168; 3510; 9106; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 54240; 4376; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	in tumors with activated RET (S891A allele)
medullary thyroid carcinoma	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448191	S727-p		NTIDLPMsPRTLDSL	17209045	199	55	67	49081; 34911; 50804; 58978; 71958; 87544; 94994; 9136; 9134	in tumors with activated RET (S891A allele)
medullary thyroid carcinoma	increased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447543	Y204-p	Pkinase	HTGFLTEyVATRWYR	17209045	1304	138	3549	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 14474; 54240; 48735; 45899; 9101; 4374; 4370; 14196; 15892	in tumors with activated RET (S891A allele)
medullary thyroid carcinoma	increased	MAPK1	ERK2	P28482	5594	22q11.22	41.39	human	447593	T185-p	Pkinase	HDHTGFLtEYVATRW	17209045	1116	120	2416	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 54240; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	in tumors with activated RET (S891A allele)
medullary thyroid carcinoma	increased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447542	T202-p	Pkinase	HDHTGFLtEYVATRW	17209045	1283	106	2017	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 54240; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	in tumors with activated RET (S891A allele)
glioblastoma multiforme	increased	AGAP2	CENTG1 iso2	Q99490-2	116986	12q14.1	90.54	human	478561	S279-p		YSSSLPSsPNVGHRE	18487454	1	2	20		
prostate cancer	increased	WWOX	WWOX	Q9NZC7	51741	16q23.1-q23.2	46.68	human	449043	Y33-p	WW	TTKDGWVyYANHTEE	15580310	21	1	0		
obesity, hyperphagic	mutation of site	NTRK2	TrkB	Q16620	4915	9q21.33	92.00	human	448811	Y706-p	PK_Tyr_Ser-Thr	RDVYSTDyYRVGGHT	15494731	14	0	49	4621	hyperphagic, early-onset obesity
acute myelogenous leukemia	increased	ACIN1	acinus	Q9UKV3	22985	14q11.2	151.86	human	456759	S1180-p	RSB_motif	GPRSRSRsRDRRRKE	18559500	4	2	0		
prostate cancer	decreased; mutation of site	NKX3-1	NKX3-1	Q99801	4824	8p21.2	26.35	human	3078000	S48-p		RQGGRTSsQRQRDPE	11980664	1	0	0		polymorphism disturbs PKC consensus motif
DSPS	mutation of site	AANAT	AA-NAT iso100	Q16613_VAR_A129T	15	17q25.1	23.37	human	3251801	T129-p	Acetyltransf_1	HVLAVHRtFRQQGRG	12736803	1	0	0		
SLE		SNRNP70	snRNP 70	P08621	6625	19q13.33	51.56	human	2103618	S140-p	RRM_1	HMVYSKRsGKPRGYA	12548559	2	0	1		recognized by antibodies from lupus patients
type 2 diabetes		GYS1	GYS1	P13807	2997	19q13.33	83.79	human	449898	S8-p		MPLNRTLsMSSLPGL	17698598	16	1	0		
type 2 diabetes		GYS1	GYS1	P13807	2997	19q13.33	83.79	human	448237	S641-p	Glycogen_syn	YRYPRPAsVPPSPSL	17698598	33	28	2	98074; 3891; 47043	
type 2 diabetes		GYS1	GYS1	P13807	2997	19q13.33	83.79	human	448238	S645-p	Glycogen_syn	RPASVPPsPSLSRHS	17698598	21	32	7		
type 2 diabetes		GYS1	GYS1	P13807	2997	19q13.33	83.79	human	451605	S11-p		NRTLSMSsLPGLEDW	17698598	10	2	1		
Marfan syndrome	increased	SMAD2	SMAD2	Q15796	4087	18q21.1	52.31	human	447495	S467-p		SVRCSSMs_______	15731757	54	1	5	18338; 26945; 8828; 11979; 68550; 3108; 56532; 67804; 55041	
Marfan syndrome	increased	SMAD2	SMAD2	Q15796	4087	18q21.1	52.31	human	447494	S465-p		SPSVRCSsMS_____	15731757	54	1	5	18338; 26945; 8828; 11979; 68550; 3108; 56532; 67804; 55041	
acute myelogenous leukemia	mutation of site	FLT3	FLT3	P36888	2322	13q12.2	112.90	human	454872	Y842-p	PK_Tyr_Ser-Thr	DIMSDSNyVVRGNAR	15345593	5	2	76	4577	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	12614922	85	33	23	62672; 66224; 12885	
obesity, hyperphagic	decreased	Pparg	PPAR-gamma	P37238	19016	6 E3|6 53.41 cM	57.60	mouse	448062	S112-p		AIKVEPAsPPYYSEK	18204460	29	7	0		
breast cancer	increased	RB1	Rb	P06400	5925	13q14.2	106.16	human	447975	S249-p		AVIPINGsPRTPRRG	17599043	18	45	86		
breast cancer	increased	RB1	Rb	P06400	5925	13q14.2	106.16	human	449821	T252-p		PINGSPRtPRRGQNR	17599043	20	23	68		
pancreatic carcinoma	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	18519681	468	74	3065	4324; 8119; 9145; 4113; 52075; 73533; 9138; 4323; 4093; 4074; 52527; 74309; 16185; 61958; 9131; 73452	
acute myelogenous leukemia	increased	SRC	Src	P12931	6714	20q11.23	59.83	human	448234	Y419-p	PK_Tyr_Ser-Thr	RLIEDNEyTARQGAK	18056483	416	102	3046	6943; 2101; 78740; 70926; 94361; 59548; 17320	
acute myelogenous leukemia	increased	EIF4EBP1	4E-BP1	Q13541	1978	8p11.23	12.58	human	447528	T70-p	eIF_4EBP	RNSPVTKtPPRDLPT	18056483	50	57	9	9455; 13396	
acute myelogenous leukemia	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	18056483	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
SLE	decreased	ELF1	Elf-1	P32519	1997	13q14.11	67.50	human	4825111	T231-p	Ets	CPKYIKWtQREKGIF	18714041	1	1	0		
Alzheimer's disease	decreased	Gsk3a	GSK3A	Q2NL51	606496	7|7 A3	51.66	mouse	448584	S21-p		SGRARTSsFAEPGGG	15033922	145	24	277	8452; 9327; 9331; 9316; 9337; 5090; 8566	
Alzheimer's disease	decreased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	449111	S9-p		SGRPRTTsFAESCKP	15033922	513	44	227	5558; 14630; 14026; 14332; 79774; 9322; 9327; 9331; 9323; 9336; 9325; 8466; 8566; 14310	
colorectal cancer		PTK2	FAK	Q05397	5747	8q24.3	119.23	human	447966	Y925-p	Focal_AT	DRSNDKVyENVTGLV	15958584	96	17	427	3284	
colorectal cancer		PTK2	FAK	Q05397	5747	8q24.3	119.23	human	447965	Y861-p		PIGNQHIyQPVGKPD	15958584	74	21	307		
colorectal cancer		SRC	Src	P12931	6714	20q11.23	59.83	human	448234	Y419-p	PK_Tyr_Ser-Thr	RLIEDNEyTARQGAK	15958584	416	102	3046	6943; 2101; 78740; 70926; 94361; 59548; 17320	
RIDDLE syndrome	increased	NBN	NBS1	O60934	4683	8q21.3	84.96	human	448605	S343-p		TTPGPSLsQGVSVDE	17940005	46	20	69	3001	in irradiated fibroblasts 
RIDDLE syndrome	increased	SMC1A	Smc1	Q14683	8243	Xp11.22	143.23	human	448698	S966-p	SMC_N	GEDSVSGsQRISSIY	17940005	20	14	67		in irradiated fibroblasts 
Huntington's disease	decreased	HTT	Huntingtin	P42858	3064	4p16.3	347.60	human	448106	S419-p		GGRSRSGsIVELIAG	18772195	14	32	21		phosphorylation decreased in HD; experimental phosphorylation restores defects in function
RIDDLE syndrome	increased	ATM	ATM	Q13315	472	11q22.3	350.69	human	448797	S1981-p		SLAFEEGsQSTTISS	17940005	203	24	4	5883; 13050; 4526	in irradiated fibroblasts 
RIDDLE syndrome	increased	TP53BP1	53BP1	Q12888	7158	15q15.3	213.57	human	458312	S1778-p		FNKQYTEsQLRAGAG	17940005	4	0	1	2675	in irradiated fibroblasts 
RIDDLE syndrome	decreased	CHEK1	Chk1	O14757	1111	11q24.2	54.43	human	447834	S345-p		LVQGISFsQPTCPDH	17940005	188	4	12	12268; 2341; 2348	in irradiated fibroblasts
diabetes mellitus	decreased	Nos3	eNOS	Q62600	24600	4q11	133.29	rat	447884	S1176-p		TSRIRTQsFSLQERQ	16085713	194	18	7	9570; 9571	
diabetes mellitus	increased	Nos3	eNOS	Q62600	24600	4q11	133.29	rat	5227904	S1176-gl		TSRIRTQsFSLQERQ	16085713	2	0	0		
infertility	mutation of site	BMP15	BMP15	O95972	9210	Xp11.22	45.06	human	9379003	Y235-p		DIAFLLLyFNDTHKS	19553676	1	0	0		Y235C mutation causes hypergonadotropic ovarian failure
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	15883264	130	44	14	20473; 71429	
astrocytoma	decreased	AQP4	AQP4	P55087	361	18q11.2	34.83	human	467301	S180-p	MIP	TIFASCDsKRTDVTG	19761816	4	0	0		
ovarian cancer	increased	PAK2	PAK2	Q13177	5062	3q29	58.04	human	448298	S20-p		APPVRMSsTIFSTGG	19876919	8	11	100	2607	
ovarian cancer	increased	PAK1	PAK1	Q13153	5058	11q13.5-q14.1	60.65	human	448177	T423-p	Pkinase	PEQSKRStMVGTPYW	19876919	37	4	11	2601	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	19821112	130	44	14	20473; 71429	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449080	S235-p		VVRTPPKsPSSAKSR	19821112	43	36	25	20473	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447929	S214-p		GSRSRTPsLPTPPTR	19821112	60	23	42	77348	
acute myelogenous leukemia	increased	CSF2RB	CSF2RB	P32927	1439	22q12.3	97.34	human	448463	S601-p		LGPPHSRsLPDILGQ	19805619	6	1	0		
ovarian cancer	increased	JUND	JunD	P17535	3727	19p13.11	35.17	human	456168	S100-p	Jun	LGLLKLAsPELERLI	17001009	5	63	12	9164	
ovarian cancer	increased	PLEKHA6	PLEKHA6	Q9Y2H5	22874	1q32.1	117.13	human	11452200	S455-p		SLQPRSHsVPRSPSQ	17001009	0	5	1		
ovarian cancer	increased	CTNNB1	CTNNB1	P35222	1499	3p22.1	85.50	human	447487	S33-p		QQQSYLDsGIHSGAT	17001009	96	3	2	2009; 4270; 9561; 13537; 60180; 41334	
ovarian cancer	increased	SYNM	DMN	O15061	23336	15q26.3	172.87	human	3207309	S429-p		QTNVRTFsPTYGLLR	17001009	1	23	3		
ovarian cancer	increased	TNS3	tensin 3	Q68CZ2	64759	7p12.3	155.27	human	4726261	S1441-p	PTB	VSKVMIGsPKKV___	17001009	1	19	0		
ovarian cancer	increased	IRS2	IRS2	Q9Y4H2	8660	13q34	137.33	human	453065	S1100-p		PEAARVAsPTSGVKR	17001009	2	43	0		
ovarian cancer	increased	RIPOR1	FAM65A	Q6ZS17	79567	16q22.1	132.31	human	10424020	S453-p		APYSRTLsHISEASV	17001009	0	1	1		
ovarian cancer	increased	JUN	Jun	P05412	3725	1p32.1	35.68	human	447943	S73-p	Jun	VGLLKLAsPELERLI	17001009	80	65	16	8752; 77955; 3270; 9164; 12714	
melanoma skin cancer	increased	USP10	USP10	Q14694	9100	16q24.1	87.13	human	480435	S547-p	UCH	LNLKKLLsPSNEKLT	17001009	0	21	1		
melanoma skin cancer	increased	JUN	Jun	P05412	3725	1p32.1	35.68	human	447943	S73-p	Jun	VGLLKLAsPELERLI	17001009	80	65	16	8752; 77955; 3270; 9164; 12714	
melanoma skin cancer	increased	RIPOR1	FAM65A	Q6ZS17	79567	16q22.1	132.31	human	10424020	S453-p		APYSRTLsHISEASV	17001009	0	1	1		
melanoma skin cancer	increased	RPS17	RPS17	P08708	6218	15q25.2	15.55	human	4710792	S115-p	Ribosomal_S17e	LLDFGSLsNLQVTQP	17001009	0	11	11		
melanoma skin cancer	increased	JUND	JunD	P17535	3727	19p13.11	35.17	human	456168	S100-p	Jun	LGLLKLAsPELERLI	17001009	5	63	12	9164	
melanoma skin cancer	increased	TNS3	tensin 3	Q68CZ2	64759	7p12.3	155.27	human	4726261	S1441-p	PTB	VSKVMIGsPKKV___	17001009	1	19	0		
melanoma skin cancer	increased	TAF13	TAF13	Q15543	6884	1p13.3	14.29	human	487235	S33-p	TFIID-18kDa	GKRKRLFsKELRCMM	17001009	0	2	10		
melanoma skin cancer	increased	SYNM	DMN	O15061	23336	15q26.3	172.87	human	3207309	S429-p		QTNVRTFsPTYGLLR	17001009	1	23	3		
melanoma skin cancer	increased	CTNNB1	CTNNB1	P35222	1499	3p22.1	85.50	human	447487	S33-p		QQQSYLDsGIHSGAT	17001009	96	3	2	2009; 4270; 9561; 13537; 60180; 41334	
melanoma skin cancer	increased	IRS2	IRS2	Q9Y4H2	8660	13q34	137.33	human	453065	S1100-p		PEAARVAsPTSGVKR	17001009	2	43	0		
melanoma skin cancer	increased	BCAR3	BCAR3	O75815	8412	1p22.1	92.57	human	7989842	T130-p		ERHIMDRtPEKLKKE	17001009	0	4	15		
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448101	S118-p	Oest_recep	LHPPPQLsPFLQPHG	19940281	89	2	0	2511	High S118 ER-alpha phosphorylation is found in some breast cancer tumors. 
sickle-cell anaemia	increased	SPTA1	SPTA1	P02549	6708	1q23.1	280.01	human	6211807	Y1499-p		ERTKLGDyANLKQFY	20206558	1	1	0		
sickle-cell anaemia	increased	SPTA1	SPTA1	P02549	6708	1q23.1	280.01	human	13421404	Y548-p	Spectrin	KLIGDDHyDSENIKA	20206558	1	1	0		
sickle-cell anaemia	increased	SPTA1	SPTA1	P02549	6708	1q23.1	280.01	human	13421405	Y422-p	Spectrin	HKHEIDSyDDRFQSA	20206558	1	1	0		
ovarian cancer	increased	ERBB3	HER3	P21860	2065	12q13.2	148.10	human	449858	Y1289-p		CPASEQGyEEMRAFQ	20227043	28	10	125	4791; 2842	
ovarian cancer	decreased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	20153512	732	14	18	5106; 48646; 13842; 4056; 2965; 43506; 77440; 9275; 13038; 86758; 80722; 5056	phosphorylated in a majority of tumor specimens
prostate cancer	increased	ARHGEF2	ARHGEF2 iso2	Q92974-2	9181	1q22	111.47	human	451365	S885-p		PVDPRRRsLPAGDAL	20406887	12	47	145	14143	
Fetal growth restriction	increased	IGFBP1	IGFBP1	P08833	3484	7p12.3	27.90	human	451658	S126-p		GSPESPEsTEITEEE	20143870	14	9	0		
Fetal growth restriction	increased	IGFBP1	IGFBP1	P08833	3484	7p12.3	27.90	human	451660	S194-p	Thyroglobulin_1	LAKAQETsGEEISKF	20143870	14	13	0		
Fetal growth restriction	increased	IGFBP1	IGFBP1	P08833	3484	7p12.3	27.90	human	4668105	S123-p		AEAGSPEsPESTEIT	20143870	7	8	0		
pancreatic carcinoma	increased	ENO1	ENO1	P06733	2023	1p36.23	47.17	human	7104866	S419-p	Enolase_C	RIEEELGsKAKFAGR	20455595	2	33	0		presence of autoantibodies directed against phosphorylated S419 in patients with pancreatic cancer
acute lymphocytic leukemia; acute myelogenous leukemia; chronic myelogenous leukemia	increased	STAT5A	STAT5A	P42229	6776	17q21.2	90.65	human	448750	S780-p		DSLDSRLsPPAGLFT	20508164	11	24	0		phosphorylation of this site was not detected in bone marrow samples obtained from healthy donors
adrenocortical carcinoma	increased	MTOR	mTOR	P42345	2475	1p36.22	288.89	human	447578	S2448-p		RSRTRTDsYSAGQSV	20484036	187	17	106	2971; 5536; 54932; 2976	mTor signaling is activated in ACT (childhood adrenocortical tumors); S2448 phosphorylation is expressed during mitosis
adrenocortical carcinoma	increased	RPS6	S6	P62753	6194	9p22.1	28.68	human	448095	S244-p		LRASTSKsESSQK__	20484036	95	34	561	9468; 5018; 13020; 2215; 14236; 5044; 34918; 35708; 88441; 5364	mTor signaling is activated in ACT (childhood adrenocortical tumors); S2448 phosphorylation is expressed during mitosis
adrenocortical carcinoma	increased	RPS6	S6	P62753	6194	9p22.1	28.68	human	448094	S240-p		RLSSLRAsTSKSESS	20484036	97	69	847	9468; 5018; 13020; 2215; 14236; 5044; 34918; 35708; 88441; 5364	mTor signaling is activated in ACT (childhood adrenocortical tumors); S2448 phosphorylation is expressed during mitosis
glioblastoma	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	20455003	468	74	3065	4324; 8119; 9145; 4113; 52075; 73533; 9138; 4323; 4093; 4074; 52527; 74309; 16185; 61958; 9131; 73452	Y705 phosphorylation is a prognostic factor for survival (patients with higher levels had shorter overall survival than those with lower levels)
Status epilepticus	increased	Slc12a5	KCC2	Q91V14	57138	2|2 H3	126.27	mouse	3087801	Y1109-p	SLC12	NRNGDENyMEFLEVL	20600929	3	0	0		phosphorylation of this site enhances lysozomal degradation of SLC12A5 (aka KCC2)
tuberous sclerosis	increased	RPS6	S6	P62753	6194	9p22.1	28.68	human	448095	S244-p		LRASTSKsESSQK__	17671177	95	34	561	9468; 5018; 13020; 2215; 14236; 5044; 34918; 35708; 88441; 5364	
tuberous sclerosis	increased	MAPK1	ERK2	P28482	5594	22q11.22	41.39	human	447593	T185-p	Pkinase	HDHTGFLtEYVATRW	17671177	1116	120	2416	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 54240; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
tuberous sclerosis	increased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447543	Y204-p	Pkinase	HTGFLTEyVATRWYR	17671177	1304	138	3549	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 14474; 54240; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
tuberous sclerosis	increased	MAPK1	ERK2	P28482	5594	22q11.22	41.39	human	447594	Y187-p	Pkinase	HTGFLTEyVATRWYR	17671177	1139	157	4003	13214; 8544; 14227; 5726; 98168; 3510; 9106; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 54240; 4376; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
tuberous sclerosis	increased	RPS6	S6	P62753	6194	9p22.1	28.68	human	448094	S240-p		RLSSLRAsTSKSESS	17671177	97	69	847	9468; 5018; 13020; 2215; 14236; 5044; 34918; 35708; 88441; 5364	
tuberous sclerosis	increased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447542	T202-p	Pkinase	HDHTGFLtEYVATRW	17671177	1283	106	2017	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 54240; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
colorectal carcinoma	increased	CASP8	CASP8	Q14790	841	2q33.1	55.39	human	460647	Y380-p	Peptidase_C14	TDSEEQPyLEMDLSS	16619028	10	3	35		
spinocerebellar ataxia type 14	decreased	PRKCG	PKCG	P05129	5582	19q13.42	78.45	human	456511	T655-p	Pkinase_C	TRAAPALtPPDRLVL	15964845	4	15	2		missense mutations of PKCG associated with familial SCA14 decrease phosphorylation of T514, T655, T674.
spinocerebellar ataxia type 14	decreased	PRKCG	PKCG	P05129	5582	19q13.42	78.45	human	451041	T514-p	Pkinase	FPGTTTRtFCGTPDY	15964845	6	45	45	9379; 38938; 2060	missense mutations of PKCG associated with familial SCA14 decrease phosphorylation of T514, T655, T674.
spinocerebellar ataxia type 14	decreased	PRKCG	PKCG	P05129	5582	19q13.42	78.45	human	456512	T674-p	Pkinase_C	QADFQGFtYVNPDFV	15964845	4	3	1		missense mutations of PKCG associated with familial SCA14 decrease phosphorylation of T514, T655, T674.
pulmonary emphysema	increased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447542	T202-p	Pkinase	HDHTGFLtEYVATRW	14764579	1283	106	2017	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 54240; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
pulmonary emphysema	increased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447543	Y204-p	Pkinase	HTGFLTEyVATRWYR	14764579	1304	138	3549	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 14474; 54240; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
pulmonary emphysema	increased	MAPK1	ERK2	P28482	5594	22q11.22	41.39	human	447593	T185-p	Pkinase	HDHTGFLtEYVATRW	14764579	1116	120	2416	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 54240; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
pulmonary emphysema	increased	MAPK1	ERK2	P28482	5594	22q11.22	41.39	human	447594	Y187-p	Pkinase	HTGFLTEyVATRWYR	14764579	1139	157	4003	13214; 8544; 14227; 5726; 98168; 3510; 9106; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 54240; 4376; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
cancer, squamous cell carcinoma	increased	PTK2	FAK	Q05397	5747	8q24.3	119.23	human	447887	Y397-p		SVSETDDyAEIIDEE	14603053	340	31	474	3283; 8556	FAK pY397 was more nuclear; however, little correlation between pY397 and tumor differentiation
colorectal cancer	decreased	PTK2	FAK	Q05397	5747	8q24.3	119.23	human	447888	Y407-p		IIDEEDTyTMPSTRD	12871985	27	13	139		pY407 and pY397 of FAK decrease as tumors go from well differentiated to poorly (correlation r=0.9).  No correlation with pY576, pY577, pY861, and pY925 and tumor differentiation.
colorectal cancer	decreased	PTK2	FAK	Q05397	5747	8q24.3	119.23	human	447887	Y397-p		SVSETDDyAEIIDEE	12871985	340	31	474	3283; 8556	pY407 and pY397 of FAK decrease as tumors go from well differentiated to poorly (correlation r=0.9).  No correlation with pY576, pY577, pY861, and pY925 and tumor differentiation.
breast cancer	increased	SRC	Src	P12931	6714	20q11.23	59.83	human	448233	Y216-p	SH2	KLDSGGFyITSRTQF	12753909	7	3	21		HER2(+) breast cancer.  Strong pY216, modest  pY419.
breast cancer	increased	SRC	Src	P12931	6714	20q11.23	59.83	human	448234	Y419-p	PK_Tyr_Ser-Thr	RLIEDNEyTARQGAK	12753909	416	102	3046	6943; 2101; 78740; 70926; 94361; 59548; 17320	HER2(+) breast cancer.  Strong pY216, modest  pY419.
spinocerebellar ataxia type 1	increased	ATXN1	ataxin-1	P54253	6310	6p22.3	86.92	human	449110	S775-p		ATRKRRWsAPESRKL	12741986	19	28	3		
Alzheimer's disease	increased	APP	APP iso4	P05067-4	351	21q21.3	78.66	human	448523	T668-p	APP_amyloid	VEVDAAVtPEERHLS	16705182	38	5	3	3823; 6986	
Alzheimer's disease	increased	Mapt	Tau	P19332	29477	10q32.1	78.56	rat	447933	T516-p		SSPGSPGtPGSRSRT	16705182	113	24	26	30505; 43964; 49561; 20060; 53001; 20739	
Alzheimer's disease	increased	Mapt	Tau	P19332	29477	10q32.1	78.56	rat	447928	S513-p		SGYSSPGsPGTPGSR	16705182	149	55	116	30505; 39357	
non-small cell large cell lung carcinoma; non-small cell squamous cell lung carcinoma	increased	EGFR	EGFR	P00533	1956	7p11.2	134.28	human	448061	Y869-p	PK_Tyr_Ser-Thr	LGAEEKEyHAEGGKV	16505275	91	20	171	2231; 6963	
rhabdomyosarcoma	mutation of site	KRT8	K8	P05787	3856	12q13.13	53.70	human	3081700	S291-p	Filament	IKYEELQsLAGKHGD	11850543	1	8	5		
ARVC	mutation of site	Ryr2	RYR2	E9Q401	20191	13 A1|13 4.38 cM	564.82	mouse	2535900	G1885-p		GEEEAKGgKRPKEGL	18326664	1	0	0		
hepatocellular carcinoma	increased	EGFR	EGFR	P00533	1956	7p11.2	134.28	human	448061	Y869-p	PK_Tyr_Ser-Thr	LGAEEKEyHAEGGKV	16936701	91	20	171	2231; 6963	
acute myelogenous leukemia	mutation of site	FLT3	FLT3	P36888	2322	13q12.2	112.90	human	448190	Y591-p		SSDNEYFyVDFREYE	17105820	14	0	0	3464; 3461; 3474; 60413; 3466; 23991; 25619	duplication of site
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	11034902	170	45	90	9632	Antibodies to phosphorylated  S396/404 stain brain sections early in the disease. 
breast cancer	increased	Erbb2	HER2	P06494	24337	10q31	138.83	rat	447614	Y1250-p		PTAENPEyLGLDVPV	9461599	57	15	200	2247; 2244	
kidney cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	12649200	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
breast cancer	increased	SRC	Src	P12931	6714	20q11.23	59.83	human	448234	Y419-p	PK_Tyr_Ser-Thr	RLIEDNEyTARQGAK	17967179	416	102	3046	6943; 2101; 78740; 70926; 94361; 59548; 17320	in selected cell lines
breast cancer	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	17967179	468	74	3065	4324; 8119; 9145; 4113; 52075; 73533; 9138; 4323; 4093; 4074; 52527; 74309; 16185; 61958; 9131; 73452	in selected cell lines
non-small cell lung cancer	increased	EGFR	EGFR	P00533	1956	7p11.2	134.28	human	448061	Y869-p	PK_Tyr_Ser-Thr	LGAEEKEyHAEGGKV	17653080	91	20	171	2231; 6963	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447930	S262-p	Tubulin-binding	NVKSKIGsTENLKHQ	15652175	108	24	2		
esophageal carcinoma	mutation of site	FBXO4	FBXO4	Q9UKT5	26272	5p13.1	44.14	human	453026	S12-p		EPRSGTNsPPPPFSD	18598945	2	37	0		
Burkitt's lymphoma	mutation of site	MYC	Myc	P01106	4609	8q24.21	48.80	human	448496	T58-p	Myc_N	KKFELLPtPPLSPSR	10713166	71	39	30	46650	
Emery-Dreifuss muscular dystrophy	mutation of site	LMNA	lamin A/C	P02545	4000	1q22	74.14	human	478681	S404-p		RSRGRASsHSSQTQG	18808171	7	49	106		
colorectal carcinoma	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	455676	S10-p	Histone	TKQTARKsTGGKAPR	12234980	228	15	1	3465; 9701; 8552; 66065; 9706; 3377; 5764; 64522; 3475; 29237; 9711; 8481; 9606; 52725; 43185; 3642; 3458; 53348	
intraocular melanoma	increased	RB1	Rb	P06400	5925	13q14.2	106.16	human	448717	S811-p	Rb_C	IYISPLKsPYKISEG	10969768	85	40	80	8974; 11917; 9308; 4277; 8957; 41359; 8516; 63276	
intraocular melanoma	increased	RB1	Rb	P06400	5925	13q14.2	106.16	human	447980	S807-p	Rb_C	PGGNIYIsPLKSPYK	10969768	89	45	112	8974; 11917; 9308; 4277; 99274; 8957; 41359; 8516	
acute myelogenous leukemia	duplication	FLT3	FLT3	P36888	2322	13q12.2	112.90	human	448190	Y591-p		SSDNEYFyVDFREYE	9305596	14	0	0	3464; 3461; 3474; 60413; 3466; 23991; 25619	
colorectal cancer		KRT8	K8	P05787	3856	12q13.13	53.70	human	448539	S74-p	Keratin_2_head	TVNQSLLsPLVLEVD	19115206	29	8	9		
colorectal cancer		KRT8	K8	P05787	3856	12q13.13	53.70	human	448540	S432-p		SAYGGLTsPGLSYSL	19115206	27	8	23		
lung cancer		Stat1	STAT1	P42225	20846	1 C1.1|1 26.81 cM	87.20	mouse	447754	Y701-p		DDPKRTGyIKTELIS	18941537	179	7	64	5375; 8062; 8009; 76285; 25809; 9167; 8183; 9174; 39205; 88845; 7649; 88211; 90145	
bladder cancer	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	18939995	468	74	3065	4324; 8119; 9145; 4113; 52075; 73533; 9138; 4323; 4093; 4074; 52527; 74309; 16185; 61958; 9131; 73452	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447933	T205-p		SSPGSPGtPGSRSRT	18725412	113	24	26	30505; 43964; 49561; 20060; 53001; 20739	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449082	S404-p		PVVSGDTsPRHLSNV	18725412	132	53	69	20194; 35834; 98523; 49562; 91600	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	18725412	170	45	90	9632	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447927	S199-p		GDRSGYSsPGSPGTP	18725412	87	30	33	29957	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447929	S214-p		GSRSRTPsLPTPPTR	18725412	60	23	42	77348	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447934	T212-p		TPGSRSRtPSLPTPP	18725412	45	16	5		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447928	S202-p		SGYSSPGsPGTPGSR	18725412	149	55	116	30505; 39357	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	450139	S320-p	Tubulin-binding	VDLSKVTsKCGSLGN	15652175	3	0	0		
acute myelogenous leukemia	duplication	FLT3	FLT3	P36888	2322	13q12.2	112.90	human	448643	Y599-p		VDFREYEyDLKWEFP	9305596	7	0	2		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449082	S404-p		PVVSGDTsPRHLSNV	11034902	132	53	69	20194; 35834; 98523; 49562; 91600	Antibodies to phosphorylated  S396/404 stain brain sections early in the disease. 
ovarian cancer	increased	TP53	p53	P04637	7157	17p13.1	43.65	human	447529	S20-p	P53_TAD	PLSQETFsDLWKLLP	20009884	123	2	0	9287	In p53-positive ovarian carinomas, S392 phosphorylation was associated with advanced tumor stage and high tumor grade. S20 phosphorylation was associated with low tumor grade in p53-positive, and high tumor grade in p53-negative, ovarian carcinomas.
ovarian cancer	increased	TP53	p53	P04637	7157	17p13.1	43.65	human	447535	S392-p		FKTEGPDsD______	20009884	110	15	0	9281	In p53-positive ovarian carinomas, S392 phosphorylation was associated with advanced tumor stage and high tumor grade. S20 phosphorylation was associated with low tumor grade in p53-positive, and high tumor grade in p53-negative, ovarian carcinomas.
type 2 diabetes	increased	ATP5F1B	ATP5B	P06576	506	12q13.3	56.56	human	12173904	T213-p	ATP-synt_ab	GGAGVGKtVLIMELI	20012595	0	5	1		22% increase in patients with type II diabetes; 37% increase in obese non-diabetic patients
type 2 diabetes	increased	ATP5F1B	ATP5B	P06576	506	12q13.3	56.56	human	12173903	Y361-p	ATP-synt_ab	ITSVQAIyVPADDLT	20012595	0	1	13		32% increase in obese non-diabetic patients and patients with type II diabetes
cancer, squamous cell carcinoma	increased	Mapk1	ERK2	P63085	26413	16 A3|16 10.53 cM	41.28	mouse	447593	T183-p	Pkinase	HDHTGFLtEYVATRW	19934324	1116	120	2416	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 54240; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
cancer, squamous cell carcinoma	increased	Mapk1	ERK2	P63085	26413	16 A3|16 10.53 cM	41.28	mouse	447594	Y185-p	Pkinase	HTGFLTEyVATRWYR	19934324	1139	157	4003	13214; 8544; 14227; 5726; 98168; 3510; 9106; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 54240; 4376; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
cancer, squamous cell carcinoma	increased	Mapk3	ERK1	Q63844	26417	7 F3|7 69.25 cM	43.07	mouse	447542	T203-p	Pkinase	HDHTGFLtEYVATRW	19934324	1283	106	2017	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 54240; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
cancer, squamous cell carcinoma	increased	Pdpk1	PDK1	Q9Z2A0	18607	17|17 A3.3	63.76	mouse	447693	S244-p	Pkinase	SKQARANsFVGTAQY	19934324	61	95	264	3061; 3438	
cancer, squamous cell carcinoma	increased	Stat3	STAT3	P42227	20848	11 D|11 63.82 cM	88.05	mouse	448192	Y705-p		DPGSAAPyLKTKFIC	19934324	468	74	3065	4324; 8119; 9145; 4113; 52075; 73533; 9138; 4323; 4093; 4074; 52527; 74309; 16185; 61958; 9131; 73452	
cancer, squamous cell carcinoma	increased	Mapk3	ERK1	Q63844	26417	7 F3|7 69.25 cM	43.07	mouse	447543	Y205-p	Pkinase	HTGFLTEyVATRWYR	19934324	1304	138	3549	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 14474; 54240; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
cancer, squamous cell carcinoma	increased	FYN	Fyn	P06241	2534	6q21	60.76	human	447882	Y420-p	PK_Tyr_Ser-Thr	RLIEDNEyTARQGAK	19934324	26	94	3048	6943; 2101; 78740; 70926; 94361; 59548; 17320	
breast cancer	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	455677	S28-p	Histone	ATKAARKsAPATGGV	19956839	48	18	0	9713	mTOR S2481 phosphorylation is useful to determine mitotic activity index (MAI), as a proliferation-associated prognostic factor for breast cancer patients.
breast cancer	increased	MTOR	mTOR	P42345	2475	1p36.22	288.89	human	447498	S2481-p		TVPESIHsFIGDGLV	19956839	64	29	1	2974	mTOR S2481 phosphorylation is useful to determine mitotic activity index (MAI), as a proliferation-associated prognostic factor for breast cancer patients.
breast cancer	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	455676	S10-p	Histone	TKQTARKsTGGKAPR	19956839	228	15	1	3465; 9701; 8552; 66065; 9706; 3377; 5764; 64522; 3475; 29237; 9711; 8481; 9606; 52725; 43185; 3642; 3458; 53348	mTOR S2481 phosphorylation is useful to determine mitotic activity index (MAI), as a proliferation-associated prognostic factor for breast cancer patients.
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	487463	Y394-p		DHGAEIVyKSPVVSG	20110615	2	15	33		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	20110615	170	45	90	9632	
hepatocellular carcinoma	increased	RELA	NFkB-p65	Q04206	5970	11q13.1	60.22	human	447800	S536-p		SGDEDFSsIADMDFS	20224721	217	4	0	73992; 31553; 4887; 80477; 76778; 3031; 5733; 13346; 3036; 3033; 4025; 4886; 87672; 83962	fibrolamellar hepatocellular carcinoma.  high levels of phosphorylation in 88% of fibrolamellar hepatocellular carcinoma sample, 10% of normal liver samples.
LVR; MI	decreased	Tnnt2	TNNT2	P50753	24837	13q13	35.73	rat	451755	S209-p	Troponin	KAQTERKsGKRQTER	20418543	9	0	0		
LVR; MI	decreased	TNNT2	TNNT2	P45379	7139	1q32.1	35.92	human	451755	S208-p	Troponin	QAQTERKsGKRQTER	20418543	9	0	0		
Parkinson's disease; Alzheimer's disease	increased	Apex1	APE1	P28352	11792	14 C1|14 26.3 cM	35.49	mouse	14645304	T232-p	Exo_endo_phos	NKKNAGFtPQERQGF	20473298	2	0	0		
Alzheimer's disease; ALS	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449077	T175-p		ATRIPAKtPPAPKTP	19046355	8	8	0		T175 phosphorylation induced increased fibril formation in ALS patient samples with cognitive impairment.
colorectal cancer	increased	TNIK	TNIK	Q9UKE5	23043	3q26.2-q26.31	154.94	human	451976	S764-p		RTRVRANsKSEGSPV	20530691	2	23	23		
Status epilepticus	increased	Slc12a5	KCC2	Q91V14	57138	2|2 H3	126.27	mouse	14932400	Y926-p	SLC12	SDISAYTyEKTLVME	20600929	1	0	0		phosphorylation of this site enhances lysozomal degradation of SLC12A5 (aka KCC2)
Alzheimer's disease	decreased	Grin2b	NMDAR2B	Q01097	14812	6 G1|6 66.38 cM	165.96	mouse	448167	Y1472-p	NMDAR2_C	GSSNGHVyEKLSSIE	20427654	40	1	104	4208	result of increased levels and activity of STEP phosphatase in aged Tg2576 mice   
prostate cancer	increased	TNK2	Ack	Q07912	10188	3q29	114.57	human	450946	Y284-p	PK_Tyr_Ser-Thr	LPQNDDHyVMQEHRK	20623637	11	27	235	3138	correlates positively with disease progression and negatively with survival of patients
Parkinson's disease	decreased	Lrrk2	LRRK2	Q5S006	66725	15|15 E3	284.73	mouse	4725893	S910-p		LVKRKSNsISVGEVY	20642453	20	17	0		phosphorylation of this site and interaction with 14-3-3 were abolished in the LRRK2[R1441C] knockin mice 
Parkinson's disease	decreased	Lrrk2	LRRK2	Q5S006	66725	15|15 E3	284.73	mouse	4725898	S935-p		NAQRHSNsLGPVFDH	20642453	38	17	2	59576	phosphorylation of this site and interaction with 14-3-3 were abolished in the LRRK2[R1441C] knockin mice 
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	448044	S620-p		AKSPVPKsPVEEKGK	20624930	3	29	24		
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	451036	S672-p		GKSPVSKsPVEEKAK	20624930	0	9	0		
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	451038	S685-p		AKSPVPKsPVEEAKS	20624930	0	16	3		
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	476043	S788-p		GGSEEEGsDKGAKGS	20624930	0	5	3		
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	451033	S646-p		GKSPVPKsPVEEKGK	20624930	0	14	2		
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	451045	S837-p		VTNGLDLsPADEKKG	20624930	1	20	0		
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	476042	S783-p		KAGGEGGsEEEGSDK	20624930	0	12	3		
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	451035	S667-p		PVEEKGKsPVSKSPV	20624930	0	9	2		
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	448045	S736-p		PEKKKAEsPVKEEAV	20624930	4	23	1		
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	451034	S659-p		GKSPVPKsPVEEKGK	20624930	0	14	2		
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	456826	S680-p		PVEEKAKsPVPKSPV	20624930	0	13	0		
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	451836	S615-p		EKPEKAKsPVPKSPV	20624930	4	20	19		
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	451032	S641-p		PVEEKGKsPVPKSPV	20624930	0	14	0		
Alzheimer's disease	increased	NEFH	NFH	P12036	4744	22q12.2	112.48	human	456829	S801-p		PVKEEVKsPEKAKSP	20624930	0	11	0		
Alzheimer's disease	increased	NEFH	NFH	P12036	4744	22q12.2	112.48	human	456928	S716-p	DUF1388; DUF1388	KSPEKAKsPVKEEAK	20624930	0	16	9		
Alzheimer's disease	increased	NEFH	NFH	P12036	4744	22q12.2	112.48	human	481067	S648-p	DUF1388	PTKEEAKsPEKAKSP	20624930	0	9	4		
Alzheimer's disease	increased	NEFH	NFH	P12036	4744	22q12.2	112.48	human	456845	S744-p		KTPEKAKsPVKEEAK	20624930	0	10	0		
Alzheimer's disease	increased	NEFH	NFH	P12036	4744	22q12.2	112.48	human	481074	S640-p	DUF1388	KSPEKAKsPTKEEAK	20624930	0	9	3		
Alzheimer's disease	increased	NEFH	NFH	P12036	4744	22q12.2	112.48	human	456921	S546-p	DUF1388; DUF1388	KSPAEVKsPEKAKSP	20624930	0	14	1		
Alzheimer's disease	increased	NEFH	NFH	P12036	4744	22q12.2	112.48	human	472627	S710-p	DUF1388; DUF1388	PVKEEAKsPEKAKSP	20624930	0	13	9		
Alzheimer's disease	increased	NEFH	NFH	P12036	4744	22q12.2	112.48	human	481063	S580-p	DUF1388	KSPAEVKsPEKAKSP	20624930	0	18	7		
Alzheimer's disease	increased	NEFH	NFH	P12036	4744	22q12.2	112.48	human	481089	S702-p	DUF1388; DUF1388	KSPEKAKsPVKEEAK	20624930	0	11	9		
Alzheimer's disease	increased	NEFH	NFH	P12036	4744	22q12.2	112.48	human	481070	S620-p	DUF1388; DUF1388	KSPAEAKsPVKEEAK	20624930	0	14	6		
cancer, squamous cell carcinoma	increased	FSCN1	fascin	Q16658	6624	7p22.1	54.53	human	450888	S39-p	Fascin	KVNASASsLKKKQIW	20713986	13	12	0		
ventricular tachycardia	increased	Ryr2	RYR2	E9Q401	20191	13 A1|13 4.38 cM	564.82	mouse	458801	S2813-p		ISQTSQVsIDAAHGY	21098440	61	8	5		
breast cancer	increased	ITGB4	ITGB4 iso2	P16144-2	3691	17q25.1	195.01	human	456323	Y1494-p	fn3	LQGYSVEyQLLNGGE	20855525	6	0	1		
breast cancer	increased	FYN	Fyn	P06241	2534	6q21	60.76	human	447882	Y420-p	PK_Tyr_Ser-Thr	RLIEDNEyTARQGAK	20855525	26	94	3048	6943; 2101; 78740; 70926; 94361; 59548; 17320	
chronic myelogenous leukemia	deletion of site	Ptpn6	SHP-1	P29351	15170	6 F2|6 59.17 cM	67.56	mouse	448506	Y536-p		QKGQESEyGNITYPP	20858858	17	24	637		
chronic myelogenous leukemia	deletion of site	Ptpn6	SHP-1	P29351	15170	6 F2|6 59.17 cM	67.56	mouse	448912	Y564-p		SKHKEEVyENVHSKS	20858858	14	19	776	8849	
glioblastoma multiforme	increased	EPHA2	EphA2	P29317	1969	1p36.13	108.27	human	1244153	S897-p		RVSIRLPsTSGSEGV	19573808	16	32	171	6347	high levels in grade IV astrocytomas (GBM)
ovarian epithelial carcinoma	increased	MTOR	mTOR	P42345	2475	1p36.22	288.89	human	447578	S2448-p		RSRTRTDsYSAGQSV	21276607	187	17	106	2971; 5536; 54932; 2976	
ovarian epithelial carcinoma	increased	EIF4EBP1	4E-BP1	Q13541	1978	8p11.23	12.58	human	447497	T37-p	eIF_4EBP	PPGDYSTtPGGTLFS	21276607	140	44	88	7547; 3929; 2855; 4923; 2846; 45613; 39788; 5123; 9459	
ovarian epithelial carcinoma	increased	RPS6KB1	p70S6K	P23443	6198	17q23.1	59.14	human	448607	T412-p	Pkinase_C	NQVFLGFtYVAPSVL	21276607	438	8	1	9209; 9205; 9234; 9206; 97596	
ovarian epithelial carcinoma	increased	EIF4EBP1	4E-BP1	Q13541	1978	8p11.23	12.58	human	447496	T46-p	eIF_4EBP	GGTLFSTtPGGTRII	21276607	140	36	91	7547; 3929; 4923; 2855; 2846; 45613; 39788; 5123; 9459	
diabetes mellitus	increased	Ubtf	UBF	P25976	21429	11|11 D	89.51	mouse	450170	S389-p		INKKQTTsPASKKPS	20943765	4	3	1		
colonic inflamation	increased	Akt1	Akt1	P31750	11651	12 F1|12 61.2 cM	55.71	mouse	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	20580720	732	14	18	5106; 48646; 13842; 4056; 2965; 43506; 77440; 9275; 13038; 86758; 80722; 5056	chronic ulcerative colitis (CUC), ulcerative colitis associated dysplasia (UCD), colitis-associated cancer (CAC)
colonic inflamation	increased	CTNNB1	CTNNB1	P35222	1499	3p22.1	85.50	human	472273	S552-p		QDTQRRTsMGGTQQQ	20580720	39	62	9	9566; 5651	chronic ulcerative colitis (CUC), ulcerative colitis associated dysplasia (UCD), colitis-associated cancer (CAC)
diabetes mellitus	increased	Ubtf	UBF	P25977	25574	10q32.1	89.44	rat	450170	S389-p		INKKQTTsPASKKPS	20943765	4	3	1		
diabetes mellitus	increased	Rps6kb1	p70S6K	P67999	83840	10q26	59.13	rat	448607	T412-p	Pkinase_C	NQVFLGFtYVAPSVL	20943765	438	8	1	9209; 9205; 9234; 9206; 97596	
SLE	decreased	SP1	SP1	P08047	6667	12q13.13	80.69	human	452233	S59-p		GGQESQPsPLALLAA	21097497	6	16	0		
B cell lymphoma	mutation of site	RAG2	RAG2	P55895	5897	11p12	59.24	human	455560	T490-p	RAG2_PHD	EIARALHtPQRVLPL	21349429	4	0	0		
scleroderma	increased	FLI1	FLI1	Q01543	2313	11q24.3	50.98	human	6406002	T312-p	Ets	TNGEFKMtDPDEVAR	21321929	6	0	0		
VHL	mutation of site	VHL	VHL	P40337	7428	3p25.3	24.15	human	22516600	S111-p	VHL	GTGRRIHsYRGHLWL	22071692	1	0	1		patient-derived S111 mutations cause the loss of tumor suppressor function in VHL; 
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	448714	S83-p	Androgen_recep	QQQQQETsPRQQQQQ	21799006	22	1	0		xenografts 
SLE	increased	PRKCQ	PKCT	Q04759	5588	10p15.1	81.86	human	447907	T538-p	Pkinase	LGDAKTNtFCGTPDY	21983831	15	7	23	9379; 2060; 38938; 9377	activation of the KHS2-PKCT-IKK pathway controls SLE pathogenesis
lung cancer	decreased	YAP1	YAP1	P46937	10413	11q22.1	54.46	human	448847	S127-p		PQHVRAHsSPASLQL	21060948	171	32	180	4911; 57706; 13008; 92367	
atrial fibrillation	increased	Ryr2	RYR2	E9Q401	20191	13 A1|13 4.38 cM	564.82	mouse	458801	S2813-p		ISQTSQVsIDAAHGY	22158709	61	8	5		inhibition of RYR2-S2814 phosphorylation prevents AF in FKBP12.6-/- mice
hepatocellular carcinoma	increased	FOXA2	FOXA2	Q9Y261	3170	20p11.21	48.31	human	22825101	S111-p	Forkhead_N	PHLSPSLsPLGGQAA	22196886	1	1	0		
hepatocellular carcinoma	increased	FOXA2	FOXA2	Q9Y261	3170	20p11.21	48.31	human	22825100	S107-p	Forkhead_N	AGMGPHLsPSLSPLG	22196886	1	1	0		
chronic myelogenous leukemia	increased	BCR	Bcr	P11274	613	22q11.23	142.82	human	447792	Y177-p		ADAEKPFyVNVEFHH	12124177	14	30	1018	3901	
breast cancer	increased	STK3	MST2	Q13188	6788	8q22.2	56.30	human	12615900	T117-p	Pkinase	IIRLRNKtLIEDEIA	20231902	2	0	1		
acute lymphocytic leukemia; acute myelogenous leukemia; B cell lymphoma	increased	STAT5B	STAT5B	P51692	6777	17q21.2	89.87	human	483615	S193-p	STAT_alpha	FGPLAQLsPQERLSR	22442148	2	18	1		constitutive phosphorylation of this site was observed
glioblastoma	increased	CTNNB1	CTNNB1	P35222	1499	3p22.1	85.50	human	471406	Y333-p		NIMRTYTyEKLLWTT	22056988	4	2	0		
hepatocellular carcinoma	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	22153071	468	74	3065	4324; 8119; 9145; 4113; 52075; 73533; 9138; 4323; 4093; 4074; 52527; 74309; 16185; 61958; 9131; 73452	
prostate cancer	decreased	CTNNB1	CTNNB1	P35222	1499	3p22.1	85.50	human	6406005	T120-p		QFDAAHPtNVQRLAE	22511927	5	0	0		
ataxia-telangiectasia	decreased	TP53BP1	53BP1	Q12888	7158	15q15.3	213.57	human	450163	S25-p		PCLIIEDsQPESQVL	19876065	3	0	0	2674	
type 2 diabetes; diabetes mellitus	increased	Mapt	Tau	P19332	29477	10q32.1	78.56	rat	447928	S513-p		SGYSSPGsPGTPGSR	20398714	149	55	116	30505; 39357	
hypertrophic cardiomyopathy	increased	Prkaa1	AMPKA1	P54645	65248	2q16	63.97	rat	448786	T183-p	Pkinase	SDGEFLRtSCGSPNY	20497424	221	16	33	5256; 2531; 2535; 4188; 50081; 74281	
hypertrophic cardiomyopathy	increased	Prkaa1	AMPKA1	Q5EG47	105787	15|15 A1	63.93	mouse	448786	T183-p	Pkinase	SDGEFLRtSCGSPNY	20497424	221	16	33	5256; 2531; 2535; 4188; 50081; 74281	
hepatocellular carcinoma	increased	PTK2	FAK	Q05397	5747	8q24.3	119.23	human	447887	Y397-p		SVSETDDyAEIIDEE	20180147	340	31	474	3283; 8556	Phosphorylated Y379 is overexpressed in hepaocellular carcinoma, and correlated with tumor stage, vascular invasion, and intrahepatic  metastasis, 
breast cancer	increased	ATF4	ATF-4	P18848	468	22q13.1	38.59	human	451446	S245-p		TRGSPNRsLPSPGVL	22052162	3	1	0		
FTLD	increased	GFAP	GFAP	P14136	2670	17q21.31	49.88	human	449619	S13-p	Filament_head	ITSAARRsYVSSGEM	20886841	11	5	0		
FTLD	decreased	MAP1A	MAP1A	P78559	4130	15q15.3	305.49	human	470449	S612-p		SKDRGLDsGAETEEE	20886841	0	25	31		
Huntington's disease	increased	TP53	p53	P04637	7157	17p13.1	43.65	human	447536	S46-p	TAD2	AMDDLMLsPDDIEQW	22011578	111	3	0	2521	
Alzheimer's disease	increased	MAP2	MAP2	P11137	4133	2q34	199.53	human	13256105	S1702-p	Tubulin-binding	VTKKIDLsHVTSKCG	21828286	0	1	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	21828286	130	44	14	20473; 71429	
Alzheimer's disease	increased	MAP1B	MAP1B	P46821	4131	5q13.2	270.63	human	454141	S1396-p		SPIEKVLsPLRSPPL	21828286	0	58	16		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	452062	S184-p		PAPKTPPsSGEPPKS	21828286	3	4	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	21828286	170	45	90	9632	
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	448045	S736-p		PEKKKAEsPVKEEAV	21828286	4	23	1		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449080	S235-p		VVRTPPKsPSSAKSR	21828286	43	36	25	20473	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	21828286	85	33	23	62672; 66224; 12885	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447930	S262-p	Tubulin-binding	NVKSKIGsTENLKHQ	21828286	108	24	2		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449078	T217-p		SRTPSLPtPPTREPK	21828286	33	31	6	51625	
Alzheimer's disease	increased	MAP2	MAP2	P11137	4133	2q34	199.53	human	7532319	S1706-p	Tubulin-binding	IDLSHVTsKCGSLKN	21828286	0	3	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	450220	S185-p		APKTPPSsGEPPKSG	21828286	2	4	1		
Alzheimer's disease	increased	NEFH	NFH	P12036	4744	22q12.2	112.48	human	25322100	S948-p		DAKAKEPsKPAEKKE	21828286	0	1	1		
Alzheimer's disease	increased	MAP1B	MAP1B	P46821	4131	5q13.2	270.63	human	456408	S1779-p		SLEGEKLsPKSDISP	21828286	0	68	53		
Alzheimer's disease	increased	MAP1B	MAP1B	P46821	4131	5q13.2	270.63	human	454142	S1400-p		KVLSPLRsPPLIGSE	21828286	0	67	24		
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	451038	S685-p		AKSPVPKsPVEEAKS	21828286	0	16	3		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447934	T212-p		TPGSRSRtPSLPTPP	21828286	45	16	5		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449131	T403-p		SPVVSGDtSPRHLSN	21828286	6	30	26	20194; 35834; 98523; 49562; 91600	
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	10273932	S33-p	Filament_head	RVSGSPSsGFRSQSW	21828286	0	1	0		
breast cancer	increased	PIN1	PIN1	Q13526	5300	19p13.2	18.24	human	25519816	S138-p	Rotamase	QKPFEDAsFALRTGE	22566623	3	2	0		
Parkinson's disease	decreased	Htra2	HTRA2	Q9JIY5	64704	6 C3|6 35.94 cM	49.35	mouse	487467	S400-p	PDZ_6; Peptidase_M50	IHKVILGsPAHRAGL	21701498	2	0	0		In a murine model G399S mutation had decreased S400 phosphorylation. 
ventricular tachycardia	decreased	KCNH2	Kv11.1	Q12809	3757	7q36.1	126.65	human	3893409	S890-p		RQRKRKLsFRRRTDK	22653970	4	0	3		phosphorylation of this site is decreased by T887H nsSNP  mutation in Kv11.1
Parkinson's disease	increased	Sh3glb1	endophilin B1	Q9JK48	54673	3|3 H2	40.86	mouse	26318403	T145-p	BAR	TSALNFLtPLRNFIE	21499257	2	0	0		in Parkinson's disease model, A53T mutant of ?-synuclein
Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	22344688	104	7	0	87281; 23706	PD patients had higher S129 phosphorylation levels compared to healthy controls. Patients with multiple system atrophy (MSA) or progressive supranuclear palsy (PSP) patient, had lower S129 phosphorylation than PD patients or healthy controls. There was a weak correlation with P-S129 levels and severity of the PD.
DCM	decreased	TNNI3	TNNI3	P19429	7137	19q13.42	24.01	human	448424	S24-p	Troponin-I_N	APIRRRSsNYRAYAT	22972900	60	10	16	4004	similar effect has been observed in ISHD (failing ischemic hearts)
DCM	decreased	TNNI3	TNNI3	P19429	7137	19q13.42	24.01	human	4707828	S5-p	Troponin-I_N	___MADGsSDAAREP	22972900	0	3	1		similar effect has been observed in ISHD (failing ischemic hearts)
DCM	decreased	TNNI3	TNNI3	P19429	7137	19q13.42	24.01	human	448423	S23-p	Troponin-I_N	PAPIRRRsSNYRAYA	22972900	63	9	11	4004	similar effect has been observed in ISHD (failing ischemic hearts)
DCM	decreased	TNNI3	TNNI3	P19429	7137	19q13.42	24.01	human	4707836	S6-p	Troponin-I_N	__MADGSsDAAREPR	22972900	0	3	1		similar effect has been observed in ISHD (failing ischemic hearts)
DCM	decreased	TNNI3	TNNI3	P19429	7137	19q13.42	24.01	human	3545720	Y26-p	Troponin-I_N	IRRRSSNyRAYATEP	22972900	1	2	7		similar effect has been observed in ISHD (failing ischemic hearts)
DCM	increased	TNNI3	TNNI3	P19429	7137	19q13.42	24.01	human	2885400	T78-p	Troponin	EKGRALStRCQPLEL	22972900	0	2	0		similar effect has been observed in ISHD (failing ischemic hearts)
DCM	increased	TNNI3	TNNI3	P19429	7137	19q13.42	24.01	human	450690	S42-p		AKKKSKIsASRKLQL	22972900	24	2	0		similar effect has been observed in ISHD (failing ischemic hearts)
DCM	increased	TNNI3	TNNI3	P19429	7137	19q13.42	24.01	human	451839	S77-p	Troponin	GEKGRALsTRCQPLE	22972900	2	2	0		similar effect has been observed in ISHD (failing ischemic hearts)
DCM	increased	TNNI3	TNNI3	P19429	7137	19q13.42	24.01	human	450691	S44-p		KKSKISAsRKLQLKT	22972900	22	3	0		similar effect has been observed in ISHD (failing ischemic hearts)
DCM	increased	TNNI3	TNNI3	P19429	7137	19q13.42	24.01	human	26572404	T181-p		KQVKKEDtEKENREV	22972900	0	1	0		similar effect has been observed in ISHD (failing ischemic hearts)
DCM	increased	TNNI3	TNNI3	P19429	7137	19q13.42	24.01	human	3146609	S166-p	Troponin	LGARAKEsLDLRAHL	22972900	1	3	0		similar effect has been observed in ISHD (failing ischemic hearts)
DCM	increased	TNNI3	TNNI3	P19429	7137	19q13.42	24.01	human	451483	T143-p	Troponin	RGKFKRPtLRRVRIS	22972900	29	2	1		similar effect has been observed in ISHD (failing ischemic hearts)
DCM	increased	TNNI3	TNNI3	P19429	7137	19q13.42	24.01	human	4707844	S199-p		RKNIDALsGMEGRKK	22972900	2	5	0		similar effect has been observed in ISHD (failing ischemic hearts)
urethral cancer; brain cancer; colorectal cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	22975685	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
HIV/AIDS	increased	Rb1	Rb	P33568	24708	15q11	105.03	rat	447979	S787-p	Rb_C	SPYKFSSsPLRIPGG	21504794	48	17	94	9301	
colorectal carcinoma	increased	ELK1	ELK1	P19419	2002	Xp11.23	44.89	human	452139	T417-p		ISVDGLStPVVLSPG	23114923	8	0	1		
lung cancer	increased	SP1	SP1	P08047	6667	12q13.13	80.69	human	448227	T739-p		SEGSGTAtPSALITT	22266860	15	1	0		
obesity, hyperphagic	decreased	LIPE	HSL	Q05469	3991	19q13.2	116.60	human	448803	S853-p		IAEPMRRsVSEAALA	18398140	38	11	2	4139	
obesity, hyperphagic	decreased	LIPE	HSL	Q05469	3991	19q13.2	116.60	human	450194	S950-p	Abhydrolase_3	EGFHPRRsSQGATQM	18398140	8	5	4		
obesity, hyperphagic	decreased	LIPE	HSL	Q05469	3991	19q13.2	116.60	human	448804	S855-p		EPMRRSVsEAALAQP	18398140	26	28	1	4137	
psoriasis	increased	EIF4E	EIF4E	P06730	1977	4q23	25.10	human	447776	S209-p		DTATKSGsTTKNRFV	19663871	60	4	0	9741	in lesional, but not in nonlesional, plaque-type psoriatic skin
glioma		Cdkn1a	p21Cip1	P39689	12575	17 A3.3|17 15.12 cM	17.79	mouse	26400605	Y76-p		SLGLPKVyLSPGSRS	23007395	1	0	0		PDGF induced glioma in mice
melanoma skin cancer	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	1458614	K79-m3	Histone	REIAQDFkTDLRFQS	23227340	17	4	0	4260; 74073	melanomas wiith metastatic potential
melanoma skin cancer	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	4710889	T80-p	Histone	EIAQDFKtDLRFQSS	23227340	1	16	23		melanomas wiith metastatic potential
leukemia	increased	Stat5a	STAT5A	P42230	20850	11 D|11 63.77 cM	90.83	mouse	448749	S725-p		TYMDQAPsPVVCPQP	24263804	19	1	0		
rheumatoid arthritis	decreased	FOXP3	FOXP3	Q9BZS1	50943	Xp11.23	47.24	human	27623902	S418-p	Forkhead	LEFRKKRsQRPSRCS	23396208	4	0	0		
diabetes mellitus	decreased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447543	Y204-p	Pkinase	HTGFLTEyVATRWYR	17272402	1304	138	3549	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 14474; 54240; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
diabetes mellitus	decreased	MAPK1	ERK2	P28482	5594	22q11.22	41.39	human	447594	Y187-p	Pkinase	HTGFLTEyVATRWYR	17272402	1139	157	4003	13214; 8544; 14227; 5726; 98168; 3510; 9106; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 54240; 4376; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
diabetes mellitus	decreased	MAPK1	ERK2	P28482	5594	22q11.22	41.39	human	447593	T185-p	Pkinase	HDHTGFLtEYVATRW	17272402	1116	120	2416	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 54240; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
diabetes mellitus	decreased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447542	T202-p	Pkinase	HDHTGFLtEYVATRW	17272402	1283	106	2017	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 54240; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
pancreatic carcinoma	decreased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448191	S727-p		NTIDLPMsPRTLDSL	18519681	199	55	67	49081; 34911; 50804; 58978; 71958; 87544; 94994; 9136; 9134	
non-small cell lung adenocarcinoma	decreased	ERBB2	HER2	P04626	2064	17q12	137.91	human	447614	Y1248-p		PTAENPEyLGLDVPV	18687633	57	15	200	2247; 2244	
non-small cell lung adenocarcinoma	decreased	SMAD1	SMAD1	Q15797	4086	4q31.21	52.26	human	448363	S465-p		HNPISSVs_______	18687633	12	20	59	13820; 85553; 9516; 12428; 9576; 11971	
non-small cell lung adenocarcinoma	decreased	IRS1	IRS1	P35568	3667	2q36.3	131.59	human	447562	S616-p		DDGYMPMsPGVAPVP	18687633	36	7	4	3193; 2386; 3203	
non-small cell lung adenocarcinoma	decreased	EGFR	EGFR	P00533	1956	7p11.2	134.28	human	448056	Y1069-p		EDSFLQRySSDPTGA	18687633	41	18	117	2237	
non-small cell lung adenocarcinoma	decreased	SMAD1	SMAD1	Q15797	4086	4q31.21	52.26	human	448362	S463-p		SPHNPISsVS_____	18687633	12	13	58	13820; 85553; 9516; 12428; 9576; 11971	
type 2 diabetes	increased	Ryr2	RYR2	E9Q401	20191	13 A1|13 4.38 cM	564.82	mouse	458801	S2813-p		ISQTSQVsIDAAHGY	23516528	61	8	5		
ovarian cancer	increased	MYC	Myc	P01106	4609	8q24.21	48.80	human	17553985	Y74-p	Myc_N	SGLCSPSyVAVTPFS	23318434	2	1	0		
prostate cancer	decreased	AR	AR	P10275	367	Xq12	99.19	human	448415	S792-p	Hormone_recep	CVRMRHLsQEFGWLQ	23945560	5	0	0		high expression correlates with increased patient survival time from disease recurrence
prostate cancer	decreased	AR	AR	P10275	367	Xq12	99.19	human	448413	S310-p	Androgen_recep	TEDTAEYsPFKGGYT	23945560	11	5	0		high levels associated with greater patient survival time
non-small cell lung cancer	increased	ATF4	ATF-4	P18848	468	22q13.1	38.59	human	451446	S245-p		TRGSPNRsLPSPGVL	23975372	3	1	0		lymph node metastasis and advanced stages
hepatocellular carcinoma; B cell lymphoma; leukemia; non-small cell lung adenocarcinoma; angiosarcoma	mutation of site	Bub1b	BUB1B	Q9Z1S0	12236	2|2 E5	118.39	mouse	7761217	K243-ac		SRVGGALkAPGQSRG	23878276	4	1	0		mutated site develop cancers in mice
Status epilepticus; CSWSS	mutation of site	GRIN2A	NMDAR2A	Q12879	2903	16p13.2	165.28	human	455471	Y1387-p	NMDAR2_C	GRCPSDPyKHSLPSQ	23933820	6	1	13		
leukemia	increased	Stat5a	STAT5A	P42230	20850	11 D|11 63.77 cM	90.83	mouse	448750	S779-p		DSLDARLsPPAGLFT	24263804	11	24	0		
CCM	mutation of site	CCM2	CCM2	Q9BSQ5	83605	7p13	48.84	human	4761921	S238-p		RAIFDGAsTPTHHLS	24466005	1	0	0		phosphorylation site
XLP	decreased	LCK	Lck	P06239	3932	1p35.2	58.00	human	447822	Y394-p	PK_Tyr_Ser-Thr	RLIEDNEyTAREGAK	24688028	53	96	2957	6943; 2101; 78740; 70926; 94361; 59548; 17320	decrease upon restimulation of XLP patient T cells
Alzheimer's disease	increased	SQSTM1	SQSTM1	Q13501	8878	5q35.3	47.69	human	14580829	S349-p		SSKEVDPsTGELQSL	24886973	42	0	1	16177; 12074; 95697	neurofibrillary tangles are positive for S349
stroke	decreased	Pygb	PYGB	G3V6Y6	25739	3q41	96.74	rat	456885	S15-p		SERQKQIsVRGIAGL	24858129	4	17	1		
MPPH1	mutation of site	CCND2	CCND2	P30279	894	12p13.32	33.07	human	469202	T280-p	Cyclin_C	DELDQAStPTDVRDI	24705253	4	3	11		
neurofibromatosis type 1	increased	Stat3	STAT3	P42227	20848	11 D|11 63.82 cM	88.05	mouse	448192	Y705-p		DPGSAAPyLKTKFIC	23318430	468	74	3065	4324; 8119; 9145; 4113; 52075; 73533; 9138; 4323; 4093; 4074; 52527; 74309; 16185; 61958; 9131; 73452	malignant peripheral nerve sheath tumors (MPNSTs)
neurofibromatosis type 1	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	23318430	468	74	3065	4324; 8119; 9145; 4113; 52075; 73533; 9138; 4323; 4093; 4074; 52527; 74309; 16185; 61958; 9131; 73452	malignant peripheral nerve sheath tumors (MPNSTs)
glioblastoma multiforme	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	13321500	T6-p	Histone	__ARTKQtARKSTGG	25553095	5	2	0		poor prognosis and overall survival
glioblastoma multiforme	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	455676	S10-p	Histone	TKQTARKsTGGKAPR	25553095	228	15	1	3465; 9701; 8552; 66065; 9706; 3377; 5764; 64522; 3475; 29237; 9711; 8481; 9606; 52725; 43185; 3642; 3458; 53348	poor prognosis and overall survival
acute myelogenous leukemia; chronic lymphocytic leukemia	increased	Lyn	LYN	P25911	17096	4 A1|4 2.05 cM	58.81	mouse	454856	Y194-p	SH2	SLDNGGYyISPRITF	25587033	2	30	528		
obesity, hyperphagic	increased	Th	TH	P24529	21823	7 F5|7 88.06 cM	55.99	mouse	448545	S40-p	TOH_N	RFIGRRQsLIEDARK	16982425	61	11	11	2791	ob/ob mice
multiple myeloma	increased	KIF11	KIF11	P52732	3832	10q23.33	119.16	human	448410	T926-p	Microtub_bind	LDIPTGTtPQRKSYL	25660025	8	29	2		
X-linked agammaglobulinaemia	increased	SRC	Src	P12931	6714	20q11.23	59.83	human	448234	Y419-p	PK_Tyr_Ser-Thr	RLIEDNEyTARQGAK	22366891	416	102	3046	6943; 2101; 78740; 70926; 94361; 59548; 17320	
X-linked agammaglobulinaemia	increased	PTK2	FAK	Q05397	5747	8q24.3	119.23	human	447889	Y576-p	PK_Tyr_Ser-Thr	RYMEDSTyYKASKGK	22366891	89	65	2523	3281	
X-linked agammaglobulinaemia	increased	PTK2	FAK	Q05397	5747	8q24.3	119.23	human	447890	Y577-p	PK_Tyr_Ser-Thr	YMEDSTYyKASKGKL	22366891	84	40	1747	3281	
X-linked agammaglobulinaemia	increased	LYN	LYN	P07948	4067	8q12.1	58.57	human	447624	Y508-p		YTATEGQyQQQP___	22366891	24	48	1560	2731	
X-linked agammaglobulinaemia	increased	SYK	Syk	P43405	6850	9q22.2	72.07	human	447661	Y525-p	PK_Tyr_Ser-Thr	ALRADENyYKAQTHG	22366891	39	7	76	12081; 46994; 12967; 5514; 6485; 2710; 2711; 4349; 16859	
X-linked agammaglobulinaemia	increased	PIK3R1	PIK3R1	P27986	5295	5q13.1	83.60	human	451830	Y508-p	PI3K_P85_iSH2	QERYSKEyIEKFKRE	22366891	3	3	39		
X-linked agammaglobulinaemia	increased	VAV1	VAV1	P15498	7409	19p13.3	98.31	human	447866	Y174-p		EAEGDEIyEDLMRSE	22366891	22	2	0		
glioblastoma multiforme	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	10897613	Y41-p	Histone	GVKKPHRyRPGTVAL	25553095	7	3	4		poor prognosis and overall survival
type 2 diabetes	increased	Rps6kb1	p70S6K	Q8BSK8	72508	11|11 C	59.15	mouse	448607	T412-p	Pkinase_C	NQVFLGFtYVAPSVL	18701453	438	8	1	9209; 9205; 9234; 9206; 97596	
mosaic variegated aneuploidy (MVA) syndrome	increased	KIF2A	KIF2A	O00139	3796	5q12.1	79.95	human	40240801	T554-p		ANRVKELtVDPTAAG	25660017	1	0	0		
Alzheimer's disease	increased	TRAPPC6A	TRAPPC6A	O75865	79090	19q13.32	17.60	human	23155168	S35-p	TRAPP	GGQKMSLsVLEGMGF	25650666	2	0	1		aggregates in human brain cortex
type 2 diabetes	decreased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	449111	S9-p		SGRPRTTsFAESCKP	15033922	513	44	227	5558; 14630; 14026; 14332; 79774; 9322; 9327; 9331; 9323; 9336; 9325; 8466; 8566; 14310	
type 2 diabetes	decreased	Gsk3a	GSK3A	Q2NL51	606496	7|7 A3	51.66	mouse	448584	S21-p		SGRARTSsFAEPGGG	15033922	145	24	277	8452; 9327; 9331; 9316; 9337; 5090; 8566	
type 2 diabetes	decreased	Insr	INSR	P15208	16337	8 A1.1|8 1.82 cM	155.61	mouse	447682	Y1180-p	PK_Tyr_Ser-Thr	DIYETDYyRKGGKGL	15033922	44	14	107	2969; 3024	
type 2 diabetes	decreased	Akt1	Akt1	P31750	11651	12 F1|12 61.2 cM	55.71	mouse	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	15033922	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
type 2 diabetes	decreased	Insr	INSR	P15208	16337	8 A1.1|8 1.82 cM	155.61	mouse	447681	Y1179-p	PK_Tyr_Ser-Thr	RDIYETDyYRKGGKG	15033922	49	36	707	2969; 3024; 3918	
Duchenne muscular dystrophy	increased	Ryr2	RYR2	E9Q401	20191	13 A1|13 4.38 cM	564.82	mouse	448848	S2807-p		YNRTRRIsQTSQVSI	20615971	52	5	3		S2808A mutation reduces cardiomyopathy and mortality in mdx mice
type 2 diabetes; diabetes mellitus	decreased	Gsk3b	GSK3B	P18266	84027	11q21	46.74	rat	449111	S9-p		SGRPRTTsFAESCKP	20398714	513	44	227	5558; 14630; 14026; 14332; 79774; 9322; 9327; 9331; 9323; 9336; 9325; 8466; 8566; 14310	A high fat diet and streptozotocin induced diabetes and decreased GSK3B S9 phosphorylation and increase tau phosphorylation. 
breast ductal carcinoma	decreased	EEF1A1	EEF1A1	P68104	1915	6q13	50.14	human	15629200	S300-p	GTP_EFTU_D2	EMHHEALsEALPGDN	20832312	1	5	0		
Down syndrome	increased	TP53	p53	P04637	7157	17p13.1	43.65	human	447490	S15-p	P53_TAD	PSVEPPLsQETFSDL	20696760	456	11	0	8514; 82530; 56979; 8695; 9286; 4030; 9284; 9235; 12571	
type 2 diabetes	decreased	TBC1D4	AS160	O60343	9882	13q22.2	146.56	human	455920	S588-p		RMRGRLGsVDSFERS	20938636	19	68	253	8730	
type 2 diabetes	decreased	TBC1D4	AS160	O60343	9882	13q22.2	146.56	human	455925	S318-p	PID	EFRSRCSsVTGVQRR	20938636	13	18	334	8619	
type 2 diabetes	decreased	TBC1D4	AS160	O60343	9882	13q22.2	146.56	human	455924	S751-p		EGRKRTSsTCSNESL	20938636	10	10	48		
type 2 diabetes	decreased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	20938636	732	14	18	5106; 48646; 13842; 4056; 2965; 43506; 77440; 9275; 13038; 86758; 80722; 5056	insulin-stimulated phosphorylation
thymic carcinoma	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	20597130	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	phosphorylation-positive patients show trend toward increased disease progression and poorer survival
acute myelogenous leukemia	decreased	Ctnnb1	CTNNB1	Q02248	12387	9 F4|9 72.19 cM	85.47	mouse	447582	S37-p		YLDSGIHsGATTTAP	21156284	97	3	12	2009; 4270; 9561; 13537; 60180; 41334	The development of LSCs led to decreased nuclear phosphorylation of beta-catenin S37 and T41. 
acute myelogenous leukemia	decreased	Ctnnb1	CTNNB1	Q02248	12387	9 F4|9 72.19 cM	85.47	mouse	447583	T41-p		GIHSGATtTAPSLSG	21156284	88	3	0	9565; 4270; 9561; 13537; 60180; 41334	The development of LSCs led to decreased nuclear phosphorylation of beta-catenin S37 and T41. 
obesity, hyperphagic	increased	Sirt1	SIRT1	Q923E4	93759	10|10 B4	80.37	mouse	452899	S46-p		DGPGLGRsPGEPSAA	21540183	8	49	9	2314	obese mice
Parkinson's disease		AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	21658387	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	Parkinson's disease associated mutations showed reduced interactions and phosphorylation of AKT1. 
Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	21865317	104	7	0	87281; 23706	
SLE	increased	S100A9	S100A9	P06702	6280	1q21.3	13.24	human	455888	T113-p		KPGLGEGtP______	22230807	4	14	22		
hypertrophic cardiomyopathy	increased	Gata4	GATA4	P46152	54254	15p12	44.60	rat	450013	S261-p		IKPQRRLsASRRVGL	22227582	9	1	1		
hypertrophic cardiomyopathy	increased	Gata4	GATA4	P46152	54254	15p12	44.60	rat	449604	S105-p	GATA-N	AYTPPPVsPRFSFPG	22227582	16	0	0		
prostate cancer	increased	CALD1	Caldesmon	Q05682	800	7q33	93.23	human	448466	S789-p		QSVDKVTsPTKV___	22197205	19	19	0		
melanoma skin cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	19996208	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
melanoma skin cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	19996208	732	14	18	5106; 48646; 13842; 4056; 2965; 43506; 77440; 9275; 13038; 86758; 80722; 5056	
melanoma skin cancer	increased	GSK3A	GSK3A	P49840	2931	19q13.2	50.98	human	448584	S21-p		SGRARTSsFAEPGGG	19996208	145	24	277	8452; 9327; 9331; 9316; 9337; 5090; 8566	
melanoma skin cancer	increased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	449111	S9-p		SGRPRTTsFAESCKP	19996208	513	44	227	5558; 14630; 14026; 14332; 79774; 9322; 9327; 9331; 9323; 9336; 9325; 8466; 8566; 14310	
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	12620701	Y52-p	Oest_recep	DSSKPAVyNYPEGAA	20101225	1	0	0		
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	12620700	Y219-p	zf-C4	SIQGHNDyMCPATNQ	20101225	2	0	0		
non-Hodgkin's lymphoma	decreased	Tp53	p53	P02340	22059	11 B3|11 42.83 cM	43.46	mouse	447490	S18-p	P53_TAD	ISLELPLsQETFSGL	20145032	456	11	0	8514; 82530; 56979; 8695; 9286; 4030; 9284; 9235; 12571	
melanoma skin cancer	increased	Marcks	MARCKS	P26645	17118	10 B1|10 19.49 cM	29.66	mouse	451837	S163-p	MARCKS	SFKLSGFsFKKSKKE	20211725	11	76	93	8722	
melanoma skin cancer	increased	Marcks	MARCKS	P26645	17118	10 B1|10 19.49 cM	29.66	mouse	447787	S156-p	MARCKS	KRFSFKKsFKLSGFS	20211725	24	30	7	11992; 2741	
melanoma skin cancer	increased	Marcks	MARCKS	P26645	17118	10 B1|10 19.49 cM	29.66	mouse	466360	S160-p	MARCKS	FKKSFKLsGFSFKKS	20211725	7	44	11	8722	
melanoma skin cancer	increased	Marcks	MARCKS	P26645	17118	10 B1|10 19.49 cM	29.66	mouse	447786	S152-p	MARCKS	KKKKKRFsFKKSFKL	20211725	26	15	10	11992; 2741	
hypertrophic cardiomyopathy	increased	Hdac2	HDAC2	P70288	15182	10 19.44 cM|10 B1	55.30	mouse	449930	S394-p		EDAVHEDsGDEDGED	21576649	6	87	52	69238	Phosphorylation of HDAC2 S394 is required for the development of cardiac hypertrophy.
Alzheimer's disease	decreased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	449111	S9-p		SGRPRTTsFAESCKP	22278060	513	44	227	5558; 14630; 14026; 14332; 79774; 9322; 9327; 9331; 9323; 9336; 9325; 8466; 8566; 14310	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	22278060	130	44	14	20473; 71429	
MI	increased	PFN1	profilin 1	P07737	5216	17p13.2	15.05	human	450514	Y129-p	Profilin	GLINKKCyEMASHLR	23000962	4	25	658		
cardiomyopathy	increased	HDAC5	HDAC5	Q9UQL6	10014	17q21.31	121.98	human	4788487	S279-p		KVAERRSsPLLRRKD	20716686	6	19	1		inhibits cardiomyocyte hypertrophy
type 2 diabetes	increased	PRKAA1	AMPKA1	Q13131	5562	5p13.1	64.01	human	448786	T183-p	Pkinase	SDGEFLRtSCGSPNY	20938636	221	16	33	5256; 2531; 2535; 4188; 50081; 74281	
breast ductal carcinoma	increased	CASP8	CASP8	Q14790	841	2q33.1	55.39	human	16855100	S387-p	Peptidase_C14	YLEMDLSsPQTRYIP	20937773	5	2	0		
hypertrophic cardiomyopathy	decreased	Map4	MAP4	P27546	17758	9 F2|9 59.83 cM	117.43	mouse	470381	S1046-p	Tubulin-binding	KAQAKVGsLDNVGHL	20889984	3	88	1		associated with increased dephosphorylation
hypertrophic cardiomyopathy	decreased	Map4	MAP4	P27546	17758	9 F2|9 59.83 cM	117.43	mouse	1210622	S914-p	Tubulin-binding	SVRSKVGsTENIKHQ	20889984	4	53	41		associated with increased dephosphorylation
non-small cell lung cancer	increased	ECT2	ECT2	Q9H8V3	1894	3q26.31	103.50	human	483847	T359-p		YLYEKANtPELKKSV	21189248	2	18	8		
Crohn disease	decreased	RIPK2	RIPK2	O43353	8767	8q21.3	61.19	human	4270705	Y474-p	CARD	DLIMKEDyELVSTKP	21123652	5	1	0		
encephalopathy	increased	Dnm1l	DRP1	O35303	114114	11q23	83.91	rat	454690	S635-p		PIPIMPAsPQKGHAV	21119009	98	78	114	4494; 3455	
colorectal carcinoma	increased	ELAVL1	HuR	Q15717	1994	19p13.2	36.09	human	2246702	S318-p		GDKILQVsFKTNKSH	21310943	8	3	0		
lymphoma	mutation of site	Tp53	p53	P02340	22059	11 B3|11 42.83 cM	43.46	mouse	447530	S312-p		LPTCTSAsPPQKKKP	20962274	49	32	7	2528	S309AA mice are mor suseptible to lymphoma and liver tumors after IR exposure.
Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	21849493	104	7	0	87281; 23706	
PEL	increased	PTEN	PTEN	P60484	5728	10q23.31	47.17	human	448313	S380-p		EPDHYRYsDTTDSDP	21819957	36	0	0	9551; 9549; 7960; 9554	
Kaposi's sarcoma	increased	PTEN	PTEN	P60484	5728	10q23.31	47.17	human	448313	S380-p		EPDHYRYsDTTDSDP	21819957	36	0	0	9551; 9549; 7960; 9554	
Kaposi's sarcoma	increased	RPS6	S6	P62753	6194	9p22.1	28.68	human	448092	S235-p		IAKRRRLsSLRASTS	21819957	225	60	972	4851; 14733; 3985; 34411; 27036; 4803; 3945; 62788; 5316; 9865; 8520; 97935; 2211; 4856; 62016; 4857; 4854; 5006; 4858; 81736	
Kaposi's sarcoma	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	21819957	732	14	18	5106; 48646; 13842; 4056; 2965; 43506; 77440; 9275; 13038; 86758; 80722; 5056	
Kaposi's sarcoma	increased	RPS6	S6	P62753	6194	9p22.1	28.68	human	448093	S236-p		AKRRRLSsLRASTSK	21819957	219	72	1124	4851; 14733; 3985; 34411; 27036; 4803; 3945; 62788; 5316; 9865; 8520; 97935; 2211; 4856; 62016; 4857; 4854; 5006; 4858; 81736	
ovarian cancer	increased	BAD	BAD	Q92934	572	11q13.1	18.39	human	447860	S75-p	Bcl-2_BAD	EIRSRHSsYPAGTED	21849418	125	22	172	9296; 94223; 9291; 11865; 5284; 5193	Higher BAD phosphorylation levels are seen in patients with incomplete response to platinum therapy. Lower levels of S75 phosphorylation were associated with increased overall survival.  
ovarian cancer	increased	BAD	BAD	Q92934	572	11q13.1	18.39	human	447862	S99-p	Bcl-2_BAD	PFRGRSRsAPPNLWA	21849418	121	55	216	5286; 4366; 9295	Higher BAD phosphorylation levels are seen in patients with incomplete response to platinum therapy. Lower levels of S75 phosphorylation were associated with increased overall survival.  
ovarian cancer	increased	BAD	BAD	Q92934	572	11q13.1	18.39	human	447863	S118-p	Bcl-2_BAD	GRELRRMsDEFVDSF	21849418	45	63	166	9297	Higher BAD phosphorylation levels are seen in patients with incomplete response to platinum therapy. Lower levels of S75 phosphorylation were associated with increased overall survival.  
hepatocellular carcinoma	increased	MET	Met	P08581	4233	7q31.2	155.54	human	448470	Y1234-p	PK_Tyr_Ser-Thr	RDMYDKEyYSVHNKT	21455220	51	36	740	4091; 98954; 3077; 3126; 3129; 4033; 12468	
hepatocellular carcinoma	increased	MET	Met	P08581	4233	7q31.2	155.54	human	448471	Y1235-p	PK_Tyr_Ser-Thr	DMYDKEYySVHNKTG	21455220	48	16	442	4091; 98954; 3077; 3126; 3129; 4033; 12468	
hepatocellular carcinoma	increased	TP53	p53	P04637	7157	17p13.1	43.65	human	447535	S392-p		FKTEGPDsD______	21455220	110	15	0	9281	
prostate cancer	increased	EIF4E	EIF4E	P06730	1977	4q23	25.10	human	447776	S209-p		DTATKSGsTTKNRFV	20679199	60	4	0	9741	hormone refractory human prostate cancer
prostate cancer	increased	Eif4e	EIF4E	P63073	13684	3 G3|3 64.3 cM	25.05	mouse	447776	S209-p		DTATKSGsTTKNRFV	20679199	60	4	0	9741	hormone refractory human prostate cancer
type 2 diabetes	decreased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	15919790	732	14	18	5106; 48646; 13842; 4056; 2965; 43506; 77440; 9275; 13038; 86758; 80722; 5056	
lung cancer	increased	Shc1	SHC1 iso2	P98083-2	20416	3 F1|3 39.11 cM	51.41	mouse	448509	Y239-p		EEPPDHQyYNDFPGK	23277357	31	22	947	2434	
lung cancer	increased	Shc1	SHC1 iso2	P98083-2	20416	3 F1|3 39.11 cM	51.41	mouse	448511	Y313-p		ELFDDPSyVNIQNLD	23277357	41	91	1971	2431	
lung cancer	increased	Shc1	SHC1 iso2	P98083-2	20416	3 F1|3 39.11 cM	51.41	mouse	448510	Y240-p		EPPDHQYyNDFPGKE	23277357	28	22	943	2434	
Bloom's syndrome	increased	H2AX	H2AX	P16104	3014	11q23.3	15.01	human	448841	S139-p		GKKATQAsQEY____	17634426	254	31	29	85410; 97148; 20304; 5438; 80312; 59141; 4309; 9719; 60566; 5763; 9720; 2577; 9718	
Bloom's syndrome	increased	CHEK2	Chk2	O96017	11200	22q12.1	60.91	human	447491	T68-p		SSLETVStQELYSIP	17634426	194	5	0	2661; 12812; 59068; 28130; 2197; 82263	
non-small cell lung cancer	increased	EGFR	EGFR	P00533	1956	7p11.2	134.28	human	448057	Y1092-p		TFLPVPEyINQSVPK	17653080	161	30	352	8543; 2236; 14565; 3777; 2234; 48576	
non-small cell lung cancer	mutation of site	EGFR	EGFR	P00533	1956	7p11.2	134.28	human	452119	S768-p	PK_Tyr_Ser-Thr	DEAYVMAsVDNPHVC	17653080	6	0	0		
Crohn disease	increased	Foxp3	FOXP3	Q99JB6	20371	X A1.1|X 3.41 cM	47.35	mouse	29672100	T175-p		CTFPRSGtPRKDSNL	23853094	1	1	0		
MI	decreased	Tnnt2	TNNT2	P50753	24837	13q13	35.73	rat	451755	S209-p	Troponin	KAQTERKsGKRQTER	23905701	9	0	0		
colorectal cancer	increased	PPP2CA	PPP2CA	P67775	5515	5q31.1	35.59	human	448571	Y307-p		VTRRTPDyFL_____	25003662	70	0	0		From 250 patient samples with metastatic CRC, 17.2% had high Y307-p levels and showed worse overall and progression-free survival. 
Crohn disease	increased	Foxp3	FOXP3	Q99JB6	20371	X A1.1|X 3.41 cM	47.35	mouse	12201088	S19-p		PSLALGPsPGVLPSW	23853094	1	1	0		
breast cancer	increased	AGO2	AGO2	Q9UKV8	27161	8q24.3	97.21	human	17533102	Y393-p	ArgoL2	ASFNTDPyVREFGIM	23636329	8	2	0		enhances cell survival and invasiveness under hypoxia and correlates with poorer overall survival in breast cancer patients
ASD autism spectrum	decreased	FMR1	FMR1	Q06787	2332	Xq27.3	71.17	human	469583	S500-p	FXMRP1_C_core	NSEASNAsETESDHR	24180586	20	6	0		reduction of phosphorylated FMR1 in superior frontal cortex in children and adults with autism, a reduction also seen in Brodman area in adults, but not in children
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448805	S305-p		IKRSKKNsLALSLTA	15193262	16	0	0		tamoxifen resistance
breast cancer	increased	ESR2	ER-beta	Q92731	2100	14q23.2-q23.3	59.22	human	34425602	Y36-p	ERbeta_N	SIYIPSSyVDSHHEY	24960160	2	0	0		Patients with p-Y36?negative tumors had shorter disease-free  and overall survival than those with p-Y36?positive tumors
breast cancer	increased	PLCG1	PLCG1	P19174	5335	20q12	148.53	human	447667	Y783-p		EGRNPGFyVEANPMP	22847294	88	42	558	14461; 25678; 14008; 2821; 88717	 higher distant relapse and shorter disease-free survival
breast cancer	increased	PLCG1	PLCG1	P19174	5335	20q12	148.53	human	448576	Y1253-p		EGSFESRyQQPFEDF	22847294	12	19	85		 higher distant relapse and shorter disease-free survival
ovarian epithelial carcinoma	increased	PTK2	FAK	Q05397	5747	8q24.3	119.23	human	447887	Y397-p		SVSETDDyAEIIDEE	24655477	340	31	474	3283; 8556	High pY397 FAK is associated with improved overall survival
uteroplacental insufficiency	increased	Mapk3	ERK1	P21708	50689	1q36	43.08	rat	447542	T203-p	Pkinase	HDHTGFLtEYVATRW	16940436	1283	106	2017	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 54240; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
uteroplacental insufficiency	increased	Irs1	IRS1	P35570	25467	9q34	131.18	rat	447562	S612-p		DDGYMPMsPGVAPVP	16940436	36	7	4	3193; 2386; 3203	
uteroplacental insufficiency	increased	Mapk1	ERK2	P63086	116590	11q23	41.28	rat	447594	Y185-p	Pkinase	HTGFLTEyVATRWYR	16940436	1139	157	4003	13214; 8544; 14227; 5726; 98168; 3510; 9106; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 54240; 4376; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
uteroplacental insufficiency	increased	Mapk1	ERK2	P63086	116590	11q23	41.28	rat	447593	T183-p	Pkinase	HDHTGFLtEYVATRW	16940436	1116	120	2416	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 54240; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
uteroplacental insufficiency	increased	Mapk3	ERK1	P21708	50689	1q36	43.08	rat	447543	Y205-p	Pkinase	HTGFLTEyVATRWYR	16940436	1304	138	3549	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 14474; 54240; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
diabetes mellitus	decreased	Nfe2l2	NRF2	Q60795	18024	2 C3|2 44.75 cM	66.90	mouse	450082	S40-p		SREVFDFsQRQKDYE	24967692	31	0	0		
glioma	increased	SRC	Src	P12931	6714	20q11.23	59.83	human	448234	Y419-p	PK_Tyr_Ser-Thr	RLIEDNEyTARQGAK	24358106	416	102	3046	6943; 2101; 78740; 70926; 94361; 59548; 17320	
obesity, hyperphagic	increased	Irs1	IRS1	P35569	16367	1 C5|1 42.0 cM	130.72	mouse	453434	S1097-p		GCRRRHSsETFSAPT	18952604	11	39	122	2385	ob/ob mice
obesity, hyperphagic	increased	Rps6kb1	p70S6K	Q8BSK8	72508	11|11 C	59.15	mouse	448607	T412-p	Pkinase_C	NQVFLGFtYVAPSVL	18952604	438	8	1	9209; 9205; 9234; 9206; 97596	ob/ob mice
obesity, hyperphagic	increased	Irs1	IRS1	P35569	16367	1 C5|1 42.0 cM	130.72	mouse	447566	S265-p		EFRPRSKsQSSSSCS	18952604	6	15	31		ob/ob mice
obesity, hyperphagic	increased	Irs1	IRS1	P35569	16367	1 C5|1 42.0 cM	130.72	mouse	450190	S302-p		TRRSRTEsITATSPA	18952604	53	12	1	2384; 2491	ob/ob mice
obesity, hyperphagic	increased	Irs1	IRS1	P35569	16367	1 C5|1 42.0 cM	130.72	mouse	447506	S632-p		NGDYMPMsPKSVSAP	18952604	40	25	1	2388	ob/ob mice
kidney cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	19118035	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	renal cell carcinoma
kidney cancer	increased	CDKN1B	p27Kip1	P46527	1027	12p13.1	22.07	human	448645	T157-p		GIRKRPAtDDSSTQN	19118035	25	0	1		renal cell carcinoma
kidney cancer	decreased	CDKN1B	p27Kip1	P46527	1027	12p13.1	22.07	human	448781	T198-p		PGLRRRQt_______	19118035	27	0	6		renal cell carcinoma
Status epilepticus	decreased	Slc12a5	KCC2 iso2	Q91V14-2	57138	2|2 H3	123.59	mouse	487533	S940-p	SLC12	ITDESRGsIRRKNPA	25733865	22	5	2		
ovarian cancer		SH2B3	LNK	Q9UQQ2	10019	12q24.12	63.23	human	14575499	S150-p		RHIFRRRsAGELPAA	24704825	0	23	4		
hypertrophic cardiomyopathy		PTPN11	SHP-2 iso1	Q06124-1	5781	12q24.13	68.44	human	27458516	S189-p	SH2	GGGERFDsLTDLVEH	25802336	1	1	0		
hypertrophic cardiomyopathy		PTPN11	SHP-2 iso1	Q06124-1	5781	12q24.13	68.44	human	40407604	T73-p	SH2	YGGEKFAtLAELVQY	25802336	1	0	0		
pancreatic carcinoma	increased	GOT2	GOT2	P00505	2806	16q21	47.52	human	466485	K159-ac	Aminotran_1_2	SRDVFLPkPTWGNHT	25755250	1	8	32		
breast cancer, triple negative	increased	PELP1	PELP1	Q8IZL8	27043	17p13.2	119.70	human	472322	S1033-p		LAPEALPsQGEVERE	25788226	2	14	29		
AC	mutation of site	DSP	Desmoplakin	P15924	1832	6p24.3	331.77	human	34833301	R2834-me		SGSRSGSrSGSRSGS	25733715	1	1	0		
colorectal cancer	increased	BCL2	Bcl-2	P10415	596	18q21.33	26.27	human	448396	S87-p		AAAGPALsPVPPVVH	25826088	22	1	0		high pBcl-2-S87 had poor outcomes
prostate cancer	increased	RUNX2	AML3	Q13950	860	6p21.1	56.65	human	10892802	S312-p		SYLSQMTsPSIHSTT	25867060	11	1	0		
colorectal cancer	increased	FER	Fer	P16591	2241	5q21.3	94.64	human	448461	Y714-p	PK_Tyr_Ser-Thr	RQEDGGVySSSGLKQ	25867068	3	34	611		
prostate cancer	increased	TLN1	talin 1	Q9Y490	7094	9p13.3	269.77	human	1984203	S425-p		TMLEDSVsPKKSTVL	24793790	7	44	2	5426; 13589	promotes bone metastasis
breast adenocarcinoma	increased	BAD	BAD	Q92934	572	11q13.1	18.39	human	447860	S75-p	Bcl-2_BAD	EIRSRHSsYPAGTED	24909179	125	22	172	9296; 94223; 9291; 11865; 5284; 5193	Her2 positive breast cancer PKACA and PIM1 overexpression promote resistance
breast adenocarcinoma	increased	BAD	BAD	Q92934	572	11q13.1	18.39	human	447862	S99-p	Bcl-2_BAD	PFRGRSRsAPPNLWA	24909179	121	55	216	5286; 4366; 9295	Her2 positive breast cancer PKACA and PIM1 overexpression promote resistance
type 2 diabetes	increased	Gria1	GluR1	P19490	50592	10q22	101.58	rat	448565	S849-p		FCLIPQQsINEAIRT	23490331	85	4	3	75574	
type 2 diabetes	increased	Syn1	SYN1	P09951	24949	Xq11	73.99	rat	450236	S603-p		AGPIRQAsQAGPGPR	23490331	21	9	11	88246	
type 2 diabetes	decreased	Camk2a	CAMK2A	P11275	25400	18q12.1	54.11	rat	447797	T286-p		SCMHRQEtVDCLKKF	23490331	143	33	72	12716	
type 2 diabetes	decreased	Camk2b	CAMK2B	P08413	24245	14q21	60.40	rat	450048	T287-p		SMMHRQEtVECLKKF	23490331	26	16	109	12716	
hypertrophic cardiomyopathy	increased	Gja1	GJA1	P08050	24392	20q11	43.03	rat	448853	S279-p		SSPTAPLsPMSPPGY	23922949	42	6	1		left ventricular hypertrophy
hypertrophic cardiomyopathy	increased	Gja1	GJA1	P08050	24392	20q11	43.03	rat	448854	S282-p		TAPLSPMsPPGYKLV	23922949	40	7	1		left ventricular hypertrophy
obesity, hyperphagic	mutation of site	Lepr	LEPR	P48356	16847	4 C6|4 46.96 cM	130.79	mouse	448435	Y985-p		QRQPSVKyATLVSND	20086094	16	0	0		
Turner-like syndrome	decreased	RAF1	RAF1	P04049	5894	3p25.2	73.05	human	447741	S259-p		SQRQRSTsTPNVHMV	20679480	57	32	142	9421; 20011	Noonan syndrome RAF1 mutations lead to dephosphorylation of S259 and impaired 14-3-3 binding.
fibrosarcoma of soft tissue	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	21575192	468	74	3065	4324; 8119; 9145; 4113; 52075; 73533; 9138; 4323; 4093; 4074; 52527; 74309; 16185; 61958; 9131; 73452	Y705 phosphorylation was significantly associated with tumor grade.
breast cancer	increased	ESR2	ER-beta	Q92731	2100	14q23.2-q23.3	59.22	human	447914	S105-p	ERbeta_N	LYAEPQKsPWCEARS	20696772	5	1	0		associated with improved disease-free and overall survival
Status epilepticus	increased	Ywhaz	14-3-3 zeta	P63101	22631	15|15 B3.1	27.77	mouse	449833	S58-p	14-3-3	VVGARRSsWRVVSSI	20813501	15	1	5	52631	
colorectal carcinoma	increased	LEPR	LEPR	P48357	3953	1p31.3	132.49	human	448434	Y1141-p		SKKTFASyMPQFQTC	21166956	16	0	0		
colorectal carcinoma	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	21166956	468	74	3065	4324; 8119; 9145; 4113; 52075; 73533; 9138; 4323; 4093; 4074; 52527; 74309; 16185; 61958; 9131; 73452	
breast cancer	increased	TWIST1	TWIST1	Q15672	7291	7p21.1	20.95	human	18905000	S68-p		GGGDEPGsPAQGKRG	21502402	5	13	0		
pancreatic cancer	increased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	449111	S9-p		SGRPRTTsFAESCKP	21474066	513	44	227	5558; 14630; 14026; 14332; 79774; 9322; 9327; 9331; 9323; 9336; 9325; 8466; 8566; 14310	phosphorylation associated with poor overall survival
pancreatic cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	21474066	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	phosphorylation associated with poor overall survival
pancreatic cancer	increased	MTOR	mTOR	P42345	2475	1p36.22	288.89	human	447578	S2448-p		RSRTRTDsYSAGQSV	21474066	187	17	106	2971; 5536; 54932; 2976	phosphorylation associated with poor overall survival
Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	21562258	104	7	0	87281; 23706	
Parkinson's disease	increased	PRKN	PARK2	O60260	5071	6q26	51.64	human	15624700	Y143-p		SPAGRSIyNSFYVYC	20823226	1	1	0		
cardiomyopathy	decreased	MYBPC3	MYBPC3	Q14896	4607	11p11.2	140.76	human	471080	S284-p		AGGGRRIsDSHEDTG	20850451	35	8	28		
cardiomyopathy	decreased	MYBPC3	MYBPC3	Q14896	4607	11p11.2	140.76	human	471079	S275-p		LSAFRRTsLAGGGRR	20850451	25	9	14		
acute myelogenous leukemia	mutation of site	CBL	CBL	P22681	867	11q23.3	99.63	human	449753	Y371-p		TQEQYELyCEMGSTF	20622007	8	10	81		
glioblastoma multiforme	increased	PTEN	PTEN	P60484	5728	10q23.31	47.17	human	448316	Y240-p	PTEN_C2	RREDKFMyFEFPQPL	22891331	3	1	0		shortened survival 
acute lymphocytic leukemia	increased	NR3C1	GR	P04150	2908	5q31.3	85.66	human	3178932	S134-p	GCR	ANLNRSTsVPENPKS	24291004	8	11	6	85060	glucocorticoid resistance
LGMD2A	decreased	CAPN3	CAPN3	P20807	825	15q15.1	94.25	human	36398901	S629-p	Calpain_u2	EEGKGKTsPDKQKQS	25252031	1	1	0		
Alzheimer's disease	increased	PPP1R1B	DARPP-32	Q9UD71	84152	17q12	22.96	human	448048	T75-p	DARPP-32	RPNPCAYtPPSLKAV	26178297	36	6	16	2301	
pancreatic carcinoma	increased	DNM1L	DRP1	O00429	10059	12p11.21	81.88	human	454690	S616-p		PIPIMPAsPQKGHAV	25658205	98	78	114	4494; 3455	human pancreatic ductal adenocarcinoma
breast cancer	increased	CCDC88A	girdin	Q3V6T2	55704	2p16.1	216.04	human	456477	S1417-p		INRERQKsLTLTPTR	25732845	9	18	1		
prostate cancer	increased	PTK2	FAK	Q05397	5747	8q24.3	119.23	human	447965	Y861-p		PIGNQHIyQPVGKPD	25868388	74	21	307		correlates with decreased survival
bladder cancer	decreased	YAP1	YAP1	P46937	10413	11q22.1	54.46	human	448847	S127-p		PQHVRAHsSPASLQL	26119935	171	32	180	4911; 57706; 13008; 92367	Yap phosphorylation decreased in cisplatin resistant tumors (xenograft model). 
endometrial cancer	increased	PAK4	PAK4	O96013	10298	19q13.2	64.07	human	448023	S474-p	Pkinase	KEVPRRKsLVGTPYW	26218748	12	66	140	3241	nuclear p-Pak4, pathogenesis of endometrial cancer especially in postmenopausal women
lung cancer		EPHA2	EphA2	P29317	1969	1p36.13	108.27	human	1244153	S897-p		RVSIRLPsTSGSEGV	26158630	16	32	171	6347	co-localized with RSK, associated with overall survival of lung cancer patients
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448805	S305-p		IKRSKKNsLALSLTA	26272591	16	0	0		AKAP13 mRNA levels correlate with ER-alpha S305 phosphorylation and poor outcome in patients who received tamoxifen treatment  
hepatocellular carcinoma		STMN1	STMN1	P16949	3925	1p36.11	17.30	human	448555	S25-p	Stathmin	QAFELILsPRSKESV	26505358	50	122	91		 there was a signifcant increase of stathmin expression in metastatic hepatic cancer, implying that the phosphorylation status of stathmin S25 may be involved in the invasion and metastasis of HCC
colorectal cancer	increased	PPARG	PPAR-gamma iso2	P37231-2	5468	3p25.2	54.68	human	9256871	Y74-p	PPARgamma_N	YDLKLQEyQSAIKVE	26718225	2	0	1		
hepatocellular carcinoma	increased	SREBF1	SREBP-1	P36956	6720	17p11.2	121.68	human	53350800	R321-m2		APASAQSrGEKRTAH	26759235	1	1	0		correlates with poor prognosis
PAAND	mutation of site	MEFV	pyrin	O15553	4210	16p13.3	86.44	human	455899	S242-p		SGKMRPRsLEVTIST	27030597	7	7	0		
CRPC	increased	NPM1	NPM1	P06748	4869	5q35.1	32.58	human	448515	T199-p		VKKSIRDtPAKNAQK	26993766	23	29	30	3541	
CRPC	increased	NPM1	NPM1	P06748	4869	5q35.1	32.58	human	449560	T237-p		KQEKTPKtPKGPSSV	26993766	7	26	21		
CRPC	increased	NPM1	NPM1	P06748	4869	5q35.1	32.58	human	449024	T234-p		SFKKQEKtPKTPKGP	26993766	7	21	17		
breast cancer	increased	HSPA1A	HSP70	P0DMV8	3303	6p21.33	70.05	human	15382304	K561-m3	HSP70	EDEGLKGkISEADKK	26448330	2	5	2		
ovarian cancer	increased	HSPA1A	HSP70	P0DMV8	3303	6p21.33	70.05	human	3898759	K561-m2	HSP70	EDEGLKGkISEADKK	26448330	1	4	3		
ovarian cancer	increased	HSPA1A	HSP70	P0DMV8	3303	6p21.33	70.05	human	9300010	K561-m1	HSP70	EDEGLKGkISEADKK	26448330	0	4	17		
ASD autism spectrum	decreased	NLGN4X	NLGN4X	Q8N0W4	57502	Xp22.32-p22.31	91.92	human	40245512	T707-p		KDKRRHEtHRRPSPQ	25675530	1	1	0		phosphorylation of this site is eliminated in individuals carrying the autism-associated mutation R704C
colorectal carcinoma; non-small cell squamous cell lung carcinoma	decreased	PRKAA1	AMPKA1	Q13131	5562	5p13.1	64.01	human	448786	T183-p	Pkinase	SDGEFLRtSCGSPNY	25679763	221	16	33	5256; 2531; 2535; 4188; 50081; 74281	
multiple sclerosis	increased	MLKL	MLKL	Q8NB16	197259	16q23.1	54.48	human	5891858	T357-p	PK_Tyr_Ser-Thr	FELRKTQtSMSLGTT	25801023	7	1	1		MS brain samples
multiple sclerosis	increased	RIPK1	RIPK1	Q13546	8737	6p25.2	75.93	human	20536000	S14-p		LNVIKMKsSDFLESA	25801023	2	1	0	53487	MS brain samples
multiple sclerosis	increased	RIPK1	RIPK1	Q13546	8737	6p25.2	75.93	human	27116401	S166-p	PK_Tyr_Ser-Thr	LASFKMWsKLNNEEH	25801023	27	2	0	53286; 31122; 96323; 65746; 44590	MS brain samples
multiple sclerosis	increased	RIPK3	RIPK3	Q9Y572	11035	14q12	56.89	human	23003800	S227-p	Pkinase	VELPTEPsLVYEAVC	25801023	23	7	0	93654; 57220; 91702	MS brain samples
multiple sclerosis	increased	RIPK1	RIPK1	Q13546	8737	6p25.2	75.93	human	20536002	S15-p		NVIKMKSsDFLESAE	25801023	2	1	1		MS brain samples
B cell lymphoma; non-Hodgkin's lymphoma; lymphoplasmacytic lymphoma; follicular lymphoma	increased	CSNK2B	CK2B	P67870	1460	6p21.33	24.94	human	451751	S209-p		QAASNFKsPVKTIR_	25788269	6	45	58		
B cell lymphoma; non-Hodgkin's lymphoma; lymphoplasmacytic lymphoma; follicular lymphoma	increased	CDC37	CDC37	Q16543	11140	19p13.2	44.47	human	450034	S13-p	CDC37_N	VWDHIEVsDDEDETH	25788269	12	29	0	13248	
rheumatoid arthritis; SLE	increased	GRN	GRN	P28799	2896	17q21.31	63.54	human	41198100	S81-p	Granulin	IFTVSGTsSCCPFPE	26005049	1	0	0		
kidney cancer; SRCC	increased	CTTN	Cortactin	Q14247	2017	11q13.3	61.59	human	447702	Y421-p		RLPSSPVyEDAASFK	21696810	43	62	745	4569	predictor for cause-specific survival
hypertrophic cardiomyopathy	increased	Gata4	GATA4	Q08369	14463	14 D1|14 33.24 cM	44.58	mouse	449604	S105-p	GATA-N	AYTPPPVsPRFSFPG	21746915	16	0	0		required for stress-induced cardiac hypertrophy
T-ALL	increased	IRAK1	IRAK1	P51617	3654	Xq28	76.54	human	450949	T209-p		LCEISRGtHNFSEEL	26068967	4	1	0		
glioblastoma multiforme	increased	TNK2	Ack	Q07912	10188	3q29	114.57	human	4251154	Y635-p		PLPPPPAyDDVAQDE	25257795	1	2	5		
non-small cell squamous cell lung carcinoma	increased	DPYSL2	CRMP-2	Q16555	1808	8p21.2	62.29	human	448082	S522-p		PASSAKTsPAKQQAP	26555036	29	49	84		CRMP2A is present within the nucleus in cancer cells
diabetes mellitus	increased	Oprm1	MOR-1	P33535	25601	1q11	44.49	rat	447785	T370-p		STRVRQNtREHPSTA	26713421	19	5	0		
obesity, hyperphagic		IRS2	IRS2	Q9Y4H2	8660	13q34	137.33	human	1984215	S391-p		SVAGSPLsPGPVRAP	26657864	3	39	80		
NAFLD	increased	Cebpa	C/EBP-alpha	P53566	12606	7 B2|7 21.02 cM	37.43	mouse	1868113505	S193-p		PPPHPHAsPAHLAAP	27373160	14	0	0		
HNSCC	increased	PDHA1	PDHA1	P08559	5160	Xp22.12	43.30	human	448257	S232-p	E1_dh	NRYGMGTsVERAAAS	27498883	45	79	7	15289	worse clinical outcome
tuberous sclerosis	increased	CTNND1	CTNND1	O60716	1500	11q12.1	108.17	human	450453	S268-p		PQVRVGGsSVDLHRF	27516388	12	73	56		
Alzheimer's disease	increased	Marcks	MARCKS	P26645	17118	10 B1|10 19.49 cM	29.66	mouse	454165	S46-p	MARCKS	VKVNGDAsPAAAEPG	27557632	3	41	0		
Alzheimer's disease	increased	MARCKS	MARCKS	P29966	4082	6q21	31.55	human	484096	S147-p	MARCKS	DGATPSPsNETPKKK	27557632	1	34	3		
Alzheimer's disease	increased	MARCKS	MARCKS	P29966	4082	6q21	31.55	human	9831684	S132-p	MARCKS	EAASAASsTSSPKAE	27557632	1	7	0		
Alzheimer's disease	increased	MARCKS	MARCKS	P29966	4082	6q21	31.55	human	454165	S46-p	MARCKS	VKVNGDAsPAAAESG	27557632	3	41	0		
Alzheimer's disease	increased	MARCKS	MARCKS	P29966	4082	6q21	31.55	human	454166	T150-p	MARCKS	TPSPSNEtPKKKKKR	27557632	1	70	8		
breast cancer	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	1308913	K27-m3	Histone	LATKAARkSAPATGG	27494834	169	21	3	9733; 89120; 4395; 12158; 98316; 5499; 91611; 14034; 10584; 4232; 35861; 20123; 40724; 54575	sites correlated and low expression associates with better survival in human breast cancers
breast cancer	increased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	449111	S9-p		SGRPRTTsFAESCKP	27494834	513	44	227	5558; 14630; 14026; 14332; 79774; 9322; 9327; 9331; 9323; 9336; 9325; 8466; 8566; 14310	sites correlated and low expression associates with better survival in human breast cancers
LBD	increased	DPYSL2	CRMP-2	Q16555	1808	8p21.2	62.29	human	454386	T514-p		SVTPKTVtPASSAKT	27609071	31	36	35	9397	
Parkinson's disease	decreased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	449111	S9-p		SGRPRTTsFAESCKP	27609071	513	44	227	5558; 14630; 14026; 14332; 79774; 9322; 9327; 9331; 9323; 9336; 9325; 8466; 8566; 14310	Parkinson's disease dementia
cardiomyopathy; hypertrophic cardiomyopathy	mutation of site	Cacna1c	CACNA1C iso5	Q0PCR6	12288	6 F1|6 55.86 cM	243.37	mouse	17620920	T1704-p	CAC1F_C	RAISGDLtAEEELDK	27864509	9	1	0		
cardiomyopathy; hypertrophic cardiomyopathy	mutation of site	Cacna1c	CACNA1C iso5	Q0PCR6	12288	6 F1|6 55.86 cM	243.37	mouse	4714250	S1700-p	CAC1F_C	PEIRRAIsGDLTAEE	27864509	17	7	0		
Parkinson's disease; LBD	decreased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	448569	Y216-p	Pkinase	RGEPNVSyICSRYYR	27609071	91	127	4206		Parkinson's disease dementia
leukemia	increased	ACAT1	ACAT1	P24752	38	11q22.3	45.20	human	10943316	Y407-p	Thiolase_C	HALKQGEyGLASICN	27867011	2	1	0		
Parkinson's disease	decreased	CRTC1	TORC1	Q6UUV9	23373	19p13.11	67.30	human	60885604	S215-p	TORC_M	KTGSRPKsCEVPGIN	27903866	1	0	0		
mesothelioma	increased	NF2	Merlin	P35240	4771	22q12.2	69.69	human	448282	S518-p	ERM_C	DTDMKRLsMEIEKEK	18835652	30	41	1	9163; 13281	in patient samples, merlin was truncated or phosphorylated on S518
diabetes mellitus	increased	Cryab	CRYAB	P23928	25420	8q23	20.09	rat	447728	S19-p	Crystallin	RPFFPFHsPSRLFDQ	24349305	26	16	2		increased at 12 weeks in all rat strains
diabetes mellitus	increased	Cryab	CRYAB	P23928	25420	8q23	20.09	rat	448748	S45-p	Crystallin	FSTATSLsPFYLRPP	24349305	35	7	1		increased at 12 weeks in all rat strains
diabetes mellitus	increased	Cryab	CRYAB	P23928	25420	8q23	20.09	rat	448783	S59-p		PSFLRAPsWIDTGLS	24349305	44	22	0		increased at 12 weeks in all rat strains
HSAN1	mutation of site	SPTLC2	SPTLC2	O15270	9517	14q24.3	62.92	human	38520203	S384-p	Aminotran_1_2	FTKSFGAsGGYIGGK	25567748	1	0	0		
uteroplacental insufficiency	increased	Nr3c1	GR	P06536	24413	18p11	87.56	rat	447968	S232-p	GCR	PSKDTNEsPWRSDLL	16002560	45	5	0	4161	
type 2 diabetes	decreased	Akt1	Akt1	P31750	11651	12 F1|12 61.2 cM	55.71	mouse	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	16777975	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	db/db mice
type 2 diabetes	decreased	Foxo1	FOXO1A	Q9R1E0	56458	3 C|3 23.19 cM	69.52	mouse	448560	T24-p		LPRQRSCtWPLPRPE	16777975	58	6	39	9464; 2599	db/db mice
type 2 diabetes	increased	Irs1	IRS1	P35569	16367	1 C5|1 42.0 cM	130.72	mouse	447558	S307-p		TESITATsPASMVGG	16777975	73	14	0	2381	db/db mice
gastric carcinoma	increased	MORC2	MORC2	Q9Y6X9	22880	22q12.2	117.82	human	3217905	S739-p		ATPSRKRsVAVSDEE	25888627	2	37	8		associated with the poor prognosis of clinical gastric cancer
colorectal cancer	increased	TP53	p53	P04637	7157	17p13.1	43.65	human	447490	S15-p	P53_TAD	PSVEPPLsQETFSDL	25860929	456	11	0	8514; 82530; 56979; 8695; 9286; 4030; 9284; 9235; 12571	FBXW7-mutations
ovarian cancer	increased	Syk	Syk	P48025	20963	13 A5|13 27.41 cM	71.38	mouse	447662	Y520-p	PK_Tyr_Ser-Thr	LRADENYyKAQTHGK	26096845	39	8	72	12081; 46994; 12967; 5514; 6485; 2710; 2711; 4349; 16859	increased in recurrent ovarian cancers
ovarian cancer	increased	Syk	Syk	P48025	20963	13 A5|13 27.41 cM	71.38	mouse	447661	Y519-p	PK_Tyr_Ser-Thr	ALRADENyYKAQTHG	26096845	39	7	76	12081; 46994; 12967; 5514; 6485; 2710; 2711; 4349; 16859	increased in recurrent ovarian cancers
Alzheimer's disease	increased	BACE1	BACE	P56817	23621	11q23.3	55.76	human	48881800	T252-p	Asp	YTGSLWYtPIRREWY	26317805	1	0	0		
ASD autism spectrum	mutation of site	UBE3A	UBE3A iso2	Q05086-2	7337	15q11.2	97.97	human	48891100	T485-p		MYSERRItVLYSLVQ	26255772	3	1	0		
psoriasis	increased	MAPK14	P38A	Q16539	1432	6p21.31	41.29	human	455799	Y323-p		DEPVADPyDQSFESR	24863062	8	1	0		
myelodysplastic syndrome	increased	ADD1	ADD1	P35611	118	4p16.3	80.96	human	449829	S726-p		KKKFRTPsFLKKSKK	26578796	24	57	158		
hypertrophic cardiomyopathy	increased	DPF3	DPF3 iso2	Q92784-2	8110	14q24.2	40.24	human	23251120	S348-p		GRRSGRGsPTADKKG	26582913	1	3	1		S348 phosphorylation is required for hypertrophy
T cell lymphoma	mutation of site	CARD11	CARD11	Q9BXL7	84433	7p22.2	133.28	human	5403700	S615-p		RYSFGPSsIHSSSSS	26551667	3	0	0		Sezary syndrome, cutaneous T cell lymphoma (CTCL)
melanoma skin cancer	increased	Akt1	Akt1	P31750	11651	12 F1|12 61.2 cM	55.71	mouse	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	26565903	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	activated AKT1 promotes melanoma formation and distant metastasis
multiple myeloma	increased	EZH2	EZH2	Q15910	2146	7q36.1	85.36	human	457606	S21-p		CWRKRVKsEYMRLRQ	26517694	7	1	1		
stroke	increased	Stk4	MST1	Q9JI11	58231	2|2 H3	55.54	mouse	463558	Y433-p	Mst1_SARAH	KIPQDGDyEFLKSWT	26721416	3	13	110		inhibition protects against ischemic stroke
microlissencephaly		NDE1	NUDE1	Q9NXR1	54820	16p13.11	38.81	human	467025	T246-p	NUDE_C	STGGTPLtPAARISA	21529751	2	14	31		T246 in maybe involved in disease
non-small cell lung adenocarcinoma	increased	ITPRID2	SSFA2	P28290	6744	2q31.3	138.39	human	484806	S92-p		CRTPLGAsLDEQSSS	26947549	1	48	2		high levels of phosphorylation had significantly reduced relapse-free survival (p < 0.01)
breast cancer; breast cancer, triple negative	increased	SRC	Src	P12931	6714	20q11.23	59.83	human	448234	Y419-p	PK_Tyr_Ser-Thr	RLIEDNEyTARQGAK	26923594	416	102	3046	6943; 2101; 78740; 70926; 94361; 59548; 17320	higher in basal subtype BC;TNBC
obesity, hyperphagic	increased	H2BC3	H2B	P33778	3018	6p22.2	13.82	human	449903	S36-p	Histone	RKRSRKEsYSIYVYK	27151441	7	13	47		
obesity, hyperphagic	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	1308913	K27-m3	Histone	LATKAARkSAPATGG	27151441	169	21	3	9733; 89120; 4395; 12158; 98316; 5499; 91611; 14034; 10584; 4232; 35861; 20123; 40724; 54575	
breast cancer	decreased	NOTCH1	Notch 1	P46531	4851	9q34.3	272.50	human	483083	T2511-p		VPEHPFLtPSPESPD	27335110	5	1	0		
breast cancer	decreased	TFRC	TfR	P02786	7037	3q29	84.87	human	448928	Y20-p		FGGEPLSyTRFSLAR	21859709	2	43	1048		enhances breast cancer cell survival
breast cancer	increased	CAMK2A	CAMK2A	Q9UQM7	815	5q32	54.09	human	447797	T286-p		SCMHRQEtVDCLKKF	27605043	143	33	72	12716	primary breast cancer and lymph node metastases tissues
breast cancer	increased	FOSL1	FRA1	P15407	8061	11q13.1	29.41	human	1270902	T217-p		LEPEALHtPTLMTTP	27816489	2	0	0		
SBMA	increased	AR	AR	P10275	367	Xq12	99.19	human	448416	S96-p	Androgen_recep	QQQGEDGsPQAHRRG	28003546	9	11	0		
ALS	increased	GFAP	GFAP	P14136	2670	17q21.31	49.88	human	31012804	K339-ac	Filament	EEEGQSLkDEMARHL	24312501	1	2	0		
ALS	increased	GFAP	GFAP	P14136	2670	17q21.31	49.88	human	31012802	K189-ac	Filament	ARLDLERkIESLEEE	24312501	1	2	0		
ALS	increased	GFAP	GFAP	P14136	2670	17q21.31	49.88	human	31012803	K228-ac	Filament	HVELDVAkPDLTAAL	24312501	1	1	0		
ALS	increased	GFAP	GFAP	P14136	2670	17q21.31	49.88	human	31012801	K154-ac	Filament	DLATVRQkLQDETNL	24312501	1	2	0		
ALS	increased	GFAP	GFAP	P14136	2670	17q21.31	49.88	human	31012800	K95-ac	Filament	RFLEQQNkALAAELN	24312501	1	2	0		
ALS	increased	GFAP	GFAP	P14136	2670	17q21.31	49.88	human	4131824	K260-ac	Filament	AEEWYRSkFADLTDA	24312501	1	2	2		
myotonic dystrophy type1	increased	CELF1	CELF1	Q92879	10658	11p11.2	52.06	human	3347300	S28-p	RRM_1	GQVPRTWsEKDLREL	24376746	3	9	1		DM1-E2 (classic phenotype)
myotonic dystrophy type1		CELF1	CELF1	Q92879	10658	11p11.2	52.06	human	3347300	S28-p	RRM_1	GQVPRTWsEKDLREL	24376746	3	9	1		DM1-E1, DM1-CDM, no change
DM2		CELF1	CELF1	Q92879	10658	11p11.2	52.06	human	3347300	S28-p	RRM_1	GQVPRTWsEKDLREL	24376746	3	9	1		DM2-PS, DM2-PDM, DM2-PROMM no change
neuroblastoma	increased	ADAM9	ADAM9	Q13443	8754	8p11.22	90.56	human	457836	Y736-p		RKKRSQTyESDGKNQ	24349301	0	3	47		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	ANTXR1	ANTXR1	Q9H6X2	84168	2p13.3	62.79	human	458176	Y425-p	Ant_C	VKMPEQEyEFPEPRN	24349301	1	11	108		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	ANKRD26	ANKRD26	Q9UPS8	22852	10p12.1	196.41	human	462968	Y296-p		RKNLEATyGTVRTGN	24349301	0	11	67		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	APP	APP	P05067	351	21q21.3	86.94	human	448202	Y757-p	APP_amyloid	SKMQQNGyENPTYKF	24349301	13	20	864		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	CD46	CD46 iso4	P15529-4	4179	1q32.2	41.36	human	451710	Y357-p		GGAEYATyQTKSTTP	24349301	0	17	604		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	CDK2	CDK2	P24941	1017	12q13.2	33.93	human	447740	Y15-p	Pkinase	EKIGEGTyGVVYKAR	24349301	32	129	3845		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	CDK5	CDK5	Q00535	1020	7q36.1	33.30	human	448022	Y15-p	Pkinase	EKIGEGTyGTVFKAK	24349301	17	47	894	94254; 19051	increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	CD46	CD46 iso2	P15529-2	4179	1q32.2	44.24	human	451710	Y387-p		GGAEYATyQTKSTTP	24349301	0	17	604		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	CDK1	CDK1	P06493	983	10q21.2	34.10	human	447610	Y15-p	Pkinase	EKIGEGTyGVVYKGR	24349301	177	145	3902	9111; 77897; 14566; 4539	increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	CDK1	CDK1	P06493	983	10q21.2	34.10	human	447608	T14-p	Pkinase	IEKIGEGtYGVVYKG	24349301	30	117	1764	2543	increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	CTNND1	CTNND1	O60716	1500	11q12.1	108.17	human	449495	Y96-p		QDHSHLLySTIPRMQ	24349301	4	35	735		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	CNNM3	CNNM3	Q8NE01	26505	2q11.2	76.12	human	467057	Y301-p		ARGGGDPySDLSKGV	24349301	0	5	125		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	JUP	CTNNG	P14923	3728	17q21.2	81.74	human	461979	Y480-p		QNSVRLNyGIPAIVK	24349301	0	4	118		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	DDR2	DDR2	Q16832	4921	1q23.3	96.74	human	456862	Y740-p	PK_Tyr_Ser-Thr	RNLYSGDyYRIQGRA	24349301	1	9	366		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	DDR2	DDR2	Q16832	4921	1q23.3	96.74	human	456861	Y736-p	PK_Tyr_Ser-Thr	FGMSRNLySGDYYRI	24349301	1	9	409		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	EPHA2	EphA2	P29317	1969	1p36.13	108.27	human	450861	Y772-p	PK_Tyr_Ser-Thr	EDDPEATyTTSGGKI	24349301	5	55	860	8862; 8244	increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	ESYT1	ESYT1	Q9BSJ8	23344	12q13.2	122.86	human	450610	Y822-p	C2	GTKHLSPyATLTVGD	24349301	1	35	1220		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	EIF3C	EIF3C	Q99613	8663	16p11.2	105.34	human	459507	Y881-p		FDHKQGTyGGYFRDQ	24349301	0	7	118		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	CCDC88A	girdin	Q3V6T2	55704	2p16.1	216.04	human	450762	Y1799-p		QSKDSNPyATLPRAS	24349301	5	13	137		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	FGFR2	FGFR2	P21802	2263	10q26.13	92.03	human	472824	Y656-p	PK_Tyr_Ser-Thr	RDINNIDyYKKTTNG	24349301	2	8	66		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	448569	Y216-p	Pkinase	RGEPNVSyICSRYYR	24349301	91	127	4206		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	H2BC11	HIST1H2BJ	P06899	8970	6p22.1	13.77	human	21691325	Y42-p	Histone	ESYSIYVyKVLKQVH	24349301	0	6	33		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	HNRNPM	hnRNP M	P52272	4670	19p13.2	77.52	human	456974	Y64-p	HnRNP_M_NLS	GGNRFEPyANPTKRY	24349301	0	14	264		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	LYN	LYN	P07948	4067	8q12.1	58.57	human	448695	Y397-p	PK_Tyr_Ser-Thr	RVIEDNEyTAREGAK	24349301	27	61	2054	6943; 2101; 78740; 70926; 94361; 59548; 17320	increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	IGF1R	IGF1R	P08069	3480	15q26.3	154.79	human	448386	Y1161-p	PK_Tyr_Ser-Thr	FGMTRDIyETDYYRK	24349301	21	31	455	3021; 80732	increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	MAPK12	P38G	P53778	6300	22q13.33	41.94	human	448032	Y185-p	Pkinase	ADSEMTGyVVTRWYR	24349301	2	34	804	24678; 8632; 9215; 9219; 4511; 62979; 4551; 14598; 4552; 6908; 9216; 4092; 9211; 14594; 41768; 51255; 4631	increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	IGF1R	IGF1R	P08069	3480	15q26.3	154.79	human	448387	Y1165-p	PK_Tyr_Ser-Thr	RDIYETDyYRKGGKG	24349301	19	38	707	2969; 3024; 3918	increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	JAK2	JAK2	O60674	3717	9p24.1	130.67	human	451494	Y570-p	PK_Tyr_Ser-Thr	VRREVGDyGQLHETE	24349301	8	40	825		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	MYH10	MYH10	P35580	4628	17p13.1	229.00	human	463833	Y1415-p	Myosin_tail_1	LEEKALAyDKLEKTK	24349301	0	12	449		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	TMIGD2	IGPR-1	Q96BF3	126259	19p13.3	30.67	human	463789	Y222-p		DQRGQSIySTSFPQP	24349301	0	3	126		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	MAP4K5	KHS1	Q9Y4K4	11183	14q22.1	95.02	human	463541	Y31-p	Pkinase	QRVGSGTyGDVYKAR	24349301	0	7	161		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	INSR	INSR	P06213	3643	19p13.2	156.33	human	447680	Y1185-p	PK_Tyr_Ser-Thr	FGMTRDIyETDYYRK	24349301	36	31	455	3021; 80732	increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	TMIGD2	IGPR-1 iso2	Q96BF3-2	126259	19p13.3	30.32	human	3422796	Y188-p		RDSGNAFySNVLYRP	24349301	0	3	117		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	INSR	INSR	P06213	3643	19p13.2	156.33	human	447681	Y1189-p	PK_Tyr_Ser-Thr	RDIYETDyYRKGGKG	24349301	49	36	707	2969; 3024; 3918	increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	UNK	UNK	Q9C0B0	85451	17q25.1	88.08	human	3663342	Y232-p		PRLCRQGyACPYYHN	24349301	0	1	3		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	RBMX	RBMX	P38159	27316	Xq26.3	42.33	human	460084	Y255-p		HSSSRDDyPSRGYSD	24349301	0	7	70		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	MPZL1	PZR	O95297	9019	1q24.2	29.08	human	449521	Y263-p		NKSESVVyADIRKN_	24349301	1	57	1101	5543; 8088	increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	TLN2	talin 2	Q9Y4G6	83660	15q22.2	271.61	human	462871	Y72-p	FERM_f0	EAGRTLDyYMLRNGD	24349301	0	5	19		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	VIM	Vimentin	P08670	7431	10p13	53.65	human	448931	Y61-p	Filament_head	ASSPGGVyATRSSAV	24349301	1	50	2170		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	SH2D3C	SHEP1	Q8N5H7	10044	9q34.11	94.41	human	460469	Y316-p		EQSGAIIyCPVNRTF	24349301	0	2	22		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	PCDH1	PCDH1	Q08174	5097	5q31.3	114.74	human	2470209	Y897-p	Protocadherin	KKETKDLyAPKPSGK	24349301	0	7	63		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	SRCIN1	SNIP	Q9C0H9	80725	17q12	112.45	human	456704	Y268-p		LVKGEGLyADPYGLL	24349301	1	18	217		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	PLD3	PLD3	Q8IV08	23646	19q13.2	54.71	human	3424010	Y7-p		_MKPKLMyQELKVPA	24349301	0	6	127		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
breast cancer		Mdm2	MDM2	P23804	17246	10 D2|10 66.32 cM	54.56	mouse	448131	S183-p		RHRKRRRsLSFDPSL	20841468	12	9	2		
breast cancer		Mdm2	MDM2	P23804	17246	10 D2|10 66.32 cM	54.56	mouse	448130	S163-p		SSRRRSIsETEENTD	20841468	47	19	5	3521	
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448102	S167-p	Oest_recep	GGRERLAsTNDKGSM	24166501	46	5	0	64508; 42101	S167/S305 and Ser167 alone, but not Ser305 phosphorylation, are significantly associated disease-free survival in breast cancer patients
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448805	S305-p		IKRSKKNsLALSLTA	24166501	16	0	0		S167/S305 and Ser167 alone, but not Ser305 phosphorylation, are significantly associated disease-free survival in breast cancer patients
Alzheimer's disease	increased	DNM1L	DRP1	O00429	10059	12p11.21	81.88	human	31872528	S40-p	Dynamin_N	TQSSGKSsVLESLVG	25192600	2	1	0		blocking phosphorylation is neuroprotective in models
Alzheimer's disease	increased	DNM1L	DRP1	O00429	10059	12p11.21	81.88	human	31866197	S44-p	Dynamin_N	GKSSVLEsLVGRDLL	25192600	2	1	0		blocking phosphorylation is neuroprotective in models
Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	25637461	104	7	0	87281; 23706	Lower pS129 levels correlated with worse clinical condition at early stages, but better condition at later stages.
neuroblastoma	increased	SDC2	syndecan-2	P34741	6383	8q22.1	22.16	human	448376	Y191-p	Syndecan	RKPSSAAyQKAPTKE	24349301	1	5	6		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	PPP1CB	PPP1CB	P62140	5500	2p23.2	37.19	human	459361	Y306-p		EKKAKYQyGGLNSGR	24349301	0	8	318		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	RAB8A	RAB8A	P61006	4218	19p13.11	23.67	human	464116	Y5-p		___MAKTyDYLFKLL	24349301	0	7	76		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	TNS2	tensin 2	Q63HR2	23371	12q13.13	152.58	human	450768	Y483-p		GPLDGSPyAQVQRPP	24349301	1	44	1536		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	TXNRD1	TRXR1	Q16881	7296	12q23.3	70.91	human	450592	Y281-p	Pyr_redox_2	KVVYENAyGQFIGPH	24349301	0	20	566		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	F2R	PAR1	P25116	2149	5q13.3	47.44	human	458505	Y420-p		SNLNNSIyKKLLT__	24349301	0	6	121		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	SHC3	SHC3	Q92529	53358	9q22.1	64.06	human	451257	Y406-p		RQGSSDIySTPEGKL	24349301	1	3	27		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	RPL35A	RPL35A	P18077	6165	3q29	12.54	human	487362	Y34-p	Ribosomal_L35Ae	LLKIEGVyARDETEF	24349301	0	7	42		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	SCARF2	SREC-II	Q96GP6	91179	22q11.21	92.38	human	450727	Y628-p		EGPGGALyARVARRE	24349301	0	11	74		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	PRKCD	PKCD	Q05655	5580	3p21.1	77.51	human	447573	Y313-p		SSEPVGIyQGFEKKT	24349301	38	60	1707	2055	increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
vulvar cancer	increased	CDK1	CDK1	P06493	983	10q21.2	34.10	human	447610	Y15-p	Pkinase	EKIGEGTyGVVYKGR	25849598	177	145	3902	9111; 77897; 14566; 4539	vulvar squamous cell carcinoma;  advanced tumor behaviors and aggressive features; decreased patient survival
vulvar cancer	increased	CDK1	CDK1	P06493	983	10q21.2	34.10	human	447609	T161-p	Pkinase	GIPIRVYtHEVVTLW	25849598	37	43	83	9114	vulvar squamous cell carcinoma;  advanced tumor behaviors and aggressive features; decreased patient survival
vulvar cancer	increased	CCNB1	CCNB1	P14635	891	5q13.2	48.34	human	448814	S126-p		PILVDTAsPSPMETS	25849598	11	2	0		vulvar squamous cell carcinoma;  advanced tumor behaviors and aggressive features; decreased patient survival
Parkinson's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	449132	S701-p		DTSPRHLsNVSSTGS	25394490	13	10	5		In midbrain, significant hyperphosphorylation in PD mouse model
Parkinson's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	447933	T497-p		SSPGSPGtPGSRSRT	25394490	113	24	26	30505; 43964; 49561; 20060; 53001; 20739	In midbrain, significant hyperphosphorylation in PD mouse model
Parkinson's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	447934	T504-p		TPGSRSRtPSLPTPP	25394490	45	16	5		In midbrain, significant hyperphosphorylation in PD mouse model
Parkinson's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	449081	S688-p		GAEIVYKsPVVSGDT	25394490	170	45	90	9632	In midbrain, significant hyperphosphorylation in PD mouse model
Parkinson's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	447930	S554-p	Tubulin-binding	NVRSKIGsTENLKHQ	25394490	108	24	2		In midbrain, significant hyperphosphorylation in PD mouse model
Parkinson's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	449080	S527-p		VVRTPPKsPSASKSR	25394490	43	36	25	20473	In midbrain, significant hyperphosphorylation in PD mouse model
Parkinson's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	449104	S648-p	Tubulin-binding	RVQSKIGsLDNITHV	25394490	33	24	0		In midbrain, significant hyperphosphorylation in PD mouse model
Parkinson's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	449083	S714-p		GSIDMVDsPQLATLA	25394490	38	9	0		In midbrain, significant hyperphosphorylation in PD mouse model
Parkinson's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	449082	S696-p		PVVSGDTsPRHLSNV	25394490	132	53	69	20194; 35834; 98523; 49562; 91600	In midbrain, significant hyperphosphorylation in PD mouse model
prostate cancer	increased	SQSTM1	SQSTM1	Q13501	8878	5q35.3	47.69	human	454787	S272-p		RSRLTPVsPESSSTE	26279575	7	80	278	13121	
prostate cancer	increased	SQSTM1	SQSTM1	Q13501	8878	5q35.3	47.69	human	457004	T269-p		GGKRSRLtPVSPESS	26279575	7	74	136	13121	
Parkinson's disease	increased	UBA52-RPS27A-UBB-UBC	ubiquitin	P62988		2p16	8.56	human	9765472	S65-p	ubiquitin	DYNIQKEsTLHLVLR	26389970	26	17	0	37642; 70973; 62802; 83816	
hyperalgesia	increased	Trpv1	TRPV1	O35433	83810	10q24	94.95	rat	473576	T406-p		IAYSSSEtPNRHDML	26376215	5	0	0		
chronic myelogenous leukemia	increased	YBX3	CSDA	P16989	8531	12p13.2	40.09	human	3181076	S134-p	CSD	NPRKYLRsVGDGETV	21368869	1	30	1		
breast cancer	increased	SIRT6	SIRT6	Q8N6T7	51548	19p13.3	39.12	human	7916000	S338-p		PKRERPTsPAPHRPP	25074979	3	7	23		poorer overall survival
breast cancer	decreased	CDKN1B	p27Kip1	P46527	1027	12p13.1	22.07	human	448645	T157-p		GIRKRPAtDDSSTQN	26701207	25	0	1		correlates with low level of Myc protein
pheochromocytoma	mutation of site	RET	Ret	P07949	5979	10q11.21	124.32	human	455479	Y791-p	PK_Tyr_Ser-Thr	HPHVIKLyGACSQDG	20080836	2	0	0		double C634Y/Y791F mutant
HIBM	mutation of site	Gne	GNE	O35826	114711	5q22	79.23	rat	21335600	M712-p	ROK	ALLGAASmVLDYTTR	21873062	1	0	0		
Parkinson's disease		PINK1	PINK1	Q9BXM7	65018	1p36.12	62.77	human	23003808	T313-p	Pkinase	EGLGHGRtLFLVMKN	22238344	1	1	0		
AIS	mutation of site	AR	AR	P10275	367	Xq12	99.19	human	23303205	R407-p	Androgen_recep	AAAAAQCrYGDLASL	22334658	1	0	0		
hypertrophic cardiomyopathy	mutation of site	JPH2	JPH2	Q9BR39	57158	20q13.12	74.22	human	12275224	Y141-p	MORN	TNGMRHGyGVRQSVP	22389502	1	0	0		Y141H
breast cancer, triple negative	increased	TAB3	TAB3	Q8N5C8	257397	Xp21.2	78.68	human	54400803	S408-gl		TATTPPSsSPSRGIS	27009840	1	2	0		cancer metastasis and poor prognosis
breast cancer	increased	STMN1	STMN1	P16949	3925	1p36.11	17.30	human	448556	S38-p	Stathmin	SVPEFPLsPPKKKDL	27130664	48	114	166	3426; 4191	higher incidence of recurrence
anal carcinoma	increased	CASP8	CASP8	Q14790	841	2q33.1	55.39	human	56640300	T273-p	Peptidase_C14	DAGALTTtFEELHFE	27325299	4	0	0		overall survival (OS) was superior for tumors showing a high pT273 caspase-8 signal 
breast cancer	mutation of site	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448103	Y537-p		CKNVVPLyDLLLEML	27748765	9	0	0		mutated in breast cancer, CRISPR-Cas9 genome editing mutation Y537S. 
Alzheimer's disease	increased	FCGR2B	FCGR2B iso2	P31994-2	2213	1q23.3	31.94	human	448507	Y273-p		GAENTITySLLMHPD	27834631	4	2	1		
melanoma skin cancer; cancer, squamous cell carcinoma; BCC	increased	NFATC4	NFAT3	Q14934	4776	14q12	95.45	human	31859079	S259-p		APGPTPAsPRPASPC	27893713	1	1	0		
cervical cancer	increased	PLK1	PLK1	P53350	5347	16p12.2	68.25	human	62370600	Y425-p	POLO_box	SDKYGLGyQLCDNSV	27899378	1	1	0		higher  PLK1  tyrosine  phosphorylation show  a  poor  5-year  survival  rate
Alzheimer's disease	decreased	H3c1	H3	P68433	360198	13|13 A3.1	15.27	mouse	481136	S57-p	Histone	EIRRYQKsTELLIRK	26199864	2	19	9		 done in 5XFAD (rapid amyloid deposition ) mice
ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084616	S409-p		GSSMDSKsSGWGM__	26192745	48	4	0		
Alzheimer's disease	decreased	H3c1	H3	P68433	360198	13|13 A3.1	15.27	mouse	481137	T58-p	Histone	IRRYQKStELLIRKL	26199864	1	10	0		 done in 5XFAD (rapid amyloid deposition ) mice
chronic myelogenous leukemia	decreased	MAPK8	JNK1	P45983	5599	10q11.22	48.30	human	447643	T183-p	Pkinase	AGTSFMMtPYVVTRY	26147002	264	33	392	5755; 9257; 4671; 4668; 9251; 58328; 4306; 5136; 9255	
chronic myelogenous leukemia	decreased	SFN	14-3-3 sigma	P31947	2810	1p36.11	27.77	human	456054	S186-p	14-3-3	FHYEIANsPEEAISL	26147002	5	0	0		
chronic lymphocytic leukemia; mantle cell lymphoma	increased	ALOX5	5-LO	P09917	240	10q11.21	77.98	human	452140	S524-p	Lipoxygenase	GMRGRKSsGFPKSVK	26210919	7	1	0		
colorectal cancer	increased	TCF3	E2A	P15923	6929	19p13.3	67.60	human	15500103	S39-p		NGKGRPAsLAGAQFG	26212009	1	2	1		
HNSCC	increased	RB1	Rb	P06400	5925	13q14.2	106.16	human	447981	T356-p		DSFETQRtPRKSNLD	26265441	14	19	36	99158	
colorectal carcinoma; ovarian cancer; non-small cell lung adenocarcinoma, surrounding tissue	increased	TOP1	TOP1	P11387	7150	20q12	90.73	human	27276101	S506-p	Topoisom_I	ADTVGCCsLRVEHIN	26248194	3	0	0		
Fanconi's anaemia	decreased	STMN1	STMN1	P16949	3925	1p36.11	17.30	human	448554	S16-p	Stathmin	KELEKRAsGQAFELI	26466335	38	98	61	3353	
Fanconi's anaemia	decreased	STMN1	STMN1	P16949	3925	1p36.11	17.30	human	448556	S38-p	Stathmin	SVPEFPLsPPKKKDL	26466335	48	114	166	3426; 4191	
hepatocellular carcinoma	increased	NPM1	NPM1	P06748	4869	5q35.1	32.58	human	449560	T237-p		KQEKTPKtPKGPSSV	26536659	7	26	21		
hepatocellular carcinoma	increased	NPM1	NPM1	P06748	4869	5q35.1	32.58	human	449024	T234-p		SFKKQEKtPKTPKGP	26536659	7	21	17		
pancreatic cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	26676747	732	14	18	5106; 48646; 13842; 4056; 2965; 43506; 77440; 9275; 13038; 86758; 80722; 5056	high BAP28  or low AktT308 increased survival and response to gemcitabine
breast cancer	increased	BCAR1	P130Cas	P56945	9564	16q23.1	93.37	human	451537	Y267-p		SQYGQEVyDTPPMAV	26867768	3	21	285		driving mammary carcinoma progression
breast cancer	increased	BCAR1	P130Cas	P56945	9564	16q23.1	93.37	human	448779	Y306-p		PSNHHAVyDVPPSVS	26867768	3	15	191		driving mammary carcinoma progression
breast cancer	increased	BCAR1	P130Cas	P56945	9564	16q23.1	93.37	human	451538	Y287-p		RDPLLEVyDVPPSVE	26867768	2	17	284		driving mammary carcinoma progression
breast cancer	increased	BCAR1	P130Cas	P56945	9564	16q23.1	93.37	human	448721	Y249-p		APGPQDIyDVPPVRG	26867768	13	44	723	4014	driving mammary carcinoma progression
breast cancer	increased	BCAR1	P130Cas	P56945	9564	16q23.1	93.37	human	449639	Y234-p		AQPEQDEyDIPRHLL	26867768	3	31	698		driving mammary carcinoma progression
RTT	mutation of site	MECP2	MECP2	P51608	4204	Xq28	52.44	human	31879716	T158-p	MBD	DPNDFDFtVTGRGSP	27064487	2	0	0		
Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	3546424	Y39-p	Synuclein	KTKEGVLyVGSKTKE	27348587	8	4	11		accumulates in Lewy bodies
cystic fibrosis	mutation of site	CFTR	CFTR	P13569	1080	7q31.2	168.14	human	56689900	S1045-p	ABC_membrane	QQLKQLEsEGRSPIF	27261451	1	0	0		S1045Y-CFTR mutation
non-small cell lung adenocarcinoma	increased	Mybl2	B-Myb	P48972	17865	2 H2|2 84.0 cM	79.10	mouse	452027	T490-p	Cmyb_C	SQKVVVTtPLHRDKT	27212033	3	2	43		
non-small cell lung adenocarcinoma	increased	MYBL2	B-Myb	P10244	4605	20q13.12	78.76	human	452027	T487-p	Cmyb_C	SQKVVVTtPLHRDKT	27212033	3	2	43		
hypertrophic cardiomyopathy	decreased	NOX4	NOX4	Q9NPH5	50507	11q14.3	66.93	human	57848101	Y566-p		LSNQNNSyGTRFEYN	27525436	1	1	0		
cardiomyopathy	increased	DNM1L	DRP1	O00429	10059	12p11.21	81.88	human	454690	S616-p		PIPIMPAsPQKGHAV	27739424	98	78	114	4494; 3455	
type 2 diabetes	increased	Cacna1c	CACNA1C iso5	Q0PCR6	12288	6 F1|6 55.86 cM	243.37	mouse	455278	S1927-p	CAC1F_C	ASLGRRAsFHLECLK	28119464	31	3	0		
breast cancer; obesity, hyperphagic		SMAD4	SMAD4	Q13485	4089	18q21.2	60.44	human	449628	T277-p		GSRTAPYtPNLPHHQ	28115363	3	0	0		
atherosclerosis		NR1H3	LXR-alpha	Q13133	10062	11p11.2	50.40	human	469114	S198-p		SLPPRASsPPQILPQ	25825525	6	0	0		
Alzheimer's disease	decreased	WWOX	WWOX	Q9NZC7	51741	16q23.1-q23.2	46.68	human	449043	Y33-p	WW	TTKDGWVyYANHTEE	15126504	21	1	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447927	S199-p		GDRSGYSsPGSPGTP	15126504	87	30	33	29957	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	15126504	130	44	14	20473; 71429	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449551	S198-p		SGDRSGYsSPGSPGT	15126504	21	15	10		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447934	T212-p		TPGSRSRtPSLPTPP	15126504	45	16	5		
Alzheimer's disease	increased	APP	APP	P05067	351	21q21.3	86.94	human	480465	S679-p	Beta-APP	DAEFRHDsGYEVHHQ	25556395	10	1	0		accumulation in the parenchyma and vasculature and is largely restricted to late-stage AD
obesity, hyperphagic	increased	Irs1	IRS1	P35570	25467	9q34	131.18	rat	447558	S307-p		TESITATsPASMVGG	16267124	73	14	0	2381	
obesity, hyperphagic	increased	Ppp1r12a	MYPT1	Q10728	116670	7q21	115.28	rat	448587	T697-p		ARQSRRStQGVTLTD	16267124	62	42	226	5163	
obesity, hyperphagic	decreased	Akt1	Akt1	P47196	24185	6q32	55.74	rat	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	16267124	732	14	18	5106; 48646; 13842; 4056; 2965; 43506; 77440; 9275; 13038; 86758; 80722; 5056	
hepatocellular carcinoma		H2AX	H2AX	P16104	3014	11q23.3	15.01	human	448841	S139-p		GKKATQAsQEY____	25537504	254	31	29	85410; 97148; 20304; 5438; 80312; 59141; 4309; 9719; 60566; 5763; 9720; 2577; 9718	recurrence/metastasis of HCC
non-small cell lung cancer	increased	PAK1	PAK1	Q13153	5058	11q13.5-q14.1	60.65	human	448177	T423-p	Pkinase	PEQSKRStMVGTPYW	25956913	37	4	11	2601	Higher in later stages vs lower stage,  inverse correlation with E-cadherin/p120-catenin expression 
non-small cell lung cancer	increased	CRK	CRK	P46108	1398	17p13.3	33.83	human	454189	S41-p	SH2	VFLVRDSsTSPGDYV	25956913	2	18	17		Higher in later stages vs lower stage,  inverse correlation with E-cadherin/p120-catenin expression 
schizophrenia; bipolar disprder	increased	SP4	SP4	Q02446	6671	7p15.3	81.98	human	17548374	S770-p		VAAISQDsNPATPNV	26049820	3	5	0		in BD cerebellum postmortem, in cerebellum schizophrenia postmortem
ovarian epithelial carcinoma	increased	PRKAA1	AMPKA1	Q13131	5562	5p13.1	64.01	human	448786	T183-p	Pkinase	SDGEFLRtSCGSPNY	26068970	221	16	33	5256; 2531; 2535; 4188; 50081; 74281	spheroids
ovarian epithelial carcinoma	increased	STK11	LKB1	Q15831	6794	19p13.3	48.64	human	448147	S428-p		SSKIRRLsACKQQ__	26068970	32	2	3	3482	spheroids
colorectal cancer		COPS6	COPS6	Q7L5N1	10980	7q22.1	36.16	human	48903200	S148-p	JAB	QVCEIIEsPLFLKLN	26267535	1	0	0		
PAH	increased	CAPN2	CAPN2	P17655	824	1q41	80.00	human	451162	S50-p	Peptidase_C2	GTLFQDPsFPAIPSA	26248159	3	1	0		
PAH	decreased	CAPN2	CAPN2	P17655	824	1q41	80.00	human	451303	S369-p	Calpain_III	DGNWRRGsTAGGCRN	26248159	2	1	2		
breast cancer, triple negative		EZH2	EZH2	Q15910	2146	7q36.1	85.36	human	10417699	T416-p		EANSRCQtPIKMKPN	26279746	5	7	7		
melanoma skin cancer	increased	ATM	ATM	Q13315	472	11q22.3	350.69	human	448797	S1981-p		SLAFEEGsQSTTISS	26275218	203	24	4	5883; 13050; 4526	nuclear S1981 is associated with melanoma progression, strong S1981 was associated with worse overall survival 
breast cancer	decreased	VASP	VASP	P50552	7408	19q13.32	39.83	human	469024	S322-p		TTLPRMKsSSSVTTS	26336132	3	15	45		Patients with high expression of PRKD2 showed an increase in relapse-free survival.
anal carcinoma	increased	CASP8	CASP8	Q14790	841	2q33.1	55.39	human	56640300	T273-p	Peptidase_C14	DAGALTTtFEELHFE	27462786	4	0	0		elevated levels of Plk3 and pT273 caspase-8  are correlated with favorable clinical outcome with  mitomycin C-based chemoradiotherapy (CRT)
bladder cancer	mutation of site	POU5F1	Oct4	Q01860	5460	6p21.33	38.57	human	57951801	K156-m1	Pou	FAKLLKQkRITLGYT	27369080	1	1	0		
bladder cancer	mutation of site	POU5F1	Oct4	Q01860	5460	6p21.33	38.57	human	57951800	K156-ub	Pou	FAKLLKQkRITLGYT	27369080	1	1	0		
bladder cancer	mutation of site	POU5F1	Oct4	Q01860	5460	6p21.33	38.57	human	57951802	K156-ac	Pou	FAKLLKQkRITLGYT	27369080	1	1	0		
FXS	mutation of site	FMR1	FMR1	Q06787	2332	Xq27.3	71.17	human	4046001	R546-me		RGQGGRGrGGGFKGN	10518318	5	0	0		arginine to a histidine
glioblastoma multiforme	increased	CDC25A	CDC25A	P30304	993	3p21.31	59.09	human	57761916	Y59-p		LQGLGSDyEQPLEVK	27485204	1	0	0		High Cdc25A pY59 levels indicate poor prognosis.
prostate cancer	increased	DBN1	DBN1	Q16643	1627	5q35.3	71.43	human	452446	S142-p		NGLARLSsPVLHRLR	28319065	6	87	28		
ovarian cancer	increased	HSF1	HSF1	Q00613	3297	8q24.3	57.26	human	455484	S326-p	Vert_HS_TF	SSVDTLLsPTALIDS	28415561	45	25	13		shorter overall survival (OS) 
melanoma skin cancer	increased	KARS1	KARS	Q15046	3735	16q23.1	68.05	human	9392600	S207-p		PYEITLLsPCLHMLP	28394346	4	1	0		
pancreatic carcinoma	increased	PIP5K1C	PIP5K1C	O60331	23396	19p13.3	73.26	human	486321	Y639-p		DAPATDIyFPTDERS	28388589	3	0	0		
breast ductal carcinoma	increased	AR	AR	P10275	367	Xq12	99.19	human	452166	S516-p		VSRVPYPsPTCVKSE	28415597	10	3	0		improved cancer-specifc survival in ductal breast cancer 
breast cancer, triple negative	increased	AR	AR	P10275	367	Xq12	99.19	human	452166	S516-p		VSRVPYPsPTCVKSE	28415597	10	3	0		poorer patient survival
breast ductal carcinoma	increased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447542	T202-p	Pkinase	HDHTGFLtEYVATRW	28415597	1283	106	2017	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 54240; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	improved cancer-specifc survival in ductal breast cancer 
breast ductal carcinoma	increased	MAPK1	ERK2	P28482	5594	22q11.22	41.39	human	447594	Y187-p	Pkinase	HTGFLTEyVATRWYR	28415597	1139	157	4003	13214; 8544; 14227; 5726; 98168; 3510; 9106; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 54240; 4376; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	improved cancer-specifc survival in ductal breast cancer 
breast ductal carcinoma	increased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447543	Y204-p	Pkinase	HTGFLTEyVATRWYR	28415597	1304	138	3549	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 14474; 54240; 48735; 45899; 9101; 4374; 4370; 14196; 15892	improved cancer-specifc survival in ductal breast cancer 
breast ductal carcinoma	increased	MAPK1	ERK2	P28482	5594	22q11.22	41.39	human	447593	T185-p	Pkinase	HDHTGFLtEYVATRW	28415597	1116	120	2416	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 54240; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	improved cancer-specifc survival in ductal breast cancer 
colorectal cancer	increased	TP53RK	PRPK	Q96S44	112858	20q13.12	28.16	human	1981300	S250-p		RLRGRKRsMVG____	28412249	3	0	7		
glioma	increased	ACSS2	ACSS2	Q9NR19	55902	20q11.22	78.58	human	83970101	S659-p	AMP-binding_C	PGLPKTRsGKIMRRV	28552616	3	1	0		
lung cancer	decreased	ZNF322	ZNF322A	Q6U7Q0	79692	6p22.2	46.94	human	31086030	S391-p		SEKGLELsPPHASEA	28581525	1	1	0		
breast cancer	increased	CDK4	CDK4	P11802	1019	12q14.1	33.73	human	448476	T172-p	Pkinase	YSYQMALtPVVVTLW	28566333	11	3	3		CDK4 T172 phosphorylation best correlated with sensitivity to PD0332991
glioma	increased	Olig2	OLIG2	Q9EQW6	50913	16 C3.3|16 52.6 cM	32.41	mouse	18357900	S13-p		SLVSSRPsSPEPDDL	28355568	4	2	0		
glioma	increased	Olig2	OLIG2	Q9EQW6	50913	16 C3.3|16 52.6 cM	32.41	mouse	18357903	S10-p		SDASLVSsRPSSPEP	28355568	4	2	0		
glioma	increased	Olig2	OLIG2	Q9EQW6	50913	16 C3.3|16 52.6 cM	32.41	mouse	18357901	S14-p		LVSSRPSsPEPDDLF	28355568	4	2	0		
pancreatic cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	28363942	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
FMD	increased	FLNA	FLNA	P21333	2316	Xq28	280.74	human	451357	S2152-p	Filamin	TRRRRAPsVANVGSH	28348077	19	80	999	4761	
breast cancer	increased	LDHA	LDH-A	P00338	3939	11p15.1	36.69	human	454712	Y10-p		TLKDQLIyNLLKEEQ	28218905	7	24	374	8176	progression of metastatic cancer
NAFLD	increased	Sirt1	SIRT1	Q923E4	93759	10|10 B4	80.37	mouse	6006904	S164-p		DDRTSHAsSSDWTPR	28533219	1	4	0		
NAFLD	increased	SIRT1	SIRT1	Q96EB6	23411	10q21.3	81.68	human	6006904	S172-p		EDRASHAsSSDWTPR	28533219	1	4	0		
Alzheimer's disease	increased	PSEN1	PSEN1	P49768	5663	14q24.2	52.67	human	452183	S310-p	Presenilin	PEAQRRVsKNSKYNA	28132667	2	0	0		
chronic lymphocytic leukemia	increased	USP7	USP7	Q93009	7874	16p13.2	128.30	human	449238	S18-p		KAGEQQLsEPEDMEM	28418900	2	63	5		
ovarian cancer	increased	RB1	Rb	P06400	5925	13q14.2	106.16	human	447980	S807-p	Rb_C	PGGNIYIsPLKSPYK	28319064	89	45	112	8974; 11917; 9308; 4277; 99274; 8957; 41359; 8516	
ovarian cancer	increased	RB1	Rb	P06400	5925	13q14.2	106.16	human	447981	T356-p		DSFETQRtPRKSNLD	28319064	14	19	36	99158	
CCA	increased	SP1	SP1	P08047	6667	12q13.13	80.69	human	452233	S59-p		GGQESQPsPLALLAA	28574228	6	16	0		
Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	28636593	104	7	0	87281; 23706	
Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	3546424	Y39-p	Synuclein	KTKEGVLyVGSKTKE	28636593	8	4	11		
non-small cell lung cancer	increased	SCD	SCD	O00767	6319	10q24.31	41.52	human	3411245	Y55-p		PDIKDDIyDPTYKDK	28724430	1	2	6		poor prognosis
non-small cell lung cancer	increased	EGFR	EGFR	P00533	1956	7p11.2	134.28	human	448057	Y1092-p		TFLPVPEyINQSVPK	28724430	161	30	352	8543; 2236; 14565; 3777; 2234; 48576	poor prognosis
prostate cancer	increased	PIK3R1	PIK3R1	P27986	5295	5q13.1	83.60	human	394748800	K513-ub	PI3K_P85_iSH2	KEYIEKFkREGNEKE	28676490	1	1	0		
prostate cancer	increased	PIK3R1	PIK3R1	P27986	5295	5q13.1	83.60	human	394748801	K519-ub	PI3K_P85_iSH2	FKREGNEkEIQRIMH	28676490	1	1	0		
clear cell kidney cancer	increased	PTPN6	SHP-1	P29350	5777	12p13.31	67.56	human	448506	Y536-p		QKGQESEyGNITYPP	28692056	17	24	637		advanced pathologic stage
Alzheimer's disease	increased	LGMN	LGMN	Q99538	5641	14q32.12	49.41	human	183811000	S226-p	Peptidase_C13	CYYDEKRsTYLGDWY	28826672	1	0	0		
Alzheimer's disease	increased	SRPK2	SRPK2	P78362	6733	7q22.3	77.53	human	483237	T492-p		PSHDRSRtVSASSTG	28826672	3	6	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449328	S324-p	Tubulin-binding	KVTSKCGsLGNIHHK	28760828	12	7	2		
breast cancer; ovarian cancer	increased	EZH2	EZH2	Q15910	2146	7q36.1	85.36	human	34490427	T311-p		NTYKRKNtETALDNK	29351847	4	2	0	27888	better survival
rheumatoid arthritis; SLE	increased	Ptpn6	SHP-1	P29351	15170	6 F2|6 59.17 cM	67.56	mouse	454019	S591-p		DKEKNKGsLKRK___	28811476	9	2	15		biomarker of lupus nephritis activity
nephrosis	increased	Ptpn6	SHP-1	P29351	15170	6 F2|6 59.17 cM	67.56	mouse	448506	Y536-p		QKGQESEyGNITYPP	28811476	17	24	637		protects mice against lethal nephritis
nephrosis	increased	PTPN6	SHP-1	P29350	5777	12p13.31	67.56	human	448506	Y536-p		QKGQESEyGNITYPP	28811476	17	24	637		protects mice against lethal nephritis
SLE		PTPN6	SHP-1	P29350	5777	12p13.31	67.56	human	454019	S591-p		DKEKSKGsLKRK___	28811476	9	2	15		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	28814543	170	45	90	9632	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447928	S202-p		SGYSSPGsPGTPGSR	28814543	149	55	116	30505; 39357	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449082	S404-p		PVVSGDTsPRHLSNV	28814543	132	53	69	20194; 35834; 98523; 49562; 91600	
Alzheimer's disease	increased	JUN	Jun	P05412	3725	1p32.1	35.68	human	447686	S63-p	Jun	KNSDLLTsPDVGLLK	28814543	127	43	4	91952; 5464; 2361; 9261	
Status epilepticus	increased	Eif4b	EIF4B	Q5RKG9	300253	7q36	69.06	rat	452271	S504-p		SSDTEQPsPTSGGGK	28874824	2	55	22		animal model of epilepsy
Alzheimer's disease	decreased	BACE1	BACE	P56817	23621	11q23.3	55.76	human	450178	S498-p		DDFADDIsLLK____	28946017	6	4	0		decreased in AD brains
Huntington's disease	decreased	HTT	Huntingtin	P42858	3064	4p16.3	347.60	human	10206804	T3-p		_____MAtLEKLMKA	29162692	12	4	0		
medulloblastoma	increased	Atoh1	ATOH1	P48985	11921	6 C1|6 30.03 cM	37.85	mouse	386186604	Y78-p		CTARAAQyLLHSPEL	29168692	1	1	0		
hepatocellular carcinoma	increased; mutation of site	TP53	p53	P04637	7157	17p13.1	43.65	human	394791401	R249-p	P53	CMGGMNRrPILTIIT	29225033	3	0	0		
chronic lymphocytic leukemia	increased	FCER2	FCER2	P06734	2208	19p13.2	36.47	human	1109469500	S254-p	Lectin_C	PGEPTSRsQGEDCVM	29763855	1	0	0		
Alzheimer's disease	increased	Set	SET iso2	Q9EQU5-2	56086	2|2 B	32.10	mouse	6308300	S9-p		SAPTAKAsKKELNSN	29760653	6	3	0		
chronic lymphocytic leukemia	increased	FCER2	FCER2	P06734	2208	19p13.2	36.47	human	1109469501	T314-p		DPDGRLPtPSAPLHS	29763855	1	0	0		
chronic lymphocytic leukemia	increased	FCER2	FCER2	P06734	2208	19p13.2	36.47	human	1109469502	S265-p	Lectin_C	DCVMMRGsGRWNDAF	29763855	1	0	0		
acute myelogenous leukemia	increased	RPS6KB1	p70S6K	P23443	6198	17q23.1	59.14	human	448607	T412-p	Pkinase_C	NQVFLGFtYVAPSVL	18056483	438	8	1	9209; 9205; 9234; 9206; 97596	
non-small cell lung cancer	mutation of site	EGFR	EGFR	P00533	1956	7p11.2	134.28	human	452119	S768-p	PK_Tyr_Ser-Thr	DEAYVMAsVDNPHVC	20522446	6	0	0		
non-small cell lung cancer	mutation of site	EGFR	EGFR	P00533	1956	7p11.2	134.28	human	452119	S768-p	PK_Tyr_Ser-Thr	DEAYVMAsVDNPHVC	26870223	6	0	0		
Parkinson's disease	mutation of site	Ndufa10	NDUFA10	Q99LC3	67273	1|1 D	40.60	mouse	32001601	S250-p	dNK	KTFLPKMsEMCEVLV	24652937	2	1	0		eventually leads to Parkinson?s disease in patients with PINK1 mutations
atrial fibrillation	mutation of site	HRC	HRC	P23327	3270	19q13.33	80.24	human	34499322	S96-p		EKEDEDVsKEYGHLL	30840693	2	4	0		rs3745297 (T>G, Ser96Ala) single nucleotide polymorphism (SNP) of HRC
		HSPB6	HSP20	O14558	126393	19q13.12	17.14	human	450706	S16-p	Crystallin	PSWLRRAsAPLPGLS	15829720	21	31	2		Inhibiting contraction
Alzheimer's disease	increased	Mapt	Tau	P19332	29477	10q32.1	78.56	rat	447927	S510-p		GERSGYSsPGSPGTP	22515493	87	30	33	29957	
Alzheimer's disease	increased	Mapt	Tau	P19332	29477	10q32.1	78.56	rat	447928	S513-p		SGYSSPGsPGTPGSR	22515493	149	55	116	30505; 39357	
liver cancer	decreased	Cebpa	C/EBP-alpha	P53566	12606	7 B2|7 21.02 cM	37.43	mouse	1868113505	S193-p		PPPHPHAsPAHLAAP	15107404	14	0	0		
liver cancer	increased	Cd274	PD-L1	Q9EP73	60533	19|19 C1	32.78	mouse	1015586	Y112-p	V-set	KLQDAGVyCCIISYG	31305264	1	1	0		required for liver cancer tumorigenesis in immunocompetent mice
liver cancer	increased	CD274	PD-L1	Q9NZQ7	29126	9p24.1	33.28	human	1015586	Y112-p	V-set	KLQDAGVyRCMISYG	31305264	1	1	0		required for liver cancer tumorigenesis in immunocompetent mice
lung cancer; non-small cell lung adenocarcinoma; glioblastoma	increased	MAP4K4	HGK	O95819	9448	2q11.2	142.10	human	480118	T187-p	Pkinase	RTVGRRNtFIGTPYW	12612079	1	10	102		
Parkinson's disease	increased	PEBP1	RKIP	P30086	5037	12q24.23	21.06	human	3189667	T42-p	PBP	DELGKVLtPTQVKNR	25104559	1	15	0		
diabetes mellitus	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	447930	S554-p	Tubulin-binding	NVRSKIGsTENLKHQ	22961084	108	24	2		
diabetes mellitus	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	449083	S714-p		GSIDMVDsPQLATLA	22961084	38	9	0		
breast cancer	increased	TRAF2	TRAF2	Q12933	7186	9q34.3	55.86	human	5397201	S11-p		ASVTPPGsLELLQPG	23007157	6	15	0	13908	
Alzheimer's disease	increased	DPYSL2	CRMP-2	Q16555	1808	8p21.2	62.29	human	448082	S522-p		PASSAKTsPAKQQAP	17683481	29	49	84		
Alzheimer's disease	decreased	MAP3K5	ASK1	Q99683	4217	6q23.3	154.54	human	447736	S966-p		NEYLRSIsLPVPVLV	24985705	17	4	1	3764	
depression	increased	PACSIN2	PACSIN2	Q9UNF0	11252	22q13.2	55.74	human	3215997	S372-p		EDEDDTGsTVSEKDD	23918399	1	3	0		
depression	increased	PACSIN2	PACSIN2	Q9UNF0	11252	22q13.2	55.74	human	4786399	S375-p		DDTGSTVsEKDDTKA	23918399	1	9	0		
Kaposi's sarcoma	increased	NFE2L2	NRF2	Q16236	4780	2q31.2	67.83	human	450082	S40-p		SREVFDFsQRRKEYE	25505069	31	0	0		Inhhibition of NRF2 signaling may serve as a therapeutic approach to improve Kaposi's sarcoma pathology.
HNSCC	increased	AURKA	AurA	O14965	6790	20q13.2	45.82	human	457655	S51-p		AQRVLCPsNSSQRIP	17895985	3	3	0		
Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	21400129	104	7	0	87281; 23706	
breast cancer; lung cancer; colorectal cancer; esophageal cancer; gastric cancer	increased	XIAP	XIAP	P98170	331	Xq25	56.68	human	450336	S87-p	BIR	VGRHRKVsPNCRFIN	23749209	10	0	0		
breast cancer	increased	GATA3	GATA3	P23771	2625	10p14	47.92	human	456464	S308-p		IKPKRRLsAARRAGT	25479686	4	0	0		
non-small cell squamous cell lung carcinoma	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	20008839	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	predicts poor prognosis
non-small cell squamous cell lung carcinoma	increased	EIF4E	EIF4E	P06730	1977	4q23	25.10	human	447776	S209-p		DTATKSGsTTKNRFV	20008839	60	4	0	9741	predicts poor prognosis
Alzheimer's disease	increased	APP	APP	P05067	351	21q21.3	86.94	human	480465	S679-p	Beta-APP	DAEFRHDsGYEVHHQ	21527912	10	1	0		
Alzheimer's disease	increased	App	APP	P12023	11820	16 C3.3|16 46.92 cM	86.72	mouse	480465	S679-p	Beta-APP	DAEFGHDsGFEVRHQ	21527912	10	1	0		
		Nox1	NOX1	Q9WV87	114243	Xq32	65.18	rat	36552501	T429-p	NAD_binding_6	RAHNKLKtQKIYFYW	25228390	1	1	0		Increased phosphorylation in vascular diseases
type 2 diabetes	increased	MAPK8	JNK1	P45983	5599	10q11.22	48.30	human	447645	Y185-p	Pkinase	TSFMMTPyVVTRYYR	21931634	259	48	1269	5755; 9257; 4671; 4668; 9251; 58328; 4306; 5136; 9255	after LPS treatment
ASD autism spectrum	decreased	Syn1	SYN1	O88935	20964	X A1.3|X 16.37 cM	74.10	mouse	448377	S553-p		ARPPASPsPQRQAGA	25463523	8	22	10		autism spectrum disorders
ASD autism spectrum	decreased	Syn1	SYN1	O88935	20964	X A1.3|X 16.37 cM	74.10	mouse	451574	S551-p		PAARPPAsPSPQRQA	25463523	10	18	10		autism spectrum disorders
HES	mutation of site	PDGFRA	PDGFRA	P16234	5156	4q12	122.67	human	448441	Y849-p	PK_Tyr_Ser-Thr	DIMHDSNyVSKGSTF	21224473	6	9	59	3170	mutated to Y849S
muscle mechanical hyperalgesia	increased	Trpv1	TRPV1	O35433	83810	10q24	94.95	rat	450017	S800-p		VPLLRDAsTRDRHAT	25451626	21	0	0		
Parkinson's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	447928	S494-p		SGYSSPGsPGTPGSR	21445308	149	55	116	30505; 39357	
CCA	decreased	SMARCA4	SMARCA4	P51532	6597	19p13.2	184.65	human	3191581	S1452-p		RPPAEKLsPNPPNLT	25083560	2	58	6		decreased in ovarian clear cell adenocarcinoma (CCA) cells
multiple myeloma	decreased	SLAMF7	SLAMF7	Q9NQ25	57823	1q23.3	37.42	human	455053	Y284-p		HSGENTEyDTIPHTN	25312647	1	2	14		
HNSCC	increased	TP73	p73	O15350	7161	1p36.32	69.62	human	2063601	T27-p		SSLEPDStYFDLPQS	25379016	3	0	0		
		HSF1	HSF1	Q00613	3297	8q24.3	57.26	human	455484	S326-p	Vert_HS_TF	SSVDTLLsPTALIDS	24516381	45	25	13		Activation of HSF1 (through phosphorylation) supports viral replication during orthopoxvirus infection
type 2 diabetes	increased	MAPK8	JNK1	P45983	5599	10q11.22	48.30	human	447643	T183-p	Pkinase	AGTSFMMtPYVVTRY	21931634	264	33	392	5755; 9257; 4671; 4668; 9251; 58328; 4306; 5136; 9255	after LPS treatment
Schwannoma	increased	CFL1	Cofilin-1	P23528	1072	11q13.1	18.50	human	448444	S3-p		_____MAsGVAVSDG	23934191	93	69	3	3313; 3311	
depression	increased	Htt	Huntingtin	P42859	15194	5 B2|5 17.92 cM	344.69	mouse	465620	S1179-p		EQASTPMsPKKVGEA	23678106	4	29	2		Anxiety
depression	increased	Htt	Huntingtin	P42859	15194	5 B2|5 17.92 cM	344.69	mouse	465621	S1159-p		LTNPPSLsPIRRKGK	23678106	4	9	20		Anxiety
cardiomyopathy	increased	RYR2	RYR2	F1PEE8			563.90	dog	458801	S2799-p		ISQTSQVsVDAAHGY	22163007	61	8	5		
cardiomyopathy	increased	RYR2	RYR2	F1PEE8			563.90	dog	455603	S2016-p		TIRGRLLsLVEKVTY	22163007	13	4	1		
	decreased	CFL1	Cofilin-1	P23528	1072	11q13.1	18.50	human	448444	S3-p		_____MAsGVAVSDG	28130864	93	69	3	3313; 3311	Cryptococcus neoformans infection
pancreatic ductal adenocarcinoma	decreased	GJA1	GJA1	P17302	2697	6q22.31	43.01	human	447813	S368-p		QRPSSRAsSRASSRP	24742583	52	8	1	52559; 3511	
pancreatic ductal adenocarcinoma	decreased	GJA1	GJA1	P17302	2697	6q22.31	43.01	human	448854	S282-p		TAPLSPMsPPGYKLV	24742583	40	7	1		
spinocerebellar ataxia type 1	increased	ATXN1	ataxin-1	P54253	6310	6p22.3	86.92	human	449110	S775-p		ATRKRRWsAPESRKL	24903464	19	28	3		
	decreased	ANXA2	ANXA2	P07355	302	15q22.2	38.60	human	449483	Y24-p		HSTPPSAyGSVKAYT	28130864	29	64	2613		Cryptococcus neoformans infection
Alzheimer's disease	increased	Kcnd2	Kv4.2	Q9Z0V2	16508	6 A2-A3.1|6 8.49 cM	70.58	mouse	457613	S616-p		EGDDRPEsPEYSGGN	25541422	8	0	0		dramatically higher in 3xTg-AD mice compared with control
stroke	decreased	Slc12a5	KCC2 iso2	Q91V14-2	57138	2|2 H3	123.59	mouse	487533	S940-p	SLC12	ITDESRGsIRRKNPA	25546454	22	5	2		
atrial fibrillation	increased	Ryr2	RYR2	E9Q401	20191	13 A1|13 4.38 cM	564.82	mouse	458801	S2813-p		ISQTSQVsIDAAHGY	24812280	61	8	5		
hypertrophic cardiomyopathy	decreased	Myl2	MRLC2V	P51667	17906	5|5 F	18.86	mouse	2846506	S15-p		KRIEGGSsNVFSMFE	26124132	6	7	15		constitutively phosphorylated S15D into  D116V mouse hearts prevented hypertrophic cardiomyopathy 
breast cancer	increased	STMN1	STMN1	P16949	3925	1p36.11	17.30	human	448556	S38-p	Stathmin	SVPEFPLsPPKKKDL	26087399	48	114	166	3426; 4191	low disease free survival (DFS)
breast cancer	increased	STMN1	STMN1	P16949	3925	1p36.11	17.30	human	448555	S25-p	Stathmin	QAFELILsPRSKESV	26087399	50	122	91		low disease free survival (DFS)
breast cancer	increased	STMN1	STMN1	P16949	3925	1p36.11	17.30	human	448557	S63-p	Stathmin	AAEERRKsHEAEVLK	26087399	26	56	32		prolonged diseased free survival (DFS)
breast cancer	increased	STMN1	STMN1	P16949	3925	1p36.11	17.30	human	448554	S16-p	Stathmin	KELEKRAsGQAFELI	26087399	38	98	61	3353	prolonged diseased free survival (DFS)
type 2 diabetes	increased	KAT2A	GCN5	Q92830	2648	17q21.2	93.93	human	33703200	T272-p	PCAF_N	LNYWKLEtPAQFRQR	24870244	1	0	0		diabetic mice
type 2 diabetes	increased	KAT2A	GCN5	Q92830	2648	17q21.2	93.93	human	33703201	S372-p		EEIYGANsPIWESGF	24870244	1	0	0		diabetic mice
glioblastoma multiforme	increased	MOB3A	MOBKL2A	Q96BX8	126308	19p13.3	25.46	human	23126813	T15-p		QVFNKDKtFRPKRKF	24872389	1	0	6		
glioblastoma multiforme	increased	MOB3A	MOBKL2A	Q96BX8	126308	19p13.3	25.46	human	14736201	S38-p	Mob1_phocein	LHKKAQAsLNAGLDL	24872389	1	3	5		
IPF	increased	MVD	MVD	P53602	4597	16q24.2	43.40	human	476192	S96-p		LARKRRNsRDGDPLP	25378391	1	21	8		
Parkinson's disease	increased	PINK1	PINK1	Q9BXM7	65018	1p36.12	62.77	human	25544600	T257-p		AGEYGAVtYRKSKRG	24962176	3	3	0		
		Mybpc3	MYBPC3	O70468	17868	2|2 E1	140.63	mouse	471079	S273-p		RSAFRRTsLAGAGRR	24058627	25	9	14		increase in cardiac function
squamous cell carcinoma of the oropharynx	increased	RPA2	RFA2	P15927	6118	1p35.3	29.25	human	470083	S8-p		MWNSGFEsYGSSSYG	27999209	40	2	0	54762; 83745; 47711; 31912	low in normal, high in dysplasias, moderate in early grade tumors, and low in late stage tumors
squamous cell carcinoma of the oropharynx	increased	RPA2	RFA2	P15927	6118	1p35.3	29.25	human	470082	S4-p		____MWNsGFESYGS	27999209	40	2	0		low in normal, high in dysplasias, moderate in early grade tumors, and low in late stage tumors
pancreatic ductal adenocarcinoma	increased	ITGB4	ITGB4	P16144	3691	17q25.1	202.17	human	450141	Y1510-p		STTLPRDySTLTSVS	27014871	6	11	166		
pancreatic ductal adenocarcinoma	increased	DDX5	DDX5	P17844	1655	17q23.3	69.15	human	470084	Y593-p		NGMNQQAyAYPATAA	27014871	4	2	1		
pancreatic ductal adenocarcinoma	increased	LMNA	lamin A/C	P02545	4000	1q22	74.14	human	452606	S392-p		ERLRLSPsPTSQRSR	27014871	9	105	85		
pancreatic ductal adenocarcinoma	increased	ABL1	Abl iso2	P00519-2	25	9q34.12	124.95	human	450304	Y204-p	SH2	TASDGKLyVSSESRF	27014871	4	14	534	3009	
pancreatic ductal adenocarcinoma	increased	RPS6KA1	p90RSK	Q15418	6195	1p36.11	82.72	human	447993	T573-p	Pkinase	AENGLLMtPCYTANF	27014871	18	16	180	9346	
pancreatic ductal adenocarcinoma	increased	CAMK1	CAMK1A	Q14012	8536	3p25.3	41.34	human	448527	T177-p	Pkinase	DPGSVLStACGTPGY	27014871	10	6	7		
pancreatic ductal adenocarcinoma	increased	PLCG2	PLCG2	P16885	5336	16q23.3	147.87	human	447940	Y753-p		ERDINSLyDVSRMYV	27014871	10	11	270		
pancreatic ductal adenocarcinoma	increased	IRS1	IRS1	P35568	3667	2q36.3	131.59	human	447506	S636-p		SGDYMPMsPKSVSAP	27014871	40	25	1	2388	
pancreatic ductal adenocarcinoma	increased	RAF1	RAF1	P04049	5894	3p25.2	73.05	human	447750	Y341-p		GQRDSSYyWEIEASE	27014871	34	1	1		
pancreatic ductal adenocarcinoma	increased	RPS6KA5	MSK1	O75582	9252	14q32.11	89.87	human	448216	S376-p	Pkinase_C	EKLFQGYsFVAPSIL	27014871	22	19	41	9591	
pancreatic ductal adenocarcinoma	increased	MYC	Myc	P01106	4609	8q24.21	48.80	human	448586	S62-p	Myc_N	LLPTPPLsPSRRSGL	27014871	72	37	33	13748	
pancreatic ductal adenocarcinoma	increased	FOS	Fos	P01100	2353	14q24.3	40.70	human	448491	T232-p		GGLPEVAtPESEEAF	27014871	6	0	0		
pancreatic ductal adenocarcinoma	decreased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	450018	S124-p		EMDFRSGsPSDNSGA	27014871	6	28	0		
pancreatic ductal adenocarcinoma	decreased	RAF1	RAF1	P04049	5894	3p25.2	73.05	human	455218	S296-p		SPSALSSsPNNLSPT	27014871	5	25	46	9431; 9423	
pancreatic ductal adenocarcinoma	decreased	KRT8	K8	P05787	3856	12q13.13	53.70	human	448540	S432-p		SAYGGLTsPGLSYSL	27014871	27	8	23		
pancreatic ductal adenocarcinoma	decreased	SMAD2	SMAD2	Q15796	4087	18q21.1	52.31	human	448795	S250-p		TGSPAELsPTTLSPV	27014871	11	1	0	3104	
pancreatic ductal adenocarcinoma	decreased	PDGFRA	PDGFRA	P16234	5156	4q12	122.67	human	448441	Y849-p	PK_Tyr_Ser-Thr	DIMHDSNyVSKGSTF	27014871	6	9	59	3170	
pancreatic ductal adenocarcinoma	decreased	GRK1	GRK1	Q15835	6011	13q34	63.53	human	456353	S21-p		AFIAARGsFDGSSSQ	27014871	4	1	1		
pancreatic ductal adenocarcinoma	decreased	BID	BID	P55957	637	22q11.21	21.99	human	456957	S78-p	BID	RIEADSEsQEDIIRN	27014871	6	6	0		
pancreatic ductal adenocarcinoma	decreased	SMAD2	SMAD2	Q15796	4087	18q21.1	52.31	human	448793	T220-p		QSNYIPEtPPPGYIS	27014871	12	0	0		
pancreatic ductal adenocarcinoma	decreased	SMAD1	SMAD1	Q15797	4086	4q31.21	52.26	human	451173	S187-p		NSHPFPHsPNSSYPN	27014871	4	0	0		
pancreatic ductal adenocarcinoma	decreased	ACTC1	ACTC1	P68032	70	15q14	42.02	human	7766153	Y55-p	Actin	GMGQKDSyVGDEAQS	27014871	1	28	960		
colonic inflamation	increased	NLRP3	NLRP3	Q96P20	114548	1q44	118.17	human	59041400	Y861-p		SHSLTRLyVGENALG	27043286	1	0	0		
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	4275600	S579-p	zf-C4	YGALTCGsCKVFFKR	27902483	3	0	0		decreased disease specific survival 
cardiomyopathy	increased	Bcl2l1	Bcl-xL	Q64373	12048	2 75.41 cM|2 H1	26.13	mouse	33668512	S14-p	BH4	ELVVDFLsYKLSQKG	24813943	2	1	0		
Schwannoma	increased	LIMK1	LIMK1	P53667	3984	7q11.23	72.58	human	447808	T508-p	PK_Tyr_Ser-Thr	PDRKKRYtVVGNPYW	23934191	29	1	1	3841	
Schwannoma	increased	LIMK2	LIMK2	P53671	3985	22q12.2	72.23	human	448683	T505-p	PK_Tyr_Ser-Thr	NDRKKRYtVVGNPYW	23934191	16	0	1	3841	
bladder cancer	increased	FOSL1	FRA1	P15407	8061	11q13.1	29.41	human	478352	S265-p		PSSDPLGsPTLLAL_	21822309	3	8	6	5841; 3880	
lung cancer	increased	Cebpb	C/EBP-beta	P28033	12608	2 H3|2 87.58 cM	31.45	mouse	447878	T188-p		SSSSPPGtPSPADAK	21847090	33	11	14	3084	
hypertrophic cardiomyopathy	decreased	SDC4	syndecan-4	P31431	6385	20q13.12	21.64	human	449863	S179-p	Syndecan	MKKKDEGsYDLGKKP	22164265	10	1	0		
pancreatic ductal adenocarcinoma	decreased	GJA1	GJA1	P17302	2697	6q22.31	43.01	human	448853	S279-p		SSPTAPLsPMSPPGY	24742583	42	6	1		
breast cancer	increased	PFN1	profilin 1	P07737	5216	17p13.2	15.05	human	2850008	S138-p	Profilin	MASHLRRsQY_____	25084196	9	0	0		
Alzheimer's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	447927	S491-p		GERSGYSsPGSPGTP	24893984	87	30	33	29957	
Alzheimer's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	449081	S688-p		GAEIVYKsPVVSGDT	24893984	170	45	90	9632	
Alzheimer's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	447933	T497-p		SSPGSPGtPGSRSRT	24893984	113	24	26	30505; 43964; 49561; 20060; 53001; 20739	
chronic myelogenous leukemia	increased	LASP1	Lasp-1	Q14847	3927	17q12	29.72	human	451675	Y171-p		IPTSAPVyQQPQQQP	24913448	5	9	426		
ALS	increased	HIPK2	HIPK2	Q9H2X6	28996	7q34	130.97	human	12119325	S359-p	Pkinase	HVSKAVCsTYLQSRY	27321923	1	4	22		
ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084616	S409-p		GSSMDSKsSGWGM__	27321923	48	4	0		
ALS	increased	HIPK2	HIPK2	Q9H2X6	28996	7q34	130.97	human	8086452	T360-p	Pkinase	VSKAVCStYLQSRYY	27321923	1	5	18		
ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084601	S410-p		SSMDSKSsGWGM___	27321923	49	4	0		
breast cancer	increased	YAP1	YAP1	P46937	10413	11q22.1	54.46	human	56813400	Y188-p	WW	KTSSGQRyFLNHIDQ	27428284	1	1	0		
DCM; cardiomyopathy	decreased	SCN5A	SCN5A	Q14524	6331	3p22.2	226.94	human	4719558	S516-p	Na_trans_cytopl	LSLTRGLsRTSMKPR	25815641	5	7	0		
Parkinson's disease	increased	YWHAQ	14-3-3 theta	P27348	10971	2p25.1	27.76	human	456053	S232-p		LTLWTSDsAGEECDA	25862939	4	16	0		
Parkinson's disease	decreased	YWHAZ	14-3-3 zeta	P63104	7534	8q22.3	27.75	human	449833	S58-p	14-3-3	VVGARRSsWRVVSSI	25862939	15	1	5	52631	
Parkinson's disease	increased	PRKN	PARK2	O60260	5071	6q26	51.64	human	25538008	S65-p	ubiquitin	NCDLDQQsIVHIVQR	24962176	31	9	0	36866	
breast ductal carcinoma	increased	PAK1	PAK1	Q13153	5058	11q13.5-q14.1	60.65	human	487520	Y285-p	Pkinase	QGASGTVyTAMDVAT	25466889	9	1	1		
CCA		ARID1A	ARID1A	O14497	8289	1p36.11	242.04	human	452533	S696-p		LPGIRGPsPSPVGSP	25083560	1	72	31		no change 
MI	decreased	Kcne2	KCNE2	P63161	171138	11q11	14.36	rat	486280	S98-p	ISK_Channel	DWQQKYRsQILHLED	22180649	2	0	0		
Parkinson's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	449082	S696-p		PVVSGDTsPRHLSNV	21445308	132	53	69	20194; 35834; 98523; 49562; 91600	
glioblastoma	increased	AXL	AXL	P30530	558	19q13.2	98.34	human	451490	Y779-p	PK_Tyr_Ser-Thr	ADCLDGLyALMSRCW	28881571	6	2	2	96453	significantly shorter overall survival
Alzheimer's disease	decreased	YWHAQ	14-3-3 theta	P27348	10971	2p25.1	27.76	human	456053	S232-p		LTLWTSDsAGEECDA	28695147	4	16	0		Triton X-100 insoluble fraction; associated with clinical and pathological severity
ADLB	decreased	YWHAQ	14-3-3 theta	P27348	10971	2p25.1	27.76	human	456053	S232-p		LTLWTSDsAGEECDA	28695147	4	16	0		Triton X-100 insoluble fraction; associated with clinical and pathological severity
DLB	decreased	YWHAQ	14-3-3 theta	P27348	10971	2p25.1	27.76	human	456053	S232-p		LTLWTSDsAGEECDA	28695147	4	16	0		Triton X-100 insoluble fraction; associated with clinical and pathological severity
Alzheimer's disease	increased	MLKL	MLKL	Q8NB16	197259	16q23.1	54.48	human	22996309	S358-p	PK_Tyr_Ser-Thr	ELRKTQTsMSLGTTR	28758999	33	3	0	37333; 91689; 18640	
Alzheimer's disease	increased	MLKL	MLKL	Q8NB16	197259	16q23.1	54.48	human	5891858	T357-p	PK_Tyr_Ser-Thr	FELRKTQtSMSLGTT	28758999	7	1	1		
diabetes mellitus	decreased	Fscn1	fascin	Q61553	14086	5 G2|5 81.84 cM	54.51	mouse	450888	S39-p	Fascin	KVNASASsLKKKQIW	28855604	13	12	0		patients with diabetic nephropathy
colorectal cancer	increased	HNRNPA1	hnRNP A1	P09651	3178	12q13.13	38.75	human	455946	S6-p		__MSKSEsPKEPEQL	29344170	2	96	4		poor prognosis
CTE	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	29298849	130	44	14	20473; 71429	colocalization of pT175 tau with the active pGSK3B
CTE	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449077	T175-p		ATRIPAKtPPAPKTP	29298849	8	8	0		colocalization of pT175 tau with the active pGSK3B
ALS; CTE	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449077	T175-p		ATRIPAKtPPAPKTP	29298849	8	8	0		CTE with ALS
ALS; CTE	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	29298849	130	44	14	20473; 71429	CTE with ALS
ALS	mutation of site	CCNF	CCNF	P41002	899	16p13.3	87.64	human	288031702	S621-p		GYEGDQEsEGEKEGD	29021214	1	1	0		
TBI		Gsk3b	GSK3B	P18266	84027	11q21	46.74	rat	448569	Y216-p	Pkinase	RGEPNVSyICSRYYR	29298849	91	127	4206		colocalized
CTE	increased	Gsk3b	GSK3B	P18266	84027	11q21	46.74	rat	448569	Y216-p	Pkinase	RGEPNVSyICSRYYR	29298849	91	127	4206		colocalization of pT175 tau with the active pGSK3B
hypertrophic cardiomyopathy	increased	PPP2R5D	PPP2R5D	Q14738	5528	6p21.1	69.99	human	457390	S573-p		KVLLRRKsELPQDVY	29294329	7	53	347		S573 is increased in the setting of pressure overload-induced cardiac hypertrophy.
PAH	increased	PDHA1	PDHA1	P08559	5160	Xp22.12	43.30	human	448258	S293-p	E1_dh	TYRYHGHsMSDPGVS	29070699	95	108	675	37115; 31866	
glioblastoma	increased	ATG4B	ATG4B	Q9Y4P1	23192	2q37.3	44.29	human	470896	S383-p	ATG4_LIR	RLERFFDsEDEDFEI	29232556	2	37	2	40592; 19386	
acute myelogenous leukemia	increased	MEF2C	MEF2C	Q06413	4208	5q14.3	51.22	human	474086	S222-p		GYGNPRNsPGLLVSP	29431698	1	33	1		AML chemotherapy resistance 
diabetes mellitus	decreased	CRYAA	CRYA1	P02489	1409	21q22.3	19.91	human	452108	T148-p	HSP20	FCGPKIQtGLDATHA	29467334	5	5	0		
diabetes mellitus	decreased	Cryaa	CRYA1	P24622	12954	17 B1|17 17.09 cM	22.49	mouse	452108	S171-p	HSP20	FSGPKVQsGLDAGHS	29467334	5	5	0		
glioblastoma	increased	TRIM9	TRIM9 iso5	Q9C026-5	114088	14q22.1	61.35	human	1046182900	S76-p		SLYSEADsGYGSYGG	29669288	1	0	0		stability of TRIM9s-MKK6-p38 complex, and it maintains the high activation state of p38 signaling to suppress glioblastoma progression
glioblastoma	increased	TRIM9	TRIM9 iso5	Q9C026-5	114088	14q22.1	61.35	human	1046182901	S80-p		EADSGYGsYGGFASA	29669288	1	0	0		stability of TRIM9s-MKK6-p38 complex, and it maintains the high activation state of p38 signaling to suppress glioblastoma progression
colorectal cancer	decreased	Dusp4	DUSP4	Q8BFV3	319520	8|8 A4	43.37	mouse	15412246	S395-p		LHSPITTsPSC____	22430215	2	1	2		
colorectal cancer	decreased	Dusp4	DUSP4	Q8BFV3	319520	8|8 A4	43.37	mouse	15412243	S390-p		SNLPYLHsPITTSPS	22430215	2	1	2		
colorectal cancer	decreased	Dusp4	DUSP4	Q8BFV3	319520	8|8 A4	43.37	mouse	25123903	T361-p		LRERGKAtPTPTSQF	22430215	1	0	0		
colorectal cancer	decreased	Dusp4	DUSP4	Q8BFV3	319520	8|8 A4	43.37	mouse	15412237	T363-p		ERGKATPtPTSQFVF	22430215	1	0	1		
Alzheimer's disease; Huntington's disease	decreased	CASP6	CASP6	P55212	839	4q25	33.31	human	452136	S257-p	Peptidase_C14	TLVNRKVsQRRVDFC	22433863	3	0	0		
liver disease		KRT18	K18	P05783	3875	12q13.13	48.06	human	447733	S34-p		RPVSSAAsVYAGAGG	15368451	14	27	13		chronic noncirrhotic hepatitis C virus (HCV) or cirrhosis
liver disease		KRT8	K8	P05787	3856	12q13.13	53.70	human	448540	S432-p		SAYGGLTsPGLSYSL	15368451	27	8	23		chronic noncirrhotic hepatitis C virus (HCV) or cirrhosis
liver disease		KRT18	K18	P05783	3875	12q13.13	48.06	human	447734	S53-p		ISVSRSTsFRGGMGS	15368451	17	12	14		chronic noncirrhotic hepatitis C virus (HCV) or cirrhosis
liver disease		KRT8	K8	P05787	3856	12q13.13	53.70	human	448539	S74-p	Keratin_2_head	TVNQSLLsPLVLEVD	15368451	29	8	9		chronic noncirrhotic hepatitis C virus (HCV) or cirrhosis
mutation causing Brugada Syndrom	mutation of site	SCN5A	SCN5A	Q14524	6331	3p22.2	226.94	human	451569	S528-p	Na_trans_cytopl	KPRSSRGsIFTFRRR	24795344	4	2	1		expression of R526H and S528A channels were reduced compared with WT
spinocerebellar ataxia type 1	increased	ATXN1	ataxin-1	P54253	6310	6p22.3	86.92	human	449110	S775-p		ATRKRRWsAPESRKL	29758256	19	28	3		Inhibition of phosphorylation at S776 results in degradation of ataxin which leads to delayed onset of ataxia
EAE	mutation of site	Ctla4	CTLA-4	P09793	12477	1 C2|1 30.58 cM	24.99	mouse	450897	Y201-p		SPLTTGVyVKMPPTE	24648182	5	0	1		
atherosclerosis	deletion of site	SIRT1	SIRT1	Q96EB6	23411	10q21.3	81.68	human	452898	S27-p		ADREAASsPAGEPLR	23754392	5	19	1	2327	
atherosclerosis	deletion of site	SIRT1	SIRT1	Q96EB6	23411	10q21.3	81.68	human	452899	S47-p		DGPGLERsPGEPGGA	23754392	8	49	9	2314	
obesity, hyperphagic	decreased	Smad3	SMAD3	Q8BUN5	17127	9|9 C	48.08	mouse	451178	S204-p		NHSMDAGsPNLSPNP	29700281	17	0	0		SMAD2/3/4 improve obesity related metabolic paramters in a MPK-38 phosphorylation dependent manner.
obesity, hyperphagic	decreased	Smad2	SMAD2	Q62432	17126	18 E3|18 51.42 cM	52.27	mouse	448794	S245-p		NQSMDTGsPAELSPT	29700281	12	0	0	3104	SMAD2/3/4 improve obesity related metabolic paramters in a MPK-38 phosphorylation dependent manner.
obesity, hyperphagic	decreased	Smad4	SMAD4	P97471	17128	18 E2|18 49.51 cM	60.34	mouse	15613801	S342-p	MH2	GETFKVPsSCPVVTV	29700281	2	0	0		SMAD2/3/4 improve obesity related metabolic paramters in a MPK-38 phosphorylation dependent manner.
Alzheimer's disease; AD	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084601	S410-p		SSMDSKSsGWGM___	25134727	49	4	0		
breast cancer	decreased	FLNA	FLNA	P21333	2316	Xq28	280.74	human	451357	S2152-p	Filamin	TRRRRAPsVANVGSH	20179208	19	80	999	4761	
breast cancer	decreased	FLNA	FLNA	P21333	2316	Xq28	280.74	human	452266	S1459-p	Filamin	KCSGPGLsPGMVRAN	20179208	2	71	16		
Huntington's disease; LBD; ADLB	increased	ELK1	ELK1	P19419	2002	Xp11.23	44.89	human	452139	T417-p		ISVDGLStPVVLSPG	20126313	8	0	1		
cancer, squamous cell carcinoma	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	21795477	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
Alzheimer's disease; AD	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084616	S409-p		GSSMDSKsSGWGM__	25134727	48	4	0		
Parkinson's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	449081	S688-p		GAEIVYKsPVVSGDT	21445308	170	45	90	9632	
hypertrophic cardiomyopathy	decreased	Gja1	GJA1	P23242	14609	10 B4|10 28.64 cM	43.00	mouse	447813	S368-p		QRPSSRAsSRASSRP	24498049	52	8	1	52559; 3511	
Parkinson's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	447930	S554-p	Tubulin-binding	NVRSKIGsTENLKHQ	21445308	108	24	2		
breast cancer	decreased	MYC	Myc	P01106	4609	8q24.21	48.80	human	448496	T58-p	Myc_N	KKFELLPtPPLSPSR	21808024	71	39	30	46650	
breast cancer, triple negative	increased	BIK	BIK	Q13323	638	22q13.2	18.02	human	32001602	S124-p	bcl-2I13	NIMRFWRsPNPGSWV	24637719	1	0	0		
colorectal cancer	decreased	EGLN1	EGLN1	Q9GZT9	54583	1q42.2	46.02	human	7322687	S125-p		ADPAAAAsPCRAAAG	28199842	3	25	5		
multiple myeloma; MGUS	increased	STOML2	SLP-2	Q9UJZ1	30968	9p13.3	38.53	human	20745207	S17-p		GALLLRGsLLASGRA	24676687	2	1	0		
hypertrophic cardiomyopathy	increased	Tpm1	TPM1	P58771	22003	9 C|9 36.27 cM	32.68	mouse	451804	S283-p	Tropomyosin	HALNDMTsI______	23960072	11	15	94		S283A TPM1 mutation rescues FHC cardiomyopathy
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	24116116	85	33	23	62672; 66224; 12885	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	24116116	130	44	14	20473; 71429	
multiple myeloma	increased	RPS6KA3	RSK2	P51812	6197	Xp22.12	83.74	human	448063	S227-p	Pkinase	DHEKKAYsFCGTVEY	23012246	12	43	151	3556	
	decreased	EZR	Ezrin	P15311	7430	6q25.3	69.41	human	448104	T567-p	ERM_C	QGRDKYKtLRQIRQG	24413175	61	9	16	3141; 3726	Microvillus inclusion disease
depression	decreased	Fmr1	FMR1	Q80WE1	24948	Xq37	66.78	rat	469583	S478-p	FXMRP1_C_core	NSEASNAsETESDHR	22539853	20	6	0		
occular surface disease	increased	WWOX	WWOX	Q9NZC7	51741	16q23.1-q23.2	46.68	human	449043	Y33-p	WW	TTKDGWVyYANHTEE	26120275	21	1	0		
hepatocellular carcinoma	increased	MYC	Myc	P01106	4609	8q24.21	48.80	human	448586	S62-p	Myc_N	LLPTPPLsPSRRSGL	25893300	72	37	33	13748	
sCJD; fCJD	increased	PRNP	PRNP	P04156	5621	20p13	27.66	human	10273948	S43-p		SRYPGQGsPGGNRYP	24360565	2	2	0		
breast cancer; clear cell kidney cancer	increased	Ctnnd1	CTNND1	P30999	12388	2 D|2 49.45 cM	104.92	mouse	449648	Y228-p		YPGGSDNyGSLSRVT	26067913	8	45	1087	2911	
Alzheimer's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	447933	T497-p		SSPGSPGtPGSRSRT	25465240	113	24	26	30505; 43964; 49561; 20060; 53001; 20739	
nasopharyngeal carcinoma	increased	EZR	Ezrin	P15311	7430	6q25.3	69.41	human	448104	T567-p	ERM_C	QGRDKYKtLRQIRQG	25375189	61	9	16	3141; 3726	
breast cancer	increased	CCDC88A	girdin	Q3V6T2	55704	2p16.1	216.04	human	450762	Y1799-p		QSKDSNPyATLPRAS	21954290	5	13	137		
breast cancer	increased	CCDC88A	girdin	Q3V6T2	55704	2p16.1	216.04	human	450761	Y1765-p		PRKTEDTyFISSAGK	21954290	3	14	36		
breast adenocarcinoma	increased	ROCK2	ROCK2	O75116	9475	2p25.1	160.90	human	23003812	S1366-p		ARSSPRTsMKIQQNQ	22273145	3	4	0		
Alzheimer's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	449081	S688-p		GAEIVYKsPVVSGDT	25465240	170	45	90	9632	
Alzheimer's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	447928	S494-p		SGYSSPGsPGTPGSR	25465240	149	55	116	30505; 39357	
Alzheimer's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	449079	T523-p		KKVAVVRtPPKSPSA	25465240	130	44	14	20473; 71429	
Alzheimer's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	447929	S506-p		GSRSRTPsLPTPPTR	25465240	60	23	42	77348	
Alzheimer's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	449551	S490-p		SGERSGYsSPGSPGT	25465240	21	15	10		
Alzheimer's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	447927	S491-p		GERSGYSsPGSPGTP	25465240	87	30	33	29957	
ALD	increased	HMGB1	HMGB1	P09429	3146	13q12.3	24.89	human	476055	S35-p	HMG_box_2	KKKHPDAsVNFSEFS	24928512	3	23	3		
ischemia; stroke	increased	Slc12a2	NKCC1	P55012	20496	18 D3|18 32.15 cM	131.03	mouse	455545	T205-p	AA_permease_N	TNTYYLRtFGHNTMD	26069258	20	15	13		
ischemia; stroke	increased	Slc12a2	NKCC1	P55012	20496	18 D3|18 32.15 cM	131.03	mouse	467235	T196-p	AA_permease_N	HQQYYYDtHTNTYYL	26069258	11	1	0		
ischemia; stroke	increased	Oxsr1	OSR1	Q6P9R2	108737	9|9 F3	58.21	mouse	456503	T185-p	Pkinase	TRNKVRKtFVGTPCW	26069258	12	6	51		
ischemia; stroke	increased	Slc12a2	NKCC1	P55012	20496	18 D3|18 32.15 cM	131.03	mouse	467236	T200-p	AA_permease_N	YYDTHTNtYYLRTFG	26069258	12	1	0		
ischemia; stroke	increased	Stk39	STLK3	Q9Z1W9	53416	2|2 C1.3	60.32	mouse	23149311	T236-p	Pkinase	LATGGDVtRNKVRKT	26069258	1	0	1		
prostate cancer; breast cancer; colorectal cancer	increased	GRB2	GRB2	P62993	2885	17q25.1	25.21	human	452038	Y160-p		QVPQQPTyVQALFDF	26103942	6	4	34		Levels of Y160 phosphorylation were clearly associated with higher-grade malignant tumours
pancreatic ductal adenocarcinoma	increased	NPM1	NPM1	P06748	4869	5q35.1	32.58	human	14577038	S48-p	Nucleoplasmin	QLSLRTVsLGAGAKD	25071014	2	3	0		
multiple sclerosis	increased	CRYAB	CRYAB	P02511	1410	11q23.1	20.16	human	448783	S59-p		PSFLRAPsWFDTGLS	28196893	44	22	0		
macrothrombocytopenia	decreased	FLNA	FLNA	P21333	2316	Xq28	280.74	human	451357	S2152-p	Filamin	TRRRRAPsVANVGSH	25061177	19	80	999	4761	 decrease in its phosphorylation at S2152 in platelets and megakaryocytes due to the defect in PKA activity
Parkinson's disease	increased	Gsk3b	GSK3B	Q9WV60	56637	16|16 B3	46.71	mouse	448569	Y216-p	Pkinase	RGEPNVSyICSRYYR	21445308	91	127	4206		
cardiomyopathy	decreased	MYBPC3	MYBPC3	Q14896	4607	11p11.2	140.76	human	471080	S284-p		AGGGRRIsDSHEDTG	23213108	35	8	28		
cardiomyopathy	decreased	TNNI3	TNNI3	P19429	7137	19q13.42	24.01	human	448423	S23-p	Troponin-I_N	PAPIRRRsSNYRAYA	23213108	63	9	11	4004	
HNSCC	increased	SMAD2	SMAD2	Q15796	4087	18q21.1	52.31	human	447494	S465-p		SPSVRCSsMS_____	21281788	54	1	5	18338; 26945; 8828; 11979; 68550; 3108; 56532; 67804; 55041	
cardiomyopathy	decreased	TTN	Titin	Q8WZ42	7273	2q31.2	3816.03	human	27842905	S4099-p		SEQPGLFsEWLRNIE	23213108	6	1	0		
cardiomyopathy	decreased	TNNI3	TNNI3	P19429	7137	19q13.42	24.01	human	448424	S24-p	Troponin-I_N	APIRRRSsNYRAYAT	23213108	60	10	16	4004	
cardiomyopathy	decreased	TTN	Titin	Q8WZ42	7273	2q31.2	3816.03	human	27842904	S4010-p		VRIEEGKsLRFPLAL	23213108	5	1	0		
cardiomyopathy	increased	TTN	Titin	Q8WZ42	7273	2q31.2	3816.03	human	10029600	S11878-p		KEEVVLKsVLRKRPE	23213108	11	1	0		
cardiomyopathy	decreased	MYL12B	MRLC2	O14950	103910	18p11.31	19.78	human	448595	S20-p		KRPQRATsNVFAMFD	23213108	60	64	295		
hypertension	mutation of site	PDE3A	PDE3A	Q14432	5139	12p12.2	124.98	human	31874032	T445-p		SSTWTTTtSATGLPT	25961942	1	1	0		in T445D mutant 
HNSCC	increased	SMAD2	SMAD2	Q15796	4087	18q21.1	52.31	human	447495	S467-p		SVRCSSMs_______	21281788	54	1	5	18338; 26945; 8828; 11979; 68550; 3108; 56532; 67804; 55041	
hypertension	increased	PDE3A	PDE3A	Q14432	5139	12p12.2	124.98	human	456821	S428-p		IPKRLRRsLPPGLLR	25961942	5	11	1		
hypertension	increased	PDE3A	PDE3A	Q14432	5139	12p12.2	124.98	human	456984	S438-p		PGLLRRVsSTWTTTT	25961942	4	6	9		
HNSCC	increased	CHEK2	Chk2	O96017	11200	22q12.1	60.91	human	447549	S33-p		TQSQGSSsQSQGISS	21281788	11	1	0	2665	
HNSCC	increased	CHEK2	Chk2	O96017	11200	22q12.1	60.91	human	447550	S35-p		SQGSSSQsQGISSSS	21281788	10	1	0	2665	
HNSCC	increased	PRKCZ	PKCZ	Q05513	5590	1p36.33	67.66	human	447510	T410-p	Pkinase	GPGDTTStFCGTPNY	21281788	43	3	10	2060; 9378	
HNSCC	increased	PRKCI	PKCI	P41743	5584	3q26.2	68.26	human	454434	T412-p	Pkinase	RPGDTTStFCGTPNY	21281788	9	15	36	2060; 9378	
HNSCC	increased	IRS1	IRS1	P35568	3667	2q36.3	131.59	human	447562	S616-p		DDGYMPMsPGVAPVP	21281788	36	7	4	3193; 2386; 3203	
HNSCC	increased	CHEK1	Chk1	O14757	1111	11q24.2	54.43	human	447834	S345-p		LVQGISFsQPTCPDH	21281788	188	4	12	12268; 2341; 2348	
HNSCC	increased	MAP2K1	MEK1	Q02750	5604	15q22.31	43.44	human	448514	S218-p	Pkinase	VSGQLIDsMANSFVG	21281788	122	13	83	9154; 9121; 86128; 3958	
HNSCC	increased	STK11	LKB1	Q15831	6794	19p13.3	48.64	human	448146	S334-p		DTKDRWRsMTVVPYL	21281788	3	0	0	3055	
HNSCC	increased	NFKBIA	IkB-alpha	P25963	4792	14q13.2	35.61	human	448203	S32-p		LLDDRHDsGLDSMKD	21281788	153	3	17	2859; 9246; 5210; 5209	
HNSCC	increased	EIF4E	EIF4E	P06730	1977	4q23	25.10	human	447776	S209-p		DTATKSGsTTKNRFV	21281788	60	4	0	9741	
HNSCC	increased	EIF4EBP1	4E-BP1	Q13541	1978	8p11.23	12.58	human	447527	S65-p	eIF_4EBP	FLMECRNsPVTKTPP	21281788	93	60	6	9456; 9451; 13443	
HNSCC	increased	MAP2K1	MEK1	Q02750	5604	15q22.31	43.44	human	448513	S222-p	Pkinase	LIDSMANsFVGTRSY	21281788	116	20	203	9154; 9121; 86128; 3958; 2338; 16211; 75262; 16780	
HNSCC	increased	MTOR	mTOR	P42345	2475	1p36.22	288.89	human	447578	S2448-p		RSRTRTDsYSAGQSV	21281788	187	17	106	2971; 5536; 54932; 2976	
HNSCC	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448191	S727-p		NTIDLPMsPRTLDSL	21281788	199	55	67	49081; 34911; 50804; 58978; 71958; 87544; 94994; 9136; 9134	
HNSCC	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	21281788	468	74	3065	4324; 8119; 9145; 4113; 52075; 73533; 9138; 4323; 4093; 4074; 52527; 74309; 16185; 61958; 9131; 73452	
HNSCC	increased	RPS6KA1	p90RSK	Q15418	6195	1p36.11	82.72	human	447990	S380-p	Pkinase_C	HQLFRGFsFVATGLM	21281788	61	48	64	9335; 13575; 13397; 11989; 12032; 13588; 9341	
HNSCC	increased	PLCG1	PLCG1	P19174	5335	20q12	148.53	human	447667	Y783-p		EGRNPGFyVEANPMP	21281788	88	42	558	14461; 25678; 14008; 2821; 88717	
HNSCC	increased	BRAF	BRAF	P15056	673	7q34	84.44	human	447804	S446-p		KTLGRRDsSDDWEIP	21281788	15	44	87	2696	
HNSCC	decreased	ERBB2	HER2	P04626	2064	17q12	137.91	human	447614	Y1248-p		PTAENPEyLGLDVPV	21281788	57	15	200	2247; 2244	
HNSCC	decreased	KDR	VEGFR2	P35968	3791	4q12	151.53	human	447904	Y996-p	PK_Tyr_Ser-Thr	EEAPEDLyKDFLTLE	21281788	7	0	0	2474	
HNSCC	decreased	RPS6KB1	p70S6K	P23443	6198	17q23.1	59.14	human	448806	S394-p	Pkinase_C	TRQTPVDsPDDSTLS	21281788	16	4	11	9208	
HNSCC	decreased	CTNNB1	CTNNB1	P35222	1499	3p22.1	85.50	human	447583	T41-p		GIHSGATtTAPSLSG	21281788	88	3	0	9565; 4270; 9561; 13537; 60180; 41334	
HNSCC	decreased	GAB1	GAB1	Q13480	2549	4q31.21	76.62	human	447948	Y627-p		KGDKQVEyLDLDLDS	21281788	24	25	438	3231; 3233	
HNSCC	decreased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	21281788	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
HNSCC	decreased	FOXO1	FOXO1A	Q12778	2308	13q14.11	69.66	human	448560	T24-p		LPRPRSCtWPLPRPE	21281788	58	6	39	9464; 2599	
HNSCC	decreased	STAT5A	STAT5A	P42229	6776	17q21.2	90.65	human	447767	Y694-p		LAKAVDGyVKPQIKQ	21281788	142	49	2180	9356; 5387; 9359; 9314; 4322; 9351; 51879; 14603; 9365; 72712; 3939; 66740	
HNSCC	decreased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447542	T202-p	Pkinase	HDHTGFLtEYVATRW	21281788	1283	106	2017	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 54240; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
HNSCC	decreased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	21281788	732	14	18	5106; 48646; 13842; 4056; 2965; 43506; 77440; 9275; 13038; 86758; 80722; 5056	
HNSCC	decreased	KDR	VEGFR2	P35968	3791	4q12	151.53	human	447903	Y951-p	PK_Tyr_Ser-Thr	RFRQGKDyVGAIPVD	21281788	19	0	3	2476; 4991; 2471	
HNSCC	decreased	FOXO3	FOXO3A	O43524	2309	6q21	71.28	human	448602	T32-p		QSRPRSCtWPLQRPE	21281788	67	8	91	9464; 2599	
HNSCC	decreased	SHC1	SHC1	P29353	6464	1q21.3	62.82	human	448511	Y427-p		ELFDDPSyVNVQNLD	21281788	41	91	1971	2431	
HNSCC	decreased	ERBB3	HER3	P21860	2065	12q13.2	148.10	human	449858	Y1289-p		CPASEQGyEEMRAFQ	21281788	28	10	125	4791; 2842	
HNSCC	decreased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447543	Y204-p	Pkinase	HTGFLTEyVATRWYR	21281788	1304	138	3549	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 14474; 54240; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
HNSCC	decreased	CTNNB1	CTNNB1	P35222	1499	3p22.1	85.50	human	447488	S45-p		GATTTAPsLSGKGNP	21281788	49	7	0	70034; 9565; 19807; 77605; 9564; 96727	
glioblastoma	increased	AXL	AXL	P30530	558	19q13.2	98.34	human	458360	Y698-p	PK_Tyr_Ser-Thr	FGLSKKIyNGDYYRQ	28881571	1	3	52	44463	significantly shorter overall survival
neuroblastoma	increased	ROCK2	ROCK2	O75116	9475	2p25.1	160.90	human	484404600	T396-p		DDKGDVEtFPIPKAF	28739902	1	0	0		
pancreatic ductal adenocarcinoma	increased	IRAK4	IRAK4	Q9NWZ3	51135	12q12	51.53	human	2045325	T345-p	PK_Tyr_Ser-Thr	KFAQTVMtSRIVGTT	29363544	7	4	0	12914; 80738; 11927; 87995	
pancreatic ductal adenocarcinoma	increased	RELA	NFkB-p65	Q04206	5970	11q13.1	60.22	human	447800	S536-p		SGDEDFSsIADMDFS	29363544	217	4	0	73992; 31553; 4887; 80477; 76778; 3031; 5733; 13346; 3036; 3033; 4025; 4886; 87672; 83962	
psoriasis	increased	RPS6KA1	p90RSK	Q15418	6195	1p36.11	82.72	human	447993	T573-p	Pkinase	AENGLLMtPCYTANF	29290690	18	16	180	9346	increase in western blot and in nuclei in lesion skin
psoriasis	decreased	RPS6KA1	p90RSK	Q15418	6195	1p36.11	82.72	human	447990	S380-p	Pkinase_C	HQLFRGFsFVATGLM	29290690	61	48	64	9335; 13575; 13397; 11989; 12032; 13588; 9341	increase in western blot and cytosolic in lesion skin
psoriasis	increased	RPS6KA3	RSK2	P51812	6197	Xp22.12	83.74	human	450152	T577-p	Pkinase	AENGLLMtPCYTANF	29290690	9	14	180		increase in western blot and in nuclei in lesion skin
psoriasis	decreased	RPS6KA3	RSK2	P51812	6197	Xp22.12	83.74	human	448065	S386-p	Pkinase_C	HQLFRGFsFVAITSD	29290690	12	19	59	9335; 13575; 13397; 11989; 12032; 13588; 9341	increase in western blot and cytosolic in lesion skin
HBL	decreased	Cebpa	C/EBP-alpha	P53566	12606	7 B2|7 21.02 cM	37.43	mouse	1868113505	S193-p		PPPHPHAsPAHLAAP	29159818	14	0	0		C/EBPa-dependent CSCs are observed in patients with aggressive hepatoblastoma and in patients with a predisposition for liver cancer. 
HBL	decreased	CEBPA	C/EBP-alpha	P49715	1050	19q13.11	37.56	human	457552	S190-p		PPPPPPPsHPHPHPP	29159818	2	0	0		C/EBPa-dependent CSCs are observed in patients with aggressive hepatoblastoma and in patients with a predisposition for liver cancer. 
lung cancer	increased	HMGA1	HMGA1	P17096	3159	6p21.31	11.68	human	452256	S99-p		KEEEEGIsQESSEEE	29038488	3	64	173		involved in lung cancer cell proliferation
breast cancer		HMMR	HMMR	O75330	3161	5q34	84.10	human	460367	T703-p	HMMR_C	KENFALKtPLKEGNT	28993511	1	10	6		predictor  of  breast  cancer-specific  survival  and  relapse-free  survival  in  patients  with  estrogen  receptor (ER)-negative breast cancer
hypertension	increased	Grin2b	NMDAR2B	Q00960	24410	4q43	166.07	rat	450171	S1303-p	NMDAR2_C	NKLRRQHsYDTFVDL	28972129	47	14	31	71335	increased phosphorylation in the hypothalamic paraventricular nucleus (PVN), but not in the hippocampus and frontal cortex,
pancreatic cancer	increased	MAPRE1	EB1	Q15691	22919	20q11.21	30.00	human	59049802	T206-p		QVNVLKLtVEDLEKE	29228685	3	1	0		correlated with high ASK1 expression; ASK1-mediated phosphorylation of EB1 may contribute to pancreatic cancer cell proliferation 
FHC	increased	Ryr2	RYR2	E9Q401	20191	13 A1|13 4.38 cM	564.82	mouse	458801	S2813-p		ISQTSQVsIDAAHGY	29402414	61	8	5		spontaneous Ca 2? transients (sCaTs) 
hepatocellular carcinoma	increased	SREBF1	SREBP-1	P36956	6720	17p11.2	121.68	human	900975702	T59-p		AGSGAGGtDPASPDT	29514980	1	0	0		T59  phosphorylation is correlated with poor prognosis in HCC patients.
non-small cell lung cancer	increased	GLS	glutaminase iso3	O94925-3	2744	2q32.2	65.46	human	937769500	S314-p	Glutaminase	RYVGKEPsGLRFNKL	29515166	1	0	0		poor survival of NSCLC patients
T cell lymphoma	increased	MAP3K7	TAK1	O43318	6885	6q15	67.20	human	969328000	T344-p		QVPATNDtIKRLESK	29511289	1	1	0		
T cell lymphoma	increased	MAP3K7	TAK1	O43318	6885	6q15	67.20	human	7444663	T444-p		RRSIQDLtVTGTEPG	29511289	1	6	0		
colonic inflamation	increased	Trim28	TIF1B	Q62318	21849	7|7 A1	88.85	mouse	452391	S473-p		SGMKRSRsGEGEVSG	29487189	26	117	20		
colonic inflamation	increased	Map3k3	MEKK3	Q61084	26406	11|11 E1	70.78	mouse	468184	S337-p		DPRGRLRsADSENAL	29487189	2	32	46		
colonic inflamation	increased	Pak1	PAK1	O88643	18479	7 E1|7 53.57 cM	60.74	mouse	448170	S144-p		SNSKKYMsFTDKSAE	29487189	23	28	138	2606	
colonic inflamation	increased	Pak2	PAK2	Q8CIN4	224105	16 B2|16 22.4 cM	57.93	mouse	448295	S141-p		TVKQKYLsFTPPEKD	29487189	17	83	76	2606	
breast ductal carcinoma	decreased	PRLR	PRLR	P16471	5618	5p13.2	69.51	human	451641	S349-p		YLDPDTDsGRGSCDS	16278670	4	0	0		
Alzheimer's disease	increased	Mapt	Tau	P19332	29477	10q32.1	78.56	rat	447928	S513-p		SGYSSPGsPGTPGSR	15719129	149	55	116	30505; 39357	
colorectal carcinoma	increased	STRAP	STRAP	Q9Y3F4	11171	12p12.3	38.44	human	11267002	T175-p		LWDHATMtEVKSLNF	29783958	2	1	0		
colorectal carcinoma	increased	MELK	MELK	Q14680	9833	9p13.2	74.64	human	2861400	S171-p	Pkinase	HLQTCCGsLAYAAPE	29783958	2	0	0		
colorectal carcinoma	increased	MELK	MELK	Q14680	9833	9p13.2	74.64	human	456039	T167-p	Pkinase	NKDYHLQtCCGSLAY	29783958	3	1	0		
colorectal carcinoma	increased	STRAP	STRAP	Q9Y3F4	11171	12p12.3	38.44	human	11267003	S179-p		ATMTEVKsLNFNMSV	29783958	2	0	0		
Alzheimer's disease	increased	Mapt	Tau	P19332	29477	10q32.1	78.56	rat	449082	S715-p		PVVSGDTsPRHLSNV	15719129	132	53	69	20194; 35834; 98523; 49562; 91600	
Alzheimer's disease	increased	Mapt	Tau	P19332	29477	10q32.1	78.56	rat	447927	S510-p		GERSGYSsPGSPGTP	15719129	87	30	33	29957	
Alzheimer's disease	increased	Mapt	Tau	P19332	29477	10q32.1	78.56	rat	449081	S707-p		GAEIVYKsPVVSGDT	15719129	170	45	90	9632	
glioblastoma	mutation of site	DOCK1	DOCK1	Q14185	1793	10q26.2	215.35	human	28698600	S1250-p	DHR-2_Lobe_A	HAKLLKWsEDVCVAH	23728337	2	0	0		citated in this paper : TCGA portal, https://tcga-data.nci.nih.gov).  " Dock180 was found to be mutated to L1250 in a clinical glioblastoma sample from a patient after treatment with temozolomide".
breast cancer	mutation of site	GAB1	GAB1	Q13480	2549	4q31.21	76.62	human	4783368	T387-p		MSPSRSNtISTVDLN	22751113	1	6	0		T387N mutation
breast ductal carcinoma	mutation of site	GAB1	GAB1	Q13480	2549	4q31.21	76.62	human	25655003	Y83-p	PH	KKEFENSyIFDINTI	22751113	2	0	0		Y83C mutation
breast cancer	molecular association	RUNX3	AML2	Q13761	864	1p36.11	44.36	human	3952612	T212-p		RMRVTPStPSPRGSL	22580604	1	1	4		
breast cancer	molecular association	RUNX3	AML2	Q13761	864	1p36.11	44.36	human	4733094	S214-p		RVTPSTPsPRGSLST	22580604	1	6	6		
breast cancer	molecular association	RUNX3	AML2	Q13761	864	1p36.11	44.36	human	25526800	T209-p		ERLRMRVtPSTPSPR	22580604	3	3	0		
breast cancer	molecular association	RUNX3	AML2	Q13761	864	1p36.11	44.36	human	471996	T231-p		HFSSQPQtPIQGTSE	22580604	1	5	21		
kidney cancer	increased	RALGAPA2	RALGAPA2	Q2PPJ7	57186	20p11.23	210.77	human	485552	S486-p		SSWGRTYsFTSAMSR	22580611	2	20	39		
kidney cancer	increased	RALGAPA2	RALGAPA2	Q2PPJ7	57186	20p11.23	210.77	human	460565	T715-p		PMRFRSAtTSGAPGV	22580611	2	7	54		
kidney cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	22580611	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
FXS	decreased	FMR1	FMR1	Q06787	2332	Xq27.3	71.17	human	469583	S500-p	FXMRP1_C_core	NSEASNAsETESDHR	17376973	20	6	0		Dephosphorylated FMRP leads to decrease in synapse number and function.
Alzheimer's disease; DLB	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	17761554	85	33	23	62672; 66224; 12885	
AC	increased	GJA1	GJA1	P17302	2697	6q22.31	43.01	human	448852	S255-p		HATSGALsPAKDCGS	18065522	23	20	1		in UM-X7.1 hamsters
glioma	increased	GRIN2B	NMDAR2B	Q13224	2904	12p13.1	166.37	human	450171	S1303-p	NMDAR2_C	NKLRRQHsYDTFVDL	25434386	47	14	31	71335	
Alzheimer's disease	decreased	EFHD2	EFHD2	Q96C19	79180	1p36.21	26.70	human	478224	S74-p		QGIGEPQsPSRRVFN	24917152	2	81	42		
Alzheimer's disease	increased	APP	APP	P05067	351	21q21.3	86.94	human	480465	S679-p	Beta-APP	DAEFRHDsGYEVHHQ	25023775	10	1	0		
occular surface disease	increased	BIRC5	Survivin	O15392	332	17q25.3	16.39	human	447705	T34-p	BIR	FLEGCACtPERMAEA	25468890	17	6	7	8888	
breast cancer	increased	BRCA1	BRCA1	P38398	672	17q21.31	207.72	human	10272402	S1191-p		GELSRSPsPFTHTHL	21706030	4	13	3		
breast cancer	increased	PIP5K1C	PIP5K1C	O60331	23396	19p13.3	73.26	human	486321	Y639-p		DAPATDIyFPTDERS	25486426	3	0	0		metastasis
colorectal cancer	increased	DAPK1	DAPK1	P53355	1612	9q21.33	160.05	human	487483	Y490-p	Ank_2	HCAAWHGyYSVAKAL	17803936	1	0	0		there is a positive correlation between elevated Src activity and DAPK Y491/492 hyperphosphorylation in human cancers
glioblastoma multiforme	increased	DOCK1	DOCK1	Q14185	1793	10q26.2	215.35	human	28698600	S1250-p	DHR-2_Lobe_A	HAKLLKWsEDVCVAH	25468898	2	0	0		
breast cancer	increased	BRCA1	BRCA1	P38398	672	17q21.31	207.72	human	450007	S1189-p		QKGELSRsPSPFTHT	21706030	6	15	6		
breast cancer	increased	BRCA1	BRCA1	P38398	672	17q21.31	207.72	human	448730	S1497-p		EPGVERSsPSKCPSL	21706030	7	4	2		
prostate cancer	increased	ETV1	ETV1	P50549	2115	7p21.2	55.13	human	3059600	S216-p	ETS_PEA3_N	PMYQRQMsEPNIPFP	23774214	3	3	2		
hypertrophic cardiomyopathy	increased	RPS6KB1	p70S6K	P23443	6198	17q23.1	59.14	human	448607	T412-p	Pkinase_C	NQVFLGFtYVAPSVL	20190034	438	8	1	9209; 9205; 9234; 9206; 97596	
colorectal cancer	increased	DAPK1	DAPK1	P53355	1612	9q21.33	160.05	human	487484	Y491-p	Ank_2	CAAWHGYySVAKALC	17803936	1	0	0		there is a positive correlation between elevated Src activity and DAPK Y491/492 hyperphosphorylation in human cancers
cancer, squamous cell carcinoma	increased	YAP1	YAP1 iso3	P46937-3	10413	11q22.1	48.76	human	54390605	Y394-p		QQNRFPDyLEAIPGT	27013234	2	0	0		
OSCC	decreased	KRT8	K8	P05787	3856	12q13.13	53.70	human	448539	S74-p	Keratin_2_head	TVNQSLLsPLVLEVD	22114688	29	8	9		
diabetes mellitus	decreased	NPHS1	NPHS1	O60500	4868	19q13.12	134.74	human	469566	Y1217-p		YQDPRGIyDQVAGDL	25404734	10	0	0		
breast cancer	increased	MYC	Myc	P01106	4609	8q24.21	48.80	human	448586	S62-p	Myc_N	LLPTPPLsPSRRSGL	21808024	72	37	33	13748	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447927	S199-p		GDRSGYSsPGSPGTP	24757378	87	30	33	29957	
atrial fibrillation		KCNK3	KCNK3	O14649	3777	2p23.3	43.52	human	2840502	T383-p		TGLHSLStFRGLMKR	25437921	3	1	0		Phosphorylation of T383 is not responsible for the phosphorylation-dependent loss of current in chronic AF.
cancer, squamous cell carcinoma	increased	YAP1	YAP1 iso3	P46937-3	10413	11q22.1	48.76	human	15565111	Y341-p		PFLNSGTyHSRDEST	27013234	5	4	3		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447933	T205-p		SSPGSPGtPGSRSRT	24757378	113	24	26	30505; 43964; 49561; 20060; 53001; 20739	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447930	S262-p	Tubulin-binding	NVKSKIGsTENLKHQ	24757378	108	24	2		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449083	S422-p		GSIDMVDsPQLATLA	24757378	38	9	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447928	S202-p		SGYSSPGsPGTPGSR	24757378	149	55	116	30505; 39357	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	24757378	130	44	14	20473; 71429	
OSCC	decreased	KRT8	K8	P05787	3856	12q13.13	53.70	human	448540	S432-p		SAYGGLTsPGLSYSL	22114688	27	8	23		
Huntington's disease	decreased	HTT	Huntingtin	P42858	3064	4p16.3	347.60	human	448106	S419-p		GGRSRSGsIVELIAG	24841383	14	32	21		rescues mitochondrial dysfunction related to energy failure
cancer, squamous cell carcinoma	increased	YAP1	YAP1 iso3	P46937-3	10413	11q22.1	48.76	human	473004	Y357-p		SGLSMSSySVPRTPD	27013234	20	3	4		
Alzheimer's disease; LBD; AGD	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084616	S409-p		GSSMDSKsSGWGM__	26091809	48	4	0		
Alzheimer's disease; LBD; AGD	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084601	S410-p		SSMDSKSsGWGM___	26091809	49	4	0		
colorectal carcinoma	increased	LRP6	LRP6	O75581	4040	12p13.2	180.43	human	3802448	T1572-p		EPVPPPPtPRSQYLS	25500543	5	0	8		
colorectal carcinoma	increased	LRP6	LRP6	O75581	4040	12p13.2	180.43	human	456289	S1490-p		AILNPPPsPATERSH	25500543	30	13	55	2568	
Alzheimer's disease	increased	Hsf1	HSF1	P38532	15499	15 D3|15 35.95 cM	57.22	mouse	449066	T142-p		DSVTRLLtDVQLMKG	25406061	4	1	0		AD mice compared to WT mice, did not observe an age-dependent increase in T142
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449082	S404-p		PVVSGDTsPRHLSNV	25355317	132	53	69	20194; 35834; 98523; 49562; 91600	
breast cancer	increased	TP73	p73	O15350	7161	1p36.32	69.62	human	18944909	S471-p		GEMSSSHsAQSMVSG	21482671	1	0	0		
lymphoma	increased	EIF6	EIF6	P56537	3692	20q11.22	26.60	human	450271	S235-p		QPSTIATsMRDSLID	21665150	3	5	2		
hepatocellular carcinoma	increased	TP53	p53	P04637	7157	17p13.1	43.65	human	447490	S15-p	P53_TAD	PSVEPPLsQETFSDL	22030623	456	11	0	8514; 82530; 56979; 8695; 9286; 4030; 9284; 9235; 12571	
cardiomyopathy	decreased	Slc9a3	NHE3	P26433	24784	1p11	93.11	rat	450899	S552-p		AEGERRGsLAFIRSP	22031782	26	5	4		in heart failure (HF) rats compared to Sham
GCT	increased	FOXL2	FOXL2	P58012	668	3q22.3	38.77	human	21697903	S33-p		EPEGPPPsPGKGGGG	25871347	3	9	1		
hypertrophic cardiomyopathy	increased	PRKD1	PRKD1	Q15139	5587	14q12	101.70	human	4960330	S421-p		KHTKRKSsTVMKEGW	24643961	2	1	3		
OSCC	increased	BIRC5	Survivin	O15392	332	17q25.3	16.39	human	447705	T34-p	BIR	FLEGCACtPERMAEA	18949405	17	6	7	8888	
Parkinson's disease; Alzheimer's disease	increased	VRK3	VRK3	Q8IV63	51231	19q13.33	52.88	human	4762306	S108-p		RPPTPKSsPQKTRKS	27346674	1	11	2		
prostate cancer	increased	PKP3	plakophilin 3	Q9Y446	11187	11p15.5	87.08	human	451533	Y195-p		PGGLDDRySLVSEQL	25501895	1	15	160		
Parkinson's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449104	S356-p	Tubulin-binding	RVQSKIGsLDNITHV	24073234	33	24	0		
Parkinson's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449084	S413-p		RHLSNVSsTGSIDMV	24073234	5	9	1		
Parkinson's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	487451	S238-p		TPPKSPSsAKSRLQT	24073234	2	5	1		
Parkinson's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	24073234	170	45	90	9632	
Parkinson's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449080	S235-p		VVRTPPKsPSSAKSR	24073234	43	36	25	20473	
Parkinson's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447933	T205-p		SSPGSPGtPGSRSRT	24073234	113	24	26	30505; 43964; 49561; 20060; 53001; 20739	
Parkinson's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447928	S202-p		SGYSSPGsPGTPGSR	24073234	149	55	116	30505; 39357	
Parkinson's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449083	S422-p		GSIDMVDsPQLATLA	24073234	38	9	0		
Parkinson's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449132	S409-p		DTSPRHLsNVSSTGS	24073234	13	10	5		
Parkinson's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447930	S262-p	Tubulin-binding	NVKSKIGsTENLKHQ	24073234	108	24	2		
Parkinson's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449082	S404-p		PVVSGDTsPRHLSNV	24073234	132	53	69	20194; 35834; 98523; 49562; 91600	
Parkinson's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447934	T212-p		TPGSRSRtPSLPTPP	24073234	45	16	5		
DLB	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449083	S422-p		GSIDMVDsPQLATLA	24073234	38	9	0		
DLB	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449082	S404-p		PVVSGDTsPRHLSNV	24073234	132	53	69	20194; 35834; 98523; 49562; 91600	
DLB	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449078	T217-p		SRTPSLPtPPTREPK	24073234	33	31	6	51625	
DLB	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	24073234	170	45	90	9632	
DLB	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	24073234	130	44	14	20473; 71429	
DLB	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447929	S214-p		GSRSRTPsLPTPPTR	24073234	60	23	42	77348	
DLB	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447934	T212-p		TPGSRSRtPSLPTPP	24073234	45	16	5		
DLB	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	487451	S238-p		TPPKSPSsAKSRLQT	24073234	2	5	1		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447929	S214-p		GSRSRTPsLPTPPTR	24073234	60	23	42	77348	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	24073234	170	45	90	9632	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447930	S262-p	Tubulin-binding	NVKSKIGsTENLKHQ	24073234	108	24	2		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449104	S356-p	Tubulin-binding	RVQSKIGsLDNITHV	24073234	33	24	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449132	S409-p		DTSPRHLsNVSSTGS	24073234	13	10	5		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449080	S235-p		VVRTPPKsPSSAKSR	24073234	43	36	25	20473	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447934	T212-p		TPGSRSRtPSLPTPP	24073234	45	16	5		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	452062	S184-p		PAPKTPPsSGEPPKS	24073234	3	4	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	450221	S195-p		PPKSGDRsGYSSPGS	24073234	7	3	17		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447928	S202-p		SGYSSPGsPGTPGSR	24073234	149	55	116	30505; 39357	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449082	S404-p		PVVSGDTsPRHLSNV	24073234	132	53	69	20194; 35834; 98523; 49562; 91600	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449078	T217-p		SRTPSLPtPPTREPK	24073234	33	31	6	51625	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449084	S413-p		RHLSNVSsTGSIDMV	24073234	5	9	1		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447933	T205-p		SSPGSPGtPGSRSRT	24073234	113	24	26	30505; 43964; 49561; 20060; 53001; 20739	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	487451	S238-p		TPPKSPSsAKSRLQT	24073234	2	5	1		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449083	S422-p		GSIDMVDsPQLATLA	24073234	38	9	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	24073234	130	44	14	20473; 71429	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	24073234	85	33	23	62672; 66224; 12885	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	452074	S237-p		RTPPKSPsSAKSRLQ	24073234	2	10	1		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449551	S198-p		SGDRSGYsSPGSPGT	24073234	21	15	10		
Alzheimer's disease; Down syndrome	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	24033439	170	45	90	9632	S396-S404 are signicantly increased compared to S199-202 and appeared early in both diseases.
Alzheimer's disease; Down syndrome	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449082	S404-p		PVVSGDTsPRHLSNV	24033439	132	53	69	20194; 35834; 98523; 49562; 91600	S396-S404 are signicantly increased compared to S199-202 and appeared early in both diseases.
breast adenocarcinoma	decreased	TUBA1A	TUBA1A	Q71U36	7846	12q13.12	50.14	human	25757493	S165-p	Tubulin	SVDYGKKsKLEFSIY	30176291	1	0	1		
prostate cancer	increased	STK4	MST1	Q13043	6789	20q13.12	55.63	human	11496001	T120-p	Pkinase	IIRLRNKtLTEDEIA	22619175	3	0	0		
glioblastoma multiforme	increased	PKM	PKM	P14618	5315	15q23	57.94	human	481749	T328-p	PK	GKPVICAtQMLESMI	30297868	2	3	0		elevated phosphorylation of this site in brain tumor samples from GBM patients correlated with poor survival
	increased	TTN	Titin	Q8WZ42	7273	2q31.2	3816.03	human	10029600	S11878-p		KEEVVLKsVLRKRPE	29760016	11	1	0		Diabetic cardiomyopathy
ovarian cancer	increased	PEA15	PEA-15	Q15121	8682	1q23.2	15.04	human	455750	S104-p		TKLTRIPsAKKYKDI	32047549	13	27	322	2776	
ovarian cancer	increased	PEA15	PEA-15	Q15121	8682	1q23.2	15.04	human	450281	S116-p		KDIIRQPsEEEIIKL	32047549	15	95	1092		
	decreased	TTN	Titin	Q8WZ42	7273	2q31.2	3816.03	human	27842905	S4099-p		SEQPGLFsEWLRNIE	29760016	6	1	0		diabetic cardiomyopathy
prostate cancer	increased	STK4	MST1	Q13043	6789	20q13.12	55.63	human	447925	T183-p	Pkinase	DTMAKRNtVIGTPFW	22619175	22	2	5	3681; 49332	
breast cancer	increased	CDKN1B	p27Kip1	P46527	1027	12p13.1	22.07	human	447874	S10-p		NVRVSNGsPSLERMD	25205104	47	36	1		
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448100	S106-p	Oest_recep	PLNSVSPsPLMLLHP	25531331	25	1	0		
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448099	S104-p	Oest_recep	FPPLNSVsPSPLMLL	25531331	24	1	0		
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448101	S118-p	Oest_recep	LHPPPQLsPFLQPHG	25531331	89	2	0	2511	
Kaposi's sarcoma	increased	NFE2L2	NRF2	Q16236	4780	2q31.2	67.83	human	450082	S40-p		SREVFDFsQRRKEYE	25340789	31	0	0		
hypertension	increased	PANX1	PANX1	Q96RD7	24145	11q21	48.05	human	462886	Y199-p	Innexin	KYPIVEQyLKTKKNS	30814251	2	0	2		
Alzheimer's disease	increased	DPYSL2	CRMP-2	Q16555	1808	8p21.2	62.29	human	448084	T555-p		DNIPRRTtQRIVAPP	29926835	18	2	8		increased in transgenic Tg576 mouse model
pancreatic cancer	increased	ITGB4	ITGB4	P16144	3691	17q25.1	202.17	human	450141	Y1510-p		STTLPRDySTLTSVS	31242404	6	11	166		
breast cancer	increased	MORC2	MORC2	Q9Y6X9	22880	22q12.2	117.82	human	30982293	T582-p		LEALQKTtPIRSQAD	32401166	1	1	0		
breast cancer	increased	CTNND1	CTNND1	O60716	1500	11q12.1	108.17	human	469141	T906-p		SLDNNYStPNERGDH	32010791	1	17	76		
glioblastoma multiforme	increased	Ctnnb1	CTNNB1	Q02248	12387	9 F4|9 72.19 cM	85.47	mouse	457120	S675-p		QDYKKRLsVELTSSL	32102932	33	55	17	9567; 4176	
ventricular tachycardia	increased	Pln	PLB	P61014	18821	10|10 B3	6.09	mouse	448115	T17-p	Phospholamban	SAIRRAStIEMPQQA	21888910	64	12	63	8496	
ventricular tachycardia	increased	Ryr2	RYR2	E9Q401	20191	13 A1|13 4.38 cM	564.82	mouse	458801	S2813-p		ISQTSQVsIDAAHGY	21888910	61	8	5		
Alzheimer's disease	increased	PPP2CA	PPP2CA	P67775	5515	5q31.1	35.59	human	448571	Y307-p		VTRRTPDyFL_____	22299660	70	0	0		
Parkinson's disease	increased	DNM1L	DRP1	O00429	10059	12p11.21	81.88	human	28716001	T595-p		NWRGMLKtSKAEELL	23813973	1	1	0		
scleroderma	increased	ABL1	Abl iso2	P00519-2	25	9q34.12	124.95	human	450303	Y245-p		KRNKPTVyGVSPNYD	22591006	27	12	304	2861; 2868	
scleroderma	increased	FLI1	FLI1	Q01543	2313	11q24.3	50.98	human	6406002	T312-p	Ets	TNGEFKMtDPDEVAR	22591006	6	0	0		
colorectal carcinoma; lymphoma; cancer, squamous cell carcinoma	decreased	H4C1	H4	P62805	8359	6p22.2	11.24	human	458960	K16-ac		GLGKGGAkRHRKVLR	15765097	103	26	531	13534; 26437; 56999; 98789	
prostate cancer	increased	PKM	PKM	P14618	5315	15q23	57.94	human	474712	K305-ac	PK	GIEIPAEkVFLAQKM	21700219	3	8	30		
liver disease; obesity, hyperphagic; NAFLD	increased	Sirt3	SIRT3	Q8R104	64384	7|7 F4-F5	36.61	mouse	206219718	K57-ac		GGGSSEKkFSLQDVA	28808064	1	1	0		Aging related diseases, glucose intolerance, liver steatosis
glioma	increased	ATF5	ATF-5	Q9Y2D1	22809	19q13.33	30.67	human	20745204	K29-ac		GWLVDYGkLPPAPAP	28473657	2	0	0		
cardiomyopathy	increased	SDHA	SDHA	P31040	6389	5p15.33	72.69	human	461207	K179-ac	FAD_binding_2	AFGGQSLkFGKGGQA	26998524	3	8	8		
breast cancer	increased	MZF1	MZF-1	P28698	7593	19q13.43	82.06	human	50784428	S27-p		VMVKLEDsEEEGEAA	30622337	1	3	0		
non-small cell lung cancer; colorectal cancer; pancreatic cancer	increased	APEX1	APE1	P27695	328	14q11.2	35.55	human	459075	K6-ac		__MPKRGkKGAVAED	27655688	5	2	0		
melanoma skin cancer	increased	BSG	BSG iso2	P35613-2	682	19p13.3	29.22	human	38486780	Y183-p	Ig_3	MEADPGQyRCNGTSS	32291412	1	2	0		
melanoma skin cancer	increased	BSG	BSG iso2	P35613-2	682	19p13.3	29.22	human	1868502601	Y140-p	Ig_3	PVTDWAWyKITDSED	32291412	1	1	0		
lung cancer	increased	RELA	NFkB-p65	Q04206	5970	11q13.1	60.22	human	459095	K218-ac	RHD_dimer	EIFLLCDkVQKEDIE	19345327	7	0	0		
lung cancer	increased	RELA	NFkB-p65	Q04206	5970	11q13.1	60.22	human	459096	K310-ac		KRTYETFkSIMKKSP	19345327	78	5	0	3045; 12629	
lung cancer	increased	RELA	NFkB-p65	Q04206	5970	11q13.1	60.22	human	459094	K221-ac	RHD_dimer	LLCDKVQkEDIEVYF	19345327	12	0	0		
breast cancer	increased	PKM	PKM	P14618	5315	15q23	57.94	human	11318768	K433-ac	PK_C	GAIIVLTkSGRSAHQ	24120661	6	2	1		
hypertrophic cardiomyopathy	decreased	Mybpc3	MYBPC3	O70468	17868	2|2 E1	140.63	mouse	471080	S282-p		AGAGRRTsDSHEDAG	31796859	35	8	28		
hypertrophic cardiomyopathy	increased	Cacna1c	CACNA1C	P22002	24239	4q42	243.48	rat	7437803	T1603-p	Ca_chan_IQ	RTALRIKtEGNLEQA	32290730	2	0	0		
ventricular tachycardia	decreased	Gja1	GJA1	P08050	24392	20q11	43.03	rat	447813	S368-p		QRPSSRAsSRASSRP	30740090	52	8	1	52559; 3511	
ventricular tachycardia	decreased	Gja1	GJA1	P08050	24392	20q11	43.03	rat	459207	S365-p		IVDQRPSsRASSRAS	30740090	15	15	2		
ventricular tachycardia	decreased	Gja1	GJA1	P08050	24392	20q11	43.03	rat	450183	S364-p		AIVDQRPsSRASSRA	30740090	6	8	0		
non-small cell squamous cell lung carcinoma	increased	IQGAP1	IQGAP1	P46940	8826	15q26.1	189.25	human	1869135500	S480-p		NTVWKQLsSSVTGLT	31431460	1	1	0		
lung cancer	increased	TRIP10	TRIP10	Q15642	9322	19p13.3	68.35	human	1868832804	T225-p		DMDERRAtRLGAGYG	31319138	1	0	0		
hepatocellular carcinoma	increased	MCM2	MCM2	P49736	4171	3q21.3	101.90	human	452311	S40-p		RRTDALTsSPGRDLP	31578521	12	29	18		
hepatocellular carcinoma	increased	MCM2	MCM2	P49736	4171	3q21.3	101.90	human	473058	S53-p	MCM2_N	LPPFEDEsEGLLGTE	31578521	16	9	16		
breast cancer	decreased	SNAI1	Snail1	O95863	6615	20q13.13	29.08	human	1867725600	S249-p		ARTFSRMsLLHKHQE	30804505	1	0	0		
acute myelogenous leukemia	decreased	HSF1	HSF1	Q00613	3297	8q24.3	57.26	human	455484	S326-p	Vert_HS_TF	SSVDTLLsPTALIDS	32959058	45	25	13		
prostate cancer		Nkx3-1	NKX3-1	P97436	18095	14 D2|14 36.02 cM	26.82	mouse	4825101	S186-p		KTKRKQLsEDLGVLE	32943441	5	3	0		
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	6855907	S369-p		EPNQAFGsGNNSYSG	32778941	2	0	0		
HER2 positive breast cancer	increased	LPIN1	LPIN1	Q14693	23175	2p25.1	98.66	human	1871177712	Y795-p	LNS2	FPNTEPFyAAFGNRP	33203880	1	1	0		
HER2 positive breast cancer	increased	Src	Src iso1	P05480-1	20779	2 H1|2 78.35 cM	60.64	mouse	448234	Y424-p	PK_Tyr_Ser-Thr	RLIEDNEyTARQGAK	33203880	416	102	3046	6943; 2101; 78740; 70926; 94361; 59548; 17320	
esophageal carcinoma	increased	GLI1	GLI1	P08151	2735	12q13.3	117.90	human	25123902	S84-p		LTKKRALsISPLSDA	22439934	1	1	0		detected in EAC tumor tissues
PFCP	decreased	GATA1	GATA1	P15976	2623	Xp11.23	42.75	human	3819000	K137-sm		TSFLETLkTERLSPD	27821551	3	0	0		
Huntington's disease	increased	HTT	Huntingtin	P42858	3064	4p16.3	347.60	human	8545504	K6-sm		__MATLEkLMKAFES	15064418	2	0	0		
Huntington's disease	increased	HTT	Huntingtin	P42858	3064	4p16.3	347.60	human	8545503	K9-sm		ATLEKLMkAFESLKS	15064418	2	0	0		
Huntington's disease	increased	HTT	Huntingtin	P42858	3064	4p16.3	347.60	human	8545505	K15-sm		MKAFESLkSFQQQQQ	15064418	2	0	0		
multiple sclerosis	increased	Dnm1l	DRP1	O35303	114114	11q23	83.91	rat	483971	S656-p		VPVARKLsAREQRDC	31305892	82	3	0	4867; 6319	
Parkinson's disease; Alzheimer's disease	increased	FYN	Fyn	P06241	2534	6q21	60.76	human	447882	Y420-p	PK_Tyr_Ser-Thr	RLIEDNEyTARQGAK	33466666	26	94	3048	6943; 2101; 78740; 70926; 94361; 59548; 17320	
Alzheimer's disease	increased	APP	APP iso4	P05067-4	351	21q21.3	78.66	human	448202	Y682-p	APP_amyloid	SKMQQNGyENPTYKF	33466666	13	20	864		
sickle-cell anaemia	increased	PRDX2	PRDX2	P32119	7001	19p13.13	21.89	human	448985	Y193-p	1-cysPrx_C	NVDDSKEyFSKHN__	33535382	1	8	119		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	33557920	85	33	23	62672; 66224; 12885	
hypertrophic cardiomyopathy	increased	Trim28	TIF1B	Q62318	21849	7|7 A1	88.85	mouse	452391	S473-p		SGMKRSRsGEGEVSG	33657380	26	117	20		
liver steatosis, fatty liver	increased	Rbm38	RBM38	Q62176	56190	2|2 H3	25.36	mouse	29606707	S193-p		DQYPYAAsPAAATSF	33664057	7	0	0		in mouse model
breast cancer	increased	TWIST1	TWIST1	Q15672	7291	7p21.1	20.95	human	58948903	K38-ub		SGKRGGRkRRSSRRS	27618486	1	0	0		promoting Twist K63-linked ubiquitination of Twist K38, regulated  by RNF8
gastric cancer; bile-duct cancer; neuroendocrine cancer; pancreatic ductal adenocarcinoma	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	459004	K4-m2	Histone	____ARTkQTARKST	19896696	104	10	0	31777; 9725	rarely observed in hepatocellular carcinoma (15.7%)
IPF	increased	H2ax	H2AX	P27661	15270	9 A5.2|9 24.84 cM	15.01	mouse	448841	S139-p		GKKASQAsQEY____	33594057	254	31	29	85410; 97148; 20304; 5438; 80312; 59141; 4309; 9719; 60566; 5763; 9720; 2577; 9718	
Alzheimer's disease	increased	Add1	ADD1	Q9QYC0	11518	5 B2|5 17.9 cM	80.65	mouse	449829	S724-p		KKKFRTPsFLKKSKK	33771994	24	57	158		
Alzheimer's disease	increased	Dpysl2	CRMP-2	O08553	12934	14 D1|14 34.6 cM	62.28	mouse	448084	T555-p		DNIPRRTtQRIVAPP	33771994	18	2	8		
Alzheimer's disease	increased	Add2	ADD2	Q9QYB8	11519	6 C3-D1|6 37.55 cM	80.64	mouse	449802	S712-p		KKKFRTPsFLKKSKK	33771994	8	58	159		
Alzheimer's disease	increased	Add1	ADD1	Q9QYC0	11518	5 B2|5 17.9 cM	80.65	mouse	449480	T445-p		QKQQREKtRWLHSGR	33771994	6	0	0		
prostate cancer	increased	CREB1	CREB	P16220	1385	2q33.3	35.14	human	448228	S119-p	pKID	EILSRRPsYRKILND	33846571	289	4	61	14001; 54960; 9187; 80120; 95995; 14228; 44864; 39561; 9196; 9198; 4095	
breast cancer	increased	PKM	PKM	P14618	5315	15q23	57.94	human	476070	S37-p		MCRLDIDsPPITARN	34185676	15	62	6		corelates with decreased overall survival
acute lymphocytic leukemia	increased	H3c1	H3	P68433	360198	13|13 A3.1	15.27	mouse	1458615	K79-m2	Histone	REIAQDFkTDLRFQS	18977325	36	20	10	5427	
acute lymphocytic leukemia	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	1458615	K79-m2	Histone	REIAQDFkTDLRFQS	18977325	36	20	10	5427	
sHLH/MAS syndrome	increased	STAT1	STAT1	P42224	6772	2q32.2	87.33	human	447754	Y701-p		DGPKGTGyIKTELIS	33815425	179	7	64	5375; 8062; 8009; 76285; 25809; 9167; 8183; 9174; 39205; 88845; 7649; 88211; 90145	
breast cancer	increased	PGR	PR	P06401	5241	11q22.1	98.98	human	447987	S294-p	Prog_receptor	APMAPGRsPLATTVM	28412963	21	3	0	13736	
acute myelogenous leukemia	mutation of site	CCND3	CCND3	P30281	896	6p21.1	32.52	human	3189694	S264-p	Cyclin_C	EASQTSSsPAPKAPR	34103301	1	6	1		found in AML patients resistant to pexidartinib
acute myelogenous leukemia	mutation of site	CCND3	CCND3	P30281	896	6p21.1	32.52	human	452160	T283-p		QGPSQTStPTDVTAI	34103301	8	4	5	53966	found in AML patients resistant to pexidartinib
breast cancer	decreased	HSD17B4	HSD17B4	P51659	3295	5q23.1	79.69	human	461239	K669-ac	SCP2	AKWTIDLkSGSGKVY	28296597	2	4	1		
gastric cancer	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	1458613	K9-m3	Histone	RTKQTARkSTGGKAP	18470569	128	22	1	5327; 4473; 6951; 55286; 13969	positively correlated with tumor stage, cancer recurrence, and a poor survival rate
glioblastoma multiforme	increased	PLIN3	perilipin 3	O60664	10226	19p13.3	47.07	human	1873650102	Y251-p	Perilipin	ERLRQHAyEHSLGKL	34077757	1	1	0		corelates with poor survival
gastric cancer	decreased	H3C1	H3	P68431	8350	6p22.2	15.27	human	463820	K9-ac	Histone	RTKQTARkSTGGKAP	18470569	218	25	341	4484; 14052; 9677; 9711; 11857; 9683; 28036; 9649	
glioblastoma multiforme	increased	PLIN2	perilipin 2	Q99541	123	9p22.1	48.08	human	1873650100	Y232-p	Perilipin	TKLHSRAyQQALSRV	34077757	1	1	0		corelates with poor survival
breast cancer	increased	SOD2	SOD2	P04179	6648	6q25.3	24.75	human	461133	K68-ac	Sod_Fe_N	NLNVTEEkYQEALAK	27721400	18	13	8		
laryngeal cancer	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	27181202	468	74	3065	4324; 8119; 9145; 4113; 52075; 73533; 9138; 4323; 4093; 4074; 52527; 74309; 16185; 61958; 9131; 73452	
type 2 diabetes	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447929	S214-p		GSRSRTPsLPTPPTR	33890983	60	23	42	77348	
type 2 diabetes	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449082	S404-p		PVVSGDTsPRHLSNV	33890983	132	53	69	20194; 35834; 98523; 49562; 91600	
type 2 diabetes	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	33890983	170	45	90	9632	
Alzheimer's disease	increased	SGK1	SGK1	O00141	6446	6q23.2	48.94	human	448431	T256-p	Pkinase	EHNSTTStFCGTPEY	33890983	14	0	0		
Alzheimer's disease	increased	SGK1	SGK1	O00141	6446	6q23.2	48.94	human	448429	S422-p	Pkinase_C	AEAFLGFsYAPPTDS	33890983	29	0	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447929	S214-p		GSRSRTPsLPTPPTR	33890983	60	23	42	77348	
breast cancer; lung cancer; colorectal cancer; ovarian cancer	increased	HSF1	HSF1	Q00613	3297	8q24.3	57.26	human	449046	S307-p	Vert_HS_TF	EPPSPPQsPRVEEAS	34239690	25	56	3		
breast cancer; lung cancer; colorectal cancer; ovarian cancer	increased	HSF1	HSF1	Q00613	3297	8q24.3	57.26	human	449045	S303-p	Vert_HS_TF	RVKEEPPsPPQSPRV	34239690	22	59	5		
clear cell kidney cancer	decreased	HSF1	HSF1	Q00613	3297	8q24.3	57.26	human	449045	S303-p	Vert_HS_TF	RVKEEPPsPPQSPRV	34239690	22	59	5		
endometrial cancer	increased	HSF1	HSF1	Q00613	3297	8q24.3	57.26	human	449045	S303-p	Vert_HS_TF	RVKEEPPsPPQSPRV	34239690	22	59	5		
breast cancer; colorectal cancer	increased	HSF1	HSF1	Q00613	3297	8q24.3	57.26	human	455486	S363-p	Vert_HS_TF	DTEGRPPsPPPTSTP	34239690	5	34	42		
endometrial cancer	decreased	HSF1	HSF1	Q00613	3297	8q24.3	57.26	human	455486	S363-p	Vert_HS_TF	DTEGRPPsPPPTSTP	34239690	5	34	42		
hypertrophic cardiomyopathy	decreased	Tcap	Telethonin	O70548	21393	11|11 D	19.08	mouse	448693	S157-p	Telethonin	GPLRRTLsRSMSQEA	34566695	4	5	3		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447928	S202-p		SGYSSPGsPGTPGSR	34536819	149	55	116	30505; 39357	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449080	S235-p		VVRTPPKsPSSAKSR	34536819	43	36	25	20473	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	34536819	130	44	14	20473; 71429	
Niemann-Pick disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447928	S202-p		SGYSSPGsPGTPGSR	34536819	149	55	116	30505; 39357	
AGD	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	34536819	170	45	90	9632	
chronic lymphocytic leukemia	increased	ITGB3	ITGB3	P05106	3690	17q21.32	87.06	human	448013	Y785-p	Integrin_b_cyt	STFTNITyRGT____	34534368	20	2	6		
ataxia-telangiectasia	increased	H3c1	H3	P68433	360198	13|13 A3.1	15.27	mouse	1308913	K27-m3	Histone	LATKAARkSAPATGG	24162653	169	21	3	9733; 89120; 4395; 12158; 98316; 5499; 91611; 14034; 10584; 4232; 35861; 20123; 40724; 54575	
Status epilepticus	mutation of site	GRIN2A	NMDAR2A	Q12879	2903	16p13.2	165.28	human	481117	S1459-p	NMDAR2_C	RVYKKMPsIESDV__	34233182	2	8	2		S1459G variant
bladder cancer; lung cancer	increased	H2AX	H2AX	P16104	3014	11q23.3	15.01	human	37036405	K134-m2		KAPSGGKkATQASQE	25487737	1	1	0		
diabetes mellitus	decreased	Acaca	ACC1	Q5SWU9	107476	11|11 C	265.26	mouse	448292	S79-p		FHMRSSMsGLHLVKQ	34425110	149	76	11	3661; 11818; 42801	
FTLD	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084616	S409-p		GSSMDSKsSGWGM__	25556531	48	4	0		
FTLD	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084601	S410-p		SSMDSKSsGWGM___	25556531	49	4	0		
ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084616	S409-p		GSSMDSKsSGWGM__	25556531	48	4	0		
ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	38520208	K145-ac	RRM_1	DLKTGHSkGFGFVRF	25556531	2	1	0		
ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084601	S410-p		SSMDSKSsGWGM___	25556531	49	4	0		
gastric cancer	increased	BCLAF1	BCLAF1	Q9NYF8	9774	6q23.3	106.12	human	455931	S290-p	THRAP3_BCLAF1	RYSPSQNsPIHHIPS	34372878	1	80	31		corelates with poor prognosis
glioblastoma multiforme	increased	YAP1	YAP1	P46937	10413	11q22.1	54.46	human	1874499600	S436-p		INQSTLPsQQNRFPD	34343821	1	0	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449078	T217-p		SRTPSLPtPPTREPK	34342183	33	31	6	51625	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	34342183	85	33	23	62672; 66224; 12885	
type 2 diabetes	decreased	Creb1	CREB	Q01147	12912	1 C2|1 32.74 cM	35.12	mouse	448228	S119-p	pKID	EILSRRPsYRKILND	34193609	289	4	61	14001; 54960; 9187; 80120; 95995; 14228; 44864; 39561; 9196; 9198; 4095	
lung cancer	increased	CASP8	CASP8	Q14790	841	2q33.1	55.39	human	460647	Y380-p	Peptidase_C14	TDSEEQPyLEMDLSS	34367939	10	3	35		
Parkinson's disease	decreased	PARK7	DJ-1	Q99497	11315	1p36.23	19.89	human	2407414	K130-sm	DJ-1_PfpI	VTTHPLAkDKMMNGG	15976810	4	0	0		Mutant DJ-1 found in PD patients, are improperly sumoylated and degraded by the proteasome.
ovarian cancer	decreased	TP53	p53	P04637	7157	17p13.1	43.65	human	474514	K120-ac	P53	FLHSGTAkSVTCTYS	28737768	41	7	0		ARID1A mutation inactivates apoptosis promoting function of p53 
CCA	decreased	SMARCA4	SMARCA4	P51532	6597	19p13.2	184.65	human	3191581	S1452-p		RPPAEKLsPNPPNLT	34237461	2	58	6		
multiple sclerosis; EAE	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	32094172	468	74	3065	4324; 8119; 9145; 4113; 52075; 73533; 9138; 4323; 4093; 4074; 52527; 74309; 16185; 61958; 9131; 73452	
chronic myelogenous leukemia	decreased	TGFBR2	TGFBR2	P37173	7048	3p24.1	64.57	human	27581511	K556-ne		GRSCSEEkIPEDGSL	23290524	1	0	0		CBL mutation results in loss of neddylation activity
chronic myelogenous leukemia	decreased	TGFBR2	TGFBR2	P37173	7048	3p24.1	64.57	human	27581513	K567-ne		DGSLNTTk_______	23290524	1	0	0		CBL mutation results in loss of neddylation activity
pancreatic ductal adenocarcinoma	increased	Acaca	ACC1	Q5SWU9	107476	11|11 C	265.26	mouse	448292	S79-p		FHMRSSMsGLHLVKQ	34588305	149	76	11	3661; 11818; 42801	
lung cancer	increased	TP53	p53	P04637	7157	17p13.1	43.65	human	458977	K382-ac		QSTSRHKkLMFKTEG	34947995	205	8	0	2570; 2525	Grade 2?3 tumours had the highest K382 in nucleus while grade 1?2 had the highest  K382 in cytoplasm
DCM	increased	Xbp1	XBP1 iso2	O35426-2	22433		39.89	mouse	13875701	K276-sm		SQTNVVVkIEEAPLS	34421344	2	0	0		U0126 treatment significantly decreased progression of DCM
DCM	increased	Xbp1	XBP1 iso2	O35426-2	22433		39.89	mouse	1876695603	S348-p		SPFSDMSsPLGTDHS	34421344	1	0	0		U0126 treatment significantly decreased progression of DCM
non-small cell lung cancer		AKR1C1	AKR1C1	Q04828	1645	10p15.1	36.79	human	12386310	K185-ub	Aldo_ket_red	NKPGLKYkPVCNQVE	32104503	1	3	7		SIRT2 expression  correlated with longer overall survival.
non-small cell lung cancer		AKR1C1	AKR1C1	Q04828	1645	10p15.1	36.79	human	12390205	K201-ub	Aldo_ket_red	HPYFNQRkLLDFCKS	32104503	1	2	2		SIRT2 expression  correlated with longer overall survival.
LAM	increased	PKM	PKM	P14618	5315	15q23	57.94	human	476070	S37-p		MCRLDIDsPPITARN	32078667	15	62	6		
Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	34658833	104	7	0	87281; 23706	
COPD	increased	Rela	NFkB-p65	Q04207	19697	19 A|19 4.34 cM	60.21	mouse	459096	K310-ac		KRTYETFkSIMKKSP	33215396	78	5	0	3045; 12629	
rheumatoid arthritis	increased	Anxa2	ANXA2	P07356	12306	9 C|9 38.58 cM	38.68	mouse	449483	Y24-p		HSTPPSAyGSVKPYT	34696809	29	64	2613		
breast cancer; lung cancer; endometrial cancer	increased	SMARCA4	SMARCA4	P51532	6597	19p13.2	184.65	human	452712	S695-p		KKIPDPDsDDVSEVD	34675941	1	52	4		
breast cancer; lung cancer; clear cell kidney cancer	increased	SMARCA4	SMARCA4	P51532	6597	19p13.2	184.65	human	8091586	S1417-p		SRKRKRDsDAGSSTP	34675941	1	15	33		
colorectal cancer	decreased	MTHFD2	MTHFD2	P13995	10797	2p13.1	37.90	human	1876877400	K88-ac	THF_DHG_CYH	SHSYVLNkTRAAAVV	32811824	1	1	0		in colorectal cancer with high SIRT3 expression
breast cancer; colorectal cancer; endometrial cancer	increased	SMARCA4	SMARCA4	P51532	6597	19p13.2	184.65	human	468776	S613-p	BRK	LDETSQMsDLPVKVI	34675941	1	34	36		
breast cancer; endometrial cancer; ovarian cancer	increased	SMARCA4	SMARCA4	P51532	6597	19p13.2	184.65	human	468777	S699-p		DPDSDDVsEVDARHI	34675941	1	33	4		
HNSCC	decreased	RPS6KB1	p70S6K	P23443	6198	17q23.1	59.14	human	448607	T412-p	Pkinase_C	NQVFLGFtYVAPSVL	21281788	438	8	1	9209; 9205; 9234; 9206; 97596	
HNSCC	increased	BAD	BAD	Q92934	572	11q13.1	18.39	human	447862	S99-p	Bcl-2_BAD	PFRGRSRsAPPNLWA	21281788	121	55	216	5286; 4366; 9295	
HNSCC	increased	PTTG1	Securin	O95997	9232	5q33.3	22.02	human	1239966004	T60-p	Securin	PPALPKAtRKALGTV	30154144	1	0	0		
prostate cancer	increased	PAK4	PAK4	O96013	10298	19q13.2	64.07	human	448023	S474-p	Pkinase	KEVPRRKsLVGTPYW	29849120	12	66	140	3241	
prostate cancer	increased	SNAI2	Snail2	O43623	6591	8q11.21	29.99	human	1162843400	S158-p		CDAQSRKsFSCKYCD	29849120	1	0	0		
esophageal carcinoma	increased	ANXA2	ANXA2	P07355	302	15q22.2	38.60	human	449483	Y24-p		HSTPPSAyGSVKAYT	30081903	29	64	2613		
breast cancer	increased	HK2	HK2	P52789	3099	2p12	102.38	human	28704601	T473-p	Hexokinase_1	QHRARQKtLEHLQLS	29985480	6	0	0		
non-Hodgkin's lymphoma	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	30054295	468	74	3065	4324; 8119; 9145; 4113; 52075; 73533; 9138; 4323; 4093; 4074; 52527; 74309; 16185; 61958; 9131; 73452	
CPA	increased	H1-4	H1E	P10412	3008	6p22.2	21.87	human	456059	S36-p		GAAKRKAsGPPVSEL	30615103	2	70	36		Cushing?s syndrome, somatic mutations in catalytic-alpha subunit of PKA
breast ductal carcinoma	decreased	PIP5K1C	PIP5K1C	O60331	23396	19p13.3	73.26	human	17550224	S448-p		NTVFRKNsSLKSSPS	30555634	2	1	0		Invasive carcinoma
cancer, squamous cell carcinoma	increased	PBK	PBK	Q96KB5	55872	8p21.1	36.09	human	451735	T9-p		EGISNFKtPSKLSEK	29904102	6	12	2	4941	
cancer, squamous cell carcinoma	increased	TP53RK	PRPK	Q96S44	112858	20q13.12	28.16	human	1981300	S250-p		RLRGRKRsMVG____	29904102	3	0	7		
NAFLD	increased	Cebpa	C/EBP-alpha	P53566	12606	7 B2|7 21.02 cM	37.43	mouse	1868113505	S193-p		PPPHPHAsPAHLAAP	30089269	14	0	0		
hypertrophic cardiomyopathy	increased	GJA1	GJA1	P17302	2697	6q22.31	43.01	human	454254	Y313-p	Connexin43	SEQNWANySAEQNRM	30448479	4	20	298		LVH
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084616	S409-p		GSSMDSKsSGWGM__	30559480	48	4	0		
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084601	S410-p		SSMDSKSsGWGM___	30559480	49	4	0		
hepatitis; NAFLD	increased	MAP3K5	ASK1	Q99683	4217	6q23.3	154.54	human	447735	S83-p		ATRGRGSsVGGGSRR	30205811	16	2	6	3761	corelates with advanced fibrosis and higher collagen deposition 
colorectal carcinoma	increased	GSR	GSR	P00390	2936	8p12	56.26	human	23111522	T507-p	Pyr_redox_dim	TKADFDNtVAIHPTS	31530934	1	1	1		
non-small cell lung cancer	increased	PARD6A	PARD6A	Q9NPB6	50855	16q22.1	37.39	human	15714600	S345-p		RGDGSGFsL______	23249950	2	9	0		
CRPC	increased	AXIN2	axin 2	Q9Y2T1	8313	17q24.1	93.57	human	53439300	S311-p		SDALTDDsMSMTDSS	26438599	1	0	0		
Alzheimer's disease	increased	SET	SET iso2	Q01105-2	6418	9q34.11	32.10	human	6308300	S9-p		SAPAAKVsKKELNSN	23374587	6	3	0		
Crohn disease	increased	STAT4	STAT4	Q14765	6775	2q32.2-q32.3	85.94	human	447790	Y693-p		TERGDKGyVPSVFIP	30770344	10	5	8	4134; 5267; 13223; 42353	LIF effectively inhibits Th17 accumulation and acts as a potential therapy for IBD
atherosclerosis	decreased	Nr1h3	LXR-alpha	Q9Z0Y9	22259	2 E1|2 50.52 cM	50.42	mouse	469114	S196-p		SVSPRVSsPPQVLPQ	29950315	6	0	0		S196A mutant in mice have increased atherosclerostic plaques
prostate cancer	increased	PAWR	PAR-4	Q96IZ0	5074	12q21.2	36.57	human	476476	S231-p		GRYKSTTsVSEEDVS	24457960	1	15	18		
HER2 positive breast cancer	decreased	STK4	MST1	Q13043	6789	20q13.12	55.63	human	463558	Y433-p	Mst1_SARAH	KIPQDGDyEFLKSWT	30903103	3	13	110		
esophageal carcinoma; hepatocellular carcinoma; breast cancer; lung cancer; gastric cancer	increased	PDK1	PDHK1	Q15118	5163	2q31.1	49.24	human	54390604	T338-p	HATPase_c	LFNYMYStAPRPRVE	31578148	4	1	0		
esophageal carcinoma; hepatocellular carcinoma; breast cancer; lung cancer; gastric cancer	increased	PGK1	PGK1	P00558	5230	Xq21.1	44.61	human	468410	S203-p	PGK	YFAKALEsPERPFLA	31578148	2	83	11		
bladder cancer	mutation of site	FGFR2	FGFR2	P21802	2263	10q26.13	92.03	human	34500854	S780-p		SQPLEQYsPSYPDTR	31146385	1	1	0		
CRPC	increased	GAD2	GAD2	Q05329	2572	10p12.1	65.41	human	12523303	S6-p		__MASPGsGFWSFGS	31182548	2	1	0		
lung cancer	increased	UGDH	UGDH	O60701	7358	4p14	55.02	human	4699451	Y473-p		VSSKRIPyAPSGEIP	31243371	1	4	4		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447933	T205-p		SSPGSPGtPGSRSRT	32437347	113	24	26	30505; 43964; 49561; 20060; 53001; 20739	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447928	S202-p		SGYSSPGsPGTPGSR	32437347	149	55	116	30505; 39357	
breast cancer	increased	PRKCZ	PKCZ	Q05513	5590	1p36.33	67.66	human	447572	T560-p	Pkinase_C	TSEPVQLtPDDEDAI	32559461	13	8	0		
gastric cancer	decreased	YAP1	YAP1	P46937	10413	11q22.1	54.46	human	27460703	T83-p		KTANVPQtVPMRLRK	32271880	1	2	0		
SLE	increased	H4c2	H4	P62806	326620	13|13 A3.1	11.24	mouse	458959	K8-ac		SGRGKGGkGLGKGGA	17530637	82	21	529	2594	
SLE	increased	H4C1	H4	P62805	8359	6p22.2	11.24	human	458960	K16-ac		GLGKGGAkRHRKVLR	17530637	103	26	531	13534; 26437; 56999; 98789	
SLE	increased	H4c2	H4	P62806	326620	13|13 A3.1	11.24	mouse	458960	K16-ac		GLGKGGAkRHRKVLR	17530637	103	26	531	13534; 26437; 56999; 98789	
SLE	increased	H4C1	H4	P62805	8359	6p22.2	11.24	human	459013	K12-ac		KGGKGLGkGGAKRHR	17530637	89	25	531	2591; 13944	
SLE	increased	H4c2	H4	P62806	326620	13|13 A3.1	11.24	mouse	459013	K12-ac		KGGKGLGkGGAKRHR	17530637	89	25	531	2591; 13944	
SLE	increased	H4C1	H4	P62805	8359	6p22.2	11.24	human	458959	K8-ac		SGRGKGGkGLGKGGA	17530637	82	21	529	2594	
hepatocellular carcinoma	decreased	H3C1	H3	P68431	8350	6p22.2	15.27	human	465520	K18-ac	Histone	TGGKAPRkQLATKAA	25613642	52	27	381	9675; 13998; 79423; 20363; 73508	
type 2 diabetes	increased	NR1H4	NR1H4	Q96RI1	9971	12q23.1	55.91	human	12159006	K227-ac		KRLRKNVkQHADQTV	19883617	1	1	0		
type 2 diabetes	increased	NR1H4	NR1H4	Q96RI1	9971	12q23.1	55.91	human	12159007	K167-ac	zf-C4	FFRRSITkNAVYKCK	19883617	1	1	0		
breast cancer; cervical cancer	increased	CCDC106	CCDC106	Q9BWC9	29903	19q13.42	32.03	human	1867984200	S147-p	CCDC106	SGASEEGsASERRRQ	30885251	1	0	0		
breast cancer; cervical cancer	increased	CCDC106	CCDC106	Q9BWC9	29903	19q13.42	32.03	human	31084482	S130-p	CCDC106	GGAGGEAsDPESAAS	30885251	1	5	0		
chronic lymphocytic leukemia	increased	NFKBIA	IkB-alpha	P25963	4792	14q13.2	35.61	human	448799	Y305-p		FTEDELPyDDCVFGG	30887112	3	0	5		
breast cancer	increased	CCDC88A	girdin	Q3V6T2	55704	2p16.1	216.04	human	456477	S1417-p		INRERQKsLTLTPTR	30935690	9	18	1		
esophageal cancer	increased	SDCBP	syntenin	O00560	6386	8q12.1	32.44	human	1869341900	T200-p	PDZ; Peptidase_M50	RPFERTItMHKDSTG	32572158	1	0	0		
esophageal cancer	increased	SDCBP	syntenin	O00560	6386	8q12.1	32.44	human	56649728	S131-p	PDZ; Peptidase_M50	KIGLRLKsIDNGIFV	32572158	1	1	0		
lymphoma	increased	SOCS1	SOCS1	O15524	8651	16p13.13	23.55	human	1868450203	Y80-p	SH2	LLDACGFyWGPLSVH	31101761	1	1	0		
acute myelogenous leukemia	increased	CEBPA	C/EBP-alpha	P49715	1050	19q13.11	37.56	human	56394105	K302-ac	bZIP_2	AVRKSRDkAKQRNVE	27005833	1	0	0		
acute myelogenous leukemia	increased	CEBPA	C/EBP-alpha	P49715	1050	19q13.11	37.56	human	56394104	K298-ac	bZIP_2	RNNIAVRkSRDKAKQ	27005833	1	0	0		
FTLD	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449083	S422-p		GSIDMVDsPQLATLA	30734106	38	9	0		phosphorylation is increased as compared to conformational changes in dementia
colorectal cancer	increased	Hk2	HK2	O08528	15277	6 C3|6 35.94 cM	102.54	mouse	28704601	T473-p	Hexokinase_1	QHRARQKtLESLKLS	30877036	6	0	0		
glioblastoma multiforme	increased	GLUD1	GLUD1	P00367	2746	10q23.2	61.40	human	25739562	S384-p	ELFV_dehydrog	DILIPAAsEKQLTKS	31447391	1	5	1		
infertility	decreased	Phb	PHB	P67778	18673	11 59.01 cM|11 D	29.82	mouse	11139253	T258-p		LSRSRNItYLPAGQS	32859869	6	0	1		in asthenospermic and oligoasthenospermic men
osteosarcoma	increased	NPM1	NPM1	P06748	4869	5q35.1	32.58	human	459897	S125-p		AVEEDAEsEDEEEED	32606971	9	94	558		
osteosarcoma	increased	Npm1	NPM1	Q61937	18148	11|11 A4	32.56	mouse	459897	S125-p		AVEEDAEsEDEDEED	32606971	9	94	558		
hypertension	increased	Eef2k	EEF2K	P70531	25435	1q36	81.49	rat	455998	S499-p		RLHLPRPsAVALEVQ	33191388	5	9	2		
hypertension	increased	Eef2	EEF2	P05197	29565	7q11	95.28	rat	448040	T57-p	GTP_EFTU	RAGETRFtDTRKDEQ	33191388	35	61	54	2331	
lung cancer	increased	PDHA1	PDHA1	P08559	5160	Xp22.12	43.30	human	1868287349	S314-p	E1_dh	IQEVRSKsDPIMLLK	33022274	1	2	0		
hypertension	decreased	Eef2k	EEF2K	P70531	25435	1q36	81.49	rat	447827	S365-p		SPRIRTLsGSRPPLL	33191388	15	11	20	3691	increased in prehypertensive state
lung cancer	increased	WT1	WT1 iso7	P19544-7	7490	11p13	56.88	human	1871128700	S63-p		ERLQGRRsRGASGSE	33184107	1	1	0		
lung cancer	increased	WT1	WT1 iso7	P19544-7	7490	11p13	56.88	human	56653434	S67-p		GRRSRGAsGSEPQQM	33184107	2	3	0		
colorectal cancer	increased	WT1	WT1 iso7	P19544-7	7490	11p13	56.88	human	56653434	S67-p		GRRSRGAsGSEPQQM	33184107	2	3	0		
lung cancer	increased	PDHA1	PDHA1	P08559	5160	Xp22.12	43.30	human	468391	S295-p	E1_dh	RYHGHSMsDPGVSYR	33022274	3	51	241		
CS	increased	RB1	Rb	P06400	5925	13q14.2	106.16	human	447978	S780-p	Rb_C	STRPPTLsPIPHIPR	21880723	91	16	128	9307; 8180; 3590	
B-Cell ALL	increased	IKZF1	Ikaros	Q13422	10320	7p12.2	57.53	human	3609103	K241-sm		GTLYPVIkEETNHSE	27315244	2	0	0		
B-Cell ALL	increased	IKZF1	Ikaros	Q13422	10320	7p12.2	57.53	human	56819000	K429-sm		ARNGLSLkEEHRAYD	27315244	1	0	0		
B-Cell ALL	increased	IKZF1	Ikaros	Q13422	10320	7p12.2	57.53	human	3609102	K58-sm		RVVASNVkVETQSDE	27315244	2	0	0		
leukemia	increased	PML	PML	P29590	5371	15q24.1	97.55	human	2295400	K160-sm	zf-B_box	EAHQWFLkHEARPLA	15710327	18	4	0		
diabetes mellitus	decreased	Mapk7	ERK5	Q9WVS8	23939	11|11 B2	87.73	mouse	2887212	K22-sm		GEPPGRVkAEPVHTA	18467627	4	0	0		
diabetes mellitus	decreased	Mapk7	ERK5	Q9WVS8	23939	11|11 B2	87.73	mouse	2887213	K6-sm		__MAEPLkEEDGEDG	18467627	4	0	0		
cervical cancer	decreased	SP1	SP1	P08047	6667	12q13.13	80.69	human	2535901	K16-sm		DEMTAVVkIEKGVGG	18572193	3	2	0		
hepatocellular carcinoma	mutation of site	TP53	p53	P04637	7157	17p13.1	43.65	human	394791401	R249-p	P53	CMGGMNRrPILTIIT	31747859	3	0	0		p53-R249S mutation
Alzheimer's disease	increased	App	APP	P12023	11820	16 C3.3|16 46.92 cM	86.72	mouse	54165901	S697-p	Beta-APP	FFAEDVGsNKGAIIG	33519377	2	0	0		
CBD	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	447928	S494-p		SGYSSPGsPGTPGSR	33519674	149	55	116	30505; 39357	
hepatocellular carcinoma	increased	PEA15	PEA-15	Q15121	8682	1q23.2	15.04	human	450281	S116-p		KDIIRQPsEEEIIKL	33574916	15	95	1092		causes a poor prognosis
hepatocellular carcinoma	increased	CDKN1B	p27Kip1	P46527	1027	12p13.1	22.07	human	447875	T187-p		NAGSVEQtPKKPGLR	33574916	50	1	1		causes a poor prognosis
clear cell kidney cancer	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448191	S727-p		NTIDLPMsPRTLDSL	33772065	199	55	67	49081; 34911; 50804; 58978; 71958; 87544; 94994; 9136; 9134	phosphorylation of this site corelates with low overall survival of patients and their susceptibility to adjuvant treatment
diabetes mellitus	decreased	Vasp	VASP	B5DEX4	361517	1q21	39.72	rat	448380	S236-p		GAKLRKVsKEEASGG	33772737	58	26	3	3114	
diabetes mellitus	decreased	Nos3	eNOS	Q62600	24600	4q11	133.29	rat	447884	S1176-p		TSRIRTQsFSLQERQ	33772737	194	18	7	9570; 9571	
gastric cancer	increased	SIAH2	SIAH2	O43255	6478	3q25.1	34.61	human	25172963	S6-p		__MSRPSsTGPSANK	33536006	1	2	0		
gastric cancer	increased	SIAH2	SIAH2	O43255	6478	3q25.1	34.61	human	1872043500	T279-p	Sina	RRLTWEAtPRSIHDG	33536006	1	0	0		
Alzheimer's disease	increased	Mecp2	MECP2	Q9Z2D6	17257	X A7.3|X 37.63 cM	52.31	mouse	470075	S421-p		EKMPRGGsLESDGCP	33551790	13	13	0		
lung cancer	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	1458614	K79-m3	Histone	REIAQDFkTDLRFQS	22190683	17	4	0	4260; 74073	
OSCC	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	459004	K4-m2	Histone	____ARTkQTARKST	19753335	104	10	0	31777; 9725	
OSCC	decreased	H3C1	H3	P68431	8350	6p22.2	15.27	human	1458621	K4-m3	Histone	____ARTkQTARKST	19753335	161	7	0	9751; 9727; 12064; 11960; 62255	
prostate cancer	decreased	H3C1	H3	P68431	8350	6p22.2	15.27	human	1458613	K9-m3	Histone	RTKQTARkSTGGKAP	19739128	128	22	1	5327; 4473; 6951; 55286; 13969	H3K4-me1, me2 and me3 levels increased in advanced prostate cancer tissue, H3K4me1 was predictor of PSA recurrence after radical prostatectomy
breast cancer	increased	PFKFB3	PFKFB3	Q16875	5209	10p15.1	59.61	human	9318263	S478-p		TKKPRINsFEEHVAS	33931981	2	6	5		
prostate cancer	decreased	H3C1	H3	P68431	8350	6p22.2	15.27	human	1458622	K4-m1	Histone	____ARTkQTARKST	19739128	43	10	9	5326; 9723; 55800	H3K4-me1, me2 and me3 levels increased in advanced prostate cancer tissue, H3K4me1 was predictor of PSA recurrence after radical prostatectomy
asthma	increased	Lck	Lck	P06240	16818	4 D2.2|4 63.26 cM	57.94	mouse	447823	Y505-p		FTATEGQyQPQP___	33684096	52	32	805	2751	
colorectal cancer	increased	G6PD	G6PD	P11413	2539	Xq28	59.26	human	455132	Y112-p	G6PD_N	NSYVAGQyDDAASYQ	33686238	1	12	344		
breast cancer	increased	Pfkfb3	PFKFB3	Q9ESY2	170768	2|2 A1	59.70	mouse	9318263	S478-p		TKKPRINsFEERVAS	33931981	2	6	5		
testicular cancer	increased	H1-4	H1E	P10412	3008	6p22.2	21.87	human	3925584	K34-ac		SAGAAKRkASGPPVS	22465951	1	1	1		testicular germ cell tumors-carcinomas and seminomas
prostate cancer	decreased	CERS2	LASS2	Q96G23	29956	1q21.3	44.88	human	1872840300	S248-p	TRAM_LAG1_CLN8	SSDYLLEsAKMFNYA	33852174	1	0	0		dephosphorylation of this site enhances prostate carcinogenesis
bladder cancer	increased	Eif4e	EIF4E	P63073	13684	3 G3|3 64.3 cM	25.05	mouse	447776	S209-p		DTATKSGsTTKNRFV	34032633	60	4	0	9741	
nasopharyngeal carcinoma	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	33824475	468	74	3065	4324; 8119; 9145; 4113; 52075; 73533; 9138; 4323; 4093; 4074; 52527; 74309; 16185; 61958; 9131; 73452	corelates with poor clinical outcome
non-small cell lung cancer; non-small cell lung adenocarcinoma; non-small cell squamous cell lung carcinoma	increased	INSIG1	INSIG1	O15503	3638	7q36.3	29.99	human	1868515111	S207-p	INSIG	LWWTFDRsRSGLGLG	33842305	2	1	0		
non-small cell lung cancer; non-small cell lung adenocarcinoma; non-small cell squamous cell lung carcinoma	increased	PCK1	PCK1	P35558	5105	20q13.31	69.19	human	1868515110	S90-p	PEPCK_N	RDVARIEsKTVIVTQ	33842305	2	1	0		
non-small cell lung cancer; non-small cell lung adenocarcinoma; non-small cell squamous cell lung carcinoma	increased	INSIG2	INSIG2	Q9Y5U4	51141	2q14.1-q14.2	24.78	human	1868515112	S151-p	INSIG	LWWTFDRsRSGFGLG	33842305	2	1	0		
Parkinson's disease	increased	Xbp1	XBP1	O35426	22433	11 A1|11 3.61 cM	29.62	mouse	21688102	S61-p	bZIP_1	RQRLTHLsPEEKALR	34030589	4	7	0		
Parkinson's disease	increased	Xbp1	XBP1	O35426	22433	11 A1|11 3.61 cM	29.62	mouse	21688103	T48-p		AGSEASGtPQARKRQ	34030589	3	0	0		
pancreatic carcinoma	decreased	H3C1	H3	P68431	8350	6p22.2	15.27	human	459004	K4-m2	Histone	____ARTkQTARKST	20142597	104	10	0	31777; 9725	corelates with low survival and worse prognosis
pancreatic carcinoma	decreased	H3C1	H3	P68431	8350	6p22.2	15.27	human	465520	K18-ac	Histone	TGGKAPRkQLATKAA	20142597	52	27	381	9675; 13998; 79423; 20363; 73508	corelates with low survival and worse prognosis
pancreatic carcinoma	decreased	H3C1	H3	P68431	8350	6p22.2	15.27	human	459006	K9-m2	Histone	RTKQTARkSTGGKAP	20142597	113	20	0	5327; 66070; 4658; 4473; 6951; 51198; 31064; 9753	corelates with low survival and worse prognosis
prostate cancer	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	1458621	K4-m3	Histone	____ARTkQTARKST	19935671	161	7	0	9751; 9727; 12064; 11960; 62255	Low grade prostate cancer, high risk of recurrence after adical  prostatectomy (RP)
prostate cancer	increased	H4C1	H4	P62805	8359	6p22.2	11.24	human	2344825	K20-m3	CENP-T_C	GGAKRHRkVLRDNIQ	19935671	35	14	0	5737	high grade  prostate cancer  increased  risk of the biochemical recurrence  after adical  prostatectomy (RP)
prostate cancer	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	463820	K9-ac	Histone	RTKQTARkSTGGKAP	19935671	218	25	341	4484; 14052; 9677; 9711; 11857; 9683; 28036; 9649	high grade  prostate cancer  increased  risk of the biochemical recurrence  after adical  prostatectomy (RP)
DN	increased	H3c1	H3	P68433	360198	13|13 A3.1	15.27	mouse	459004	K4-m2	Histone	____ARTkQTARKST	20067909	104	10	0	31777; 9725	advanced diabetic glomerulosclerosis
DN	increased	H3c1	H3	P68433	360198	13|13 A3.1	15.27	mouse	455676	S10-p	Histone	TKQTARKsTGGKAPR	20067909	228	15	1	3465; 9701; 8552; 66065; 9706; 3377; 5764; 64522; 3475; 29237; 9711; 8481; 9606; 52725; 43185; 3642; 3458; 53348	advanced diabetic glomerulosclerosis
DN	increased	H3c1	H3	P68433	360198	13|13 A3.1	15.27	mouse	458999	K23-ac	Histone	PRKQLATkAARKSAP	20067909	26	28	422	14932	advanced diabetic glomerulosclerosis
DN	increased	H3c1	H3	P68433	360198	13|13 A3.1	15.27	mouse	459006	K9-m2	Histone	RTKQTARkSTGGKAP	20067909	113	20	0	5327; 66070; 4658; 4473; 6951; 51198; 31064; 9753	advanced diabetic glomerulosclerosis
Duchenne muscular dystrophy	increased	H3c1	H3	P68433	360198	13|13 A3.1	15.27	mouse	463820	K9-ac	Histone	RTKQTARkSTGGKAP	19264835	218	25	341	4484; 14052; 9677; 9711; 11857; 9683; 28036; 9649	
hypertrophic cardiomyopathy	increased	H3C14	HIST2H3A/C/D	Q71DI3	126961	1q21.2	15.26	human	18465124	K9-ac	Histone	RTKQTARkSTGGKAP	20075197	1	5	55	11857	renal failure-induced cardiac hypertrophy in diabetes type 2
hypertrophic cardiomyopathy	increased	H3C14	HIST2H3A/C/D	Q71DI3	126961	1q21.2	15.26	human	18465114	K23-ac	Histone	PRKQLATkAARKSAP	20075197	1	5	63		renal failure-induced cardiac hypertrophy in diabetes type 2
hypertrophic cardiomyopathy	increased	H3C14	HIST2H3A/C/D	Q71DI3	126961	1q21.2	15.26	human	33597100	K4-m2	Histone	____ARTkQTARKST	20075197	1	0	0		renal failure-induced cardiac hypertrophy in diabetes type 2
hypertrophic cardiomyopathy	increased	H3C14	HIST2H3A/C/D	Q71DI3	126961	1q21.2	15.26	human	18465104	S10-p	Histone	TKQTARKsTGGKAPR	20075197	1	2	0		renal failure-induced cardiac hypertrophy in diabetes type 2
breast ductal carcinoma	increased	NUCKS1	NUCKS	Q9H1E3	64710	1q32.1	27.30	human	2586362	K9-ac		SRPVRNRkVVDYSQF	18491381	0	2	3		
Duchenne muscular dystrophy	increased	H3c1	H3	P68433	360198	13|13 A3.1	15.27	mouse	455676	S10-p	Histone	TKQTARKsTGGKAPR	19264835	228	15	1	3465; 9701; 8552; 66065; 9706; 3377; 5764; 64522; 3475; 29237; 9711; 8481; 9606; 52725; 43185; 3642; 3458; 53348	
Duchenne muscular dystrophy	increased	H3c1	H3	P68433	360198	13|13 A3.1	15.27	mouse	1458615	K79-m2	Histone	REIAQDFkTDLRFQS	19264835	36	20	10	5427	
Duchenne muscular dystrophy	increased	H3c1	H3	P68433	360198	13|13 A3.1	15.27	mouse	458954	K14-ac	Histone	ARKSTGGkAPRKQLA	19264835	153	31	355	7627; 9677; 26828	
breast ductal carcinoma	increased	NUCKS1	NUCKS	Q9H1E3	64710	1q32.1	27.30	human	2586352	K188-ac		SPVKGKGkVGRPTAS	18491381	0	3	15		
breast ductal carcinoma	increased	NUCKS1	NUCKS	Q9H1E3	64710	1q32.1	27.30	human	2586359	K218-me		EPESPPEkKTSTSPP	18491381	0	1	0		
breast ductal carcinoma	increased	NUCKS1	NUCKS	Q9H1E3	64710	1q32.1	27.30	human	2586355	K196-ac		VGRPTASkASKEKTP	18491381	0	1	27		
hepatocellular carcinoma; lung cancer	increased	BCL9	Bcl-9	O00512	607	1q21.2	149.29	human	3150953	T172-p		EPTPAQKtPAKVVYV	30217955	1	5	10		
colorectal cancer	decreased	MLKL	MLKL	Q8NB16	197259	16q23.1	54.48	human	22996309	S358-p	PK_Tyr_Ser-Thr	ELRKTQTsMSLGTTR	30029665	33	3	0	37333; 91689; 18640	
breast cancer	increased	ERBB2	HER2	P04626	2064	17q12	137.91	human	448675	Y1222-p		PAFDNLYyWDQDPPE	19239686	31	1	8	2249; 2243	HER2 phosphorylation was associated with high tumor grade and shorter disease-free and overall survival
breast cancer	increased	ERBB2	HER2	P04626	2064	17q12	137.91	human	449744	Y1221-p		SPAFDNLyYWDQDPP	19239686	28	1	14	2249; 2243	HER2 phosphorylation was associated with high tumor grade and shorter disease-free and overall survival
Fetal growth restriction	increased	IGFBP1	IGFBP1	P08833	3484	7p12.3	27.90	human	451660	S194-p	Thyroglobulin_1	LAKAQETsGEEISKF	25957086	14	13	0		hyperphosphorylation of this site is observed in decreased amino acid availability 
Fetal growth restriction	increased	IGFBP1	IGFBP1	P08833	3484	7p12.3	27.90	human	451658	S126-p		GSPESPEsTEITEEE	25957086	14	9	0		hyperphosphorylation of this site is observed in decreased amino acid availability 
Fetal growth restriction	increased	IGFBP1	IGFBP1	P08833	3484	7p12.3	27.90	human	451659	S144-p		NFHLMAPsEEDHSIL	25957086	14	10	0		hyperphosphorylation of this site is observed in decreased amino acid availability 
non-small cell lung cancer	increased	DLG1	DLG1	Q12959	1739	3q29	100.46	human	22496705	T657-p		KERARLKtVKFNSKT	22027822	1	0	0		
Parkinson's disease	increased	PPP2CA	PPP2CA	P67775	5515	5q31.1	35.59	human	448571	Y307-p		VTRRTPDyFL_____	24395787	70	0	0		
breast cancer	decreased	PHB2	BAP37	Q99623	11331	12p13.31	33.30	human	1868188300	S39-p		VAYGVREsVFTVEGG	28555617	2	0	0		ER-alpha positive breast cancers-poor prognosis
GCT	increased	FOXL2	FOXL2	P58012	668	3q22.3	38.77	human	21697903	S33-p		EPEGPPPsPGKGGGG	24390485	3	9	1		in patents carrying FOXL2 C134W mutation
hepatocellular carcinoma	increased	XIAP	XIAP	P98170	331	Xq25	56.68	human	450336	S87-p	BIR	VGRHRKVsPNCRFIN	30867140	10	0	0		
lung cancer; gastric cancer; liver cancer	increased	STMN2	STMN2	Q93045	11075	8q21.13	20.83	human	455606	S50-p	Stathmin	KQINKRAsGQAFELI	23893240	5	5	0		
pancreatic carcinoma	increased	CAP1	CAP1	Q01518	10487	1p34.2	51.90	human	485063	S308-p		SAPKPQTsPSPKRAT	30894654	4	46	29		
pancreatic carcinoma	increased	CAP1	CAP1	Q01518	10487	1p34.2	51.90	human	2525971	S310-p		PKPQTSPsPKRATKK	30894654	5	47	6		
type 2 diabetes	increased	Klhl3	KLHL3	E0CZ16	100503085	13|13 B1	64.92	mouse	36440206	S433-p	Kelch_1	PMNTRRSsVGVGVVE	30914436	6	2	0		
gastric cancer	increased	RHOA	RHOA	P61586	387	3p21.31	21.77	human	150180312	Y42-p	Ras	VPTVFENyVADIEVD	31056743	4	0	0		
vitamin B12 metabolism disorder	decreased	Elavl1	HuR	P70372	15568	8 A1.1|8 2.0 cM	36.17	mouse	478357	S221-p		QAQRFRFsPMGVDHM	30016500	11	0	0		
breast cancer	increased	TSC1	TSC1	Q92574	7248	9q34.13	129.77	human	3208191	S511-p	Hamartin	DSPFYRDsLPGSQRK	17693255	4	6	11		
lung cancer	increased	PTPN12	PTP-PEST	Q05209	5782	7q11.23	88.11	human	1983755	S571-p		KTVSLTPsPTTQVET	21876001	1	13	3		
lung cancer	decreased	PTK2	FAK	Q05397	5747	8q24.3	119.23	human	447887	Y397-p		SVSETDDyAEIIDEE	21876001	340	31	474	3283; 8556	
neuroblastoma	increased	DPYSL3	CRMP-4	Q14195	1809	5q32	61.96	human	454328	T509-p		PVFDLTTtPKGGTPA	30154149	3	50	16		
neuroblastoma	increased	DPYSL3	CRMP-4	Q14195	1809	5q32	61.96	human	458799	S518-p		KGGTPAGsARGSPTR	30154149	1	23	10		
neuroblastoma	increased	DPYSL3	CRMP-4	Q14195	1809	5q32	61.96	human	458798	T514-p		TTTPKGGtPAGSARG	30154149	1	27	16		
neuroblastoma	increased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	449111	S9-p		SGRPRTTsFAESCKP	30154149	513	44	227	5558; 14630; 14026; 14332; 79774; 9322; 9327; 9331; 9323; 9336; 9325; 8466; 8566; 14310	
MI	decreased	Gata4	GATA4	P46152	54254	15p12	44.60	rat	449604	S105-p	GATA-N	AYTPPPVsPRFSFPG	32060996	16	0	0		
Huntington's disease	increased	Myrf	MRF	Q3UR85	225908	19|19 A	123.29	mouse	20804942	S259-p		PSKKRKHsESPPNTL	32270922	1	2	0		
prostate cancer	decreased	MKNK2	Mnk2	Q9HBH9	2872	19p13.3	51.87	human	456328	S74-p		KRGRATDsFSGRFED	32170339	1	11	3		
ovarian cancer	increased	YES1	Yes	P07947	7525	18p11.32	60.80	human	447619	Y426-p	PK_Tyr_Ser-Thr	RLIEDNEyTARQGAK	32294438	7	93	3048	6943; 2101; 78740; 70926; 94361; 59548; 17320	Decreased phosphorylation was found in patients receiving neoadjuvant chemotherapy and showing excellent response.
ovarian cancer	increased	LCK	Lck	P06239	3932	1p35.2	58.00	human	447822	Y394-p	PK_Tyr_Ser-Thr	RLIEDNEyTAREGAK	32294438	53	96	2957	6943; 2101; 78740; 70926; 94361; 59548; 17320	Decreased phosphorylation was found in patients receiving neoadjuvant chemotherapy and showing excellent response.
ovarian cancer	increased	SRC	Src	P12931	6714	20q11.23	59.83	human	448234	Y419-p	PK_Tyr_Ser-Thr	RLIEDNEyTARQGAK	32294438	416	102	3046	6943; 2101; 78740; 70926; 94361; 59548; 17320	Decreased phosphorylation was found in patients receiving neoadjuvant chemotherapy and showing excellent response.
ovarian cancer	increased	YES1	Yes	P07947	7525	18p11.32	60.80	human	2192564	T427-p	PK_Tyr_Ser-Thr	LIEDNEYtARQGAKF	32294438	0	10	14		Decreased phosphorylation was found in patients receiving neoadjuvant chemotherapy and showing excellent response.
ovarian cancer	increased	LCK	Lck	P06239	3932	1p35.2	58.00	human	2192555	T395-p	PK_Tyr_Ser-Thr	LIEDNEYtAREGAKF	32294438	1	10	20		Decreased phosphorylation was found in patients receiving neoadjuvant chemotherapy and showing excellent response.
ovarian cancer	increased	FYN	Fyn	P06241	2534	6q21	60.76	human	2192561	T421-p	PK_Tyr_Ser-Thr	LIEDNEYtARQGAKF	32294438	0	10	14		Decreased phosphorylation was found in patients receiving neoadjuvant chemotherapy and showing excellent response.
ovarian cancer	increased	SRC	Src	P12931	6714	20q11.23	59.83	human	2192579	T420-p	PK_Tyr_Ser-Thr	LIEDNEYtARQGAKF	32294438	0	10	14		Decreased phosphorylation was found in patients receiving neoadjuvant chemotherapy and showing excellent response.
ovarian cancer	increased	FYN	Fyn	P06241	2534	6q21	60.76	human	447882	Y420-p	PK_Tyr_Ser-Thr	RLIEDNEyTARQGAK	32294438	26	94	3048	6943; 2101; 78740; 70926; 94361; 59548; 17320	Decreased phosphorylation was found in patients receiving neoadjuvant chemotherapy and showing excellent response.
hepatocellular carcinoma	increased	INSIG2	INSIG2	Q9Y5U4	51141	2q14.1-q14.2	24.78	human	1868515112	S151-p	INSIG	LWWTFDRsRSGFGLG	32322062	2	1	0		
hepatocellular carcinoma	increased	PCK1	PCK1	P35558	5105	20q13.31	69.19	human	1868515110	S90-p	PEPCK_N	RDVARIEsKTVIVTQ	32322062	2	1	0		
hepatocellular carcinoma	increased	INSIG1	INSIG1	O15503	3638	7q36.3	29.99	human	1868515111	S207-p	INSIG	LWWTFDRsRSGLGLG	32322062	2	1	0		
multiple sclerosis	increased	DPYSL2	CRMP-2	Q16555	1808	8p21.2	62.29	human	448084	T555-p		DNIPRRTtQRIVAPP	21421798	18	2	8		
acute myelogenous leukemia	increased	RMDN3	FAM82A2	Q96TC7	55177	15q15.1	52.12	human	19009800	Y176-p		DAESEGGyTTANAES	21513978	4	0	1		
cardiomyopathy	decreased	Fxyd1	PLM	O08589	58971	1q21	10.37	rat	451425	S88-p		RSSIRRLsTRRR___	21849407	27	3	74		
pre-ecalampsia	increased	SLC12A1	NKCC2	Q13621	6557	15q21.1	121.45	human	478420	S130-p	AA_permease_N	GPKVNRPsLLEIHEQ	30248150	8	2	0		compared to normal pregnancy
pre-ecalampsia	decreased	SLC12A1	NKCC2	Q13621	6557	15q21.1	121.45	human	458228	T105-p	AA_permease_N	LQTFGHNtMDAVPKI	30248150	14	2	0		compared to norman pregnancy
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449078	T217-p		SRTPSLPtPPTREPK	31178717	33	31	6	51625	Hyperphosphorylation found in cerebrospinal fluid samples of Alzheimer's disease
pre-ecalampsia	decreased	SLC12A3	NCCT	P55017	6559	16q13	113.14	human	469617	T60-p	AA_permease_N	MRTFGYNtIDVVPTY	30248150	24	3	0		compared to norman pregnancy
pre-ecalampsia	decreased	SLC12A1	NKCC2	Q13621	6557	15q21.1	121.45	human	458227	T100-p	AA_permease_N	TNTYYLQtFGHNTMD	30248150	15	2	0		compared to norman pregnancy
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447933	T205-p		SSPGSPGtPGSRSRT	31178717	113	24	26	30505; 43964; 49561; 20060; 53001; 20739	Hyperphosphorylation found in cerebrospinal fluid samples of Alzheimer's disease
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	487449	S208-p		GSPGTPGsRSRTPSL	31178717	3	7	5		Hyperphosphorylation found in cerebrospinal fluid samples of Alzheimer's disease
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	31178717	130	44	14	20473; 71429	Hyperphosphorylation found in cerebrospinal fluid samples of Alzheimer's disease
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	450217	T111-p		EEAGIGDtPSLEDEA	31178717	2	7	0		Hyperphosphorylation found in cerebrospinal fluid samples of Alzheimer's disease
colorectal cancer	increased	H4C1	H4	P62805	8359	6p22.2	11.24	human	459013	K12-ac		KGGKGLGkGGAKRHR	19057998	89	25	531	2591; 13944	increased in moderate and well differentiated tumors, decreased in poorly differentiated tumors
colorectal cancer	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	465520	K18-ac	Histone	TGGKAPRkQLATKAA	19057998	52	27	381	9675; 13998; 79423; 20363; 73508	increased in moderate and well differentiated tumors, decreased in poorly differentiated tumors
Alzheimer's disease; FTLD; AGD; TPSD	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	25223700	K280-ac	Tubulin-binding	GKVQIINkKLDLSNV	23885714	9	1	0		
lung cancer	increased	ZNF322	ZNF322A	Q6U7Q0	79692	6p22.2	46.94	human	114810402	S224-p	zf-C2H2	EKSYRHRsAFIVHKR	31399647	2	1	0		
	Hypophosphataemic rickets (HR); mutation of site	SGK3	SGK3	Q96BR1	23678	8q13.1	57.11	human	448197	T320-p	Pkinase	AISDTTTtFCGTPEY	31821448	8	3	0	5642	deletion of the part of SGK3 gene carrying SGK3 T320 phosphorylation site
diabetes mellitus	increased	Hist1h2ail1	H3	Q6LED0	291159	17p11	15.27	rat	463820	K9-ac	Histone	RTKQTARkSTGGKAP	26298192	218	25	341	4484; 14052; 9677; 9711; 11857; 9683; 28036; 9649	
chronic lymphocytic leukemia	increased	IDH2	IDH2	P48735	3418	15q26.1	50.91	human	1204122	K413-ac	Iso_dh	VESGAMTkDLAGCIH	26631723	4	3	5		IDH2 catalytic activity was reduced in mitochondrial extracts in CLL.
prostate cancer	decreased	H3C1	H3	P68431	8350	6p22.2	15.27	human	465520	K18-ac	Histone	TGGKAPRkQLATKAA	19885564	52	27	381	9675; 13998; 79423; 20363; 73508	
prostate cancer	decreased	H3C1	H3	P68431	8350	6p22.2	15.27	human	463820	K9-ac	Histone	RTKQTARkSTGGKAP	19885564	218	25	341	4484; 14052; 9677; 9711; 11857; 9683; 28036; 9649	
prostate cancer	decreased	H3C1	H3	P68431	8350	6p22.2	15.27	human	458954	K14-ac	Histone	ARKSTGGkAPRKQLA	19885564	153	31	355	7627; 9677; 26828	
prostate cancer	decreased	H3C1	H3	P68431	8350	6p22.2	15.27	human	458999	K23-ac	Histone	PRKQLATkAARKSAP	19885564	26	28	422	14932	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	25223700	K280-ac	Tubulin-binding	GKVQIINkKLDLSNV	21427723	9	1	0		
lymphoma	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	458927	K685-ac		PKEEAFGkYCRPESQ	27582487	25	1	0	2523	cutaneous T-cell lymphoma, acetylated STAT3 wassignificantly increased in CTCL tissues after  vorinostat  treatment
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	55529800	K174-ac		NATRIPAkTPPAPKT	26390242	4	1	0		
diabetes mellitus	increased	Rela	NFkB-p65	Q7TQN4	309165	1q43	60.27	rat	459096	K310-ac		KRTYETFkSIMKKSP	26298192	78	5	0	3045; 12629	
DLB	molecular association	NUB1	NYREN18	Q9Y5A7	51667	7q36.1	70.54	human	1868140201	S46-p		KDLAKQYsDRLECCE	31006160	1	0	0		
hyperalgesia	increased	Ap2m1	AP2M1	P84092	116563	11q23	49.65	rat	2048345	S45-p	Clat_adaptor_s	HARQQVRsPVTNIAR	31186372	1	6	0		CFA induced inflammatory rat model
colorectal cancer	decreased	TRIM65	TRIM65	Q6PJ69	201292	17q25.1	57.35	human	1868914501	S167-p		LELRKQSsQIQNSAC	31332286	1	1	0		
Alzheimer's disease	increased; molecular association	BIN1	BIN1	O00499	274	2q14.3	64.70	human	7532308	T348-p		VPPPPKHtPSKEVKQ	31065832	1	7	4		association with MAPT (Tau)
breast cancer	increased	PKM	PKM	P14618	5315	15q23	57.94	human	474712	K305-ac	PK	GIEIPAEkVFLAQKM	27197174	3	8	30		
colorectal cancer	decreased	TRIM65	TRIM65	Q6PJ69	201292	17q25.1	57.35	human	1868914502	S367-p		RGPGGPGsFELWQVQ	31332286	1	1	0		
colorectal cancer	decreased	TRIM65	TRIM65	Q6PJ69	201292	17q25.1	57.35	human	1868914503	T413-p	SPRY	RCRLGPHtDNIGRGP	31332286	1	1	0		
breast cancer	increased	FBP1	FBPase	P09467	2203	9q22.32	36.84	human	15501075	S144-p	FBPase	FGIYRKKsTDEPSEK	32754266	1	4	3		
breast cancer	increased	Fbp1	FBPase	Q9QXD6	14121	13|13 B3	36.91	mouse	15501075	S144-p	FBPase	FGIYRKKsTDEPSEK	32754266	1	4	3		
Status epilepticus	mutation of site	Grin2a	NMDAR2A	P35436	14811	16 A1|16 5.28 cM	165.42	mouse	481117	S1459-p	NMDAR2_C	RVYKKMPsIESDV__	32877683	2	8	2		
Status epilepticus	mutation of site	GRIN2A	NMDAR2A	Q12879	2903	16p13.2	165.28	human	481117	S1459-p	NMDAR2_C	RVYKKMPsIESDV__	32877683	2	8	2		
Status epilepticus	decreased	RPS6	S6	P62753	6194	9p22.1	28.68	human	448093	S236-p		AKRRRLSsLRASTSK	32833881	219	72	1124	4851; 14733; 3985; 34411; 27036; 4803; 3945; 62788; 5316; 9865; 8520; 97935; 2211; 4856; 62016; 4857; 4854; 5006; 4858; 81736	
Status epilepticus	decreased	RPS6	S6	P62753	6194	9p22.1	28.68	human	448092	S235-p		IAKRRRLsSLRASTS	32833881	225	60	972	4851; 14733; 3985; 34411; 27036; 4803; 3945; 62788; 5316; 9865; 8520; 97935; 2211; 4856; 62016; 4857; 4854; 5006; 4858; 81736	
Status epilepticus	increased	FMR1	FMR1 iso3	Q06787-3	2332	Xq27.3	70.03	human	14323700	S499-p	FXMRP1_C_core	SDHRDELsDWSLAPT	32833881	3	1	0		
glioma	decreased	PTBP2	PTBP2	Q9UKA9	58155	1p21.3	57.49	human	31089521	K137-sm		YSNHKELkTDNTLNQ	24286314	1	0	0		
acute myelogenous leukemia	increased	IGF1R	IGF1R	P08069	3480	15q26.3	154.79	human	12723518	K1055-sm	PK_Tyr_Ser-Thr	LNEASVMkEFNCHHV	25448401	2	0	0		
acute myelogenous leukemia	increased	IGF1R	IGF1R	P08069	3480	15q26.3	154.79	human	12723517	K1130-sm	PK_Tyr_Ser-Thr	MAYLNANkFVHRDLA	25448401	2	0	0		
DC	mutation of site	DKC1	dyskerin	O60832	1736	Xq28	57.67	human	31910300	K39-sm		HAEEFLIkPESKVAK	23660516	1	0	0		
Parkinson's disease	decreased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	3829801	K102-sm	Synuclein	VKKDQLGkNEEGAPQ	21746851	5	1	0		decreases survival of VMAT2+ neurons inalpha-synuclein?2KR  in a rat  model of PD
Parkinson's disease	decreased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	3755605	K96-sm	Synuclein	AAATGFVkKDQLGKN	21746851	5	1	0		decreases survival of VMAT2+ neurons inalpha-synuclein?2KR  in a rat  model of PD
colorectal cancer	increased	MAT2A	MAT2A	P31153	4144	2p11.2	43.66	human	50455000	K340-sm	S-AdoMet_synt_C	FHYGTSQkSERELLE	26416353	1	0	0		
colorectal cancer	increased	MAT2A	MAT2A	P31153	4144	2p11.2	43.66	human	50455001	K368-sm	S-AdoMet_synt_C	VRDLDLKkPIYQRTA	26416353	1	0	0		
colorectal cancer	increased	MAT2A	MAT2A	P31153	4144	2p11.2	43.66	human	50455002	K394-sm		WEVPKKLkY______	26416353	1	0	0		
diabetes mellitus	increased	Mapk7	ERK5	Q9WVS8	23939	11|11 B2	87.73	mouse	2887213	K6-sm		__MAEPLkEEDGEDG	18218985	4	0	0		increased in the aortas from diabetic mice
diabetes mellitus	increased	Mapk7	ERK5	Q9WVS8	23939	11|11 B2	87.73	mouse	2887212	K22-sm		GEPPGRVkAEPVHTA	18218985	4	0	0		increased in the aortas from diabetic mice
cardiomyopathy	increased	H2ax	H2AX	D3ZXP3	500987	8q22	14.98	rat	448841	S139-p		GKKASQAsQEY____	33737606	254	31	29	85410; 97148; 20304; 5438; 80312; 59141; 4309; 9719; 60566; 5763; 9720; 2577; 9718	
breast cancer	increased	Tmcc3	TMCC3	Q8R310	319880	10|10 C2	53.72	mouse	4033272	S216-p	Tmemb_cc2	LIRNKFGsADNIAHL	33742122	0	41	0		
schizophrenia	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	33762974	85	33	23	62672; 66224; 12885	
clear cell kidney cancer	increased	HMGB1	HMGB1	P09429	3146	13q12.3	24.89	human	31094520	K112-me	HMG_box	FCSEYRPkIKGEHPG	24289579	1	1	0		
Status epilepticus	decreased	Prkar2b	PKAR2B	P31324	19088	12|12 A3	46.17	mouse	452036	S112-p		NRFTRRAsVCAEAYN	33649504	5	69	173		
breast cancer; lung cancer; liver cancer	decreased	H3C1	H3	P68431	8350	6p22.2	15.27	human	1458621	K4-m3	Histone	____ARTkQTARKST	26301496	161	7	0	9751; 9727; 12064; 11960; 62255	H3K4me3 generally shortened for tumor supressors in tumors. eg. lung and other cancers 
SLE	increased	PPP1R12A	MYPT1	O14974	4659	12q21.2-q21.31	115.28	human	448587	T696-p		ARQSRRStQGVTLTD	33762326	62	42	226	5163	
gastric cancer	increased	RHOA	RHOA	P61586	387	3p21.31	21.77	human	150180312	Y42-p	Ras	VPTVFENyVADIEVD	33388549	4	0	0		corelates with poor survival
breast cancer, triple negative	increased	PRMT7	PRMT7	Q9NVM4	54496	16q22.1	78.46	human	63128900	R531-m1		FRDLWRIrSPCGDCE	28188177	1	1	0		
breast cancer	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	459006	K9-m2	Histone	RTKQTARkSTGGKAP	19943104	113	20	0	5327; 66070; 4658; 4473; 6951; 51198; 31064; 9753	
Turner-like syndrome	decreased	Akt1	Akt1	P31750	11651	12 F1|12 61.2 cM	55.71	mouse	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	33910978	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
Turner-like syndrome	increased	Irs1	IRS1	P35569	16367	1 C5|1 42.0 cM	130.72	mouse	447562	S612-p		DDGYMPMsPGVAPVP	33910978	36	7	4	3193; 2386; 3203	
hepatocellular carcinoma; colorectal cancer; kidney cancer	increased	ECHS1	ECHS1	P30084	1892	10q26.3	31.39	human	467120	K101-ac	ECH_1	FAAGADIkEMQNLSF	28878358	1	7	16		
Parkinson's disease	increased	LRRK2	LRRK2	Q5S007	120892	12q12	286.10	human	13204416	S1292-p	LRR_4	PNEMGKLsKIWDLPL	25009464	10	3	0	65837	
Parkinson's disease	increased	SARM1	SARM1	Q6SZW1	23098	17q11.2	79.39	human	4739912	S548-p		AAREMLHsPLPCTGG	30333228	2	9	3		
cardiomyopathy	increased	Cfl1	Cofilin-1	P18760	12631	19|19 A	18.56	mouse	7990494	T25-p	Cofilin_ADF	MKVRKSStPEEVKKR	29878125	2	19	15		LMNA cardiomyopathy, caused by mutations in the lamin A/C gene
HER2 positive breast cancer	increased	CKMT1A	CKMT1A	P12532	548596	15q15.3	47.04	human	475235	Y153-p		ASKIRSGyFDERYVL	30174304	1	12	183		
MI; hypertrophic cardiomyopathy; TOF	increased	Map4	MAP4	P27546	17758	9 F2|9 59.83 cM	117.43	mouse	476119	S737-p		ATATARPsTLPARDV	30327268	3	2	0		
MI; hypertrophic cardiomyopathy; TOF	increased	Map4	MAP4	P27546	17758	9 F2|9 59.83 cM	117.43	mouse	448480	S760-p		KVAEKRTsPSKPSSA	30327268	7	34	6		
DCM	decreased	Dnm1l	DRP1	Q8K1M6	74006	16|16 A2	82.66	mouse	454690	S622-p		PIPIMPAsPQKGHAV	30511961	98	78	114	4494; 3455	
DCM	decreased	Ulk1	ULK1	O70405	22241	5|5 F	112.46	mouse	3176155	S555-p		GLGCRLHsAPNLSDF	30511961	44	26	48	5869	
PAH	decreased	Ace2	ACE2	Q8R0I0	70008	X F5|X 76.12 cM	92.37	mouse	1868162500	S680-p	Collectrin	SDLKPRVsFYFFVTS	29570986	2	0	0		lung biopsies from humans
bile-duct cancer; cholangiocellular carcinoma	decreased	F11r	JAM-A	O88792	16456	1 H3|1 79.43 cM	32.42	mouse	467829	S285-p		KVIYSQPsTRSEGEF	30723104	5	51	19		
non-small cell lung cancer	increased	BECN1	beclin 1	Q14457	8678	17q21.31	51.90	human	28850301	Y352-p	APG6	KSKELPLyCSGGLRF	24034250	2	0	0		
non-small cell lung cancer	increased	BECN1	beclin 1	Q14457	8678	17q21.31	51.90	human	477225	Y233-p	APG6_N	EAQYQREySEFKRQQ	24034250	3	0	0		
non-small cell lung cancer	increased	BECN1	beclin 1	Q14457	8678	17q21.31	51.90	human	28850302	Y229-p	APG6_N	LDQEEAQyQREYSEF	24034250	2	0	0		
hepatocellular carcinoma	increased	Sqstm1	SQSTM1	Q64337	18412	11|11 B1.3	48.16	mouse	14580829	S351-p		SSKEVDPsTGELQSL	24011591	42	0	1	16177; 12074; 95697	
gastric cancer	decreased	H2AX	H2AX	P16104	3014	11q23.3	15.01	human	3397700	Y142-p		ATQASQEy_______	31151422	9	2	2	5438	
nasopharyngeal carcinoma	increased	DNM1L	DRP1	O00429	10059	12p11.21	81.88	human	454690	S616-p		PIPIMPAsPQKGHAV	32433544	98	78	114	4494; 3455	
nasopharyngeal carcinoma	decreased	DNM1L	DRP1	O00429	10059	12p11.21	81.88	human	483971	S637-p		VPVARKLsAREQRDC	32433544	82	3	0	4867; 6319	
luminal B breast cancer	increased	IDH2	IDH2	P48735	3418	15q26.1	50.91	human	1204122	K413-ac	Iso_dh	VESGAMTkDLAGCIH	28536275	4	3	5		
SBMA	decreased	ACLY	ACLY	P53396	47	17q21.2	120.84	human	455371	T447-p		NASGSTStPAPSRTA	26039450	2	3	62		
SBMA	decreased	ACLY	ACLY	P53396	47	17q21.2	120.84	human	455372	S451-p		STSTPAPsRTASFSE	26039450	2	4	16		
Alzheimer's disease	decreased	PRDX1	PRDX1	Q06830	5052	1p34.1	22.11	human	11318619	K197-ac	1-cysPrx_C	KSKEYFSkQK_____	28241840	1	3	0		
syndromic cleft lip and palate	mutation of site	Irf6	IRF6	P97431	54139	1 H6|1 97.6 cM	53.11	mouse	56649936	S90-p	IRF	LRCALNKsREFNLMY	31578523	1	2	0		
luminal A breast cancer	decreased	IDH2	IDH2	P48735	3418	15q26.1	50.91	human	1204122	K413-ac	Iso_dh	VESGAMTkDLAGCIH	28536275	4	3	5		
less severe BPS syndrome	mutation of site	Irf6	IRF6	P97431	54139	1 H6|1 97.6 cM	53.11	mouse	27451041	S424-p		GSVRLQIsTPDIKDN	31578523	3	9	0		
spontaneous clinical pregnancy loss	deletion of site	KHDC3L	KHDC3L	Q587J8	154288	6q13	24.31	human	25285513	T156-p		VEVREAGtQRSVEVQ	31609975	1	0	1		pateients with KHDC3L (p.E150_V160del and p.E150_V172del) mutations harbor a common loss of T156
colorectal cancer	decreased	ME1	ME1	P48163	4199	6q14.2	64.15	human	4701731	S336-p	Malic_M	KKIWLVDsKGLIVKG	31735643	1	10	0		dephosphorylation of this site promotes colorectal tumorigenesis in mouse model
colorectal cancer	increased	ME1	ME1	P48163	4199	6q14.2	64.15	human	33350408	K337-ac	Malic_M	KIWLVDSkGLIVKGR	31735643	1	3	0		acetylation of this site promotes  colorectal tumorigenesis in mouse model
hypertrophic cardiomyopathy	increased	MAPK14	P38A	Q16539	1432	6p21.31	41.29	human	18575504	K53-ac	Pkinase	TGLRVAVkKLSRPFQ	21444723	1	1	0		
hypertrophic cardiomyopathy	increased	MAPK14	P38A	Q16539	1432	6p21.31	41.29	human	18575505	K152-ac	Pkinase	DIIHRDLkPSNLAVN	21444723	1	1	0		
non-small cell lung cancer	increased	ACSS2	ACSS2	Q9NR19	55902	20q11.22	78.58	human	83970101	S659-p	AMP-binding_C	PGLPKTRsGKIMRRV	31750240	3	1	0		
pancreatic ductal adenocarcinoma	increased	ACOT4	ACOT4	Q8N9L9	122970	14q24.3	46.33	human	1871177703	S392-p	BAAT_C	GGEPRAHsKAQEDAW	33148467	1	1	0		
ovarian cancer	increased	IRF1	IRF1	P10914	3659	5q31.1	36.50	human	2134717	K299-sm		QRVFTDLkNMDATWL	17942705	1	0	0		
ovarian cancer	increased	IRF1	IRF1	P10914	3659	5q31.1	36.50	human	2134718	K275-sm		VYGDFSCkEEPEIDS	17942705	1	0	0		
hypertrophic cardiomyopathy	decreased	Pln	PLB	P61016	64672	20q11	6.09	rat	448114	S16-p	Phospholamban	RSAIRRAsTIEMPQQ	33624728	65	15	66	8496	
Alzheimer's disease	increased	Mapt	Tau	P19332	29477	10q32.1	78.56	rat	449081	S707-p		GAEIVYKsPVVSGDT	33705924	170	45	90	9632	
Alzheimer's disease	increased	Mapt	Tau	P19332	29477	10q32.1	78.56	rat	447932	T492-p		KTTPSPKtPPGSGEP	33705924	85	33	23	62672; 66224; 12885	
Alzheimer's disease	increased	Mapt	Tau	P19332	29477	10q32.1	78.56	rat	447933	T516-p		SSPGSPGtPGSRSRT	33705924	113	24	26	30505; 43964; 49561; 20060; 53001; 20739	
EAE	increased	Irf3	IRF3	P70671	54131	7|7 B3	46.85	mouse	448696	S378-p		MAREGGAsSLKTVDL	33710283	12	2	0		
gastric cancer	increased	CHEK2	Chk2	O96017	11200	22q12.1	60.91	human	447491	T68-p		SSLETVStQELYSIP	33747205	194	5	0	2661; 12812; 59068; 28130; 2197; 82263	
colorectal cancer	increased	STAT1	STAT1	P42224	6772	2q32.2	87.33	human	447753	S727-p	STAT1_TAZ2bind	TDNLLPMsPEEFDEV	33747209	107	32	90	8826; 9177; 62390	
breast cancer	increased	PIP5K1C	PIP5K1C	O60331	23396	19p13.3	73.26	human	486880	K97-ub		TVGHLSSkPERDVLM	23572508	1	8	97		
breast cancer, triple negative	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	458927	K685-ac		PKEEAFGkYCRPESQ	29137356	25	1	0	2523	
CIN	decreased	H3C1	H3	P68431	8350	6p22.2	15.27	human	458954	K14-ac	Histone	ARKSTGGkAPRKQLA	28716899	153	31	355	7627; 9677; 26828	
CIN	decreased	H3C1	H3	P68431	8350	6p22.2	15.27	human	465521	K27-ac	Histone	LATKAARkSAPATGG	28716899	66	16	13	14056; 30342; 8173; 15562; 13027; 15485; 23349; 39030; 4353; 87261	
breast cancer	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	34066153	468	74	3065	4324; 8119; 9145; 4113; 52075; 73533; 9138; 4323; 4093; 4074; 52527; 74309; 16185; 61958; 9131; 73452	
FRDA	decreased	H4C1	H4	P62805	8359	6p22.2	11.24	human	458959	K8-ac		SGRGKGGkGLGKGGA	18045775	82	21	529	2594	
FRDA	decreased	H4C1	H4	P62805	8359	6p22.2	11.24	human	458958	K5-ac		___SGRGkGGKGLGK	18045775	67	22	516	8647; 9672	
FRDA	decreased	H4C1	H4	P62805	8359	6p22.2	11.24	human	458960	K16-ac		GLGKGGAkRHRKVLR	18045775	103	26	531	13534; 26437; 56999; 98789	
FRDA	decreased	H4C1	H4	P62805	8359	6p22.2	11.24	human	459013	K12-ac		KGGKGLGkGGAKRHR	18045775	89	25	531	2591; 13944	
FRDA	decreased	H3C1	H3	P68431	8350	6p22.2	15.27	human	458954	K14-ac	Histone	ARKSTGGkAPRKQLA	18045775	153	31	355	7627; 9677; 26828	
FRDA	decreased	H3C1	H3	P68431	8350	6p22.2	15.27	human	463820	K9-ac	Histone	RTKQTARkSTGGKAP	18045775	218	25	341	4484; 14052; 9677; 9711; 11857; 9683; 28036; 9649	
FRDA	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	1458613	K9-m3	Histone	RTKQTARkSTGGKAP	18045775	128	22	1	5327; 4473; 6951; 55286; 13969	
FRDA	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	459006	K9-m2	Histone	RTKQTARkSTGGKAP	18045775	113	20	0	5327; 66070; 4658; 4473; 6951; 51198; 31064; 9753	
prostate cancer	molecular association	H3C1	H3	P68431	8350	6p22.2	15.27	human	459006	K9-m2	Histone	RTKQTARkSTGGKAP	19513555	113	20	0	5327; 66070; 4658; 4473; 6951; 51198; 31064; 9753	association of H3K9me2 to IGF2/H19 imprinting control region in benign prostate hyperplasia (BPH) but not in prostate cancer (PCa) 
diabetes mellitus	decreased	Nos3	eNOS	P70313	18127	5 A3|5 11.32 cM	132.92	mouse	447884	S1176-p		TSRIRTQsFSLQERQ	34116361	194	18	7	9570; 9571	
obesity, hyperphagic	increased	Nos3	eNOS	Q62600	24600	4q11	133.29	rat	447884	S1176-p		TSRIRTQsFSLQERQ	24113524	194	18	7	9570; 9571	obese Zucker rats
obesity, hyperphagic	decreased	Tp53	p53	P10361	24842	10q24	43.45	rat	458977	K380-ac		QSTSRHKkPMIKKVG	24113524	205	8	0	2570; 2525	obese Zucker rats
breast cancer	increased	BAZ1B	WSTF	Q9UIG0	9031	7q11.23	170.90	human	9905197	K426-ac		GNSKSPKkGLKTPKT	32518374	1	1	1		Patients with higher K426 acetylatiion levels have shorter survival.
esophageal carcinoma	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	33986510	468	74	3065	4324; 8119; 9145; 4113; 52075; 73533; 9138; 4323; 4093; 4074; 52527; 74309; 16185; 61958; 9131; 73452	corelates with worse overall survival
acute lymphocytic leukemia; acute myelogenous leukemia	increased	PDP1	PDP1	Q9P0J1	54704	8q22.1	61.05	human	15422109	Y94-p		SILKANEySFKVPEF	24962578	2	1	0		
breast ductal carcinoma	increased	NUCKS1	NUCKS	Q9H1E3	64710	1q32.1	27.30	human	2586358	K64-me		DSEDSEDkDVKTKKD	18491381	0	1	0		
breast ductal carcinoma	increased	NUCKS1	NUCKS	Q9H1E3	64710	1q32.1	27.30	human	2586349	K184-ac		TVTPSPVkGKGKVGR	18491381	0	2	0		
breast ductal carcinoma	increased	NUCKS1	NUCKS	Q9H1E3	64710	1q32.1	27.30	human	2586360	K175-me		KMPKPRLkATVTPSP	18491381	0	1	0		
Alzheimer's disease	increased	TBK1	TBK1	Q9UHD2	29110	12q14.2	83.64	human	447732	S172-p	Pkinase	EDDEQFVsLYGTEEY	33965374	54	7	47	14586; 5483; 13498; 14590; 70483; 54382; 20399	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449104	S356-p	Tubulin-binding	RVQSKIGsLDNITHV	33965374	33	24	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	487448	S191-p		SSGEPPKsGDRSGYS	33965374	2	7	7		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	487456	S289-p	Tubulin-binding	LDLSNVQsKCGSKDN	33965374	4	3	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447929	S214-p		GSRSRTPsLPTPPTR	33965374	60	23	42	77348	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449328	S324-p	Tubulin-binding	KVTSKCGsLGNIHHK	33965374	12	7	2		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	487457	S305-p	Tubulin-binding	KHVPGGGsVQIVYKP	33965374	3	4	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	487455	S285-p	Tubulin-binding	INKKLDLsNVQSKCG	33965374	2	3	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449551	S198-p		SGDRSGYsSPGSPGT	33965374	21	15	10		
ovarian cancer	increased	HSPD1	HSP60	P10809	3329	2q33.1	61.05	human	468008	S70-p	Cpn60_TCP1	IIEQSWGsPKVTKDG	34557266	1	66	0		
lung cancer	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	34543857	468	74	3065	4324; 8119; 9145; 4113; 52075; 73533; 9138; 4323; 4093; 4074; 52527; 74309; 16185; 61958; 9131; 73452	corelates with poor prognosis 
glioma	increased	EZR	Ezrin	P15311	7430	6q25.3	69.41	human	448104	T567-p	ERM_C	QGRDKYKtLRQIRQG	34540823	61	9	16	3141; 3726	
B cell lymphoma	decreased	BMI1	BMI1	P35226	648	10p12.2	36.95	human	6150348	S316-p		ANRPRKSsVNGSSAT	23092893	2	1	50		small data set, correlated with worse survival 
lung cancer	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	1668801	K9-me	Histone	RTKQTARkSTGGKAP	21765477	26	1	0		
T-ALL	decreased	H3c1	H3	P68433	360198	13|13 A3.1	15.27	mouse	1308913	K27-m3	Histone	LATKAARkSAPATGG	22237151	169	21	3	9733; 89120; 4395; 12158; 98316; 5499; 91611; 14034; 10584; 4232; 35861; 20123; 40724; 54575	
acute myelogenous leukemia	decreased	H3C1	H3	P68431	8350	6p22.2	15.27	human	1308913	K27-m3	Histone	LATKAARkSAPATGG	22897849	169	21	3	9733; 89120; 4395; 12158; 98316; 5499; 91611; 14034; 10584; 4232; 35861; 20123; 40724; 54575	
lung cancer	increased	HELLS	HELLS	Q9NRZ9	3070	10q23.33	97.07	human	9764950	S503-p	SNF2-rel_dom	EKETIELsPTGRPKR	32994405	1	20	0		
breast cancer	increased	GLI2	GLI2	P10070	2736	2q14.2	167.78	human	10414536	S149-p		ISAARGLsPADVAQE	25416949	1	4	0		
breast cancer; lung cancer; colorectal cancer; endometrial cancer	increased	EZH2	EZH2	Q15910	2146	7q36.1	85.36	human	452848	T487-p		APAEDVDtPPRKKKR	34381492	12	58	66		
glioblastoma multiforme	increased	BUB3	BUB3	O43684	9184	10q26.13	37.15	human	463080	Y207-p		EGRVAVEyLDPSPEV	24316223	1	3	2		correlated with histone H3S10 phosphorylation in human glioblastoma 
obesity, hyperphagic	increased	Sort1	SORT1	Q6PHU5	20661	3|3 F2.3-F3	91.20	mouse	3823097	S791-p		RFLVHRYsVLQQHAE	24986865	3	8	0		increased in obese mice but not in WT mice
glioblastoma multiforme	increased	IKBKB	IKKB	O14920	3551	8p11.21	86.56	human	447492	S177-p	Pkinase	AKELDQGsLCTSFVG	23123196	39	1	0	92255; 2697; 36516; 2078; 2694; 36214; 14938	
glioblastoma multiforme	increased	IKBKB	IKKB	O14920	3551	8p11.21	86.56	human	447489	S181-p	Pkinase	DQGSLCTsFVGTLQY	23123196	70	2	0	92255; 2697; 36516; 2694; 36214; 14938	
osteosarcoma	increased	SIRT6	SIRT6	Q8N6T7	51548	19p13.3	39.12	human	7916000	S338-p		PKRERPTsPAPHRPP	34359939	3	7	23		
T-ALL	increased	H3c1	H3	P68433	360198	13|13 A3.1	15.27	mouse	1458621	K4-m3	Histone	____ARTkQTARKST	22237151	161	7	0	9751; 9727; 12064; 11960; 62255	
T-ALL	increased	H3c1	H3	P68433	360198	13|13 A3.1	15.27	mouse	463820	K9-ac	Histone	RTKQTARkSTGGKAP	22237151	218	25	341	4484; 14052; 9677; 9711; 11857; 9683; 28036; 9649	
colorectal cancer	increased	H2AC11	H2A.1	P0C0S8	8329	6p22.1	13.96	human	482914	T120-p	Histone_H2A_C	AVLLPKKtESHHKAK	34312968	15	8	0		
colorectal cancer	increased	BRD4	BRD4	O60885	23476	19p13.12	152.22	human	1874101904	Y98-p	Bromodomain	KLNLPDYyKIIKTPM	34290255	1	1	0		
colorectal cancer	increased	BRD4	BRD4	O60885	23476	19p13.12	152.22	human	1874101902	Y97-p	Bromodomain	VKLNLPDyYKIIKTP	34290255	1	1	0		
non-small cell lung cancer; PAH	increased	MFN2	MFN2	O95140	9927	1p36.22	86.40	human	4746700	S442-p		AEEIRRLsVLVDDYQ	34275172	4	2	0		
colorectal cancer	increased	BECN1	beclin 1	Q14457	8678	17q21.31	51.90	human	1874101912	Y333-p	APG6	QRYRLVPyGNHSYLE	34131122	1	0	0		
acute myelogenous leukemia	increased	AXL	AXL	P30530	558	19q13.2	98.34	human	451490	Y779-p	PK_Tyr_Ser-Thr	ADCLDGLyALMSRCW	33786587	6	2	2	96453	
Alzheimer's disease	decreased	Prkaa2	AMPKA2	Q8BRK8	108079	4|4 C6	62.02	mouse	448026	T172-p	Pkinase	SDGEFLRtSCGSPNY	34497121	169	13	33	5256; 2531; 2535; 50081; 74281	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	34493616	130	44	14	20473; 71429	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449078	T217-p		SRTPSLPtPPTREPK	34493616	33	31	6	51625	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	34493616	85	33	23	62672; 66224; 12885	
colorectal cancer	decreased	PRPS2	PRPS2	P11908	5634	Xp22.2	34.77	human	1874748502	T285-p	Pribosyl_synth	EDKMKHCtKIQVIDI	34465890	1	1	0		
colorectal cancer	decreased	PRPS1	PRPS1	P60891	5631	Xq22.3	34.83	human	1874748500	S285-p	Pribosyl_synth	EDKMKHCsKIQVIDI	34465890	1	1	0		
breast cancer	increased	Pcna	PCNA	P17918	18538	2 F2|2 64.15 cM	28.78	mouse	471414	Y211-p	PCNA_C	HLTFALRyLNFFTKA	34433039	6	2	2		corelates with low O.S
Parkinson's disease	increased	ZNF746	PARIS	Q6NUN9	155061	7q36.1	69.14	human	13831906	Y137-p		ETLVSLDyAISKPEV	34581802	1	1	0		
FTLD	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	447932	T473-p		KTTPSPKtPPGSGEP	34551296	85	33	23	62672; 66224; 12885	
Huntington's disease	decreased	CASP6	CASP6	P55212	839	4q25	33.31	human	60885600	C264-pa	Peptidase_C14	SQRRVDFcKDPSAIG	27911442	1	0	0		Palmitoylation of CASP6 is decreased in HD models.
Huntington's disease	decreased	CASP6	CASP6	P55212	839	4q25	33.31	human	60885601	C277-pa	Peptidase_C14	IGKKQVPcFASMLTK	27911442	1	0	0		Palmitoylation of CASP6 is decreased in HD models.
pancreatic ductal adenocarcinoma	increased	VCP	VCP	P55072	7415	9p13.3	89.32	human	456210	S784-p		NQGGAGPsQGSGGGT	34680224	3	4	33		negatively correlate with patient survival
diabetes mellitus	mutation of site	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	1876813500	K15-ac		TSFAESCkPVQQPSA	33107080	1	0	0		K15R mutant alleviates meiotic defects in oocytes from diabetic mice
type 2 diabetes	decreased	Mafa	MAFA	Q8CF90	378435	15|15 D3	37.58	mouse	5403102	S65-p		PCSSVPSsPSFCAPS	34644565	9	0	0		
breast cancer	increased	ARHGDIA	RhoGDI alpha	P52565	396	17q25.3	23.21	human	1876737500	S176-p	Rho_GDI	MLARGSYsIKSRFTD	24820414	1	0	0		
asthma	increased	CASP9	CASP9	P55211	842	1p36.21	46.28	human	448454	S196-p	Peptidase_C14	KLRRRFSsLHFMVEV	34705620	4	1	0		
prostate cancer	decreased	HSD17B4	HSD17B4	P51659	3295	5q23.1	79.69	human	461239	K669-ac	SCP2	AKWTIDLkSGSGKVY	32678070	2	4	1		K669 acetylation promotes degradation in PCa cells.
lung cancer; colorectal cancer	increased	NGEF	ephexin-1	Q8N5V2	25791	2q37.1	82.50	human	34501054	S16-p		LEKTRRKsASDQWNT	34711817	1	2	0		corelates with poor overall survival rates
lung cancer; colorectal cancer	increased	NGEF	ephexin-1	Q8N5V2	25791	2q37.1	82.50	human	34499273	S18-p		KTRRKSAsDQWNTDN	34711817	1	2	0		corelates with poor overall survival rates
ESCC	increased	HMGA2	HMGA2	P52926	8091	12q14.3	11.83	human	474713	K26-ac	AT_hook	PAAPAPQkRGRGRPR	32313942	1	0	27		predicts a poor prognosis of ESCC patients
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	34928318	85	33	23	62672; 66224; 12885	
hypertrophic cardiomyopathy	increased	Gja1	GJA1	P08050	24392	20q11	43.03	rat	447813	S368-p		QRPSSRAsSRASSRP	34931018	52	8	1	52559; 3511	
hypertrophic cardiomyopathy	increased	Gja1	GJA1	P08050	24392	20q11	43.03	rat	448854	S282-p		TAPLSPMsPPGYKLV	34931018	40	7	1		
hypertrophic cardiomyopathy	increased	Gja1	GJA1	P08050	24392	20q11	43.03	rat	450694	S262-p		SPSKDCGsPKYAYFN	34931018	29	5	4		
breast cancer	increased	PHGDH	PHGDH	O43175	26227	1p12	56.65	human	36311760	K58-ac	2-Hacid_dh	LIVRSATkVTADVIN	32783943	1	2	0		K58 acetylation levels were higher in tumors than in the adjacent tissues 
liver cancer	increased	MYC	Myc	P01106	4609	8q24.21	48.80	human	448586	S62-p	Myc_N	LLPTPPLsPSRRSGL	34758313	72	37	33	13748	
cervical adenocarcinoma	decreased	TP53	p53	P04637	7157	17p13.1	43.65	human	458977	K382-ac		QSTSRHKkLMFKTEG	32976537	205	8	0	2570; 2525	pathogenesis of cervical cancer in the ethnically distinct population of Northeast India
cervical adenocarcinoma	decreased	TP53	p53	P04637	7157	17p13.1	43.65	human	458979	K305-ac		ELPPGSTkRALPNNT	32976537	7	3	13		pathogenesis of cervical cancer in the ethnically distinct population of Northeast India
clear cell kidney cancer	increased	OTUB1	OTUB1	Q96FW1	55611	11q13.1	31.28	human	3208998	S16-p		QKQEPLGsDSEGVNC	34785775	3	14	0		
colonic inflamation	increased	IKBKB	IKKB	O14920	3551	8p11.21	86.56	human	447492	S177-p	Pkinase	AKELDQGsLCTSFVG	34803708	39	1	0	92255; 2697; 36516; 2078; 2694; 36214; 14938	ulcerative colitis
colonic inflamation	increased	RELA	NFkB-p65	Q04206	5970	11q13.1	60.22	human	447800	S536-p		SGDEDFSsIADMDFS	34803708	217	4	0	73992; 31553; 4887; 80477; 76778; 3031; 5733; 13346; 3036; 3033; 4025; 4886; 87672; 83962	ulcerative colitis
colonic inflamation	increased	IKBKB	IKKB	O14920	3551	8p11.21	86.56	human	447489	S181-p	Pkinase	DQGSLCTsFVGTLQY	34803708	70	2	0	92255; 2697; 36516; 2694; 36214; 14938	ulcerative colitis
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449078	T217-p		SRTPSLPtPPTREPK	34928318	33	31	6	51625	
breast cancer; colorectal cancer; endometrial cancer	increased	MSH6	MSH6	P52701	2956	2p16.3	152.79	human	452728	S830-p	MutS_III	SKIHNVGsPLKSQNH	34941572	1	30	0		
breast cancer; colorectal cancer; endometrial cancer	increased	MSH6	MSH6	P52701	2956	2p16.3	152.79	human	452723	S227-p		EEDNEIEsEEEVQPK	34941572	1	34	2		
lung cancer; clear cell kidney cancer	increased	MSH6	MSH6	P52701	2956	2p16.3	152.79	human	452723	S227-p		EEDNEIEsEEEVQPK	34941572	1	34	2		
ovarian cancer	increased	MSH6	MSH6	P52701	2956	2p16.3	152.79	human	452728	S830-p	MutS_III	SKIHNVGsPLKSQNH	34941572	1	30	0		
pancreatic ductal adenocarcinoma	increased	RPS6KB1	p70S6K iso2	P23443-2	6198	17q23.1	56.19	human	448358	T421-p		RFIGSPRtPVSPVKF	27014871	105	37	109	9204	
pancreatic ductal adenocarcinoma	increased	RPS6KB1	p70S6K iso2	P23443-2	6198	17q23.1	56.19	human	448806	S371-p	Pkinase_C	TRQTPVDsPDDSTLS	27014871	16	4	11	9208	
pancreatic ductal adenocarcinoma	decreased	RPS6KB1	p70S6K iso2	P23443-2	6198	17q23.1	56.19	human	450015	S418-p		SPRRFIGsPRTPVSP	27014871	11	31	89		
pancreatic ductal adenocarcinoma	increased	TAGLN2	TAGLN2	P37802	8407	1q23.2	22.39	human	31885453	S145-p		ARDDGLFsGDPNWFP	30041673	1	3	0		
glioblastoma multiforme	increased	PGK1	PGK1	P00558	5230	Xq21.1	44.61	human	2525475	T243-p	PGK	IGGGMAFtFLKVLNN	30029001	1	1	0		phosphorylation co-ralates with malignance and prognosis
pancreatic carcinoma	increased	DMAP1	DMAP1	Q9NPF5	55929	1p34.1	52.99	human	998916	Y246-p	DMAP1	EQVAEEEyLLQELRK	30553276	1	2	2		corelates with poor prognosis in cancer patients
hypertrophic cardiomyopathy	decreased	Ryr2	RYR2	E9Q401	20191	13 A1|13 4.38 cM	564.82	mouse	455603	S2030-p		TIRGRLLsLVEKVTY	30541771	13	4	1		
cervical adenocarcinoma	increased	PHB	PHB	P35232	5245	17q21.33	29.80	human	11139253	T258-p		LSRSRNItYLPAGQS	22410782	6	0	1		
breast cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	21908616	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
glioblastoma multiforme	increased	Pfn1	profilin 1	P62962	18643	11 B3|11 43.21 cM	14.96	mouse	450514	Y129-p	Profilin	GLINKKCyEMASHLR	24747440	4	25	658		
bladder cancer	increased	TFCP2L1	TFCP2L1	Q9NZI6	29842	2q14.2	54.63	human	38489957	T177-p	CP2	HCISTEFtPRKHGGE	31709755	1	1	1		
chronic myelogenous leukemia	increased	THOC5	FMIP	Q13769	8563	22q12.2	78.51	human	25802102	Y225-p	FmiP_Thoc5	EIEVKKEyLSSLQPR	23032722	2	1	0		
prostate cancer	increased	LIFR	LIFR	P42702	3977	5p13.1	123.74	human	450385	S1044-p		WNLVSPDsPRSIDSN	30851421	6	5	0		
cardiomyopathy	decreased	MYBPC3	MYBPC3	Q14896	4607	11p11.2	140.76	human	471080	S284-p		AGGGRRIsDSHEDTG	23277198	35	8	28		
cardiomyopathy	decreased	MYBPC3	MYBPC3	Q14896	4607	11p11.2	140.76	human	471079	S275-p		LSAFRRTsLAGGGRR	23277198	25	9	14		
cardiomyopathy	decreased	MYBPC3	MYBPC3	Q14896	4607	11p11.2	140.76	human	471081	S304-p		SLLKKRDsFRTPRDS	23277198	28	6	0		
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	452166	S516-p		VSRVPYPsPTCVKSE	23321516	10	3	0		presence of metastasis, lymphovascular invasion
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	448714	S83-p	Androgen_recep	QQQQQETsPRQQQQQ	23321516	22	1	0		presence of metastasis, lymphovascular invasion
prostate cancer	decreased	AR	AR	P10275	367	Xq12	99.19	human	448416	S96-p	Androgen_recep	QQQGEDGsPQAHRRG	23321516	9	11	0		corelates with high Ki67 score
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	448413	S310-p	Androgen_recep	TEDTAEYsPFKGGYT	23321516	11	5	0		associated with high PSA level
cancer, squamous cell carcinoma	increased	SMAD1	SMAD1	Q15797	4086	4q31.21	52.26	human	25546600	S239-p		DPMTQDGsQPMDTNM	22588298	1	0	0		Oesophageal cancer
colorectal cancer	increased	PRKCD	PKCD	Q05655	5580	3p21.1	77.51	human	447573	Y313-p		SSEPVGIyQGFEKKT	24260357	38	60	1707	2055	biomarker for dasitinib treatment response for colorectal cancer in HCT-116 cells 
atrial fibrillation	increased	SCN5A	SCN5A	Q14524	6331	3p22.2	226.94	human	27281507	S571-p	Na_trans_cytopl	PWPLRRTsAQGQPSP	31622781	10	4	0		
prostate cancer	increased	NEK1	NEK1	Q96PY6	4750	4q33	142.83	human	65958203	T141-p	Pkinase	IFLTKDGtVQLGDFG	30928383	3	0	0		
cervical adenocarcinoma	increased	PHB	PHB	P35232	5245	17q21.33	29.80	human	6374000	Y259-p		SRSRNITyLPAGQSV	22410782	5	2	0		
glioblastoma multiforme	increased	AKAP12	AKAP12	Q02952	9590	6q25.1	191.48	human	3801512	T767-p	WSK	ESFKRLVtPRKKSKS	23063527	2	2	2		
bladder cancer	increased	Tcfcp2l1	TFCP2L1	Q3UNW5	81879	1|1 E2.3	54.74	mouse	38489957	T177-p	CP2	HCISTEFtPRKHGGE	31709755	1	1	1		
ovarian cancer	increased	PHB	PHB	P35232	5245	17q21.33	29.80	human	6374000	Y259-p		SRSRNITyLPAGQSV	32169072	5	2	0		
glioblastoma multiforme	increased	ATG5	ATG5	Q9H1Y0	9474	6q21	32.45	human	23084709	T101-p	APG5	SALPWNItVHFKSFP	32186433	2	1	1		is related to poor prognosis
brain cancer	increased	Ezh2	EZH2	Q61188	14056	6 B2.3|6 22.92 cM	85.29	mouse	463307	Y696-p	SET	HSVNPNCyAKVMMVN	32461334	1	1	1		
breast cancer	increased	VCP	VCP	P55072	7415	9p13.3	89.32	human	456210	S784-p		NQGGAGPsQGSGGGT	32521270	3	4	33		corelates with poor chemotherapy outcome
acute lymphocytic leukemia	decreased	NCF1	p47phox	P14598	653361	7q11.23	44.68	human	451729	S359-p	p47_phox_C	EERQTQRsKPQPAVP	26073130	12	0	0		
acute lymphocytic leukemia	decreased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447543	Y204-p	Pkinase	HTGFLTEyVATRWYR	26073130	1304	138	3549	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 14474; 54240; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
acute lymphocytic leukemia	decreased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447542	T202-p	Pkinase	HDHTGFLtEYVATRW	26073130	1283	106	2017	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 54240; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
glioma; testicular cancer; laryngeal cancer; colorectal cancer; thyroid cancer; astrocytoma; oligodendroglioma	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	3804954	K56-ac	Histone	REIRRYQkSTELLIR	19270680	30	13	2	4243	correlates with tumor grade
breast cancer	molecular association	PDHA1	PDHA1	P08559	5160	Xp22.12	43.30	human	448257	S232-p	E1_dh	NRYGMGTsVERAAAS	30697423	45	79	7	15289	resistance to metformin treatment
breast cancer	increased	PAK1	PAK1	Q13153	5058	11q13.5-q14.1	60.65	human	448173	S204-p		TKSVYTRsVIEPLPV	30664689	16	16	0	2605	
breast cancer	increased	Braf	BRAF iso1	P28028-1	109880	6 B1|6 18.43 cM	88.78	mouse	447807	T636-p	PK_Tyr_Ser-Thr	IGDFGLAtVKSRWSG	30659267	11	0	0		in mouse model
breast cancer	increased	Braf	BRAF iso1	P28028-1	109880	6 B1|6 18.43 cM	88.78	mouse	447805	S639-p	PK_Tyr_Ser-Thr	FGLATVKsRWSGSHQ	30659267	11	0	0		in mouse model
hepatocellular carcinoma	increased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	1867735501	Y56-p	Pkinase	DRPQEVSyTDTKVIG	30711629	1	1	0		
lung cancer	increased	ACLY	ACLY	P53396	47	17q21.2	120.84	human	11323411	K546-ac	CoA_binding	QKFYWGHkEILIPVF	23932781	2	3	0		
Parkinson's disease; Alzheimer's disease; PSP; FTLD; Niemann-Pick disease; CTE	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	27738305	K274-ac	Tubulin-binding	KHQPGGGkVQIINKK	23371364	3	0	0		
lung cancer	increased	ACLY	ACLY	P53396	47	17q21.2	120.84	human	4131806	K554-ac	CoA_binding	EILIPVFkNMADAMR	23932781	2	5	1		
lung cancer	increased	ACLY	ACLY	P53396	47	17q21.2	120.84	human	31068004	K540-ac	CoA_binding	FTGDHKQkFYWGHKE	23932781	2	1	7		
lung cancer; esophageal cancer	increased	SOD1	SOD1	P00441	6647	21q22.11	15.94	human	466539	K71-ac	Sod_Cu	HFNPLSRkHGGPKDE	26008972	1	1	4		increased responsiveness to chemotherapy
liver cancer	increased	PGK1	PGK1	P00558	5230	Xq21.1	44.61	human	479484	K323-ac	PGK	CGPESSKkYAEAVTR	27774669	1	5	22		
cardiomyopathy	increased	SCN5A	SCN5A	Q14524	6331	3p22.2	226.94	human	63044906	K1479-ac	Ion_trans	NFNQQKKkLGGQDIF	28191886	2	1	0		
breast cancer	increased	CEP131	CEP131	Q9UPN4	22994	17q25.3	122.15	human	41451326	S21-p		SPAGVDLsLTGLPPP	31358734	1	3	0		mouse model of a breast carcinogenesis
Alzheimer's disease	decreased	TUBA1A	TUBA1A	Q71U36	7846	12q13.12	50.14	human	460619	K40-ac	Tubulin	DGQMPSDkTIGGGDD	27311773	61	7	11	35652; 14652; 87488; 5335; 58241; 93271; 81502	
cardiomyopathy	decreased	Vgll4	VGLL4	Q80V24	232334	6|6 E3	31.00	mouse	59149206	K216-ac	VGLL4	HFRRSLGkNYKEPEP	27720608	1	1	0		
macrothrombocytopenia	increased	Myh9	MYH9	Q8VDD5	17886	15 E1|15 36.81 cM	226.37	mouse	456730	S1943-p		RKGTGDCsDEEVDGK	32315395	12	118	916	5026; 14611	
Parkinson's disease; DLB	decreased	NQO1	NQO1	P15559	1728	16q22.1	30.87	human	1868914500	T128-p	Flavodoxin_2	FIGEFAYtYAAMYDK	31358653	2	1	0		
endometrial cancer	increased	PRKAA1	AMPKA1	Q13131	5562	5p13.1	64.01	human	7445995	S467-p	AdenylateSensor	LQLYQVDsRTYLLDF	31358902	1	2	0		
CRPC	increased	MED1	MED1	Q15648	5469	17q12	168.48	human	449866	T1457-p		HSKSPAYtPQNLDSE	31466944	7	2	0		
colorectal cancer	increased	PTS	PTS	Q03393	5805	11q23.1	16.39	human	1869465810	T58-p	PTPS	HNYKVVVtVHGEIDP	31628042	1	1	0		
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	448714	S83-p	Androgen_recep	QQQQQETsPRQQQQQ	32846021	22	1	0		is associated with reduced cancer specific survival
breast cancer	increased	CEP131	CEP131	Q9UPN4	22994	17q25.3	122.15	human	1868722300	T205-p		PLKSSNQtAPSLNNI	31358734	1	1	0		mouse model of a breast carcinogenesis
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	448577	S215-p	Androgen_recep	SGRAREAsGAPTSSK	32846021	15	0	0		when combined with high CD8+ T-lymphocyte infiltration, is associated with poor clinico-pathological features
Parkinson's disease	increased	YAP1	YAP1	P46937	10413	11q22.1	54.46	human	448847	S127-p		PQHVRAHsSPASLQL	32929029	171	32	180	4911; 57706; 13008; 92367	
Parkinson's disease	increased	UNC5B	UNC5B	Q8IZJ1	219699	10q22.1	103.64	human	1870414700	T428-p		FHPVNFKtARPSNPQ	32929029	1	0	0		
cardiomyopathy	decreased	ATP2A2	SERCA2	P16615	488	12q24.11	114.76	human	25092200	K585-sm		EDSANFIkYETNLTF	21900893	2	0	0		
cardiomyopathy	decreased	ATP2A2	SERCA2	P16615	488	12q24.11	114.76	human	25092201	K480-sm	Cation_ATPase	SVIKQLMkKEFTLEF	21900893	2	0	0		
acute myelogenous leukemia; myelodysplastic syndrome	decreased	ARHGAP21	ARHGAP21	Q5T5U3	57584	10p12.1|10p12.3	217.46	human	27850501	K1443-sm		ELDNVFFkKENVEQC	22922005	1	1	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	486345	K311-ub	Tubulin-binding	GSVQIVYkPVDLSKV	16443603	1	3	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	486344	K254-ub	Tubulin-binding	PVPMPDLkNVKSKIG	16443603	2	4	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	486346	K353-ub	Tubulin-binding	FKDRVQSkIGSLDNI	16443603	1	3	0		
breast adenocarcinoma	increased	CTNNB1	CTNNB1	P35222	1499	3p22.1	85.50	human	27850504	K394-ub		NLSDAATkQEGMEGL	22705350	1	0	0		
diabetes mellitus	increased	Nos1	nNOS	Q9Z0J4	18125	5 F|5 57.29 cM	160.47	mouse	449830	S1412-p		TNRLRSEsIAFIEES	33434144	13	0	0		
acute myelogenous leukemia	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	1458608	K36-m3	Histone	APATGGVkKPHRYRP	17589499	59	10	4	46287; 4909; 9763	HoxA7 and HoxA9 expression induced by NUP98?NSD1 
anaplastic large cell lymphoma	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	1308913	K27-m3	Histone	LATKAARkSAPATGG	22899583	169	21	3	9733; 89120; 4395; 12158; 98316; 5499; 91611; 14034; 10584; 4232; 35861; 20123; 40724; 54575	
ASD autism spectrum	decreased	H3C1	H3	P68431	8350	6p22.2	15.27	human	1308913	K27-m3	Histone	LATKAARkSAPATGG	23423141	169	21	3	9733; 89120; 4395; 12158; 98316; 5499; 91611; 14034; 10584; 4232; 35861; 20123; 40724; 54575	trimethylation mark in the EN-2 promoter 
ASD autism spectrum	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	1458621	K4-m3	Histone	____ARTkQTARKST	23423141	161	7	0	9751; 9727; 12064; 11960; 62255	H3K4 trimethylation was elevated.
breast cancer	increased	RASAL2	RASAL2 iso2	Q9UJF2-2	9462	1q25.2	143.90	human	1872043503	S351-p	C2	TLFARTTsKTKADNI	33563064	1	1	0		co-relates with poor clnical outcome
Status epilepticus	increased	Hcn1	HCN1	Q9JKB0			102.42	rat	1872043505	S791-p		PKNEVHKsTQALHNT	33571596	1	1	0		
acute myelogenous leukemia	mutation of site	CSF3R	GCSFR	Q99062	1441	1p34.3	92.16	human	9381806	K704-ub		TVLEEDEkKPVPWES	28439110	2	0	0		
melanoma skin cancer	molecular association	GPS2	GPS2	Q13227	2874	17p13.1	36.69	human	11263012	R323-m1		IQHSQNPrFYHK___	19917673	1	1	0		strong binding in melanoma patients, but not in healthy controls
ovarian cancer	decreased	H4C1	H4	P62805	8359	6p22.2	11.24	human	2344825	K20-m3	CENP-T_C	GGAKRHRkVLRDNIQ	20053926	35	14	0	5737	
ovarian cancer	decreased	H3C1	H3	P68431	8350	6p22.2	15.27	human	1308913	K27-m3	Histone	LATKAARkSAPATGG	20053926	169	21	3	9733; 89120; 4395; 12158; 98316; 5499; 91611; 14034; 10584; 4232; 35861; 20123; 40724; 54575	
type 2 diabetes	decreased	Prkaa2	AMPKA2	Q09137	78975	5q34	62.26	rat	448026	T172-p	Pkinase	SDGEFLRtSCGSPNY	33848515	169	13	33	5256; 2531; 2535; 50081; 74281	
melanoma skin cancer; malignant peripheral nerve sheath tumor	decreased	H3C1	H3	P68431	8350	6p22.2	15.27	human	1308913	K27-m3	Histone	LATKAARkSAPATGG	28752843	169	21	3	9733; 89120; 4395; 12158; 98316; 5499; 91611; 14034; 10584; 4232; 35861; 20123; 40724; 54575	cannot distinguish malignant peripheral nerve sheath tumor from melanoma
Marfan syndrome	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	458954	K14-ac	Histone	ARKSTGGkAPRKQLA	20829218	153	31	355	7627; 9677; 26828	
Marfan syndrome	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	463820	K9-ac	Histone	RTKQTARkSTGGKAP	20829218	218	25	341	4484; 14052; 9677; 9711; 11857; 9683; 28036; 9649	
Marfan syndrome	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	1668802	K4-me	Histone	____ARTkQTARKST	20829218	28	1	0		
Parkinson's disease	decreased	LRRK2	LRRK2	Q5S007	120892	12q12	286.10	human	4725898	S935-p		NLQRHSNsLGPIFDH	34144124	38	17	2	59576	
type 2 diabetes	increased	RORA	RORA	P35398	6095	15q22.2	58.97	human	1212279800	S100-p	zf-C4	CKGFFRRsQQSNATY	34157297	4	1	0		
type 2 diabetes	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	12127402	S212-p	zf-C4	CKAFFKRsIQGHNDY	34157297	8	1	0		
SMA	decreased	Braf	BRAF	P28028	109880	6 B1|6 18.43 cM	82.51	mouse	447804	S431-p		KTLGRRDsSDDWEIP	33931501	15	44	87	2696	in SMA patients and in SMA mouse model 
SMA	decreased	BRAF	BRAF	P15056	673	7q34	84.44	human	447804	S446-p		KTLGRRDsSDDWEIP	33931501	15	44	87	2696	in SMA patients and in SMA mouse model 
diabetes mellitus	decreased	H3C1	H3	P68431	8350	6p22.2	15.27	human	459006	K9-m2	Histone	RTKQTARkSTGGKAP	23423566	113	20	0	5327; 66070; 4658; 4473; 6951; 51198; 31064; 9753	
diabetes mellitus	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	463820	K9-ac	Histone	RTKQTARkSTGGKAP	23423566	218	25	341	4484; 14052; 9677; 9711; 11857; 9683; 28036; 9649	
B cell lymphoma	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	22116549	468	74	3065	4324; 8119; 9145; 4113; 52075; 73533; 9138; 4323; 4093; 4074; 52527; 74309; 16185; 61958; 9131; 73452	
SLE	increased	H2BC3	H2B	P33778	3018	6p22.2	13.82	human	458956	K12-ac	Histone	KSAPAPKkGSKKAIT	19747733	7	12	467	9861; 5410; 9072	in patients with active SLE and in diseased mice
colorectal cancer	increased	GLI2	GLI2	P10070	2736	2q14.2	167.78	human	1874115100	T1546-p		QNSSRLTtPRNSLTL	34267186	1	1	0		corelates with shorter survival time
Alzheimer's disease		APP	APP iso4	P05067-4	351	21q21.3	78.66	human	448202	Y682-p	APP_amyloid	SKMQQNGyENPTYKF	34572510	13	20	864		
hypertrophic cardiomyopathy	increased	Stat1	STAT1	P42225	20846	1 C1.1|1 26.81 cM	87.20	mouse	447753	S727-p	STAT1_TAZ2bind	TDNLLPMsPEEFDEM	34569651	107	32	90	8826; 9177; 62390	
breast ductal carcinoma	increased	NUCKS1	NUCKS	Q9H1E3	64710	1q32.1	27.30	human	475696	K35-ac		RDSGPPTkKIRSSPR	18491381	0	3	35		
DCM	mutation of site	HSPB1	HSP27	P04792	3315	7q11.23	22.78	human	448403	S82-p		RALSRQLsSGVSEIR	34477462	70	103	289	9709; 11892; 64293; 2406; 2401	
DCM	mutation of site	HSPB1	HSP27	P04792	3315	7q11.23	22.78	human	448401	S15-p		FSLLRGPsWDPFRDW	34477462	48	78	30	2404	
DCM	mutation of site	HSPB1	HSP27	P04792	3315	7q11.23	22.78	human	448402	S78-p		PAYSRALsRQLSSGV	34477462	36	25	30	2405	
hepatocellular carcinoma; liver steatosis, fatty liver	increased	AR	AR	P10275	367	Xq12	99.19	human	448416	S96-p	Androgen_recep	QQQGEDGsPQAHRRG	34435708	9	11	0		
bipolar disprder	increased	DPYSL2	CRMP-2	Q16555	1808	8p21.2	62.29	human	448082	S522-p		PASSAKTsPAKQQAP	34330827	29	49	84		
Alzheimer's disease	molecular association	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	27738305	K274-ac	Tubulin-binding	KHQPGGGkVQIINKK	27356871	3	0	0		missorted into the somatodendritic compartment
Alzheimer's disease	molecular association	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	1873575602	K281-ac	Tubulin-binding	KVQIINKkLDLSNVQ	27356871	4	1	0		missorted into the somatodendritic compartment
schizophrenia	decreased	DPYSL2	CRMP-2	Q16555	1808	8p21.2	62.29	human	448082	S522-p		PASSAKTsPAKQQAP	34330827	29	49	84		
Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	34220490	104	7	0	87281; 23706	
paraplegia	mutation of site	KIF1A	KIF1A iso3	Q12756-3	547	2q37.3	202.06	human	1874046600	S1758-p	PH	GILLQAAsDKDMHDW	34287616	1	0	0		KIF1A-associated neurological disorder is a neurodegenerative disorder characterized by symptoms including spastic paraple- gia, ataxia, and intellectual disability. 
SLE	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	34522717	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
SLE	decreased	RPS6	S6	P62753	6194	9p22.1	28.68	human	448093	S236-p		AKRRRLSsLRASTSK	34522717	219	72	1124	4851; 14733; 3985; 34411; 27036; 4803; 3945; 62788; 5316; 9865; 8520; 97935; 2211; 4856; 62016; 4857; 4854; 5006; 4858; 81736	
SLE	decreased	RPS6	S6	P62753	6194	9p22.1	28.68	human	448092	S235-p		IAKRRRLsSLRASTS	34522717	225	60	972	4851; 14733; 3985; 34411; 27036; 4803; 3945; 62788; 5316; 9865; 8520; 97935; 2211; 4856; 62016; 4857; 4854; 5006; 4858; 81736	
hepatocellular carcinoma	increased	RELA	NFkB-p65	Q04206	5970	11q13.1	60.22	human	447800	S536-p		SGDEDFSsIADMDFS	34380537	217	4	0	73992; 31553; 4887; 80477; 76778; 3031; 5733; 13346; 3036; 3033; 4025; 4886; 87672; 83962	
hepatocellular carcinoma	increased	RELA	NFkB-p65	Q04206	5970	11q13.1	60.22	human	447799	S529-p		GLPNGLLsGDEDFSS	34380537	23	3	1	96874	
hepatocellular carcinoma	increased	RELA	NFkB-p65	Q04206	5970	11q13.1	60.22	human	447798	S276-p	RHD_dimer	SMQLRRPsDRELSEP	34380537	83	0	0		
SDS	increased	EFL1	EFTUD1	Q7Z2Z2	79631	15q25.2	125.43	human	1875329200	T1069-p		SDPFWVPtTEEEYLH	34115847	1	0	0		
clear cell kidney cancer		CTNNB1	CTNNB1	P35222	1499	3p22.1	85.50	human	472273	S552-p		QDTQRRTsMGGTQQQ	34657130	39	62	9	9566; 5651	
gallbladder cancer	increased	JUN	Jun	P05412	3725	1p32.1	35.68	human	447943	S73-p	Jun	VGLLKLAsPELERLI	34703881	80	65	16	8752; 77955; 3270; 9164; 12714	corelates with poor survival rate
AD	decreased	H4C1	H4	P62805	8359	6p22.2	11.24	human	458960	K16-ac		GLGKGGAkRHRKVLR	32973937	103	26	531	13534; 26437; 56999; 98789	
hepatocellular carcinoma	decreased	PKM	PKM	P14618	5315	15q23	57.94	human	11318760	K62-ac	PK	SRSVETLkEMIKSGM	33279948	2	7	1		shorter survival times with lower K62 acetylation
TAAD	mutation of site	ACTA1	ACTA1	P68133	58	1q42.13	42.05	human	1876986202	R256-m1	Actin	VITIGNErFRCPETL	32997990	1	1	0		
colorectal carcinoma	increased	YBX1	YB-1	P67809	4904	1p34.2	35.92	human	1876986200	R205-m2		MRRPYGRrPQYSNPP	32985589	1	1	0		
colorectal cancer	increased	SIRT1	SIRT1	Q96EB6	23411	10q21.3	81.68	human	452898	S27-p		ADREAASsPAGEPLR	34826187	5	19	1	2327	
colorectal cancer	increased	CHEK1	Chk1	O14757	1111	11q24.2	54.43	human	447834	S345-p		LVQGISFsQPTCPDH	32357935	188	4	12	12268; 2341; 2348	CHK1 K132 ubiquitination is required for maintaining chemoresistance
colorectal cancer	increased	CHEK1	Chk1	O14757	1111	11q24.2	54.43	human	447833	S317-p		ENVKYSSsQPEPRTG	32357935	94	11	17	2344; 8191; 12302	CHK1 K132 ubiquitination is required for maintaining chemoresistance
colorectal cancer	increased	CHEK1	Chk1	O14757	1111	11q24.2	54.43	human	31914110	K132-ub	Pkinase	GITHRDIkPENLLLD	32357935	3	3	0		CHK1 K132 ubiquitination is required for maintaining chemoresistance
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084601	S410-p		SSMDSKSsGWGM___	34880495	49	4	0		
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084616	S409-p		GSSMDSKsSGWGM__	34880495	48	4	0		
breast cancer; ovarian cancer	increased	COPB2	COPB2	P35606	9276	3q23	102.49	human	3189937	T861-p		DGKPASPtPVIVASH	34676262	1	21	1		
breast cancer; ovarian cancer	increased	COPB2	COPB2	P35606	9276	3q23	102.49	human	3071335	S859-p		ELDGKPAsPTPVIVA	34676262	1	49	2		
colorectal cancer	decreased	COPB2	COPB2	P35606	9276	3q23	102.49	human	3189937	T861-p		DGKPASPtPVIVASH	34676262	1	21	1		
breast cancer	increased	FLII	FLI	Q13045	2314	17p11.2	144.75	human	470489	S436-p		RLRRRKDsAQDDQAK	29898994	3	28	255		negative patient outcome
breast cancer	increased	FLII	FLI	Q13045	2314	17p11.2	144.75	human	1163832400	S64-p	LRR_8	KLEHLSVsHNNLTTL	29898994	1	0	0		better clinical prognosis 
cardiomyopathy	increased	SCN5A	SCN5A	Q14524	6331	3p22.2	226.94	human	27281507	S571-p	Na_trans_cytopl	PWPLRRTsAQGQPSP	30385719	10	4	0		
glioblastoma multiforme	increased	PGD	PGD	P52209	5226	1p36.22	53.14	human	465221	Y481-p		GTVSSSSyNA_____	30824700	1	1	45		
glioblastoma multiforme	increased	PKM	PKM	P14618	5315	15q23	57.94	human	476070	S37-p		MCRLDIDsPPITARN	23178880	15	62	6		
cardiomyopathy	increased	BECN1	beclin 1	Q14457	8678	17q21.31	51.90	human	29606706	T108-p	BH3	GEASDGGtMENLSRR	24141421	1	1	0		
breast adenocarcinoma	increased	H1-4	H1E	P10412	3008	6p22.2	21.87	human	458356	T146-p		KKATGAAtPKKSAKK	24601643	5	11	8		
breast adenocarcinoma	increased	H1-2	H1C	P16403	3006	6p22.2	21.36	human	9765189	T146-p		KKAAGGAtPKKSAKK	24601643	4	17	8		
non-small cell lung adenocarcinoma	increased	NCL	NCL	P19338	4691	2q37.1	76.61	human	21697921	T707-p		HKPQGKKtKFE____	25173817	2	0	0		
non-small cell lung adenocarcinoma	increased	NCL	NCL	P19338	4691	2q37.1	76.61	human	21697920	T641-p	RRM_1	EIDGNKVtLDWAKPK	25173817	2	0	1		
breast cancer	increased	HSF1	HSF1	Q00613	3297	8q24.3	57.26	human	455484	S326-p	Vert_HS_TF	SSVDTLLsPTALIDS	24469056	45	25	13		
breast cancer	increased	RAPGEF2	RAPGEF2	Q9Y4G8	9693	4q32.1	167.42	human	30995201	S1244-p		ASLDAADsGRGSWTS	24290981	1	0	0		
breast cancer	increased	RAPGEF2	RAPGEF2	Q9Y4G8	9693	4q32.1	167.42	human	30995200	S1248-p		AADSGRGsWTSCSSG	24290981	1	0	0		
cervical squamous cell carcinoma	decreased	CASP8	CASP8	Q14790	841	2q33.1	55.39	human	56640300	T273-p	Peptidase_C14	DAGALTTtFEELHFE	31475104	4	0	0		
colorectal carcinoma	increased	FOXC1	FOXC1	Q12948	2296	6p25.3	56.79	human	3195017	S241-p		PSPPQPLsPAAALGS	31650548	1	21	1		
colorectal carcinoma	increased	FOXC1	FOXC1	Q12948	2296	6p25.3	56.79	human	460580	S272-p		SSLSSGSsPPGSLPS	31650548	2	2	0		
breast ductal carcinoma	decreased	SNAI1	Snail1	O95863	6615	20q13.13	29.08	human	11493500	S11-p		SFLVRKPsDPNRKPN	22276203	4	0	0		
colorectal cancer	increased	E2F4	E2F4	Q16254	1874	16q22.1	43.96	human	4763386	S384-p		FAPLLRLsPPPGDHD	23919615	2	5	0		colorectal adenoma
colorectal cancer	increased	E2F4	E2F4	Q16254	1874	16q22.1	43.96	human	28843800	S244-p		QEASRPNsPQLTPTA	23919615	1	1	0		colorectal adenoma
lung cancer	increased	LYN	LYN	P07948	4067	8q12.1	58.57	human	454717	Y32-p		RNTERTIyVRDPTSN	23764002	1	12	105		corelates with poor survival
lung cancer	increased	MCM7	MCM7	P33993	4176	7q22.1	81.31	human	463418	Y600-p	MCM_lid	WASKDATyTSARTLL	23764002	1	3	39		corelates with poor survival
breast cancer	increased	SLC39A7	SLC39A7	Q92504	7922	6p21.32	50.12	human	457019	S275-p	Zip	RSTKEKQsSEEEEKE	31483418	2	19	9		corelates with tumour  grade
breast cancer	increased	SLC39A7	SLC39A7	Q92504	7922	6p21.32	50.12	human	457020	S276-p	Zip	STKEKQSsEEEEKET	31483418	2	19	9		corelates with tumour  grade
hepatocellular carcinoma; pancreatic cancer; pancreatic ductal adenocarcinoma	increased	TERT	TERT	O14746	7015	5p15.33	127.00	human	1868023600	T249-p		AAPEPERtPVGQGSW	32214089	2	1	0		
major depressive disorder	decreased	EIF4B	EIF4B	P23588	1975	12q13.13	69.15	human	452271	S504-p		SSDTEQQsPTSGGGK	21635931	2	55	22		
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084616	S409-p		GSSMDSKsSGWGM__	21678031	48	4	0		
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084601	S410-p		SSMDSKSsGWGM___	21678031	49	4	0		
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084617	S403-p		GFNGGFGsSMDSKSS	23922830	13	3	0		
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084635	S404-p		FNGGFGSsMDSKSSG	23922830	13	2	0		
clear cell kidney cancer	increased	PML	PML	P29590	5371	15q24.1	97.55	human	465867	S518-p	DUF3583	PSTSKAVsPPHLDGP	25293974	3	61	25		
Alzheimer's disease	increased	KLC1	KLC1	Q07866	3831	14q32.33	65.31	human	477826	S460-p		YKACKVDsPTVTTTL	31806024	3	41	3		
Merkel cell carcinoma	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	465521	K27-ac	Histone	LATKAARkSAPATGG	25941994	66	16	13	14056; 30342; 8173; 15562; 13027; 15485; 23349; 39030; 4353; 87261	
non-small cell lung cancer	increased	FH	fumarase	P07954	2271	1q43	54.64	human	36132325	S46-p		PNAARMAsQNSFRIE	30683654	1	5	0		
diabetes mellitus	increased	Rela	NFkB-p65	Q04207	19697	19 A|19 4.34 cM	60.21	mouse	459096	K310-ac		KRTYETFkSIMKKSP	26836609	78	5	0	3045; 12629	
lung cancer	increased	HOXB9	HOXB9	P17482	3219	17q21.32	28.06	human	58948902	K27-ac	Hox9_act	SEDAPPAkFPSGQYA	27613418	1	1	0		K27 acetylation decreases lung cancer cell migration and xenograft tumor growth.
diabetes mellitus	increased	Brp44	MPC2	Q9D023	70456	1|1 H2.2	14.29	mouse	1195924	K26-ac		KVELLLPkKLRPLYN	28154187	1	2	6		
diabetes mellitus	increased	Brp44	MPC2	Q9D023	70456	1|1 H2.2	14.29	mouse	467165	K19-ac		TYHRLMDkVELLLPK	28154187	1	5	2		
gastric carcinoma	molecular association	GFI1	GFI1	Q99684	2672	1p22.1	45.30	human	41452096	S94-p		EDFWRPPsPSASPAS	31289136	1	2	0		
gastric carcinoma	molecular association	GFI1	GFI1	Q99684	2672	1p22.1	45.30	human	1868711303	S98-p		RPPSPSAsPASEKSM	31289136	1	1	0		
type 2 diabetes		MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447934	T212-p		TPGSRSRtPSLPTPP	30837891	45	16	5		associated with better memory function in type 2- diabetes patients
hepatocellular carcinoma	increased	SQSTM1	SQSTM1	Q13501	8878	5q35.3	47.69	human	3195656	S28-p	PB1	RRFSFCCsPEPEAEA	31032410	1	10	7		corelates with shorter patient survival durations
lung cancer	decreased	SECISBP2L	SECISBP2L	Q93073	9728	15q21.1	121.78	human	1868832803	T573-p		IAKLKRPtALKKVIL	31314582	1	0	0		
atrial fibrillation	increased	Ryr2	RYR2	E9Q401	20191	13 A1|13 4.38 cM	564.82	mouse	4777888	S2367-p		GPSPTSGsSKTLDIE	32683896	1	3	0		
schizophrenia	increased	MAP2	MAP2	P11137	4133	2q34	199.53	human	456422	S1782-p		GAEIITQsPGRSSVA	33526823	2	63	14		
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	7911901	K846-ub	Hormone_recep	LDRIIACkRKNPTSC	19345326	5	1	0		In castrated male nude mice, ARcs-K845R  mutant tumor growth was dramatically reduced compared to that of cells expressing ARcs-WT.
prostate cancer	increased	NDRG1	NDRG1	Q92597	10397	8q24.22	42.84	human	452879	S330-p		LMRSRTAsGSSVTSL	33398037	10	74	485	11899; 3506	
ovarian cancer	decreased	Kdr	VEGFR2	P35918	16542	5 C3.3|5 40.23 cM	150.46	mouse	447903	Y949-p	PK_Tyr_Ser-Thr	RFRQGKDyVGELSVD	33726754	19	0	3	2476; 4991; 2471	
liver disease	increased	Foxo3	FOXO3A	Q9WVH4	56484	10 B2|10 22.79 cM	71.06	mouse	20799900	S573-p		SAKHQQQsPASQSMQ	33649241	5	2	0		
acute myelogenous leukemia	increased	H2AX	H2AX	P16104	3014	11q23.3	15.01	human	448841	S139-p		GKKATQAsQEY____	33691101	254	31	29	85410; 97148; 20304; 5438; 80312; 59141; 4309; 9719; 60566; 5763; 9720; 2577; 9718	
ALS	increased	EIF2S1	eIF2-alpha	P05198	1965	14q23.3	36.11	human	447635	S52-p	S1	MILLSELsRRRIRSI	33705388	120	2	0	53085; 3597; 3398; 9721; 5199	
ALS	increased	MARK2	MARK2	Q7KZI7	2011	11q13.1	87.91	human	453427	T596-p		RGVSSRStFHAGQLR	33705388	5	19	1		
Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	31933723	104	7	0	87281; 23706	
esophageal carcinoma	decreased; increased	CTNNB1	CTNNB1	P35222	1499	3p22.1	85.50	human	447488	S45-p		GATTTAPsLSGKGNP	31933784	49	7	0	70034; 9565; 19807; 77605; 9564; 96727	Decreased in ESCC. Increases with tumor
esophageal carcinoma; cancer, squamous cell carcinoma	decreased	Ctnnb1	CTNNB1	Q02248	12387	9 F4|9 72.19 cM	85.47	mouse	447488	S45-p		GATTTAPsLSGKGNP	31934197	49	7	0	70034; 9565; 19807; 77605; 9564; 96727	correlates with better survival rate
esophageal carcinoma; cancer, squamous cell carcinoma	increased	Ctnnb1	CTNNB1	Q02248	12387	9 F4|9 72.19 cM	85.47	mouse	447488	S45-p		GATTTAPsLSGKGNP	31934197	49	7	0	70034; 9565; 19807; 77605; 9564; 96727	correlates with high grade carcinoma
hypertension	decreased	Gja1	GJA1	P08050	24392	20q11	43.03	rat	447813	S368-p		QRPSSRAsSRASSRP	31947691	52	8	1	52559; 3511	
pancreatic cancer; liver cancer	increased	IL17RB	IL17RB	Q9NRM6	55540	3p21.1	55.88	human	5756439	Y447-p	SEFIR	LHKYVVVyFREIDTK	33658352	2	0	0		corelates with worse prognosis
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	33842885	85	33	23	62672; 66224; 12885	
breast cancer, triple negative	increased	RARA	RARA	P10276	5914	17q21.2	50.77	human	455459	S77-p		EIVPSPPsPPPLPRI	33902658	11	2	0		
Parkinson's disease	increased	SOD2	SOD2	P04179	6648	6q25.3	24.75	human	461133	K68-ac	Sod_Fe_N	NLNVTEEkYQEALAK	28369333	18	13	8		
Marfan syndrome	increased	Vasp	VASP	P70460	22323	7|7 A3	39.67	mouse	448380	S235-p		GAKLRKVsKQEEASG	33976159	58	26	3	3114	
esophageal carcinoma	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	465520	K18-ac	Histone	TGGKAPRkQLATKAA	20142251	52	27	381	9675; 13998; 79423; 20363; 73508	corelates with poor recurrence free survival
esophageal carcinoma	increased	H4C1	H4	P62805	8359	6p22.2	11.24	human	477687	R3-m2		_____SGrGKGGKGL	20142251	9	2	0	92326	corelates with poor recurrence free survival
breast cancer	decreased	H3C1	H3	P68431	8350	6p22.2	15.27	human	455676	S10-p	Histone	TKQTARKsTGGKAPR	21146603	228	15	1	3465; 9701; 8552; 66065; 9706; 3377; 5764; 64522; 3475; 29237; 9711; 8481; 9606; 52725; 43185; 3642; 3458; 53348	decreased at diagnosis as compared to after completion of treatment
breast cancer	decreased	H4C1	H4	P62805	8359	6p22.2	11.24	human	459013	K12-ac		KGGKGLGkGGAKRHR	21146603	89	25	531	2591; 13944	decreased at diagnosis as compared to after completion of treatment
breast cancer	decreased	H4C1	H4	P62805	8359	6p22.2	11.24	human	458959	K8-ac		SGRGKGGkGLGKGGA	21146603	82	21	529	2594	decreased at diagnosis as compared to after completion of treatment
CCA	increased	PTK2	FAK	Q05397	5747	8q24.3	119.23	human	447887	Y397-p		SVSETDDyAEIIDEE	34052254	340	31	474	3283; 8556	
CCA	increased	YAP1	YAP1	P46937	10413	11q22.1	54.46	human	3190672	S397-p		TYHSRDEsTDSGLSM	34052254	24	13	5	13619	
pancreatic ductal adenocarcinoma	increased	PIN1	PIN1	Q13526	5300	19p13.2	18.24	human	25519816	S138-p	Rotamase	QKPFEDAsFALRTGE	34052323	3	2	0		
chronic lymphocytic leukemia	mutation of site	GLI2	GLI2	P10070	2736	2q14.2	167.78	human	15410484	S941-p		PLGPRRGsDGPTYGH	30923040	2	1	3		
chronic lymphocytic leukemia	increased	BCL2L11	BIM	O43521	10018	2q13	22.17	human	458219	S87-p		FIFMRRSsLLSRSSS	30923040	2	10	1		
chronic myelogenous leukemia	increased	PDHA1	PDHA1	P08559	5160	Xp22.12	43.30	human	454753	Y301-p	E1_dh	MSDPGVSyRTREEIQ	25104357	2	36	1386		
Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	34115198	104	7	0	87281; 23706	
psoriasis	decreased	ULK1	ULK1	O75385	8408	12q24.33	112.63	human	3176155	S556-p		GLGCRLHsAPNLSDL	34421918	44	26	48	5869	
Alzheimer's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	55529800	K466-ac		NATRIPAkTTPSPKT	33910019	4	1	0		
HBL	decreased	CEBPA	C/EBP-alpha	P49715	1050	19q13.11	37.56	human	457552	S190-p		PPPPPPPsHPHPHPP	34245919	2	0	0		
Parkinson's disease	decreased	TH	TH	P07101	7054	11p15.5	58.60	human	448545	S71-p	TOH_N	RFIGRRQsLIEDARK	34238765	61	11	11	2791	
Parkinson's disease	decreased	PAK4	PAK4	O96013	10298	19q13.2	64.07	human	448023	S474-p	Pkinase	KEVPRRKsLVGTPYW	34238765	12	66	140	3241	
breast cancer	increased	STAT5A	STAT5A	P42229	6776	17q21.2	90.65	human	448749	S726-p		TYMDQAPsPAVCPQA	34188118	19	1	0		
hepatocellular carcinoma	increased	CHEK2	Chk2	O96017	11200	22q12.1	60.91	human	1872610001	T378-gl	Pkinase	HSKILGEtSLMRTLC	33690219	1	0	0		
PAH	increased	Creb1	CREB	P15337	81646	9q32	36.63	rat	448228	S133-p	pKID	EILSRRPsYRKILND	34635097	289	4	61	14001; 54960; 9187; 80120; 95995; 14228; 44864; 39561; 9196; 9198; 4095	
prostate cancer		KLF5	KLF5	Q13887	688	13q22.1	50.79	human	458937	K369-ac		RSNPDLEkRRIHYCD	32685011	3	1	1		DTX resistance in prostate cancer cells
melanoma skin cancer	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	465521	K27-ac	Histone	LATKAARkSAPATGG	32079144	66	16	13	14056; 30342; 8173; 15562; 13027; 15485; 23349; 39030; 4353; 87261	
type 2 diabetes		PPARG	PPAR-gamma	P37231	5468	3p25.2	57.62	human	25780500	K268-ac		ARAILTGkTTDKSPF	32409492	3	1	0		2KR:Ldlr -/- mice demonstrated a residual antiatherogenic response and protection against bone loss and ?uid retention
type 2 diabetes		PPARG	PPAR-gamma	P37231	5468	3p25.2	57.62	human	25780501	K293-ac		GEDKIKFkHITPLQE	32409492	3	1	0		2KR:Ldlr -/- mice demonstrated a residual antiatherogenic response and protection against bone loss and ?uid retention
ALS	molecular association	UBA52-RPS27A-UBB-UBC	ubiquitin	P62988		2p16	8.56	human	486303	K48-ub	ubiquitin	QRLIFAGkQLEDGRT	31951008	79	45	157	12805	nearly all neuronal cytoplasmic inclusions (NCIs) immunolabeled with  lysine 48-linked poly-ubiquitin chain (K48-Ub) were labeled, majority were triple immulabeled with K48-Ub, K63-Ub, and linear polyubiquitin chain (L- Ub)
ALS	molecular association	UBA52-RPS27A-UBB-UBC	ubiquitin	P62988		2p16	8.56	human	486304	K63-ub	ubiquitin	LSDYNIQkESTLHLV	31951008	85	33	155	12930	nearly all neuronal cytoplasmic inclusions (NCIs) immunolabeled with  lysine 48-linked poly-ubiquitin chain (K48-Ub) were labeled, majority were triple immulabeled with K48-Ub, K63-Ub, and linear polyubiquitin chain (L- Ub)
Parkinson's disease	decreased	VDAC1	VDAC1	P21796	7416	5q31.1	30.77	human	486986	K274-ub	Porin_3; TM	NVNAGGHkLGLGLEF	32047033	1	9	99		T415N mutation lacks the ability to induce VDAC1 monoubiquitination
hepatocellular carcinoma	increased	FIS1	FIS1	Q9Y3D6	51024	7q22.1	16.94	human	1875830300	Y38-p	Fis1_TPR_N	SKSTQFEyAWCLVRS	34848680	1	1	0		
DN	increased	Itgb1	ITGB1	P49134	24511	19q12	88.49	rat	447709	T790-p	Integrin_b_cyt	IYKSAVTtVVNPKYE	34859416	14	3	1		
DN	increased	Itgb1	ITGB1	P49134	24511	19q12	88.49	rat	448600	T789-p	Integrin_b_cyt	PIYKSAVtTVVNPKY	34859416	15	2	1		
EAE; GvHD	mutation of site	NFATC1	NFAT2	O95644	4772	18q23	101.24	human	6413903	K349-sm		QPPSVALkVEPVGED	32986812	3	1	0		SUMO modification of NFAT2 is prevented
EAE; GvHD	mutation of site	NFATC1	NFAT2	O95644	4772	18q23	101.24	human	6413901	K914-sm		APIPVTVkREPEELD	32986812	2	1	0		SUMO modification of NFAT2 is prevented
EAE; GvHD	mutation of site	NFATC1	NFAT2	O95644	4772	18q23	101.24	human	6413902	K702-sm		PANVPIIkTEPTDDY	32986812	2	1	0		SUMO modification of NFAT2 is prevented
psoriasis	increased	TLR7	TLR7	Q9NYK1	51284	Xp22.2	120.92	human	1875831802	Y1024-p	TIR	TNPQAHPyFWQCLKN	34936223	1	0	0		
non-small cell lung cancer; breast cancer; gastric cancer; pancreatic cancer	increased	TPI1	TPI1 iso3	P60174-3	7167	12p13.31	30.79	human	465652	S58-p	TIM	KMNGRKQsLGELIGT	34936872	2	66	124		
breast cancer	increased	DDX5	DDX5	P17844	1655	17q23.3	69.15	human	1875793000	T69-p		HPDLARRtAQEVETY	34936874	1	0	0		corelates with poor outcome
polyarthritis	decreased	Sting1	STING	Q3TBT3	72512	18 B2|18	42.83	mouse	31064700	S365-p		QEPRLLIsGMDQPLP	34901991	20	3	0	85735; 99309; 19781; 72971; 51865; 41622; 43499; 40818; 50907; 62912; 72650	STING S365A/S365A mice displaying polyarthritis
DCM; cardiomyopathy	increased	Gsk3b	GSK3B	Q9WV60	56637	16|16 B3	46.71	mouse	454221	S389-p		ARIQAAAsPPANATA	34948382	7	12	0		
DCM; cardiomyopathy	increased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	454221	S389-p		ARIQAAAsTPTNATA	34948382	7	12	0		
colorectal cancer	decreased	COPB2	COPB2	P35606	9276	3q23	102.49	human	3071335	S859-p		ELDGKPAsPTPVIVA	34676262	1	49	2		
endometrial cancer	increased	COPB2	COPB2	P35606	9276	3q23	102.49	human	23095583	T828-p		AKQYPLVtPNEERNV	34676262	1	2	1		
Huntington's disease	increased	DPYSL2	CRMP-2	Q16555	1808	8p21.2	62.29	human	454386	T514-p		SVTPKTVtPASSAKT	34831395	31	36	35	9397	
Huntington's disease	increased	DPYSL2	CRMP-2	Q16555	1808	8p21.2	62.29	human	448083	T509-p		PVCEVSVtPKTVTPA	34831395	14	63	34		
Huntington's disease	increased	DPYSL2	CRMP-2	Q16555	1808	8p21.2	62.29	human	448082	S522-p		PASSAKTsPAKQQAP	34831395	29	49	84		
diabetes mellitus	decreased	GLO1	GLO1	Q04760	2739	6p21.2	20.78	human	463450	Y136-p	Glyoxalase	GIAVPDVySACKRFE	34838714	1	0	19		experimental diabetes
CTE	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	34854540	130	44	14	20473; 71429	
CTE	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	34854540	170	45	90	9632	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	34854540	170	45	90	9632	
COPD	decreased	Kdm1a	LSD1	Q6ZQ88	99982	4 D3|4 68.8 cM	92.85	mouse	3828907	S112-p		TPEGRRTsRRKRAKV	34078525	3	1	10		
PAH	increased	Pik3c3	PIK3C3	Q6PF93	225326	18|18 B1	101.49	mouse	31077507	K840-sm		LEPDKTVkKVQDKFR	30703554	2	0	0		
Parkinson's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447927	S199-p		GDRSGYSsPGSPGTP	34983390	87	30	33	29957	
Parkinson's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447928	S202-p		SGYSSPGsPGTPGSR	34983390	149	55	116	30505; 39357	
Parkinson's disease	increased	APP	APP	P05067	351	21q21.3	86.94	human	448523	T743-p	APP_amyloid	VEVDAAVtPEERHLS	34983390	38	5	3	3823; 6986	
DLB	decreased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447928	S202-p		SGYSSPGsPGTPGSR	34983390	149	55	116	30505; 39357	
DLB	decreased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447927	S199-p		GDRSGYSsPGSPGTP	34983390	87	30	33	29957	
DLB	increased	APP	APP	P05067	351	21q21.3	86.94	human	448523	T743-p	APP_amyloid	VEVDAAVtPEERHLS	34983390	38	5	3	3823; 6986	
DN	increased	UBA52-RPS27A-UBB-UBC	ubiquitin	P62988		2p16	8.56	human	3931595	K27-ub	ubiquitin	SDTIENVkAKIQDKE	30741721	19	19	142		
DN	increased	PTEN	PTEN	P60484	5728	10q23.31	47.17	human	27205464	K80-ub		ERHYDTAkFNCRVAQ	30741721	3	5	0		
Alzheimer's disease	increased	Gsk3b	GSK3B	Q9WV60	56637	16|16 B3	46.71	mouse	448569	Y216-p	Pkinase	RGEPNVSyICSRYYR	34987593	91	127	4206		
Alzheimer's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	447927	S491-p		GERSGYSsPGSPGTP	34987593	87	30	33	29957	
Alzheimer's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	449082	S696-p		PVVSGDTsPRHLSNV	34987593	132	53	69	20194; 35834; 98523; 49562; 91600	
Alzheimer's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	449081	S688-p		GAEIVYKsPVVSGDT	34987593	170	45	90	9632	
Alzheimer's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	447928	S494-p		SGYSSPGsPGTPGSR	34987593	149	55	116	30505; 39357	
diabetes mellitus	decreased	Pdha1	PDHA1	P35486	18597	X F4|X 73.95 cM	43.23	mouse	448257	S232-p	E1_dh	NRYGMGTsVERAAAS	34988082	45	79	7	15289	
Silk road disease	increased	BIRC5	Survivin	O15392	332	17q25.3	16.39	human	447705	T34-p	BIR	FLEGCACtPERMAEA	32373497	17	6	7	8888	
type 2 diabetes; obesity, hyperphagic	decreased	Nos3	eNOS	P70313	18127	5 A3|5 11.32 cM	132.92	mouse	447884	S1176-p		TSRIRTQsFSLQERQ	35017029	194	18	7	9570; 9571	
Alzheimer's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	449082	S696-p		PVVSGDTsPRHLSNV	35017410	132	53	69	20194; 35834; 98523; 49562; 91600	
Alzheimer's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	449081	S688-p		GAEIVYKsPVVSGDT	35017410	170	45	90	9632	
glioblastoma multiforme	decreased	SMURF2	SMURF2	Q9HAU4	64750	17q23.3-q24.1	86.20	human	27457334	T249-p		MSRTHLHtPPDLPEG	35017630	2	2	0		
bipolar disprder	increased	SP4	SP4	Q02446	6671	7p15.3	81.98	human	17548374	S770-p		VAAISQDsNPATPNV	25915526	3	5	0		
pancreatic cancer	deletion of site	MEF2A	MEF2A	Q02078	4205	15q26.3	54.81	human	4728301	Y105-p	HJURP_C	SPDPDTSyVLTPHTE	28176830	1	3	0		pfsSNV at position 105 is significantly associated with decreased survival rate
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	448714	S83-p	Androgen_recep	QQQQQETsPRQQQQQ	27902483	22	1	0		decreased disease specific survival 
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	4275600	S579-p	zf-C4	YGALTCGsCKVFFKR	27902483	3	0	0		 High cytoplasmic and nuclear pAR S579 were associated with disease-specific survival (plt0.001 and p=0.036  respectively). High nuclear PKC was associated with lower disease-specifc survival. 
lung cancer	increased	IRS2	IRS2	Q9Y4H2	8660	13q34	137.33	human	453065	S1100-p		PEAARVAsPTSGVKR	25297629	2	43	0		
Alzheimer's disease	increased	Srpk2	SRPK2	O54781	20817	5 A3|5 10.36 cM	76.76	mouse	483237	T485-p		PSHDRSRtVSASSTG	30373880	3	6	0		
Alzheimer's disease	increased	MAPT	Tau	P10636	4137	17q21.31	78.93	human	3847081	S214-p		GGKERPGsKEEVDED	30373880	1	5	1		
prostate cancer; breast cancer	decreased	ATP1A1	ATP1A1	P05023	476	1p13.1	112.90	human	454981	Y260-p	E1-E2_ATPase	TARGIVVyTGDRTVM	30120256	2	44	1345		acts as a tumor suppresor 
OSCC	increased	NPM1	NPM1	P06748	4869	5q35.1	32.58	human	459897	S125-p		AVEEDAEsEDEEEED	24857377	9	94	558		
bladder cancer	increased	F3	F3	P13726	2152	1p21.3	33.07	human	451613	S290-p		GQSWKENsPLNVS__	30579699	11	1	0		increase of unphosphorylated F3 (later stage bladder cancer) and phosphorylated F3 p-S290  in the cohort with bladder cancer 
PAH	decreased	HSPA1A	HSP70	P0DMV8	3303	6p21.33	70.05	human	483567	S631-p		AQGPKGGsGSGPTIE	30485823	2	13	0		
non-small cell lung cancer	increased	NCL	NCL	P19338	4691	2q37.1	76.61	human	483581	T76-p		TKKVAVAtPAKKAAV	30320343	4	33	23		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447928	S202-p		SGYSSPGsPGTPGSR	29950669	149	55	116	30505; 39357	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449082	S404-p		PVVSGDTsPRHLSNV	29950669	132	53	69	20194; 35834; 98523; 49562; 91600	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	487456	S289-p	Tubulin-binding	LDLSNVQsKCGSKDN	29950669	4	3	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	29950669	170	45	90	9632	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447933	T205-p		SSPGSPGtPGSRSRT	29950669	113	24	26	30505; 43964; 49561; 20060; 53001; 20739	
breast cancer; colorectal cancer; liver cancer	increased	UBE2I	UBC9	P63279	7329	16p13.3	18.01	human	3803343	S71-p	UQ_con	FKDDYPSsPPKCKFE	22407595	4	6	8		
cardiomyopathy	increased	RYR2	RYR2	Q92736	6262	1q43	564.57	human	458801	S2814-p		ISQTSQVsVDAAHGY	22511749	61	8	5		
lung cancer	increased	NCL	NCL	P19338	4691	2q37.1	76.61	human	21697920	T641-p	RRM_1	EIDGNKVtLDWAKPK	21998300	2	0	1		
breast cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	21743495	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
myeloproliferative disorder	increased	JAK2	JAK2	O60674	3717	9p24.1	130.67	human	470070	Y201-p	FERM_F2	DQTPLAIyNSISYKT	22837531	3	1	0		Y201F mutant inhibited constitutive activation of JAK2V617F; Y201 is required for induction of MPN-like disease in mice
cardiomyopathy	increased	Ppp3ca	PPP3CA	P63329	24674	2q43	58.64	rat	2048309	S411-p		GKMARVFsVLREESE	19608982	1	4	1		
breast adenocarcinoma	increased	HSF1	HSF1	Q00613	3297	8q24.3	57.26	human	54414377	T120-p		ENIKRKVtSVSTLKS	31409638	1	1	0		
Alzheimer's disease	decreased	APP	APP	P05067	351	21q21.3	86.94	human	480465	S679-p	Beta-APP	DAEFRHDsGYEVHHQ	30210271	10	1	0		Injection with phosphorylated  S679 peptides reduced amyloid plaques in mouse model of AD.
Huntington's disease	decreased	Htt	Huntingtin	P42859	15194	5 B2|5 17.92 cM	344.69	mouse	10206805	S13-p		KLMKAFEsLKSFQQQ	31088970	18	3	0		
hepatocellular carcinoma	decreased	NCOA3	SRC-3	Q9Y6Q9	8202	20q13.12	155.29	human	3217872	S1330-p	DUF1518	PAFGRVSsPPNAMMS	31066068	1	14	0		
non-small cell lung cancer	increased	PAK1	PAK1	Q13153	5058	11q13.5-q14.1	60.65	human	448177	T423-p	Pkinase	PEQSKRStMVGTPYW	31660987	37	4	11	2601	Inhibitors of PAK1-inhibits the tumor growth
non-small cell lung cancer	increased	PAK1	PAK1	Q13153	5058	11q13.5-q14.1	60.65	human	448173	S204-p		TKSVYTRsVIEPLPV	31660987	16	16	0	2605	Inhibitors of PAK1-inhibits the tumor growth
non-small cell lung cancer	increased	PAK1	PAK1	Q13153	5058	11q13.5-q14.1	60.65	human	448176	T212-p		VIEPLPVtPTRDVAT	31660987	16	27	19		Inhibitors of PAK1-inhibits the tumor growth
non-small cell lung cancer	increased	PAK1	PAK1	Q13153	5058	11q13.5-q14.1	60.65	human	448170	S144-p		SNSQKYMsFTDKSAE	31660987	23	28	138	2606	Inhibitors of PAK1-inhibits the tumor growth
breast cancer, triple negative	increased	Ezh2	EZH2	Q61188	14056	6 B2.3|6 22.92 cM	85.29	mouse	10417699	T416-p		EANSRCQtPIKMKPN	31704972	5	7	7		
prostate cancer	increased	NFATC1	NFAT2	O95644	4772	18q23	101.24	human	56629000	S151-p		VLPSSKRsPSTATLS	31730483	2	2	0		multiple sites mutant
prostate cancer	increased	NFATC1	NFAT2	O95644	4772	18q23	101.24	human	41453273	S278-p		NGRQPPYsPHHSPTP	31730483	2	3	0		multiple sites mutant
clear cell kidney cancer	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	3190177	T714-p		KTKFICVtPTTCSNT	24615012	1	13	11		
prostate cancer	increased	NFATC1	NFAT2	O95644	4772	18q23	101.24	human	1869090803	S153-p		PSSKRSPsTATLSLP	31730483	1	1	0		multiple sites mutant
prostate cancer	increased	NFATC1	NFAT2	O95644	4772	18q23	101.24	human	1869090804	T338-p		VPVKSRKtTLEQPPS	31730483	1	0	0		multiple sites mutant
prostate cancer	increased	NFATC1	NFAT2	O95644	4772	18q23	101.24	human	40512526	S257-p		SWLGARSsRPASPCN	31730483	5	3	0		multiple sites mutant
prostate cancer	increased	NFATC1	NFAT2	O95644	4772	18q23	101.24	human	1869090805	T339-p		PVKSRKTtLEQPPSV	31730483	1	0	0		multiple sites mutant
prostate cancer	increased	NFATC1	NFAT2	O95644	4772	18q23	101.24	human	448861	S245-p		PSTSPRAsVTEESWL	31730483	3	7	1		multiple sites mutant
prostate cancer	increased	NFATC1	NFAT2	O95644	4772	18q23	101.24	human	448862	S269-p		PCNKRKYsLNGRQPP	31730483	3	6	1		multiple sites mutant
prostate cancer	increased	NFATC1	NFAT2	O95644	4772	18q23	101.24	human	1869090800	S335-p		GDGVPVKsRKTTLEQ	31730483	1	1	0		multiple sites mutant
prostate cancer	increased	NFATC1	NFAT2	O95644	4772	18q23	101.24	human	1869090801	T154-p		SSKRSPStATLSLPS	31730483	1	1	0		multiple sites mutant
prostate cancer	increased	NFATC1	NFAT2	O95644	4772	18q23	101.24	human	1869090802	S256-p		ESWLGARsSRPASPC	31730483	1	1	0		multiple sites mutant
clear cell kidney cancer	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448191	S727-p		NTIDLPMsPRTLDSL	24615012	199	55	67	49081; 34911; 50804; 58978; 71958; 87544; 94994; 9136; 9134	
clear cell kidney cancer	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	24615012	468	74	3065	4324; 8119; 9145; 4113; 52075; 73533; 9138; 4323; 4093; 4074; 52527; 74309; 16185; 61958; 9131; 73452	
Alzheimer's disease; PSP; Niemann-Pick disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449076	T153-p		DGKTKIAtPRGAAPP	24113872	4	2	6		
Alzheimer's disease; PSP; Niemann-Pick disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	487446	T149-p		AKGADGKtKIATPRG	24113872	1	2	1		
Crohn disease; colonic inflamation	increased	TNFRSF1A	TNF-R1	P19438	7132	12p13.31	50.49	human	20831307	S381-p	Death	FVRRLGLsDHEIDRL	21724995	1	0	0		
RTT	increased	Mecp2	MECP2	Q9Z2D6	17257	X A7.3|X 37.63 cM	52.31	mouse	28699600	T308-p		LPIKKRKtRETVSIE	23770587	1	0	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447930	S262-p	Tubulin-binding	NVKSKIGsTENLKHQ	23001711	108	24	2		human AD brains
Huntington's disease	decreased	Itpr1	IP3R1	P11881	16438	6 E1|6 49.74 cM	313.17	mouse	450682	S1755-p		RPSGRREsLTSFGNG	31256144	13	24	15	3760; 8548	
Huntington's disease	decreased	Itpr1	IP3R1	P11881	16438	6 E1|6 49.74 cM	313.17	mouse	450681	S1588-p		RNAARRDsVLAASRD	31256144	10	51	3		
GS	mutation of site	Slc12a3	NCCT	P59158	20497	8 C5|8 46.46 cM	110.69	mouse	469617	T58-p	AA_permease_N	MRTFGYNtIDVVPAY	23833262	24	3	0		
EAE	increased	Zc3h12a	MCPIP1	Q5D1E7	230738	4|4 D2.2	65.60	mouse	22730006	S439-p		CLDSGIGsLESQMSE	31072819	3	1	0		
asthma	increased	GMFG	GMF-gamma	O60234	9535	19q13.2	16.80	human	33670301	Y104-p	Cofilin_ADF	KPEQQMMyAGSKNRL	30811945	2	0	0		
EAE	increased	Zc3h12a	MCPIP1	Q5D1E7	230738	4|4 D2.2	65.60	mouse	22730005	S435-p		TSQECLDsGIGSLES	31072819	2	0	0		
colorectal cancer	increased	FERMT2	kindlin-2	Q96AC1	10979	14q22.1	77.86	human	3208605	S159-p		KKKLDDQsEDEALEL	32104508	2	37	5		
glioblastoma multiforme	increased	G6pd2	G6PD-2	P97324	14380	5 C3.1|5 31.99 cM	59.13	mouse	1869062303	T10-p		EQVTLSRtQVCGILR	32259365	1	0	0		
cardiomyopathy	mutation of site	Hspb6	HSP20	Q5EBG6	243912	7|7 B1	17.52	mouse	36703149	S10-p	Crystallin	IPVPVQPsWLRRASA	32218573	1	1	0		
hepatocellular carcinoma	increased	ILF3	NFAT90	Q12906	3609	19p13.2	95.34	human	456735	S382-p		EEDGEEKsPSKKKKK	32123579	1	55	13		
breast cancer	increased	SHC1	SHC1	P29353	6464	1q21.3	62.82	human	448508	S36-p		TPPEELPsPSASSLG	31941526	20	1	0		
gastric cancer	increased	NCOA3	SRC-3	Q9Y6Q9	8202	20q13.12	155.29	human	4252800	T1067-p	Nuc_rec_co-act	LLSNTDAtGLEEIDR	31975428	2	1	0		
gastric cancer	increased	NCOA3	SRC-3	Q9Y6Q9	8202	20q13.12	155.29	human	4252805	S1062-p	Nuc_rec_co-act	DQLHTLLsNTDATGL	31975428	2	1	1		
type 2 diabetes	increased	NUP62	NUP62	P37198	23636	19q13.33	53.25	human	36440512	T269-p		GAASGTStTTSTAAT	30401435	1	0	0		
type 2 diabetes	increased	NUP62	NUP62	P37198	23636	19q13.33	53.25	human	36440511	S272-p		SGTSTTTsTAATATA	30401435	1	0	0		
breast cancer	increased	SKP2	SKP2	Q13309	6502	5p13.2	47.76	human	1296362400	S256-p		QTLLSSCsRLDELNL	30413706	2	1	0		
breast cancer	increased	PRKAA1	AMPKA1	Q13131	5562	5p13.1	64.01	human	448786	T183-p	Pkinase	SDGEFLRtSCGSPNY	30413706	221	16	33	5256; 2531; 2535; 4188; 50081; 74281	
breast cancer	increased	Skp2	SKP2	Q9Z0Z3	27401	15|15 A1	47.77	mouse	1296362400	S256-p		ATLLSSCsRLDELNL	30413706	2	1	0		
breast cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	30413706	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
HIV/AIDS	increased	STAT5A	STAT5A	P42229	6776	17q21.2	90.65	human	447767	Y694-p		LAKAVDGyVKPQIKQ	21716071	142	49	2180	9356; 5387; 9359; 9314; 4322; 9351; 51879; 14603; 9365; 72712; 3939; 66740	
HIV/AIDS	increased	STAT5A	STAT5A	P42229	6776	17q21.2	90.65	human	448749	S726-p		TYMDQAPsPAVCPQA	21716071	19	1	0		
DCM; hypertrophic cardiomyopathy	decreased	TTN	Titin	Q8WZ42	7273	2q31.2	3816.03	human	27842905	S4099-p		SEQPGLFsEWLRNIE	23764881	6	1	0		
DCM; hypertrophic cardiomyopathy	decreased	TTN	Titin	Q8WZ42	7273	2q31.2	3816.03	human	5474103	S4185-p		IQQGAKTsLQEEMDS	23764881	3	1	2		
DCM; hypertrophic cardiomyopathy	decreased	TTN	Titin	Q8WZ42	7273	2q31.2	3816.03	human	27842904	S4010-p		VRIEEGKsLRFPLAL	23764881	5	1	0		
DCM; hypertrophic cardiomyopathy	increased	TTN	Titin	Q8WZ42	7273	2q31.2	3816.03	human	10029600	S11878-p		KEEVVLKsVLRKRPE	23764881	11	1	0		
DCM; hypertrophic cardiomyopathy	decreased	Ttn	Titin	A2ASS6	22138	2 C3|2 45.13 cM	3906.49	mouse	27842905	S4080-p		REQANLFsEWLRNID	23764881	6	1	0		
DCM; hypertrophic cardiomyopathy	decreased	Ttn	Titin	XP_008773743	84015	3q24	3800.81	rat	27842905	S3986-p		REQASLFsEWLRNID	23764881	6	1	0		
DCM; hypertrophic cardiomyopathy	decreased	Ttn	Titin	XP_008773743	84015	3q24	3800.81	rat	27842904	S3897-p		LRTEEGKsLSFPLAL	23764881	5	1	0		
DCM; hypertrophic cardiomyopathy	decreased	Ttn	Titin	A2ASS6	22138	2 C3|2 45.13 cM	3906.49	mouse	27842904	S3991-p		LRTEEGKsLSFPLAL	23764881	5	1	0		
meningioma	decreased	RB1	Rb	P06400	5925	13q14.2	106.16	human	447978	S780-p	Rb_C	STRPPTLsPIPHIPR	31615938	91	16	128	9307; 8180; 3590	hyperphosphorylation associated with decreased progression/recurrence-free survival
NAFLD	decreased	INSIG1	INSIG1	O15503	3638	7q36.3	29.99	human	1868139204	T222-p	TM; INSIG	ITIAFLAtLITQFLV	30733434	1	1	0		in HFHS-diet mice with controlled INSIG1 expression by AMPK knockout
NAFLD	mutation of site	Nr1h3	LXR-alpha	Q9Z0Y9	22259	2 E1|2 50.52 cM	50.42	mouse	469114	S196-p		SVSPRVSsPPQVLPQ	30673619	6	0	0		
nasopharyngeal carcinoma	increased	PDHA1	PDHA1	P08559	5160	Xp22.12	43.30	human	448258	S293-p	E1_dh	TYRYHGHsMSDPGVS	30745576	95	108	675	37115; 31866	
non-small cell lung adenocarcinoma; non-small cell squamous cell lung carcinoma	increased	HMOX1	HMOX1	P09601	3162	22q12.3	32.82	human	206219704	K256-ac		PVETPRGkPPLNTRS	28846111	1	1	0		
non-small cell lung adenocarcinoma; non-small cell squamous cell lung carcinoma	increased	HMOX1	HMOX1	P09601	3162	22q12.3	32.82	human	206219703	K243-ac		LRQRASNkVQDSAPV	28846111	1	1	0		
breast cancer	decreased	HMGN2	HMGN2	P05204	3151	1p36.11	9.39	human	458861	K3-ac	HMG14_17	_____MPkRKAEGDA	27358110	3	1	0		
pancreatic ductal adenocarcinoma	increased	Tgif1	TGIF	P70284	21815	17|17 E1.3	29.57	mouse	1868546603	T239-p		LFNTPPPtPPDLNQD	31152009	2	0	0		
pancreatic ductal adenocarcinoma	increased	Tgif1	TGIF	P70284	21815	17|17 E1.3	29.57	mouse	1868546604	T235-p		PQSGLFNtPPPTPPD	31152009	2	0	0		
pancreatic ductal adenocarcinoma	decreased	LDHA	LDH-A	P00338	3939	11p15.1	36.69	human	461532	K5-ac		___MATLkDQLIYNL	23523103	1	5	78		
hepatocellular carcinoma	molecular association	ZRANB1	ZRANB1	Q9UGI0	54764	10q26.13	80.97	human	23077543	S209-p		RWRGSCSsGNSQRRS	30686098	1	1	2		
hepatocellular carcinoma	molecular association	UVRAG	UVRAG	Q9P2Y5	7405	11q13.5	78.15	human	471489	S522-p		QYKTPPPsYNSALAQ	30686098	2	3	1		
hepatocellular carcinoma	molecular association	ZRANB1	ZRANB1	Q9UGI0	54764	10q26.13	80.97	human	50840530	T35-p		RAQRPSGtIITEDPF	30686098	1	2	0		
breast cancer, triple negative	increased	Trim71	TRIM71	Q1PSW8	636931	9|9 F3	92.05	mouse	18914372	S3-p		_____MAsFPETDFQ	31160797	1	2	0		corelates with outcome of patients treated with immunotherapy
breast cancer, triple negative	increased	TRIM71	TRIM71	Q2Q1W2	131405	3p22.3	93.38	human	18914372	S3-p		_____MAsFPETDFQ	31160797	1	2	0		corelates with outcome of patients treated with immunotherapy
FXS	decreased	PCSK9	PCSK9	Q8NBP7	255738	1p32.3	74.29	human	2811403	S47-p		ELVLALRsEEDGLAE	31553664	2	5	0		
Alzheimer's disease	increased	Tnfaip1	TNFAIP1	O70479	21927	11 B5|11 46.74 cM	36.13	mouse	3195881	S280-p		SRSQASPsEDEDTFE	33159672	2	11	0		
breast cancer	increased	YWHAH	14-3-3 eta	Q04917	7533	22q12.3	28.22	human	14159200	S25-p	14-3-3	ERYDDMAsAMKAVTE	33116123	1	4	0		
Huntington's disease	increased	HTT	Huntingtin	P42858	3064	4p16.3	347.60	human	40422833	T2335-p		SPERRTNtPKAISEE	32668197	1	2	0		
Huntington's disease	increased	HTT	Huntingtin	P42858	3064	4p16.3	347.60	human	1870026105	S2114-p		QCWTRSDsALLEGAE	32668197	1	1	0		
Huntington's disease	increased	HTT	Huntingtin	P42858	3064	4p16.3	347.60	human	15720685	S1862-p		QQTPKRHsLSSTKLL	32668197	1	12	2		
Huntington's disease	increased	HTT	Huntingtin	P42858	3064	4p16.3	347.60	human	465620	S1199-p		EQASVPLsPKKGSEA	32668197	4	29	2		
Huntington's disease	increased	HTT	Huntingtin	P42858	3064	4p16.3	347.60	human	448106	S419-p		GGRSRSGsIVELIAG	32668197	14	32	21		
Huntington's disease	increased	HTT	Huntingtin	P42858	3064	4p16.3	347.60	human	457592	S432-p		AGGGSSCsPVLSRKQ	32668197	3	50	60		
Huntington's disease	increased	HTT	Huntingtin	P42858	3064	4p16.3	347.60	human	486083	S1874-p		KLLSPQMsGEEEDSD	32668197	1	36	3		
Huntington's disease	increased	HTT	Huntingtin	P42858	3064	4p16.3	347.60	human	465621	S1179-p		LTNPPSLsPIRRKGK	32668197	4	9	20		
Huntington's disease	decreased	HTT	Huntingtin	P42858	3064	4p16.3	347.60	human	10206805	S13-p		KLMKAFEsLKSFQQQ	32757223	18	3	0		
multiple sclerosis; Status epilepticus	increased	CREB1	CREB iso1	P16220-1	1385	2q33.3	36.69	human	448228	S133-p	pKID	EILSRRPsYRKILND	33661276	289	4	61	14001; 54960; 9187; 80120; 95995; 14228; 44864; 39561; 9196; 9198; 4095	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447928	S202-p		SGYSSPGsPGTPGSR	33730588	149	55	116	30505; 39357	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	33730588	170	45	90	9632	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449082	S404-p		PVVSGDTsPRHLSNV	33730588	132	53	69	20194; 35834; 98523; 49562; 91600	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449082	S404-p		PVVSGDTsPRHLSNV	33649324	132	53	69	20194; 35834; 98523; 49562; 91600	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449083	S422-p		GSIDMVDsPQLATLA	33649324	38	9	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	33649324	170	45	90	9632	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447933	T205-p		SSPGSPGtPGSRSRT	33649324	113	24	26	30505; 43964; 49561; 20060; 53001; 20739	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	33649324	130	44	14	20473; 71429	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447928	S202-p		SGYSSPGsPGTPGSR	33649324	149	55	116	30505; 39357	
pancreatic ductal adenocarcinoma	increased	Ulk1	ULK1	O70405	22241	5|5 F	112.46	mouse	23070960	S405-p		HGRTPSPsPTCSSSP	33654220	1	0	1		
pancreatic ductal adenocarcinoma	increased	Ulk1	ULK1	O70405	22241	5|5 F	112.46	mouse	4958506	S415-p		CSSSPSPsGRPGPFS	33654220	1	1	2		
prostate cancer	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	458927	K685-ac		PKEEAFGkYCRPESQ	28489571	25	1	0	2523	increase associated with overexpression in patients with lower Gleason scores
ovarian cancer	decreased	H4C1	H4	P62805	8359	6p22.2	11.24	human	458960	K16-ac		GLGKGGAkRHRKVLR	28866885	103	26	531	13534; 26437; 56999; 98789	HRD ovarian cancer
ovarian cancer	decreased	H4C1	H4	P62805	8359	6p22.2	11.24	human	459013	K12-ac		KGGKGLGkGGAKRHR	28866885	89	25	531	2591; 13944	HRD ovarian cancer
	increased	HOXA10	HOXA10	P31260	3206	7p15.2	42.41	human	1873286912	K164-sm		CSFAQNIkEESSYCL	29018572	1	0	0		Condition: recurrent implanation failure
	increased	PDCD4	PDCD4	Q53EL6	27250	10q25.2	51.74	human	1873375608	R110-me		RSRSGKGrGLPKKGG	21700716	1	0	0		coexpression of PRMT5
non-small cell lung cancer	decreased	H4C1	H4	P62805	8359	6p22.2	11.24	human	2344825	K20-m3	CENP-T_C	GGAKRHRkVLRDNIQ	18974389	35	14	0	5737	
non-small cell lung cancer	increased	H4C1	H4	P62805	8359	6p22.2	11.24	human	458959	K8-ac		SGRGKGGkGLGKGGA	18974389	82	21	529	2594	
non-small cell lung cancer	increased	H4C1	H4	P62805	8359	6p22.2	11.24	human	458958	K5-ac		___SGRGkGGKGLGK	18974389	67	22	516	8647; 9672	
non-small cell lung cancer	decreased	H4C1	H4	P62805	8359	6p22.2	11.24	human	459013	K12-ac		KGGKGLGkGGAKRHR	18974389	89	25	531	2591; 13944	
non-small cell lung cancer	decreased	H4C1	H4	P62805	8359	6p22.2	11.24	human	458960	K16-ac		GLGKGGAkRHRKVLR	18974389	103	26	531	13534; 26437; 56999; 98789	
prostate cancer	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	13321500	T6-p	Histone	__ARTKQtARKSTGG	20228790	5	2	0		correlates with high Gleason scores of prostate carcinomas
PAH	increased	Ace2	ACE2	Q8R0I0	70008	X F5|X 76.12 cM	92.37	mouse	1869999601	K788-ub		YDSMDIGkGESNAGF	32755395	1	0	0		pathogenesis of pulmonary hypertension and experimental PH
PAH	decreased	Ace2	ACE2	Q8R0I0	70008	X F5|X 76.12 cM	92.37	mouse	1868162500	S680-p	Collectrin	SDLKPRVsFYFFVTS	32755395	2	0	0		
breast cancer	increased	Ezr	Ezrin	P26040	22350	17|17 A1	69.41	mouse	454875	Y478-p		PPPPPPVyEPVNYHV	22397367	10	4	137		mouse model 
sporadic inclusion-body myositis	decreased	NBR1	NBR1	Q14596	4077	17q21.31	107.41	human	33602700	T586-p		HNTPVDVtPCMSPLP	24879152	1	1	0		
hepatitis	increased	Pparg	PPAR-gamma	P37238	19016	6 E3|6 53.41 cM	57.60	mouse	15175800	S273-p		TGKTTDKsPFVIYDM	30008738	19	2	0		steatohepatitis
acute lymphocytic leukemia	increased	SRSF1	SF2	Q07955	6426	17q22	27.74	human	474154	Y19-p	RRM_1	GNNDCRIyVGNLPPD	30320932	1	2	1		in newly diagnosed samples
glioblastoma multiforme	increased	PFKP	PFKP	Q01813	5214	10p15.2	85.60	human	1426260400	Y64-p	PFK	VYFIYEGyQGMVDGG	29677490	3	1	0		corelates with poor patient prognosis
DCM	increased	Tpm1	TPM1	P58771	22003	9 C|9 36.27 cM	32.68	mouse	451804	S283-p	Tropomyosin	HALNDMTsI______	30567734	11	15	94		
cardiomyopathy	decreased	MYBPC3	MYBPC3	Q14896	4607	11p11.2	140.76	human	27463600	S133-p		ELGESAPsPKGSSSA	23277198	1	2	0		
colorectal carcinoma	increased	HSP90AA1	HSP90A	P07900	3320	14q32.31	84.66	human	31909111	S595-p	HSP90	VSNRLVTsPCCIVTS	24962213	2	3	0		
cardiomyopathy	increased	Ttn	Titin	A2ASS6	22138	2 C3|2 45.13 cM	3906.49	mouse	10029600	S12742-p		KEEVVLKsVLRKKPE	21835910	11	1	0		
Alexander's disease	increased	GFAP	GFAP	P14136	2670	17q21.31	49.88	human	449619	S13-p	Filament_head	ITSAARRsYVSSGEM	31682229	11	5	0		
non-small cell lung adenocarcinoma; non-small cell squamous cell lung carcinoma	increased	Ctnnd1	CTNND1	P30999	12388	2 D|2 49.45 cM	104.92	mouse	450452	S288-p		GLEDDQRsMGYDDLD	21468542	7	35	27		
glioblastoma	increased	HNRNPA1	hnRNP A1	P09651	3178	12q13.13	38.75	human	451555	S199-p		SQRGRSGsGNFGGGR	21454539	5	9	8		
Alzheimer's disease	increased	PIN1	PIN1	Q13526	5300	19p13.2	18.24	human	447772	S16-p	WW	PGWEKRMsRSSGRVY	22926167	12	2	0		
prostate cancer	increased	TNIK	TNIK	Q9UKE5	23043	3q26.2-q26.31	154.94	human	451976	S764-p		RTRVRANsKSEGSPV	30901730	2	23	23		
gastric cancer; pancreatic cancer	increased	KRT8	K8	P05787	3856	12q13.13	53.70	human	448540	S432-p		SAYGGLTsPGLSYSL	22344252	27	8	23		
cardiomyopathy	increased	Hspb6	HSP20	Q5EBG6	243912	7|7 B1	17.52	mouse	450706	S16-p	Crystallin	PSWLRRAsAPLPGFS	31061921	21	31	2		
cardiomyopathy	decreased	Ttn	Titin	A2ASS6	22138	2 C3|2 45.13 cM	3906.49	mouse	4693667	S12884-p		RKKLRPGsGGEKPPD	21835910	8	7	0		
breast adenocarcinoma	increased	Cdkn1b	p27Kip1	P46414	12576	6 G1|6 65.77 cM	22.19	mouse	23128659	T183-p		DGSPNAGtVEQTPKK	23602409	1	1	1		
colorectal cancer	increased	BCKDK	BCKDK	O14874	10295	16p11.2	46.36	human	1868515109	Y246-p		RRLCEHKyGNAPRVR	32238881	1	0	0		
primary biliary cirrhosis 	decreased	NR1H4	NR1H4	Q96RI1	9971	12q23.1	55.91	human	1186568001	Y77-p		QISSSSYySNLGFYP	29968724	2	1	0		
ovarian cancer	increased	SNAI1	Snail1	O95863	6615	20q13.13	29.08	human	455882	S107-p		SQPPSPPsPAPSSFS	31209060	6	1	0		
breast cancer	decreased	DNPEP	DNPEP iso2	Q9ULA0-2	23549	2q35	52.43	human	34733463	S109-p	Peptidase_M18	VKRRSRRsQVGFQQV	31219614	1	1	8		
colorectal carcinoma	increased	PRPS1	PRPS1	P60891	5631	Xq22.3	34.83	human	56655989	S103-p	Pribosyltran_N	RQDKKDKsRAPISAK	31253668	1	2	0		
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448805	S305-p		IKRSKKNsLALSLTA	24449872	16	0	0		
breast cancer	decreased	STMN1	STMN1	P16949	3925	1p36.11	17.30	human	448554	S16-p	Stathmin	KELEKRAsGQAFELI	21768358	38	98	61	3353	
lung cancer	increased	EP300	p300	Q09472	2033	22q13.2	264.16	human	31828207	S2039-p	Creb_binding	GLGQVGIsPLKPGTV	24530506	1	0	0		
lung cancer	increased	EP300	p300	Q09472	2033	22q13.2	264.16	human	10941006	S1038-p		STSATQSsPAPGQSK	24530506	1	27	0		
obesity, hyperphagic	increased	Slc12a1	NKCC2	P55014	20495	2 F1|2 61.23 cM	120.36	mouse	478420	S126-p	AA_permease_N	GPKVNRPsLLEIHEQ	24808538	8	2	0		S126 phosphorylation leads to enhanced sodium reabsorption in obesity
hepatocellular carcinoma	decreased	BSG	BSG iso2	P35613-2	682	19p13.3	29.22	human	476131	S252-p		GSAPLKSsGQHQNDK	31016558	2	11	0		HCC metastasis, poor prognosis
hepatocellular carcinoma	decreased	BSG	BSG iso2	P35613-2	682	19p13.3	29.22	human	471136	S246-p		LDDDDAGsAPLKSSG	31016558	1	36	0		HCC metastasis, poor prognosis
Status epilepticus	increased	Glul	GLUL	P15105	14645	1|1 G3	42.12	mouse	15501403	T301-p		LDNARRLtGFHETSN	31178690	1	3	2		
Alzheimer's disease	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084601	S410-p		SSMDSKSsGWGM___	32349792	49	4	0		
Alzheimer's disease	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084616	S409-p		GSSMDSKsSGWGM__	32349792	48	4	0		
Status epilepticus	increased	Kcnq2	Kv7.2 iso12	Q9Z351-12	16536	2 H4|2 103.57 cM	95.72	mouse	11082901	S559-p	KCNQ_channel	SKRKFKEsLRPYDVM	30146722	3	0	0		S559A knock-in mice have milder seizures in kainate- and pilocarpine- induced seizure models
liver cancer	decreased	Ncoa3	SRC-3	O09000	17979	2|2 H3	151.57	mouse	454109	S498-p	NCOA_u2	SPAAGAHsPMGPSGN	20534466	7	0	0		
liver cancer	decreased	Ncoa3	SRC-3	O09000	17979	2|2 H3	151.57	mouse	454108	S536-p	NCOA_u2	SLLSTLSsPGPKLDN	20534466	7	0	0		
liver cancer	decreased	Ncoa3	SRC-3	O09000	17979	2|2 H3	151.57	mouse	454106	S850-p		NRAVSLDsPVSVGSG	20534466	7	16	0		
liver cancer	decreased	Ncoa3	SRC-3	O09000	17979	2|2 H3	151.57	mouse	453084	S847-p		PPYNRAVsLDSPVSV	20534466	11	48	5		
acute myelogenous leukemia	increased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447542	T202-p	Pkinase	HDHTGFLtEYVATRW	26073130	1283	106	2017	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 54240; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
acute myelogenous leukemia	increased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447543	Y204-p	Pkinase	HTGFLTEyVATRWYR	26073130	1304	138	3549	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 14474; 54240; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
hepatocellular carcinoma	decreased	MAT2A	MAT2A	P31153	4144	2p11.2	43.66	human	11319857	K81-ac	S-AdoMet_synt_N	RAAVDYQkVVREAVK	25925782	1	2	0		
neuroendocrine cancer	increased	SSTR2	SSTR2	P30874	6752	17q25.1	41.33	human	7652103	S341-p		GTDDGERsDSKQDKS	22538189	10	0	0		
neuroendocrine cancer	increased	SSTR2	SSTR2	P30874	6752	17q25.1	41.33	human	7652105	S343-p		DDGERSDsKQDKSRL	22538189	10	0	0		
glioma	increased	MAPK7	ERK5	Q13164	5598	17p11.2	88.39	human	455520	T733-p		LPPVFSGtPKGSGAG	31201162	7	13	1		
Huntington's disease	decreased	UBTF	UBF	P17480	7343	17q21.31	89.41	human	25344501	K352-ac	HMG_box_2	KKCDQKKkDYEVELL	21546905	1	1	0		represses rDNA transcription
glioma	increased	MAPK7	ERK5	Q13164	5598	17p11.2	88.39	human	455519	S731-p		DPLPPVFsGTPKGSG	31201162	5	11	0		
acute myelogenous leukemia	decreased	G6PD	G6PD	P11413	2539	Xq28	59.26	human	11320991	K403-ac	G6PD_C	PNEAVYTkMMTKKPG	27586085	2	2	3		
type 2 diabetes; hypertrophic cardiomyopathy	decreased	Tp53	p53	P10361	24842	10q24	43.45	rat	458980	K371-ac		SSYPKTKkGQSTSRH	18192848	91	4	0		
type 2 diabetes; hypertrophic cardiomyopathy	decreased	Tp53	p53	P10361	24842	10q24	43.45	rat	458977	K380-ac		QSTSRHKkPMIKKVG	18192848	205	8	0	2570; 2525	
impaired spermatogenesis	decreased	H4C1	H4	P62805	8359	6p22.2	11.24	human	459013	K12-ac		KGGKGLGkGGAKRHR	18001726	89	25	531	2591; 13944	may contribute to lower sperm production in mixed atrophy
Parkinson's disease	increased	DNM1L	DRP1	O00429	10059	12p11.21	81.88	human	454690	S616-p		PIPIMPAsPQKGHAV	31308800	98	78	114	4494; 3455	
clear cell kidney cancer	decreased	H4C1	H4	P62805	8359	6p22.2	11.24	human	458960	K16-ac		GLGKGGAkRHRKVLR	23394073	103	26	531	13534; 26437; 56999; 98789	
cardiomyopathy	increased	Ppara	PPAR-alpha	P23204	19013	15 E2|15 40.42 cM	52.35	mouse	1867858200	S280-p	Hormone_recep	FHCCQCMsVETVTEL	30745182	1	1	0		lipotoxic cardiomyopathy
breast cancer	increased	ANXA2	ANXA2	P07355	302	15q22.2	38.60	human	449483	Y24-p		HSTPPSAyGSVKAYT	31113450	29	64	2613		multidrug-resistant breast cancer
colorectal cancer	increased	PRMT5	PRMT5	O14744	10419	14q11.2	72.68	human	1868989002	S15-p		GAGGSRVsSGRDLNC	32456215	1	0	0		
SLE	increased	H4C1	H4	P62805	8359	6p22.2	11.24	human	458958	K5-ac		___SGRGkGGKGLGK	25611806	67	22	516	8647; 9672	
SLE	increased	H4C1	H4	P62805	8359	6p22.2	11.24	human	459013	K12-ac		KGGKGLGkGGAKRHR	25611806	89	25	531	2591; 13944	
SLE	increased	H4C1	H4	P62805	8359	6p22.2	11.24	human	458959	K8-ac		SGRGKGGkGLGKGGA	25611806	82	21	529	2594	
SLE	increased	H4C1	H4	P62805	8359	6p22.2	11.24	human	458960	K16-ac		GLGKGGAkRHRKVLR	25611806	103	26	531	13534; 26437; 56999; 98789	
rheumatoid arthritis	increased	Rela	NFkB-p65	Q04207	19697	19 A|19 4.34 cM	60.21	mouse	459096	K310-ac		KRTYETFkSIMKKSP	24211200	78	5	0	3045; 12629	collagen-induced arthritis (CIA) mouse model for RA
glioblastoma multiforme	increased	TWIST1	TWIST1	Q15672	7291	7p21.1	20.95	human	18905000	S68-p		GGGDEPGsPAQGKRG	31540485	5	13	0		
breast cancer	increased	Twist1	TWIST1	P26687	22160	12 A3|12 14.81 cM	21.20	mouse	14821304	S42-p		GARKRRSsRRSAGGS	32922123	5	1	0		induces metastatic phenotype
breast cancer	increased	Twist1	TWIST1	P26687	22160	12 A3|12 14.81 cM	21.20	mouse	38546302	T125-p	HLH	NVRERQRtQSLNEAF	32922123	4	0	0		induces metastatic phenotype
Alzheimer's disease; Down syndrome	increased	App	APP	P12023	11820	16 C3.3|16 46.92 cM	86.72	mouse	480465	S679-p	Beta-APP	DAEFGHDsGFEVRHQ	32727580	10	1	0		
Alzheimer's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	447929	S506-p		GSRSRTPsLPTPPTR	32660121	60	23	42	77348	
Alzheimer's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	447934	T504-p		TPGSRSRtPSLPTPP	32660121	45	16	5		
diabetes mellitus	decreased	Nos3	eNOS	P70313	18127	5 A3|5 11.32 cM	132.92	mouse	456466	Y80-p		WEVGSITyDTLSAQA	32653904	5	2	0		
breast cancer; lung cancer; endometrial cancer; ovarian cancer; clear cell kidney cancer	increased	SND1	SND1	Q7KZF4	27044	7q32.1	102.00	human	3203808	S426-p	SNase	VDYIRPAsPATETVP	32645525	2	39	10		
depression	increased	Htt	Huntingtin	P42859	15194	5 B2|5 17.92 cM	344.69	mouse	465621	S1159-p		LTNPPSLsPIRRKGK	32640230	4	9	20		
depression	increased	Htt	Huntingtin	P42859	15194	5 B2|5 17.92 cM	344.69	mouse	465620	S1179-p		EQASTPMsPKKVGEA	32640230	4	29	2		
Parkinson's disease	increased	RAB10	RAB10	P61026	10890	2p23.3	22.54	human	471953	T73-p	Ras	AGQERFHtITTSYYR	32601174	11	13	13		
Parkinson's disease	increased	LRRK2	LRRK2	Q5S007	120892	12q12	286.10	human	4725898	S935-p		NLQRHSNsLGPIFDH	32601174	38	17	2	59576	
cardiomyopathy	decreased	LMNA	lamin A/C	P02545	4000	1q22	74.14	human	8545502	K201-sm	Filament	ENRLQTMkEELDFQK	18606848	1	0	0		
papillary thyroid carcinoma	decreased	PDGFC	PDGFC	Q9NRA1	56034	4q32.1	39.03	human	3875800	K314-sm	PDGF	EVLQLRPkTGVRGLH	16443219	1	0	0		
CMC	mutation of site	STAT1	STAT1	P42224	6772	2q32.2	87.33	human	1870810800	T387-p	STAT_bind	FNILGTHtKVMNMEE	33096415	1	0	0		gain of function in T387A mutant
acute myelogenous leukemia	mutation of site	RUNX1	AML1	Q01196	861	21q22.12	48.74	human	41481876	K83-ub	Runt	PTHWRCNkTLPIAFK	11830488	2	3	0		second mutation has to occur, either in AML1 or another gene, to cause leukemia
leukemia	increased	H3c1	H3	P68433	360198	13|13 A3.1	15.27	mouse	1458615	K79-m2	Histone	REIAQDFkTDLRFQS	23361907	36	20	10	5427	MLL-AF6 positive leukemia
acute myelogenous leukemia; SCN	deletion of site	Csf3r	GCSFR	P40223	12986	4 D2.2|4 59.77 cM	93.38	mouse	4664705	K786-ub		GGPTPSPkSYENIWF	18923646	2	0	0		
Fanconi's anaemia	deletion of site	FANCI	FANCI	Q9NVI1	55215	15q26.1	149.32	human	486579	K523-ub	FANCI_S2	CLILVLRkAMFANQL	17460694	7	10	93		devoid of ubiquitination, ballelic mutations
hypertrophic cardiomyopathy	decreased	Mybpc3	MYBPC3	O70468	17868	2|2 E1	140.63	mouse	471080	S282-p		AGAGRRTsDSHEDAG	33705529	35	8	28		
breast cancer	increased	PCGF2	PCGF2	P35227	7703	17q12	37.79	human	34606690	T334-p		TSRGRKMtVNGAPVP	33664452	1	1	1		correlates with poor survival and distant metastasis-free survival
breast cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	33664452	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	correlates with poor survival and distant metastasis-free survival
leukemia	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	1458615	K79-m2	Histone	REIAQDFkTDLRFQS	23361907	36	20	10	5427	MLL-AF6 positive leukemia
diabetes mellitus	decreased	Prkaa1	AMPKA1	Q5EG47	105787	15|15 A1	63.93	mouse	15407586	S172-p	Pkinase	KIADFGLsNMMSDGE	33400924	7	1	4		
glioblastoma	decreased	Ptpn11	SHP-2	P35235	19247	5|5 F	68.03	mouse	448492	Y542-p		SKRKGHEyTNIKYSL	33574084	36	25	442	15543; 3751	higher level of phosphorylation of this site (after for example TMZ tratment) increases survival rate of GBM patients
breast cancer	decreased	H3C1	H3	P68431	8350	6p22.2	15.27	human	1458621	K4-m3	Histone	____ARTkQTARKST	19943104	161	7	0	9751; 9727; 12064; 11960; 62255	
ovarian cancer	increased	ETS1	Ets-1	P14921	2113	11q24.3	50.41	human	31087093	T265-p	Ets1_N_flank	YDSCDRLtQSWSSQS	34023818	1	2	0		
glioma	increased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447542	T202-p	Pkinase	HDHTGFLtEYVATRW	33820494	1283	106	2017	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 54240; 14474; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
glioma	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	33820494	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
glioma	increased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447543	Y204-p	Pkinase	HTGFLTEyVATRWYR	33820494	1304	138	3549	13214; 8544; 14227; 5726; 3510; 9106; 98168; 4377; 9488; 75165; 13148; 33370; 9524; 4375; 14095; 55088; 4376; 14474; 54240; 48735; 45899; 9101; 4374; 4370; 14196; 15892	
pancreatic ductal adenocarcinoma	decreased	MDH1	MDH1	P11708	396894		36.45	pig	29429248	R230-m1	Ldh_1_C	FITTVQQrGAAVIKA	27840030	1	2	2		
OSCC	increased	BIRC5	Survivin	O15392	332	17q25.3	16.39	human	25558401	K129-ac		KEFEETAkKVRRAIE	28384094	2	1	0		nuclear localization, nuclear survivin associates with TNM stage and tumor grade of OSCC
ovarian cancer	increased	ETS1	Ets-1	P14921	2113	11q24.3	50.41	human	1873117008	S269-p	Ets1_N_flank	DRLTQSWsSQSSFNS	34023818	1	1	0		
Merkel cell carcinoma	decreased	ALK	ALK	Q9UM73	238	2p23.2-p23.1	176.44	human	447828	Y1604-p		TAPGAGHyEDTILKS	34029351	11	5	53	3341	corelates with better survival and absence of metastasis
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	1873286918	K303-ub		LMIKRSKkNSLALSL	29100376	1	0	0		ER-alpha positive breast cancer
clear cell kidney cancer	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	1458610	K36-m2	Histone	APATGGVkKPHRYRP	28754676	42	18	7	15090; 26917; 2901; 15091	associated with poor outcome
mastocytoma	decreased	H3C1	H3	P68431	8350	6p22.2	15.27	human	1458608	K36-m3	Histone	APATGGVkKPHRYRP	28663576	59	10	4	46287; 4909; 9763	mast cell leukemia
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	2134725	K302-ub		PLMIKRSkKNSLALS	29100376	3	1	0		ER-alpha positive breast cancer
astrocytoma	increased	PGR	PR	P06401	5241	11q22.1	98.98	human	449842	S400-p	Prog_receptor	GAEASARsPRSYLVA	34168461	8	3	0		
FXS	decreased	H4C1	H4	P62805	8359	6p22.2	11.24	human	458960	K16-ac		GLGKGGAkRHRKVLR	18628788	103	26	531	13534; 26437; 56999; 98789	two rare males with an unmethylated full mutation, compared to previous FXS families, pattern of K4 and K27 on histone H3 similar to that of normal controls, while histone H3/H4 acetylation and K9 methylation on  H3 are other similar  FXS cell lines
FXS	decreased	H4C1	H4	P62805	8359	6p22.2	11.24	human	459013	K12-ac		KGGKGLGkGGAKRHR	18628788	89	25	531	2591; 13944	two rare males with an unmethylated full mutation, compared to previous FXS families, pattern of K4 and K27 on histone H3 similar to that of normal controls, while histone H3/H4 acetylation and K9 methylation on  H3 are other similar  FXS cell lines
FXS	decreased	H4C1	H4	P62805	8359	6p22.2	11.24	human	458959	K8-ac		SGRGKGGkGLGKGGA	18628788	82	21	529	2594	two rare males with an unmethylated full mutation, compared to previous FXS families, pattern of K4 and K27 on histone H3 similar to that of normal controls, while histone H3/H4 acetylation and K9 methylation on  H3 are other similar  FXS cell lines
FXS	decreased	H4C1	H4	P62805	8359	6p22.2	11.24	human	458958	K5-ac		___SGRGkGGKGLGK	18628788	67	22	516	8647; 9672	two rare males with an unmethylated full mutation, compared to previous FXS families, pattern of K4 and K27 on histone H3 similar to that of normal controls, while histone H3/H4 acetylation and K9 methylation on  H3 are other similar  FXS cell lines
type 2 diabetes	decreased	Igf1r	IGF1R	P24062	25718	1q22	155.40	rat	448387	Y1166-p	PK_Tyr_Ser-Thr	RDIYETDyYRKGGKG	34057658	19	38	707	2969; 3024; 3918	
FXS	decreased	H3C1	H3	P68431	8350	6p22.2	15.27	human	1668802	K4-me	Histone	____ARTkQTARKST	18628788	28	1	0		two rare males with an unmethylated full mutation, compared to previous FXS families, pattern of K4 and K27 on histone H3 similar to that of normal controls, while histone H3/H4 acetylation and K9 methylation on  H3 are other similar  FXS cell lines
FXS	increased	H3C1	H3	P68431	8350	6p22.2	15.27	human	459006	K9-m2	Histone	RTKQTARkSTGGKAP	18628788	113	20	0	5327; 66070; 4658; 4473; 6951; 51198; 31064; 9753	
type 2 diabetes	decreased	Akt1	Akt1	P47196	24185	6q32	55.74	rat	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	34057658	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
type 2 diabetes	decreased	Igf1r	IGF1R	P24062	25718	1q22	155.40	rat	448388	Y1167-p	PK_Tyr_Ser-Thr	DIYETDYyRKGGKGL	34057658	16	15	107	2969; 3024; 3918	
type 2 diabetes	decreased	Foxo1	FOXO1A	G3V7R4	84482	2q26	69.34	rat	448075	S250-p		SPRRRAAsMDNNSKF	34057658	90	8	48	84192; 9461	
breast cancer	increased	MTOR	mTOR	P42345	2475	1p36.22	288.89	human	447498	S2481-p		TVPESIHsFIGDGLV	27721400	64	29	1	2974	
hypertrophic cardiomyopathy	decreased	Tcap	Telethonin	O70548	21393	11|11 D	19.08	mouse	3893741	S161-p	Telethonin	RTLSRSMsQEAQRG_	34566695	3	8	3		
acute myelogenous leukemia	mutation of site	DNMT3A	DNMT3A	Q9Y6K1	1788	2p23.3	101.86	human	1877292601	R882-me		TDVSNMSrLARQRLL	32673568	4	0	0		DNMT3A ablation in HSCs, and in leukemia samples
acute myelogenous leukemia	mutation of site	DNMT3A	DNMT3A	Q9Y6K1	1788	2p23.3	101.86	human	1877292602	R771-me	DNA_methylase	SDKRDISrFLESNPV	32673568	2	0	0		DNMT3A ablation in HSCs, and in leukemia samples
breast cancer	increased	SOD2	SOD2	P04179	6648	6q25.3	24.75	human	461133	K68-ac	Sod_Fe_N	NLNVTEEkYQEALAK	31591207	18	13	8		progression of breast cancer leading to poor outcomes
ALD	decreased	CYP2E1	CYP2E1	P05181	1571	10q26.3	56.85	human	1878196104	R379-me		ATRDTIFrGYLIPKG	31077594	1	1	0		methylated CYP2E1 is reduced in human ALD
endometrial cancer	increased	FUBP1	FBP1	Q96AE4	8880	1p31.1	67.56	human	452895	S630-p		AAYYAQTsPQGMPQH	35274005	1	25	26		
ovarian cancer	increased	FUBP1	FBP1	Q96AE4	8880	1p31.1	67.56	human	452895	S630-p		AAYYAQTsPQGMPQH	35274005	1	25	26		
ovarian cancer	increased	FUBP1	FBP1	Q96AE4	8880	1p31.1	67.56	human	4768043	S99-p		MHQQQSRsVMTEEYK	35274005	1	7	0		
breast cancer	increased	Snai1	Snail1	Q02085	20613	2 H3|2 87.33 cM	29.19	mouse	1876128600	S165-p	zf-C2H2_6	YCNKEYLsLGALKMH	35066576	1	1	0		
Huntington's disease	mutation of site	Htt	Huntingtin	P42859	15194	5 B2|5 17.92 cM	344.69	mouse	1879784803	K69-sm		EPLHRPKkELSATKK	31076452	1	0	0		K to R mutations
Huntington's disease	mutation of site	Htt	Huntingtin	P42859	15194	5 B2|5 17.92 cM	344.69	mouse	8545503	K9-sm		ATLEKLMkAFESLKS	31076452	2	0	0		K to R mutations
Huntington's disease	mutation of site	Htt	Huntingtin	P42859	15194	5 B2|5 17.92 cM	344.69	mouse	8545505	K15-sm		MKAFESLkSFQQQQQ	31076452	2	0	0		K to R mutations
Huntington's disease	mutation of site	Htt	Huntingtin	P42859	15194	5 B2|5 17.92 cM	344.69	mouse	8545504	K6-sm		__MATLEkLMKAFES	31076452	2	0	0		K to R mutations
glioblastoma multiforme	increased	Ulk1	ULK1	O70405	22241	5|5 F	112.46	mouse	1876620100	R170-me	Pkinase	IADFGFArYLQSNMM	35246531	1	1	0		corelates with poor survival
breast cancer	increased	MORC2	MORC2	Q9Y6X9	22880	22q12.2	117.82	human	1879871300	T556-gl		TFRKDMKtQEEKQKQ	34974534	1	0	0		high expression of MORC2, OGT, and SNAIL/CTGF in breast tumors is associated with poor patient prognosis
esophageal cancer; gastric cancer	increased	ATF1	ATF-1	P18846	466	12q13.12	29.23	human	31858260	T184-p		QTYQIRTtPSATSLP	35397606	2	0	0		
leukemia	mutation of site	DNMT3A	DNMT3A	Q9Y6K1	1788	2p23.3	101.86	human	1877292601	R882-me		TDVSNMSrLARQRLL	31582562	4	0	0		loss of DNMT3A activity
CRPC	increased	MED1	MED1	Q15648	5469	17q12	168.48	human	458308	T1032-p		SSSNRPFtPPTSTGG	35394046	4	8	2		
NAFLD	decreased	HADHA	HADHA	P40939	3030	2p23.3	83.00	human	56842400	K383-ac	3HCDH_N	IAQVSVDkGLKTILK	27457618	2	0	0		
NAFLD	decreased	HADHA	HADHA	P40939	3030	2p23.3	83.00	human	466489	K350-ac		YHGQVLCkKNKFGAP	27457618	2	7	33		
NAFLD	decreased	HADHA	HADHA	P40939	3030	2p23.3	83.00	human	461764	K406-ac	3HCDH_N	RGQQQVFkGLNDKVK	27457618	2	9	23		
liver steatosis, fatty liver	decreased	HADHA	HADHA	P40939	3030	2p23.3	83.00	human	461764	K406-ac	3HCDH_N	RGQQQVFkGLNDKVK	27457618	2	9	23		acetylation of MTPa ameliorates hepatic steatosis in mice challenged by a high-fat/high-sucrose (HF/HS) diet 
liver steatosis, fatty liver	decreased	HADHA	HADHA	P40939	3030	2p23.3	83.00	human	56842400	K383-ac	3HCDH_N	IAQVSVDkGLKTILK	27457618	2	0	0		acetylation of MTPa ameliorates hepatic steatosis in mice challenged by a high-fat/high-sucrose (HF/HS) diet 
liver steatosis, fatty liver	decreased	HADHA	HADHA	P40939	3030	2p23.3	83.00	human	466489	K350-ac		YHGQVLCkKNKFGAP	27457618	2	7	33		acetylation of MTPa ameliorates hepatic steatosis in mice challenged by a high-fat/high-sucrose (HF/HS) diet 
non-small cell lung cancer; non-small cell squamous cell lung carcinoma; non-small cell lung adenocarcinoma, surrounding tissue	increased	CHKA	CHKA	P35790	1119	11q13.2	52.25	human	1876872804	S279-p	Choline_kinase	KKLHKLLsYNLPLEL	35463311	1	0	0		
non-small cell lung cancer; non-small cell squamous cell lung carcinoma; non-small cell lung adenocarcinoma, surrounding tissue	increased	ACACA	ACC1	Q13085	31	17q12	265.55	human	448292	S80-p		LHIRSSMsGLHLVKQ	35463311	149	76	11	3661; 11818; 42801	
non-small cell lung cancer	increased	RPS6	S6	P62753	6194	9p22.1	28.68	human	448093	S236-p		AKRRRLSsLRASTSK	35596155	219	72	1124	4851; 14733; 3985; 34411; 27036; 4803; 3945; 62788; 5316; 9865; 8520; 97935; 2211; 4856; 62016; 4857; 4854; 5006; 4858; 81736	
non-small cell lung cancer	increased	RPS6	S6	P62753	6194	9p22.1	28.68	human	448092	S235-p		IAKRRRLsSLRASTS	35596155	225	60	972	4851; 14733; 3985; 34411; 27036; 4803; 3945; 62788; 5316; 9865; 8520; 97935; 2211; 4856; 62016; 4857; 4854; 5006; 4858; 81736	
clear cell kidney cancer	increased	SHC1	SHC1	P29353	6464	1q21.3	62.82	human	448791	S139-p		EEWTRHGsFVNKPTR	35601500	4	35	16		
colorectal cancer; endometrial cancer	decreased	SHC1	SHC1	P29353	6464	1q21.3	62.82	human	448791	S139-p		EEWTRHGsFVNKPTR	35601500	4	35	16		
CCA	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447857	T450-p	Pkinase_C	TAQMITItPPDQDDS	35625759	29	5	1	12178; 9267	
Parkinson's disease	increased	RAB10	RAB10	P61026	10890	2p23.3	22.54	human	471953	T73-p	Ras	AGQERFHtITTSYYR	35675433	11	13	13		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	35768637	85	33	23	62672; 66224; 12885	corelates with cognitive decline and dementia
leukemia	increased	RUNX1/RUNX1T1 fusion	AML1-ETO	A0A7S8LV65			6.42	human	1880752700	K58-m1		AGAALAGkLRSGDRS	31699991	1	1	0		
diabetes mellitus	decreased	Crtc2	TORC2	Q3LRZ1	310615	2q34	73.15	rat	454622	S171-p	TORC_M	SALNRTSsDSALHTS	32020874	19	10	12		
diabetes mellitus	decreased	Sik1	SIK	Q9R1U5	59329	20p12	84.91	rat	456034	T182-p	Pkinase	KPGEPLStWCGSPPY	32020874	7	0	0		
diabetes mellitus	increased	Sik1	SIK	Q9R1U5	59329	20p12	84.91	rat	465992	S577-p		FQEGRRAsDTSLTQG	32020874	10	21	4		
ALS	increased	FUS	hnRNP P2	P35637	2521	16p11.2	53.43	human	36293641	K510-ac		RGGFGPGkMDSRGEH	32691043	1	2	2		
breast cancer, triple negative	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	35091679	468	74	3065	4324; 8119; 9145; 4113; 52075; 73533; 9138; 4323; 4093; 4074; 52527; 74309; 16185; 61958; 9131; 73452	corelates with poor prognosis
ovarian cancer	increased	SPDL1	CCDC99	Q96EA4	54908	5q35.1	70.17	human	4770009	S555-p		RSGNTPNsPRLAAES	35093072	1	13	5		
lung cancer; pancreatic cancer; liver cancer	increased	TERT	TERT	O14746	7015	5p15.33	127.00	human	1868023600	T249-p		AAPEPERtPVGQGSW	35094384	2	1	0		
glioblastoma multiforme	increased	ACSS2	ACSS2	Q9NR19	55902	20q11.22	78.58	human	460828	S267-p	AMP-binding	MGDSTSQsPPIKRSC	35190642	1	37	1		
Parkinson's disease	increased	Snca	SNCA	O55042	20617	6 B3|6 29.15 cM	14.49	mouse	448278	S129-p	Synuclein	SEAYEMPsEEGYQDY	35250825	104	7	0	87281; 23706	
endometrial cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	35253622	732	14	18	5106; 48646; 13842; 4056; 2965; 43506; 77440; 9275; 13038; 86758; 80722; 5056	
endometrial cancer	increased	MTOR	mTOR	P42345	2475	1p36.22	288.89	human	447578	S2448-p		RSRTRTDsYSAGQSV	35253622	187	17	106	2971; 5536; 54932; 2976	
ovarian cancer	increased	MYLK	smMLCK	Q15746	4638	3q21.1	210.72	human	468783	S343-p	23ISL	PVLQKTSsSITLQAA	35278271	1	10	1		
cardiomyopathy		Mybpc3	MYBPC3	P56741	295929	3q24	140.76	rat	471079	S279-p		RSAFRRTsLAGTGRR	35288601	25	9	14		
cardiomyopathy		Mybpc3	MYBPC3	P56741	295929	3q24	140.76	rat	471080	S288-p		AGTGRRTsDSHEDAG	35288601	35	8	28		
DCM	increased	Mybpc3	MYBPC3	P56741	295929	3q24	140.76	rat	471080	S288-p		AGTGRRTsDSHEDAG	35288601	35	8	28		
acute lymphocytic leukemia	increased	FLT3	FLT3	P36888	2322	13q12.2	112.90	human	1879733100	R972-m2		CPHTYQNrRPFSREM	31395602	2	2	0		MLL-rearranged acute lymphoblastic leukemia
acute lymphocytic leukemia	increased	FLT3	FLT3	P36888	2322	13q12.2	112.90	human	1879733101	R973-m2		PHTYQNRrPFSREMD	31395602	2	2	0		MLL-rearranged acute lymphoblastic leukemia
diabetes mellitus; cardiomyopathy	decreased	Yap1	YAP1	P46938	22601	9|9 A1	52.38	mouse	448847	S112-p		PQHVRAHsSPASLQL	35358489	171	32	180	4911; 57706; 13008; 92367	
NAFLD	increased	ACLY	ACLY	P53396	47	17q21.2	120.84	human	31068004	K540-ac	CoA_binding	FTGDHKQkFYWGHKE	31197036	2	1	7		SIRT2 protein level is decreased
NAFLD	increased	ACLY	ACLY	P53396	47	17q21.2	120.84	human	11323411	K546-ac	CoA_binding	QKFYWGHkEILIPVF	31197036	2	3	0		SIRT2 protein level is decreased
diabetes mellitus; cardiomyopathy	increased	Gsk3b	GSK3B	Q9WV60	56637	16|16 B3	46.71	mouse	449111	S9-p		SGRPRTTsFAESCKP	35358489	513	44	227	5558; 14630; 14026; 14332; 79774; 9322; 9327; 9331; 9323; 9336; 9325; 8466; 8566; 14310	
diabetes mellitus; cardiomyopathy	increased	Akt1	Akt1	P31750	11651	12 F1|12 61.2 cM	55.71	mouse	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	35358489	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
Alexander's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447933	T205-p		SSPGSPGtPGSRSRT	35358703	113	24	26	30505; 43964; 49561; 20060; 53001; 20739	associates with decline in white matter
NAFLD	increased	ACLY	ACLY	P53396	47	17q21.2	120.84	human	4131806	K554-ac	CoA_binding	EILIPVFkNMADAMR	31197036	2	5	1		SIRT2 protein level is decreased
liver steatosis, fatty liver	increased	ACLY	ACLY	P53396	47	17q21.2	120.84	human	31068004	K540-ac	CoA_binding	FTGDHKQkFYWGHKE	31197036	2	1	7		mice challenged by HF/HS diet
liver steatosis, fatty liver	increased	ACLY	ACLY	P53396	47	17q21.2	120.84	human	4131806	K554-ac	CoA_binding	EILIPVFkNMADAMR	31197036	2	5	1		mice challenged by HF/HS diet
liver steatosis, fatty liver	increased	ACLY	ACLY	P53396	47	17q21.2	120.84	human	11323411	K546-ac	CoA_binding	QKFYWGHkEILIPVF	31197036	2	3	0		mice challenged by HF/HS diet
ovarian cancer	increased	ITPKB	ITPKB	P27987	3707	1q42.12	102.38	human	3189511	S174-p		PRLGRARsPSPCPFR	35039634	1	26	8		corelates with cisplatin resistance
NAFLD	increased	Xbp1	XBP1 iso2	O35426-2	22433		39.89	mouse	1879877100	K257-ac		RFDHVYTkPLVLEIP	31541078	1	1	0		 increases in acetylation contribute to the disease progression of NAFLD in patients
NAFLD	increased	Xbp1	XBP1 iso2	O35426-2	22433		39.89	mouse	1879877103	K297-ac		PEFIVSVkKEPLEDD	31541078	1	1	0		 increases in acetylation contribute to the disease progression of NAFLD in patients
glioma	mutation of site	H3C1	H3	P68431	8350	6p22.2	15.27	human	1308913	K27-m3	Histone	LATKAARkSAPATGG	31254135	169	21	3	9733; 89120; 4395; 12158; 98316; 5499; 91611; 14034; 10584; 4232; 35861; 20123; 40724; 54575	pediatric midline glioma, both H3F3A K27M and BRAF V600E mutations, pathologically low-grade and likely localized rather than difusely infiltrating, long-term survivor
breast cancer	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	455717	S234-p	Osteopontin	TSQLDDQsAETHSHK	35433956	2	13	5		
breast cancer	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	455745	S219-p	Osteopontin	NAPSDWDsRGKDSYE	35433956	2	14	1		
breast cancer	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	455724	S280-p	Osteopontin	FHSHEFHsHEDMLVV	35433956	1	7	2		
breast cancer	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	455721	S258-p	Osteopontin	NDESNEHsDVIDSQE	35433956	2	8	1		
breast cancer	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	455713	S195-p	Osteopontin	DITSHMEsEELNGAY	35433956	2	11	0		
colorectal carcinoma	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	1825301	S263-p	Osteopontin	EHSDVIDsQELSKVS	35433956	2	11	0		
colorectal carcinoma	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	455706	S63-p	Osteopontin	APQNAVSsEETNDFK	35433956	2	24	0		
colorectal carcinoma	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	455719	S254-p	Osteopontin	KRKANDEsNEHSDVI	35433956	2	21	2		
colorectal carcinoma	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	455721	S258-p	Osteopontin	NDESNEHsDVIDSQE	35433956	2	8	1		
colorectal carcinoma	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	455745	S219-p	Osteopontin	NAPSDWDsRGKDSYE	35433956	2	14	1		
colorectal carcinoma	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	455705	S62-p	Osteopontin	LAPQNAVsSEETNDF	35433956	2	23	0		
non-small cell lung adenocarcinoma	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	455745	S219-p	Osteopontin	NAPSDWDsRGKDSYE	35433956	2	14	1		
non-small cell lung adenocarcinoma	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	455705	S62-p	Osteopontin	LAPQNAVsSEETNDF	35433956	2	23	0		
non-small cell lung adenocarcinoma	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	455706	S63-p	Osteopontin	APQNAVSsEETNDFK	35433956	2	24	0		
non-small cell lung adenocarcinoma	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	455721	S258-p	Osteopontin	NDESNEHsDVIDSQE	35433956	2	8	1		
non-small cell lung adenocarcinoma	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	28702652	T190-p	Osteopontin	DATDEDItSHMESEE	35433956	1	4	0		
endometrial cancer	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	1825301	S263-p	Osteopontin	EHSDVIDsQELSKVS	35433956	2	11	0		
endometrial cancer	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	455719	S254-p	Osteopontin	KRKANDEsNEHSDVI	35433956	2	21	2		
endometrial cancer	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	455745	S219-p	Osteopontin	NAPSDWDsRGKDSYE	35433956	2	14	1		
endometrial cancer	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	455713	S195-p	Osteopontin	DITSHMEsEELNGAY	35433956	2	11	0		
nephrosis	decreased	Acaca	ACC1	Q5SWU9	107476	11|11 C	265.26	mouse	448292	S79-p		FHMRSSMsGLHLVKQ	35483524	149	76	11	3661; 11818; 42801	
diabetes mellitus	decreased	Akt1	Akt1	P31750	11651	12 F1|12 61.2 cM	55.71	mouse	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	35490780	732	14	18	5106; 48646; 13842; 4056; 2965; 43506; 77440; 9275; 13038; 86758; 80722; 5056	
diabetes mellitus	decreased	Akt1	Akt1	P31750	11651	12 F1|12 61.2 cM	55.71	mouse	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	35490780	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
breast cancer	decreased	ERBB2	HER2	P04626	2064	17q12	137.91	human	447614	Y1248-p		PTAENPEyLGLDVPV	35505646	57	15	200	2247; 2244	corelates with poor disease free survival
ovarian cancer	increased	IRS4	IRS4	O14654	8471	Xq22.3	133.77	human	10781335	Y779-p		DNDSESDyMFMAPGA	35550247	1	2	3		
ovarian cancer	increased	IRS4	IRS4	O14654	8471	Xq22.3	133.77	human	456294	Y921-p		EADSSSDyVNMDFTK	35550247	1	6	14		
ovarian cancer	increased	IRS4	IRS4	O14654	8471	Xq22.3	133.77	human	1877150802	Y847-p		GLDKEVSyNWDPKDA	35550247	1	1	0		
ovarian cancer	increased	IRS4	IRS4	O14654	8471	Xq22.3	133.77	human	456293	Y828-p		GQNDNSEyVPMLPGK	35550247	1	4	24		
ovarian cancer	increased	IRS4	IRS4	O14654	8471	Xq22.3	133.77	human	1877150800	Y656-p		SGGRFRLyFCVDRGA	35550247	1	1	0		
Status epilepticus	increased	Akt1	Akt1	P47196	24185	6q32	55.74	rat	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	35562960	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
Status epilepticus	increased	Dnm1l	DRP1	O35303	114114	11q23	83.91	rat	483971	S656-p		VPVARKLsAREQRDC	35562960	82	3	0	4867; 6319	
Status epilepticus	decreased	Dnm1l	DRP1	O35303	114114	11q23	83.91	rat	454690	S635-p		PIPIMPAsPQKGHAV	35562960	98	78	114	4494; 3455	
glioblastoma multiforme	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	35670018	468	74	3065	4324; 8119; 9145; 4113; 52075; 73533; 9138; 4323; 4093; 4074; 52527; 74309; 16185; 61958; 9131; 73452	
glioblastoma multiforme	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448191	S727-p		NTIDLPMsPRTLDSL	35670018	199	55	67	49081; 34911; 50804; 58978; 71958; 87544; 94994; 9136; 9134	
glioblastoma multiforme	increased	DNM1L	DRP1	O00429	10059	12p11.21	81.88	human	483971	S637-p		VPVARKLsAREQRDC	35697672	82	3	0	4867; 6319	
prostate cancer	decreased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	1877503800	T622-p	SH2	KEGGVTFtWVEKDIS	35722967	1	0	0		corelates with longer survival time
obesity, hyperphagic	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	35413055	732	14	18	5106; 48646; 13842; 4056; 2965; 43506; 77440; 9275; 13038; 86758; 80722; 5056	
obesity, hyperphagic	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	35413055	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
non-small cell lung adenocarcinoma	increased	KIF26B	KIF26B	Q2KJY2	55083	1q44	223.88	human	31909292	S1953-p		RRLIPALsLDTSSPV	35359341	1	4	0		
endometrial cancer	increased	KIF26B	KIF26B	Q2KJY2	55083	1q44	223.88	human	1876872806	S1773-p		AVGQGSSsPPGGKHT	35359341	1	0	0		
non-small cell lung adenocarcinoma	increased	KIF26B	KIF26B	Q2KJY2	55083	1q44	223.88	human	20651725	S977-p		GASPLSEsDKEDNGS	35359341	1	2	0		
endometrial cancer	increased	KIF26B	KIF26B	Q2KJY2	55083	1q44	223.88	human	20651725	S977-p		GASPLSEsDKEDNGS	35359341	1	2	0		
breast cancer; clear cell kidney cancer	increased	KIF26B	KIF26B	Q2KJY2	55083	1q44	223.88	human	20651725	S977-p		GASPLSEsDKEDNGS	35359341	1	2	0		
breast cancer	increased	CD274	PD-L1	Q9NZQ7	29126	9p24.1	33.28	human	56667601	T290-p		SDTHLEEt_______	35385574	1	2	0		corelates with poor overall survival
breast cancer	increased	CD274	PD-L1	Q9NZQ7	29126	9p24.1	33.28	human	1876861204	T285-p		NSKKQSDtHLEET__	35385574	1	1	0		corelates with poor overall survival
CCA	increased	FGFR2	FGFR2	P21802	2263	10q26.13	92.03	human	472825	Y657-p	PK_Tyr_Ser-Thr	DINNIDYyKKTTNGR	35428876	2	6	36		
CCA	increased	FGFR2	FGFR2	P21802	2263	10q26.13	92.03	human	472824	Y656-p	PK_Tyr_Ser-Thr	RDINNIDyYKKTTNG	35428876	2	8	66		
breast cancer	mutation of site	Rbl2	Rb-like 2	Q64700	19651	8 C4|8 44.25 cM	127.49	mouse	15207808	K1079-ac		YFSNSPSkRLREINS	35385527	3	1	0		
breast cancer	mutation of site	Rbl2	Rb-like 2	Q64700	19651	8 C4|8 44.25 cM	127.49	mouse	15207809	K1111-ac		DGSESPAkRICPENH	35385527	2	1	0		
breast cancer	mutation of site	Rbl2	Rb-like 2	Q64700	19651	8 C4|8 44.25 cM	127.49	mouse	15207807	K1068-ac		AMPSPREkIFYYFSN	35385527	2	1	0		
prostate cancer	increased	TNK2	Ack	Q07912	10188	3q29	114.57	human	450946	Y284-p	PK_Tyr_Ser-Thr	LPQNDDHyVMQEHRK	35704598	11	27	235	3138	
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	1877421608	K610-ac	zf-C4	TIDKFRRkNCPSCRL	35704598	1	1	0		
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	478250	Y269-p	Androgen_recep	QLRGDCMyAPLLGVP	35704598	7	2	0		
Alzheimer's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	449081	S688-p		GAEIVYKsPVVSGDT	35834993	170	45	90	9632	
Alzheimer's disease	decreased	Akt1	Akt1	P31750	11651	12 F1|12 61.2 cM	55.71	mouse	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	35834993	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
Alzheimer's disease	increased	XRCC6	Ku70	P12956	2547	22q13.2	69.84	human	1875071710	T401-p	Ku	VAALCRYtPRRNIPP	34635772	0	1	0		
Alzheimer's disease	increased	XRCC6	Ku70	P12956	2547	22q13.2	69.84	human	1875071712	T90-p	Ku_N	LAVVFYGtEKDKNSV	34635772	0	1	0		
Alzheimer's disease	increased	XRCC6	Ku70	P12956	2547	22q13.2	69.84	human	1875071708	S78-p	Ku_N	YISKIISsDRDLLAV	34635772	1	1	0		
Alzheimer's disease	increased	XRCC6	Ku70	P12956	2547	22q13.2	69.84	human	1875071706	S77-p	Ku_N	VYISKIIsSDRDLLA	34635772	1	1	0		
Alzheimer's disease	increased	XRCC6	Ku70	P12956	2547	22q13.2	69.84	human	4763166	S520-p	Ku_C	AMNKRLGsLVDEFKE	34635772	0	28	5		
Alzheimer's disease	decreased; increased	Marcks	MARCKS	P26645	17118	10 B1|10 19.49 cM	29.66	mouse	454165	S46-p	MARCKS	VKVNGDAsPAAAEPG	31980612	3	41	0		increases during asymptomatic phase and decreased during symptomatic phase
paraplegia	increased	Snca	SNCA	O55042	20617	6 B3|6 29.15 cM	14.49	mouse	448278	S129-p	Synuclein	SEAYEMPsEEGYQDY	32024799	104	7	0	87281; 23706	paralysis
Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	32156613	104	7	0	87281; 23706	
DCM; cardiomyopathy	increased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	449111	S9-p		SGRPRTTsFAESCKP	34948382	513	44	227	5558; 14630; 14026; 14332; 79774; 9322; 9327; 9331; 9323; 9336; 9325; 8466; 8566; 14310	
DCM; cardiomyopathy	increased	Gsk3b	GSK3B	Q9WV60	56637	16|16 B3	46.71	mouse	449111	S9-p		SGRPRTTsFAESCKP	34948382	513	44	227	5558; 14630; 14026; 14332; 79774; 9322; 9327; 9331; 9323; 9336; 9325; 8466; 8566; 14310	
acute myelogenous leukemia	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	34525179	468	74	3065	4324; 8119; 9145; 4113; 52075; 73533; 9138; 4323; 4093; 4074; 52527; 74309; 16185; 61958; 9131; 73452	
Alzheimer's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	447933	T497-p		SSPGSPGtPGSRSRT	35024199	113	24	26	30505; 43964; 49561; 20060; 53001; 20739	
lung cancer; colorectal cancer; endometrial cancer; ovarian cancer	increased	KRT17	K17	Q04695	3872	17q21.2	48.11	human	483240	S13-p		RQFTSSSsIKGSSGL	35116305	1	11	1		
lung cancer; colorectal cancer; endometrial cancer; ovarian cancer	increased	KRT17	K17	Q04695	3872	17q21.2	48.11	human	3194318	S39-p		SGGLGAGsCRLGSAG	35116305	1	13	0		
lung cancer; colorectal cancer; endometrial cancer; ovarian cancer	increased	KRT17	K17	Q04695	3872	17q21.2	48.11	human	23117181	S24-p		SSGLGGGsSRTSCRL	35116305	1	5	1		
lung cancer; colorectal cancer; endometrial cancer; ovarian cancer	increased	KRT17	K17	Q04695	3872	17q21.2	48.11	human	483641	S32-p		SRTSCRLsGGLGAGS	35116305	1	16	5		
multiple myeloma	increased	CHEK1	Chk1	O14757	1111	11q24.2	54.43	human	447834	S345-p		LVQGISFsQPTCPDH	35190641	188	4	12	12268; 2341; 2348	
multiple myeloma	increased	CHEK1	Chk1	O14757	1111	11q24.2	54.43	human	447833	S317-p		ENVKYSSsQPEPRTG	35190641	94	11	17	2344; 8191; 12302	
multiple myeloma	increased	H2AX	H2AX	P16104	3014	11q23.3	15.01	human	448841	S139-p		GKKATQAsQEY____	35190641	254	31	29	85410; 97148; 20304; 5438; 80312; 59141; 4309; 9719; 60566; 5763; 9720; 2577; 9718	
ovarian cancer	increased	PTK2	FAK	Q05397	5747	8q24.3	119.23	human	447887	Y397-p		SVSETDDyAEIIDEE	35201437	340	31	474	3283; 8556	
lung cancer; colorectal cancer; endometrial cancer	decreased	RIPOR1	FAM65A	Q6ZS17	79567	16q22.1	132.31	human	453541	S351-p	PL48	RFSTYSQsPPDTPSL	35201499	1	59	11		
Southeast Asian Ovalocytosis	increased	SLC4A1	SLC4A1	P02730	6521	17q21.31	101.79	human	455384	Y359-p		AKPDSSFyKGLDLNG	32411010	8	5	50		
diabetes mellitus	increased	Per2	PER2	Q9Z301	63840	9q36	136.03	rat	470017	S662-p		GKAESVVsLTSQCSY	35227001	3	1	1		
Parkinson's disease; DLB	decreased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	35353605	104	7	0	87281; 23706	
hepatocellular carcinoma	increased	AFP	AFP	P02771	174	4q13.3	68.68	human	1879738503	K194-ac		KIIPSCCkAENAVEC	31811908	1	1	0		associated with poorer prognosis and survival of HCC patients
hepatocellular carcinoma	increased	AFP	AFP	P02771	174	4q13.3	68.68	human	1879738502	K242-ac		FQAITVTkLSQKFTK	31811908	1	1	0		associated with poorer prognosis and survival of HCC patients
hepatocellular carcinoma	increased	AFP	AFP	P02771	174	4q13.3	68.68	human	1879738501	K211-ac		TKAATVTkELRESSL	31811908	1	1	0		associated with poorer prognosis and survival of HCC patients
breast cancer	increased	KDM1A	LSD1	O60341	23028	1p36.12	92.90	human	1879738504	R838-m2		GAMYTLPrQATPGVP	31833203	1	1	0		associated with grade of breast carcinoma
CRPC	increased	CAD	CAD	P27708	790	2p23.3	242.98	human	451247	S1859-p		PPRIHRAsDPGLPAE	35046532	9	88	86	12662; 67235; 70307	
TBI	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	447928	S494-p		SGYSSPGsPGTPGSR	35453615	149	55	116	30505; 39357	
TBI	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	447933	T497-p		SSPGSPGtPGSRSRT	35453615	113	24	26	30505; 43964; 49561; 20060; 53001; 20739	
chronic lymphocytic leukemia	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448191	S727-p		NTIDLPMsPRTLDSL	35595309	199	55	67	49081; 34911; 50804; 58978; 71958; 87544; 94994; 9136; 9134	
hypertension; MI; stroke; Chronic Kidney Disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449078	T217-p		SRTPSLPtPPTREPK	35618838	33	31	6	51625	
hypertension; MI; stroke; Chronic Kidney Disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	35618838	85	33	23	62672; 66224; 12885	
Parkinson's disease; DLB; MSA	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	35659116	104	7	0	87281; 23706	
colonic inflamation	decreased	Fadd	FADD	Q61160	14082	7 F5|7 88.85 cM	22.96	mouse	447653	S191-p		VSKSENMsPVLRDST	35753028	14	28	0	2781	
Alzheimer's disease	decreased	Nr3c1	GR	P06537	14815	18 B3|18 21.09 cM	87.16	mouse	3178938	S284-p	GCR	TGDTILSsPSSVALP	35733193	3	13	0		
Alzheimer's disease	decreased	Nr3c1	GR	P06537	14815	18 B3|18 21.09 cM	87.16	mouse	3178932	S152-p	GCR	ANLNRSTsRPENPKS	35733193	8	11	6	85060	
Alzheimer's disease	increased	SEPTIN5	SEPT5	Q99719	5413	22q11.21	42.78	human	454379	S327-p		TQDSRMEsPIPILPL	34954322	2	27	2		
asthma	increased	NR3C1	GR	P04150	2908	5q31.3	85.66	human	451796	S226-p	GCR	IDENCLLsPLAGEDD	31974640	35	9	1	97285	
glioblastoma multiforme	increased	PKM	PKM	P14618	5315	15q23	57.94	human	27110046	S222-p	PK	AVDLPAVsEKDIQDL	35048565	1	7	0		
colorectal cancer	increased	APC	APC	P25054	324	5q22.2	311.65	human	3188828	S2260-p	APC_basic	LKTPASKsPSEGQTA	35303016	1	11	1		
pancreatic carcinoma	increased	EEF1A1	EEF1A1	P68104	1915	6q13	50.14	human	3898705	K55-m2	GTP_EFTU	EMGKGSFkYAWVLDK	30612740	2	6	11		
colorectal cancer	increased	MYC	Myc	P01106	4609	8q24.21	48.80	human	448586	S62-p	Myc_N	LLPTPPLsPSRRSGL	35039060	72	37	33	13748	
colorectal cancer	increased	APC	APC	P25054	324	5q22.2	311.65	human	3188846	T1438-p		MPPSRSKtPPPPPQT	35303016	1	20	0		
glioblastoma	increased	HNRNPA1	hnRNP A1	P09651	3178	12q13.13	38.75	human	476707	R225-m2		RGGNFSGrGGFGGSR	31473880	2	6	21		PRMT5 activity is stimulated in response to mTOR inhibitors
glioblastoma	increased	HNRNPA1	hnRNP A1	P09651	3178	12q13.13	38.75	human	4153100	R218-m2		GGNDNFGrGGNFSGR	31473880	2	5	18		PRMT5 activity is stimulated in response to mTOR inhibitors
Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	35418851	104	7	0	87281; 23706	
hepatitis	decreased	Map3k5	ASK1	O35099	26408	10|10 A3	154.51	mouse	451423	S1040-p		EDHSAPPsPEEKDSG	35438255	2	32	0		Alcohol associated hepatitis
hepatitis	decreased	MAP3K5	ASK1	Q99683	4217	6q23.3	154.54	human	451423	S1033-p		EDHSAPPsPEEKDSG	35438255	2	32	0		Alcohol associated hepatitis
ALS	increased	Crmp1	CRMP-1	P97427	12933	5 B3|5 19.96 cM	62.17	mouse	1295503	S522-p		PAPSAKSsPSKHQPP	35523582	4	12	7		
diabetes mellitus	increased	Irs1	IRS1	P35569	16367	1 C5|1 42.0 cM	130.72	mouse	447558	S307-p		TESITATsPASMVGG	35739993	73	14	0	2381	
hepatitis	increased	Map3k5	ASK1	O35099	26408	10|10 A3	154.51	mouse	1984030	S1036-p		DENFEDHsAPPSPEE	35438255	0	21	0		Alcohol associated hepatitis
hepatitis	increased	MAP3K5	ASK1	Q99683	4217	6q23.3	154.54	human	448394	T838-p	Pkinase	GINPCTEtFTGTLQY	35438255	18	2	1	3765	Alcohol associated hepatitis
diabetes mellitus	decreased	Akt1	Akt1	P31750	11651	12 F1|12 61.2 cM	55.71	mouse	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	35739993	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
diabetes mellitus	decreased	Nos3	eNOS	P70313	18127	5 A3|5 11.32 cM	132.92	mouse	447884	S1176-p		TSRIRTQsFSLQERQ	35739993	194	18	7	9570; 9571	
diabetes mellitus	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	35835217	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	
diabetes mellitus	increased	RPS6KB1	p70S6K	P23443	6198	17q23.1	59.14	human	448607	T412-p	Pkinase_C	NQVFLGFtYVAPSVL	35835217	438	8	1	9209; 9205; 9234; 9206; 97596	
diabetes mellitus	increased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	449111	S9-p		SGRPRTTsFAESCKP	35835217	513	44	227	5558; 14630; 14026; 14332; 79774; 9322; 9327; 9331; 9323; 9336; 9325; 8466; 8566; 14310	
diabetes mellitus	increased	Ppp1r12a	MYPT1	Q9DBR7	17931	10 D1|10 56.33 cM	115.00	mouse	452075	T852-p		PREKRRStGVSFWTQ	32182257	41	1	17	4563	
prostate cancer	increased	MAPKAPK5	MAPKAPK5	Q8IW41	8550	12q24.12-q24.13	54.22	human	27452609	S354-p		VSLKPLHsVNNPILR	35064619	1	10	1		
Alzheimer's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	447928	S494-p		SGYSSPGsPGTPGSR	31645758	149	55	116	30505; 39357	Induced by high-salt diet; Cdk5 peptide inhibitor TFP5 (40mg/kg, twice/week; i.p.) attenuated p-tau and prevented cognitive dysfunction in mice
Alzheimer's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	449081	S688-p		GAEIVYKsPVVSGDT	31645758	170	45	90	9632	Induced by high-salt diet; Cdk5 peptide inhibitor TFP5 (40mg/kg, twice/week; i.p.) attenuated p-tau and prevented cognitive dysfunction in mice
Alzheimer's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	447927	S491-p		GERSGYSsPGSPGTP	31645758	87	30	33	29957	Induced by high-salt diet; Cdk5 peptide inhibitor TFP5 (40mg/kg, twice/week; i.p.) attenuated p-tau and prevented cognitive dysfunction in mice
hepatitis; ALD	increased	MAT1A	MAT1A	Q00266	4143	10q22.3	43.65	human	27996470	S114-p	S-AdoMet_synt_N	LVALEQQsPDIAQCV	35091576	1	3	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	35250029	85	33	23	62672; 66224; 12885	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	35310828	85	33	23	62672; 66224; 12885	corelates with disease progression to dementia
colorectal cancer; ovarian cancer	increased	PTBP3	ROD1 iso2	O95758-2	9991	9q32	59.11	human	10858926	S30-p		DRPPCSPsRVLHLRK	35359851	1	2	1		
insulinomatosis	decreased	MAFA	MAFA	Q8NHW3	389692	8q24.3	36.98	human	5403102	S65-p		PCSSVPSsPSFCAPS	35406570	9	0	0		
endometrial cancer	increased	PTBP3	ROD1 iso2	O95758-2	9991	9q32	59.11	human	14579375	S426-p	RRM_5	LTKDFSNsPLHRFKK	35359851	1	13	0		
insulinomatosis	mutation of site	MAFA	MAFA	Q8NHW3	389692	8q24.3	36.98	human	456028	T57-p		LSSTPLStPCSSVPS	35406570	8	1	0		
lung cancer	increased	PKM	PKM	P14618	5315	15q23	57.94	human	476070	S37-p		MCRLDIDsPPITARN	35790734	15	62	6		
liver cancer	increased	IKBKB	IKKB	O14920	3551	8p11.21	86.56	human	447489	S181-p	Pkinase	DQGSLCTsFVGTLQY	35476515	70	2	0	92255; 2697; 36516; 2694; 36214; 14938	
Huntington's disease	increased	Snca	SNCA	O55042	20617	6 B3|6 29.15 cM	14.49	mouse	448278	S129-p	Synuclein	SEAYEMPsEEGYQDY	35659303	104	7	0	87281; 23706	
gastric cancer	decreased	ZBTB33	Kaiso	Q86T24	10009	Xq24	74.48	human	34353150	T606-p		YLSDRSStIPAMKDD	35851744	1	0	1		
diffuse intrinsic pontine glioma	increased	Axl	AXL	Q00993	26362	7 A3|7 14.02 cM	98.19	mouse	451490	Y773-p	PK_Tyr_Ser-Thr	VDCLDGLyALMSRCW	32165429	6	2	2	96453	
colorectal cancer	increased	ATM	ATM	Q13315	472	11q22.3	350.69	human	448797	S1981-p		SLAFEEGsQSTTISS	32203529	203	24	4	5883; 13050; 4526	
mantle cell lymphoma	increased	CXCR4	CXCR4	P61073	7852	2q22.1	39.75	human	458320	S339-p		GKRGGHSsVSTESES	35078860	13	6	7	59028	corelates with poor prognosis
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	35078917	85	33	23	62672; 66224; 12885	
celiac	decreased	CCDC88A	girdin	Q3V6T2	55704	2p16.1	216.04	human	450762	Y1799-p		QSKDSNPyATLPRAS	32307399	5	13	137		
hepatocellular carcinoma	increased	ZFP64	ZFP64	Q9NTW7	55734	20q13.2	72.22	human	7322830	S226-p	zf-H2C2_5	NKHLRIHsDERPFKC	35219791	1	8	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	35260470	85	33	23	62672; 66224; 12885	
hepatocellular carcinoma	increased	YAP1	YAP1	P46937	10413	11q22.1	54.46	human	473004	Y407-p		SGLSMSSySVPRTPD	35041461	20	3	4		
rheumatoid arthritis	increased	RPS6KB1	p70S6K	P23443	6198	17q23.1	59.14	human	448607	T412-p	Pkinase_C	NQVFLGFtYVAPSVL	35015571	438	8	1	9209; 9205; 9234; 9206; 97596	
T cell lymphoma	decreased	Myc	Myc	P01108	17869	15 D1|15 26.19 cM	48.97	mouse	448586	S62-p	Myc_N	LLPTPPLsPSRRSGL	35380701	72	37	33	13748	
T cell lymphoma	decreased	Myc	Myc	P01108	17869	15 D1|15 26.19 cM	48.97	mouse	448496	T58-p	Myc_N	KKFELLPtPPLSPSR	35380701	71	39	30	46650	
B cell lymphoma	decreased	Myc	Myc	P01108	17869	15 D1|15 26.19 cM	48.97	mouse	448586	S62-p	Myc_N	LLPTPPLsPSRRSGL	35380701	72	37	33	13748	
lung cancer	increased	VCP	VCP	P55072	7415	9p13.3	89.32	human	1876872800	T76-p	CDC48_N	CIVLSDDtCSDEKIR	35430615	1	0	0		
nasopharyngeal carcinoma	increased	PARVA	PARVA	Q9NVD7	55742	11p15.3	42.24	human	4270099	S8-p		MATSPQKsPSVPKSP	35559353	4	33	0		
chronic lymphocytic leukemia	increased	TRIM28	TIF1B	Q13263	10155	19q13.43	88.55	human	452391	S473-p		SGVKRSRsGEGEVSG	35533307	26	117	20		
acute myelogenous leukemia	mutation of site	RUNX1	AML1 iso8	Q01196-8	861	21q22.12	51.82	human	2363102	R237-me		QLRRTAMrVSPHHPA	32573733	2	1	0		
acute myelogenous leukemia	mutation of site	RUNX1	AML1 iso8	Q01196-8	861	21q22.12	51.82	human	2363103	R233-me		SELEQLRrTAMRVSP	32573733	2	1	0		
PAH	increased	IKZF3	Aiolos	Q9UKT9	22806	17q12-q21.1	58.02	human	4696322	S378-p		VPSERGLsPNNSGHD	34966541	1	9	0		
Sjogren syndrome	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	34948236	1771	23	44	5012; 4051; 4070; 68035; 4075; 5315; 31957; 9271; 3787; 5102; 2337; 11962; 88106; 4058; 15116; 26580; 4054; 4071; 2336; 4060; 9563; 9018; 23430; 12694	..."Akt signaling pathway is activated in the MSGs of pSS patients"...
Sjogren syndrome	increased	FOXO1	FOXO1A	Q12778	2308	13q14.11	69.66	human	449113	S319-p		TFRPRTSsNASTISG	34948236	27	4	27	2486	..."Akt signaling pathway is activated in the MSGs of pSS patients"...
Sjogren syndrome	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	34948236	732	14	18	5106; 48646; 13842; 4056; 2965; 43506; 77440; 9275; 13038; 86758; 80722; 5056	..."Akt signaling pathway is activated in the MSGs of pSS patients"...
Sjogren syndrome	increased	AKT1S1	PRAS40	Q96B36	84335	19q13.33	27.38	human	470067	T246-p	PRAS	LPRPRLNtSDFQKLK	34948236	44	69	781	13175; 2997; 2640; 60202	..."Akt signaling pathway is activated in the MSGs of pSS patients"...
ovarian epithelial carcinoma	increased	TP53	p53	P04637	7157	17p13.1	43.65	human	464662	K386-ub		RHKKLMFkTEGPDSD	31002112	10	0	1		role of SMYD3 is associated with the metastasis process of EOC and poor prognosis
ovarian epithelial carcinoma	increased	TP53	p53	P04637	7157	17p13.1	43.65	human	464658	K382-ub		QSTSRHKkLMFKTEG	31002112	10	0	0		role of SMYD3 is associated with the metastasis process of EOC and poor prognosis
ovarian epithelial carcinoma	increased	TP53	p53	P04637	7157	17p13.1	43.65	human	464657	K381-ub		GQSTSRHkKLMFKTE	31002112	10	0	0		role of SMYD3 is associated with the metastasis process of EOC and poor prognosis
HNSCC	increased	PKM	PKM	P14618	5315	15q23	57.94	human	450528	Y105-p	PK	FASDPILyRPVAVAL	35054968	25	33	414	3827	
Parkinson's disease	increased	LRRK2	LRRK2	Q5S007	120892	12q12	286.10	human	4725898	S935-p		NLQRHSNsLGPIFDH	34983390	38	17	2	59576	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	35052691	130	44	14	20473; 71429	
lung cancer	decreased	H2BC3	H2B	P33778	3018	6p22.2	13.82	human	465519	K120-ub		EGTKAVTkYTSSK__	30942468	27	20	138	86653; 5546	
breast cancer	increased	YBX1	YB-1	P67809	4904	1p34.2	35.92	human	455636	S102-p	CSD	NPRKYLRsVGDGETV	35022570	20	33	2	2900	indicates poor outcome
HNSCC	increased	SMAD2	SMAD2	Q15796	4087	18q21.1	52.31	human	447495	S467-p		SVRCSSMs_______	35022323	54	1	5	18338; 26945; 8828; 11979; 68550; 3108; 56532; 67804; 55041	
HNSCC	increased	SMAD2	SMAD2	Q15796	4087	18q21.1	52.31	human	447494	S465-p		SPSVRCSsMS_____	35022323	54	1	5	18338; 26945; 8828; 11979; 68550; 3108; 56532; 67804; 55041	
colorectal cancer	decreased	FOSL1	FRA1	P15407	8061	11q13.1	29.41	human	40663031	K116-ac	bZIP_1	RVRRERNkLAAAKCR	30804456	1	0	5		poor prognosis among colorectal cancer (CRC) patients
acute myelogenous leukemia	increased	FLT3	FLT3	P36888	2322	13q12.2	112.90	human	1879733100	R972-m2		CPHTYQNrRPFSREM	31217189	2	2	0		
acute myelogenous leukemia	increased	FLT3	FLT3	P36888	2322	13q12.2	112.90	human	1879733101	R973-m2		PHTYQNRrPFSREMD	31217189	2	2	0		
acute myelogenous leukemia	mutation of site	DNMT3A	DNMT3A	Q9Y6K1	1788	2p23.3	101.86	human	1877292602	R771-me	DNA_methylase	SDKRDISrFLESNPV	30705090	2	0	0		R771P led to a 3-fold increase in enzymatic activity relative to WT,  R771Q showed 6-fold hypermethylation with a 6-fold increase in activity of p15-pCpGL substrate, R771Q showed a slight decrease of DNA methyltransferase activity compared with the WT cells expressing DNMT3A in murine embryonic stem cells
acute myelogenous leukemia	mutation of site	DNMT3A	DNMT3A	Q9Y6K1	1788	2p23.3	101.86	human	1877292601	R882-me		TDVSNMSrLARQRLL	31076446	4	0	0		associated with poor survival
ESCC	increased	PFKFB3	PFKFB3	Q16875	5209	10p15.1	59.61	human	448801	S461-p		NPLMRRNsVTPLASP	35707221	9	47	83		corelates with worse prognosis
colonic inflamation	increased	RELA	NFkB-p65	Q04206	5970	11q13.1	60.22	human	450278	T254-p	RHD_dimer	QVAIVFRtPPYADPS	35487976	5	0	1		
liver cancer	increased	LRP6	LRP6	O75581	4040	12p13.2	180.43	human	456289	S1490-p		AILNPPPsPATERSH	35637196	30	13	55	2568	
Myopia	increased	Gjd2	GJD2	O54851	14617	2|2 E4	36.08	mouse	471387	S293-p		GAQAKRKsVYEIRNK	32547367	4	3	0		
type 2 diabetes	increased	Dnm1l	DRP1	Q8K1M6	74006	16|16 A2	82.66	mouse	454690	S622-p		PIPIMPAsPQKGHAV	35865967	98	78	114	4494; 3455	